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A B S T R A C T
Background
Melanoma has one of the fastest rising incidence rates of any cancer. It accounts for a small percentage of skin cancer cases but is
responsible for the majority of skin cancer deaths. History-taking and visual inspection of a suspicious lesion by a clinician is usually
the first in a series of ‘tests’ to diagnose skin cancer. Establishing the accuracy of visual inspection alone is critical to understating the
potential contribution of additional tests to assist in the diagnosis of melanoma.
Objectives
To determine the diagnostic accuracy of visual inspection for the detection of cutaneous invasive melanoma and atypical intraepidermal
melanocytic variants in adults with limited prior testing and in those referred for further evaluation of a suspicious lesion. Studies were
separated according to whether the diagnosis was recorded face-to-face (in-person) or based on remote (image-based) assessment.
Search methods
We undertook a comprehensive search of the following databases from inception up to August 2016: CENTRAL; CINAHL; CPCI;
Zetoc; Science Citation Index; US National Institutes of Health Ongoing Trials Register; NIHR Clinical Research Network Portfolio
Database; and the World Health Organization International Clinical Trials Registry Platform. We studied reference lists and published
systematic review articles.
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Selection criteria
Test accuracy studies of any design that evaluated visual inspection in adults with lesions suspicious for melanoma, compared with a
reference standard of either histological confirmation or clinical follow-up. We excluded studies reporting data for ‘clinical diagnosis’
where dermoscopy may or may not have been used.
Data collection and analysis
Two review authors independently extracted all data using a standardised data extraction and quality assessment form (based on
QUADAS-2). We contacted authors of included studies where information related to the target condition or diagnostic threshold
were missing. We estimated summary sensitivities and specificities per algorithm and threshold using the bivariate hierarchical model.
We investigated the impact of: in-person test interpretation; use of a purposely developed algorithm to assist diagnosis; and observer
expertise.
Main results
We included 49 publications reporting on a total of 51 study cohorts with 34,351 lesions (including 2499 cases), providing 134 datasets
for visual inspection. Across almost all study quality domains, the majority of study reports provided insufficient information to allow
us to judge the risk of bias, while in three of four domains that we assessed we scored concerns regarding applicability of study findings
as ’high’. Selective participant recruitment, lack of detail regarding the threshold for deciding on a positive test result, and lack of detail
on observer expertise were particularly problematic.
Attempts to analyse studies by degree of prior testing were hampered by a lack of relevant information and by the restricted inclusion of
lesions selected for biopsy or excision. Accuracy was generally much higher for in-person diagnosis compared to image-based evaluations
(relative diagnostic odds ratio of 8.54, 95% CI 2.89 to 25.3, P < 0.001). Meta-analysis of in-person evaluations that could be clearly
placed on the clinical pathway showed a general trade-off between sensitivity and specificity, with the highest sensitivity (92.4%, 95%
CI 26.2% to 99.8%) and lowest specificity (79.7%, 95% CI 73.7% to 84.7%) observed in participants with limited prior testing
(n = 3 datasets). Summary sensitivities were lower for those referred for specialist assessment but with much higher specificities (e.g.
sensitivity 76.7%, 95% CI 61.7% to 87.1%) and specificity 95.7%, 95% CI 89.7% to 98.3%) for lesions selected for excision, n = 8
datasets). These differences may be related to differences in the spectrum of included lesions, differences in the definition of a positive
test result, or to variations in observer expertise. We did not find clear evidence that accuracy is improved by the use of any algorithm
to assist diagnosis in all settings. Attempts to examine the effect of observer expertise in melanoma diagnosis were hindered due to poor
reporting.
Authors’ conclusions
Visual inspection is a fundamental component of the assessment of a suspicious skin lesion; however, the evidence suggests that
melanomas will be missed if visual inspection is used on its own. The evidence to support its accuracy in the range of settings in which
it is used is flawed and very poorly reported. Although published algorithms do not appear to improve accuracy, there is insufficient
evidence to suggest that the ‘no algorithm’ approach should be preferred in all settings. Despite the volume of research evaluating visual
inspection, further prospective evaluation of the potential added value of using established algorithms according to the prior testing or
diagnostic difficulty of lesions may be warranted.
P L A I N L A N G U A G E S U M M A R Y
How accurate is visual inspection of skin lesions with the naked eye for diagnosis of melanoma in adults?
What is the aim of the review?
Melanoma is one of the most dangerous forms of skin cancer. The aim of this Cochrane Review was to find out how accurate checking
suspicious skin lesions (lumps, bumps, wounds, scratches or grazes) with the naked eye (visual inspection) can be to diagnose melanoma
(diagnostic accuracy). The Review also investigated whether diagnostic accuracy was different depending on whether the clinician was
face to face with the patient (in-person visual inspection), or looked at an image of the lesion (image-based visual inspection). Cochrane
researchers included 19 studies to answer this question.
Why is it important to know the diagnostic accuracy of visual examination of skin lesions suspected to be melanomas?
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Not recognising a melanoma when it is present (a false-negative test result) delays surgery to remove it (excision), risking cancer
spreading to other organs in the body and possibly death. Diagnosing a skin lesion (a mole or area of skin with an unusual appearance in
comparison with the surrounding skin) as a melanoma when it is not (a false-positive result) may result in unnecessary surgery, further
investigations, and patient anxiety. Visual inspection of suspicious skin lesions by a clinician using the naked eye is usually the first of
a series of ‘tests’ to diagnose melanoma. Knowing the diagnostic accuracy of visual inspection alone is important to decide whether
additional tests, such as a biopsy (removing a part of the lesion for examination under a microscope) are needed to improve accuracy
to an acceptable level.
What did the review study?
Researchers wanted to find out the diagnostic accuracy of in-person compared with image-based visual inspection of suspicious skin
lesions. Researchers also wanted to find out whether diagnostic accuracy was improved if doctors used a ’visual inspection checklist’
or depending on how experienced in visual inspection they were (level of clinical expertise). They considered the diagnostic accuracy
of the first visual inspection of a lesion, for example, by a general practitioner (GP), and of lesions that had been referred for further
evaluation, for example, by a dermatologist (doctor specialising in skin problems).
What are the main results of the review?
Only 19 studies (17 in-person studies and 2 image-based studies) were clear whether the test was the first visual inspection of a lesion
or was a visual inspection following referral (for example, when patients are referred by a GP to skin specialists for visual inspection).
First in-person visual inspection (3 studies)
The results of three studies of 1339 suspicious skin lesions suggest that in a group of 1000 lesions, of which 90 (9%) actually are
melanoma:
- An estimated 268 will have a visual inspection result indicating melanoma is present. Of these, 185 will not be melanoma and will
result in an unnecessary biopsy (false-positive results).
- An estimated 732 will have a visual inspection result indicating that melanoma is not present. Of these, seven will actually have
melanoma and would not be sent for biopsy (false-negative results).
Two further studies restricted to 4228 suspicious skin lesions that were all selected to be excised found similar results.
In-person visual inspection after referral, all lesions selected to be excised (8 studies)
The results of eight studies of 5331 suspicious skin lesions suggest that in a group of 1000 lesions, of which 90 (9%) actually are
melanoma:
- An estimated 108 will have a visual inspection result indicating melanoma is present, and of these, 39 will not be melanoma and will
result in an unnecessary biopsy (false-positive results).
- Of the 892 lesions with a visual inspection result indicating that melanoma is not present, 21 will actually be melanoma and would
not be sent for biopsy (false-negative results).
Overall, the number of false-positive results (diagnosing a skin lesion as a melanoma when it is not) was observed to be higher and the
number of false-negative results (not recognising a melanoma when it is present) lower for first visual inspections of suspicious skin
lesions compared to visual inspection following referral.
Visual inspection of images of suspicious skin lesions (2 studies)
Accuracy was much lower for visual inspection of images of lesions compared to visual inspection in person.
Value of visual inspection checklists
There was no evidence that use of a visual inspection checklist or the level of clinical expertise changed diagnostic accuracy.
How reliable are the results of the studies of this review?
The majority of included studies diagnosed melanoma by lesion biopsy and confirmed that melanoma was not present by biopsy or
by follow-up over time to make sure the skin lesion remained negative for melanoma. In these studies, biopsy, clinical follow-up, or
specialist clinician diagnosis were the reference standards (means of establishing final diagnoses). Biopsy or follow-up are likely to have
been reliable methods for deciding whether patients really had melanoma. In a few studies, experts diagnosed the absence of melanoma
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(expert diagnosis), which is less likely to have been a reliable method for deciding whether patients really had melanoma. There was
lots of variation in the results of the studies in this review and the studies did not always describe fully the methods they used, which
made it difficult to assess their reliability.
Who do the results of this review apply to?
Thirteen studies were undertaken in Europe (68%), with the remainder undertaken in Asia (n = 1), Oceania (n = 4), and North America
(n = 1). Mean age ranged from 30 to 73.6 years (reported in 10 studies). The percentage of individuals with melanoma ranged between
4% and 20% in first visualised lesions and between 1% and 50% in studies of referred lesions. In the majority of studies, the lesions
were unlikely to be representative of the range of those seen in practice, for example, only including skin lesions of a certain size or
with a specific appearance. In addition, variation in the expertise of clinicians performing visual inspection and in the definition used
to decide whether or not melanoma was present across studies makes it unclear as to how visual inspection should be carried out and
by whom in order to achieve the accuracy observed in studies.
What are the implications of this review?
Error rates from visual inspection are too high for it to be relied upon alone. Although not evaluated in this review, other technologies
need to be used to ensure accurate diagnosis of skin cancer. There is considerable variation and uncertainty about the diagnostic
accuracy of visual inspection alone for the diagnosis of melanoma. There is no evidence to suggest that visual inspection checklists
reliably improve the diagnostic accuracy of visual inspection, so recommendations cannot be made about when they should be used.
Despite the existence of numerous research studies, further, well-reported studies assessing the diagnostic accuracy of visual inspection
with and without visual inspection checklists and by clinicians with different levels of expertise are needed.
How up-to-date is this review?
The review authors searched for and used studies published up to August 2016.
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S U M M A R Y O F F I N D I N G S F O R T H E M A I N C O M P A R I S O N [Explanation]
Question What is the diagnostic accuracy of visual inspection for the detection of cutaneous invasive melanoma and atypical intraepidermalmelanocytic
variants in adults?
Population Adults with lesions suspicious for melanoma, including:
• those with lim ited prior test ing (present ing in primary, community or private dermatology sett ings)
• referred populat ions (present ing in secondary care or specialist skin cancer clinics)
Index test Visual inspect ion with or without the use of any established algorithms or checklist to aid diagnosis, including:
• in-person evaluat ions (face-to-face diagnosis)
• image-based evaluat ions (diagnosis based on assessment of a clinical image)
Target condition Cutaneous invasive melanoma and atypical intraepidermal melanocyt ic variants
Reference standard Histology with or without long-term follow-up
Action If accurate, posit ive results ensure melanoma lesions are not missed but are appropriately referred and excised and those with negat ive results can
be safely reassured and discharged
Number of studies Total lesions Total cases
Quantity of evidence 49a 34,351 2499
Limitations
Risk of bias Potent ial risk for part icipant select ion f rom case-control design (6), inappropriate exclusion criteria (7) or lack of detail (27/ 49)
All index test interpretat ion was blinded to reference standard diagnosis. Index test thresholds not clearly pre-specif ied (22/ 33 in-person evaluat ions;
13/ 16 image-based)
Low risk for reference standard (42/ 49); high concern f rom use of expert diagnosis (6). Blinding of reference standard to visual inspect ion diagnosis
not reported in any study
High risk for part icipant f low due to dif ferent ial verif icat ion (11), and exclusions following recruitment (15); 37 studies did not mention t im ing of tests
Applicability of evi-
dence to question
Part icipant select ion restricted to those with melanocyt ic lesions only (10), or to those with histopathology results (37) and included mult iple lesions
per part icipant (14)
No descript ion of index test diagnost ic thresholds (24 in-person; 13 image-based) or report ing of average or consensus diagnoses (7 in-person; 13
image-based)
Clinical images interpreted blinded to clinical information (11/ 16). Lit t le information given concerning the expert ise of the histopathologist (40/ 49)5
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Findings
37 studies (providing 39 datasets) reported accuracy data for the primary target condit ion. We separated them a priori into in-person (n = 28) and image-based (n = 11)
evaluat ions. Subsequent analysis conf irmed dif ferences in accuracy according to the dif ferent approaches to diagnosis (P < 0.001). Attempts to analyse studies by degree
of prior test ing were hampered by a lack of relevant information provided in the study publicat ions and by the inclusion of lesions selected for biopsy or excision. Of the 28
in-person evaluat ions, we could only clearly place 17 on the clinical pathway, and considered 11 to have provided insuf f icient information to allow us to ident if y the pathway
(coded ‘unclear’ on pathway). The f indings presented are based on results for in-person evaluat ions that could be clearly placed on the clinical pathway
Test: In-person visual inspection using any or no algorithm at any threshold
Data: Number of datasets Total lesions Total melanomas
All in-person evaluat ions 28 25,604 1748
Studies clearly placed on the clinical pathway 17 14,700 622
Place on pathway: participants with limited prior testing (all lesions)
Datasets (n) Lesions (n) Melanomas (n) Sensitivity (95% CI) Specificity (95% CI)
3 1339 55 92% (26 to 100) 80% (74 to 85)
Numbers in a cohort of
1000 lesionsb
TP FP FN TN PPV NPV
At a prevalence of 4% 37
(10 to 40)
195
(252 to 147)
3
(30 to 0)
765
(708 to 813)
16% (4 to 21) 100%
(96 to 100)
At a prevalence of 9% 83
(24 to 90)
185
(239 to 139)
7
(66 to 0)
725
(671 to 771)
31%
(9 to 39)
99%
(91 to 100)
At a prevalence of 16% 148
(42 to 160)
171
(221 to 129)
12
(118 to 0)
669
(619 to 711)
46%
(16 to 55)
98%
(84 to 100)
Place on pathway: participants with limited prior testing (only lesions selected for excision)
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Datasets (n) Lesions (n) Melanomas (n) Sensitivity (95% CI) Specificity (95% CI)
2 4228 160 90% (70 to 97) 81% (67 to 90)
Numbers in a cohort of
1000 lesionsb
TP FP FN TN PPV NPV
At a prevalence of 4% 36
(28 to 39)
180
(312 to 96)
4
(12 to 1)
780
(648 to 864)
17%
(8 to 29)
99%
(98 to 100)
At a prevalence of 9% 81
(63 to 88)
170
(296 to 91)
9
(27 to 2)
740
(614 to 819)
32%
(18 to 49)
99%
(96 to 100)
At a prevalence of 16% 144
(112 to 156)
157
(273 to 84)
16
(48 to 4)
683
(567 to 756)
48%
(29 to 65)
98%
(92 to 99)
Place on pathway: referred participants (all lesions)
Datasets (n) Lesions (n) Melanomas (n) Sensitivity (95% CI) Specificity (95% CI)
2 3494 61 75% (49 to 90) 99% (95 to 100)
Numbers in a cohort of
1000 lesionsb
TP FP FN TN PPV NPV
At a prevalence of 4% 30
(20 to 36)
13
(51 to 4)
10
(20 to 4)
947
(909 to 956)
69%
(28 to 90)
99%
(98 to 100)
At a prevalence of 9% 67
(44 to 81)
13
(48 to 4)
23
(46 to 9)
897
(862 to 906)
84%
(48 to 96)
98%
(95 to 99)
At a prevalence of 16% 119
(78 to 144)
12
(45 to 3)
41
(82 to 16)
828
(795 to 837)
91%
(64 to 98)
95%
(91 to 98)
Referred participants (only lesions selected for excision)
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Datasets (n) Lesions (n) Melanomas (n) Sensitivity (95% CI) Specificity (95% CI)
8 5331 258 77% (62 to 87) 96% (90 to 98)
Numbers in a cohort of
1000 lesionsb
TP FP FN TN PPV NPV
At a prevalence of 4% 31
(25 to 35)
41
(99 to 16)
9
(15 to 5)
919
(861 to 944)
43%
(20 to 68)
99%
(98 to 99)
At a prevalence of 9% 69
(56 to 78)
39
(94 to 15)
21
(34 to 12)
871
(816 to 895)
64%
(37 to 84)
98%
(96 to 99)
At a prevalence of 16% 123
(99 to 139)
36
(87 to 14)
37
(61 to 21)
804
(753 to 826)
77%
(53 to 91)
96%
(92 to 98)
Referred participants with equivocal lesions (only lesions selected for excision)
Datasets (n) Lesions (n) Melanomas (n) Sensitivity (95% CI) Specificity (95% CI)
2 930 88 85% (56 to 96) 89% (79 to 95)
Numbers in a cohort of
1000 lesionsb
TP FP FN TN PPV NPV
At a prevalence of 4% 34
(22 to 38)
101
(197 to 48)
6
(18 to 2)
859
(763 to 912)
25%
(10 to 44)
99%
(98 to 100)
At a prevalence of 9% 76
(50 to 86)
96
(187 to 46)
14
(40 to 4)
814
(723 to 865)
44%
(21 to 66)
98%
(95 to 100)
At a prevalence of 16% 136
(89 to 154)
88
(172 to 42)
24
(71 to 6)
752
(668 to 798)
61%
(34 to 79)
97%
(90 to 99)
CI: conf idence interval; FN: f alse-negat ive; FP: f alse-posit ive; NPV: negat ive predict ive value; PPV: posit ive predict ive value; TN: t rue negat ive; TP: t rue posit ive
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a37 of the 49 included studies (report ing on 39 cohorts of lesions) provide data for the primary target condit ion (def ined as
detect ion of cutaneous invasive melanoma and atypical intraepidermal melanocyt ic variants) and are the main focus of
this ’Summary of f indings’ table; the summary of methodological quality is based on the full sample of 49 studies.
bWe estimated number of true posit ives (TP), false-posit ives (FP), false-negat ives (FN) and true negat ives (TN) for a
hypothet ical cohort of 1000 lesions at the median and interquart ile ranges of prevalence (25th and 75th percent iles), at
average sensit ivity and specif icity and using the lower and upper lim its of the 95% conf idence intervals, denoted in brackets
(lower lim it to upper lim it).
xxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxx
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B A C K G R O U N D
This review is one of a series of Cochrane Diagnostic Test Ac-
curacy (DTA) reviews on the diagnosis and staging of melanoma
and keratinocyte skin cancers conducted for the National Insti-
tute for Health Research (NIHR) Cochrane Systematic Reviews
Programme. Appendix 1 shows the content and structure of the
programme. Appendix 2 provides a glossary of terms used, and a
table of acronyms used is provided in Appendix 3.
Target condition being diagnosed
Melanoma is one of the most aggressive forms of skin cancer,
with the potential to metastasise to other parts of the body via
the lymphatic system and blood stream. It accounts for a small
percentage of skin cancer cases but is responsible for up to 75%
of skin cancer deaths (Boring 1994; Cancer Research UK 2017).
Melanoma arises from uncontrolled proliferation of melanocytes,
the epidermal cells that produce pigment ormelanin. It most com-
monly arises in the skin but can occur in any organ that contains
melanocytes, including mucosal surfaces, the back of the eye, and
lining around the spinal cord and brain. Cutaneous melanoma
refers to a skin lesion with malignant melanocytes present in the
dermis, and includes superficial spreading, nodular, acral lentig-
inous, and lentigo maligna melanoma variants (see Figure 1).
Melanoma in situ refers to malignant melanocytes that are con-
tained within the epidermis and have not yet invaded the der-
mis, but are at risk of progression to melanoma if left untreated.
Lentigo maligna, a subtype of melanoma-in-situ in chronically
sun-damaged skin, denotes another form of proliferation of ab-
normal melanocytes. Lentigo maligna can progress to invasive
melanoma if its growth breaches the dermo-epidermal junction
during a vertical growth phase (when it becomes known as ’lentigo
maligna melanoma’); however, its rate of malignant transforma-
tion is both lower and slower than for melanoma in situ (Kasprzak
2015). Melanoma in situ and lentigo maligna are both atypical
intraepidermal melanocytic variants.
10Visual inspection for diagnosing cutaneous melanoma in adults (Review)
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Figure 1. Sample photographs of superficial spreading melanoma (left) and nodular melanoma (right).
Copyright © 2010 Dr Rubeta Matin: reproduced with permission.
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The incidence of melanoma rose to over 200,000 newly diagnosed
cases worldwide in 2012 (Erdmann 2013; Ferlay 2015), with an
estimated 55,000 deaths (Ferlay 2015). The highest incidence is
observed in Australia with 13,134 new cases of melanoma of the
skin in 2014 (ACIM 2017) and in New Zealand with 2341 reg-
istered cases in 2010 (HPA and MelNet NZ 2014). For 2014 in
the USA, the predicted incidence was 73,870 per annum and the
predicted number of deaths was 9940 (Siegel 2015). The highest
rates in Europe are seen in north-western Europe and the Scandi-
navian countries, with a highest incidence reported in Switzerland:
25.8 per 100,000 in 2012. Rates in England have tripled from 4.6
and 6.0 per 100,000 in men and women, respectively, in 1990, to
18.6 and 19.6 per 100,000 in 2012 (EUCAN 2012). In the UK,
melanoma has one of the fastest rising incidence rates of any cancer
and has the biggest projected increase in incidence between 2007
and 2030 (Mistry 2011). In the decade leading up to 2013, age-
standardised incidence increased by 46%, with 14,500 new cases
in 2013 and 2459 deaths in 2014 (Cancer Research UK 2017).
While overall incidence rates are higher in women than in men,
the rate of incidence in men is increasing faster than in women
(Arnold 2014).
The rising incidence in melanoma is thought to be primarily re-
lated to an increase in recreational sun exposure and use of tan-
ning beds, and an increasingly ageing population with higher
lifetime ultraviolet (UV) exposure, in conjunction with possible
earlier detection (Belbasis 2016; Linos 2009). Putative risk fac-
tors are reviewed in detail elsewhere (Belbasis 2016), but can be
broadly divided into host or environmental factors. Host factors
include fair skin and light hair or eye colour; older age (Geller
2002);male sex (Geller 2002); previous skin cancer (Tucker 1985);
predisposing skin lesions, for example, high melanocytic naevus
counts (Gandini 2005), clinically atypical naevi (Gandini 2005),
or large congenital naevi (Swerdlow 1995); genetically inherited
skin disorders, for example, xeroderma pigmentosum (Lehmann
2011); and a family history of melanoma (Gandini 2005). Envi-
ronmental factors include recreational, occupational, and work-
related exposure to sunlight (both cumulative and episodic burn-
ing) (Armstrong 2017; Gandini 2005); artificial tanning (Boniol
2012); and immunosuppression, for example, in organ transplant
recipients or HIV-positive individuals (DePry 2011). Lower so-
cioeconomic classmay be associatedwith delayed presentation and
thus more advanced disease at diagnosis (Reyes-Ortiz 2006).
A database of over 40,000 US patients from 1998 onwards, which
assisted the development of the Eighth Edition American Joint
Committee on Cancer (AJCC) Staging System indicated a five-
year survival of 99% for stage IA melanoma (melanoma ≤ 1 mm
thick without ulceration, mitosis or involvement of the lymph
nodes), dropping to anything between 32% and 93% in stage III
disease (melanoma of any thickness with metastasis to the lymph
nodes) depending on tumour thickness, the presence of ulcera-
tion and number of involved nodes (Gershenwald 2017). Before
the advent of targeted and immuno-therapies, stage IV melanoma
(melanoma disseminated to distant sites/visceral organs) was asso-
ciated with median survival of six to nine months, one-year sur-
vival rate of 25%, and three-year survival of 15% (Balch 2009;
Korn 2008).
Between 1975 and 2010, five-year relative survival for melanoma
(i.e. not including deaths from other causes) in the USA increased
from80% to 94%,with survival for localised, regional, and distant
disease estimated at 99%, 70%, and 18%, respectively in 2010
(Cho2014).Overall,mortality rates however showed little change,
at 2.1 per 100,000 deaths in 1975 and 2.7 per 100,000 in 2010
(Cho 2014). Increasing incidence in localised disease over the same
period (from 5.7 to 21 per 100,000) suggests that much of the
observed improvement in survival may be due to earlier detection
and heightened vigilance (Cho 2014). New targeted therapies for
stage IV melanoma (e.g. BRAF inhibitors) have improved survival
and immunotherapies are evolving such that long-term survival
is being documented (Pasquali 2018). No new data regarding the
survival prospects for people with stage IV disease were analysed
for the AJCC Eighth Edition Staging Guidelines due to lack of
contemporary data (Gershenwald 2017).
Treatment of melanoma
For primary melanoma, the mainstay of definitive treatment is
early detection and excision of the lesion, to remove both the
tumour and any malignant cells that might have spread into the
surrounding skin (Garbe 2016; Marsden 2010; NICE 2015a;
SIGN 2017; Sladden 2009). Recommended surgical margins vary
according to tumour thickness (Garbe 2016) and stage of disease
at presentation (NICE 2015a).
Index test(s)
For the purposes of our series of reviews, each component of the
diagnostic process, including visual inspection or clinical exami-
nation, is considered a diagnostic or index ‘test’, the accuracy of
which can be established in comparison with a reference standard
of diagnosis, either alone or in combination with other available
technologies that may assist the diagnostic process.
Clinical history-taking to identify risk factors and visual inspec-
tion of the lesion, surrounding skin and comparison with other
lesions on the rest of the body is fundamental to the diagnosis of
skin cancer. The strongest common phenotypic risk factor is the
presence of atypical naevi; typically the presence of over a hundred
moles or naevi of abnormal appearance that may pose diagnos-
tic challenges (Goodson 2010; Rademaker 2010; Salerni 2012).
In the UK, clinical examination is typically done at two decision
points - first in the general practice (GP) surgery, where a decision
is made to refer or not to refer, and then a second time by a der-
12Visual inspection for diagnosing cutaneous melanoma in adults (Review)
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matologist or other secondary care clinician, where a decision is
made to biopsy or not. Specialist advice can also be sought using
teledermatology, where lesion images are forwarded with variable
clinical information (such as age, gender, and location of lesion)
to specialist clinics or to commercial organisations for interpre-
tation. The accuracy of these diagnostic encounters (defined as
the proportion of ’correct’ diagnoses, i.e. true positive plus true
negative diagnoses out of the total number of diagnoses) is known
to vary according to qualifications and experience (Morton 1998;
Westerhoff 2000); the accuracy of ‘image-based’ as opposed to
face-to-face diagnosis is less clear.
Research into the cognitive processes involved in dermatological
diagnoses suggests that two main strategies are employed simul-
taneously and iteratively (Elstein 2002; Norman 1989; Norman
2009). Non-analytical pattern recognition formulates an initial
hypothesis; identification is made implicitly, without conscious
thought or reference to specific rules and hidden from the con-
scious view of the diagnostician (Norman 2009). Analytical pat-
tern recognition, using more explicit rules based on conscious an-
alytical reasoning, is then employed to test the initial hypothesis.
Analytical pattern recognition has been described as the “careful
and systematic gathering of data and weighing the elicited infor-
mation against mental rules” (Norman 2009). The balance be-
tween non-analytical and analytical reasoning varies between clin-
icians, according to factors such as experience and familiarity with
the diagnostic question.
Various attempts have been made to formalise the ’mental rules’
involved in analytical pattern recognition for melanoma, ranging
from setting out criteria that should be considered (e.g. ‘pattern
analysis’; Friedman 1985; Sober 1979) to formal scoring systems
with explicit numerical thresholds (MacKie 1985; MacKie 1990).
The most commonly used algorithms are described in detail in
Appendix 4.
The ABCD (asymmetry, border irregularity, colour variegation,
diameter > 6 mm) algorithm of clinical warning signs was devel-
oped in 1985 to help distinguish melanoma from a benign nae-
vus (Friedman 1985), and then extended to include an E for ’en-
largement’ criterion (Thomas 1998). As a result of its simplic-
ity, ABCD(E) is now widely advocated for use by non-experts
or lay persons (American Academy of Dermatology 2015). The
approach has been criticised for its inability to capture nodular
and amelanotic melanomas, which account for a relatively small
proportion (~15% to 20%) of incident melanomas but a large
proportion (~50%) of melanoma-related deaths (Moreau 2013;
Shaikh 2012). In addition, up to a third of melanomas may be
smaller than 6 mm in diameter (Maley 2014), a proportion which
is likely to increase due to improved skin surveillance. The validity
of ABCD(E) as a useful tool for the lay public has also been called
into question (Aldridge 2011a; Girardi 2006; Liu 2005). Subse-
quent modifications have been suggested, including altering the
meaning of the ABCD acronym for use in paediatric populations
(Cordoro 2013); changing ’D’ to ’dark’ (Goldsmith 2014)); or
changing the acronym altogether (e.g. CCC for colour, contour,
and change (Moynihan 1994); or “Do UC” the melanoma for
different, uneven, changing (Yagerman 2014)). To date, the latter
three have not been evaluated in populations with lesions sugges-
tive for melanoma.
The seven-point checklist assessing change in size, shape, colour,
inflammation, crusting or bleeding, sensory change, or diameter
of 7 mm or more was developed by UK researchers as a guide to
help non-dermatologists detect possiblemelanoma (MacKie 1985;
MacKie 1990). The revised, weighted version (MacKie 1990), is
currently recommended for GP use in the evaluation of pigmented
lesions (NICE 2015a). A primary care-based evaluation found
moderately good performance for the identification of clinically
significant lesions (including malignant and premalignant lesions
as disease-positive) in primary care (sensitivity and specificity for
the presence of at least three features were 62.7% and 65.0%,
respectively), with higher sensitivity for the detection ofmelanoma
(80.6%) at the expense of low specificity (61.7%) (Walter 2013).
Unlike most formalised rules, the ’ugly duckling’ sign is based on
differential pattern recognition, where abnormal lesion identifica-
tion is achieved by noticing the odd one out, that is, a melanoma
will be the pigmented lesion that does not match the rest of a
person’s naevi, for example a very dark or pale/pink lesion that is
different in colour compared to the rest of the pigmented naevi
(Grob 1998). Although ’ugly duckling’ is inherently a form of
subjective pattern recognition, sensitivity has been reported to be
100% for pigmented-lesion experts and 85% for non-clinicians
(Scope 2008). The assumption that an individual has a “normal”
naevus phenotype is debatable, however. Many individuals have
multiple ’atypical’ pigmented lesions which, although very similar
morphologically, allow malignancy to easily disguise itself amidst
an abnormal complex of pigmented lesions (also referred to as
‘The Little Red Riding Hood’ phenomenon) (Mascaro 1998).
Clinical pathway
The diagnosis of melanoma can take place in primary, secondary,
and tertiary care settings by both generalist and specialist health-
care providers. In the UK, people with concerns about a new or
changing lesion will usually present first to their GP or, less com-
monly, directly to a specialist in secondary care, which could in-
clude a dermatologist, plastic surgeon, general surgeon or other
specialist surgeon (such as an ear, nose, and throat (ENT) spe-
cialist or maxillofacial surgeon), or ophthalmologist (Figure 2).
Current UK guidelines recommend that all suspicious pigmented
lesions presenting in primary care should be assessed by taking a
clinical history and visual inspection using the seven-point check-
list (MacKie 1990); lesions suspected to be melanoma should be
referred urgently for appropriate specialist assessment within two
weeks (Chao 2013; Marsden 2010; NICE 2015b; SIGN 2017).
13Visual inspection for diagnosing cutaneous melanoma in adults (Review)
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Figure 2. Current clinical pathway for people with skin lesions.
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Teledermatology consultations can aid more appropriate triage of
lesions into urgent referral; non-urgent secondary care referral (e.g.
for suspected basal cell carcinoma (BCC)); or where available, re-
ferral to an intermediate care setting, for example, clinics run by
GPs with a special interest in dermatology. The distinction be-
tween setting and examiner qualifications and experience is im-
portant as specialist clinicians might work in primary care settings
(for example, in theUK,GPswith a special interest in dermatology
and skin surgery who have undergone appropriate training), and
generalists might practice in secondary care settings (for example,
plastic surgeons who do not specialise in skin cancer). The level
of skill and experience in skin cancer diagnosis will vary for both
generalist and specialist care providers and will also impact on test
accuracy.
The specialist clinician will also use history-taking and visual in-
spection of the lesion (in comparison with other lesions on the
skin), usually in conjunction with dermoscopic examination, to
inform a clinical decision. If melanoma is suspected, then urgent
excision biopsy is recommended; for suspected cutaneous squa-
mous cell carcinoma (cSCC) urgent excision with predetermined
surgical margins. Other lesions such as BCC or pre-malignant le-
sions such as lentigo maligna may also be referred for a diagnostic
biopsy, followed by appropriate treatment or further surveillance
or reassurance and discharge.
Prior test(s)
Although smartphone applications and community-based teled-
ermatology services can increasingly be directly accessed by peo-
ple who have concerns about a skin lesion (Chuchu 2018), visual
inspection of a suspicious lesion by a clinician is usually the first in
a series of tests to diagnose skin cancer. In the UK first visual in-
spection of a suspicious lesion usually takes place in primary care;
however, in some countries, people with suspicious lesions can
present directly to a secondary care setting. Considering the degree
of prior testing that study participants have undergone is key to
interpretation of resulting test accuracy indices, which are known
to vary according to the spectrum or case-mix of included par-
ticipants (Lachs 1992; Leeflang 2013; Moons 1997; Usher-Smith
2016). Studies of people with suspicious lesions at the initial clini-
cal presentation stage (’test-naïve’), are likely to have a wider range
of differential diagnoses and include a higher proportion of people
with benign diagnoses compared with studies of participants who
have been referred for a specialist opinion on the basis of visual
inspection (with or without dermoscopy) by a generalist practi-
tioner. Furthermore, studies in more specialist settings may focus
on equivocal or difficult-to-diagnose lesions, rather than lesions
with a more general level of clinical suspicion. A simple categori-
sation of studies according to primary, secondary, or specialist set-
ting may not always adequately reflect differences in spectrum.
Role of index test(s)
Visual inspection and history-taking are key to diagnosing skin
cancer and are always undertaken as part of a clinical examination
regardless of examiner experience and whatever additional tech-
nologies are available. For the generalist practitioner, the key is to
minimise the proportion of people who are referred unnecessarily
and identify those lesions that require urgent referral. For the spe-
cialist, the aim is not only to identify those in need of urgent exci-
sion due to invasive cancer, but also to identify high-risk lesions,
with considerable potential to progress to invasive disease, such as
those with severe dysplasia or in situ disease, for example, lentigo
maligna. Given differences in setting, prior testing, observer qual-
ifications, experience and training, the anticipated performance in
terms of accuracy is likely to vary.
When diagnosing potentially life-threatening conditions such as
melanoma, the consequences of falsely reassuring a person that
they do not have skin cancer can be serious and potentially fa-
tal, as the resulting delay to diagnosis means that the window
for successful early treatment may be missed. To minimise these
false-negative diagnoses, a good diagnostic test will demonstrate
high sensitivity and a high negative predictive value (NPV), where
very few of those with a negative test result will actually have a
melanoma. Giving falsely positive test results (meaning the test
has poor specificity and a high false-positive rate) resulting in the
removal of lesions that turn out to be benign is arguably less of
an error than missing a potentially fatal melanoma, but is not cost
free. False-positive diagnoses not only cause unnecessary scarring
from the biopsy or excision procedure, but also increase patient
anxiety whilst they await the definite histology results and increase
healthcare costs as the number needed to remove to yield one
melanoma diagnosis increases.
Alternative test(s)
We have reviewed a number of other tests as part of our series
of Cochrane diagnostic test accuracy (DTA) reviews on the di-
agnosis of melanoma. In particular, dermoscopy has become an
essential tool for the specialist clinician and is increasingly being
taken up in primary care settings. Dermoscopy (also referred to
as dermatoscopy or epiluminescence microscopy or ELM) uses
a hand-held microscope and incident light (with or without oil
immersion) to reveal subsurface images of the skin at increased
magnification of x 10 to x 100 (Kittler 2011). Used alongside
clinical examination, dermoscopy has been shown in some stud-
ies to increase the sensitivity of clinical diagnosis of melanoma
from around 60% to as much as 90% (Bono 2006; Carli 2002a;
Kittler 1999; Stanganelli 2000) with much smaller effects in oth-
ers (Benelli 1999; Bono 2002a). The accuracy of dermoscopy de-
pends on the experience of the examiner (Kittler 2011), with ac-
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curacy when used by untrained or less experienced examiners po-
tentially no better than clinical inspection alone (Binder 1997;
Kittler 2002).
Pattern analysis (Pehamberger 1993; Steiner 1987) is thought to
be the most specific and reliable technique to aid dermoscopy in-
terpretation when used by specialists (Maley 2014); however, der-
moscopic histological correlations have been established and di-
agnostic algorithms developed based on colour, aspect, pigmen-
tation pattern, and skin vessels (e.g. the ABCD rule for der-
moscopy (Nachbar 1994; Stolz 1994), the Menzies (Menzies
1996) and the seven-point dermoscopy checklist (Annessi 2007;
Argenziano 1998; Argenziano 2001; Gereli 2010; amongst oth-
ers). Dermoscopy used in addition to visual inspection (in-person
evaluations) or used alone (dermoscopic image interpretation re-
motely from the patient concerned) are the subject of a separate
systematic review (Dinnes 2018).
Other relevant tests that we have looked at as part of this series
of reviews include teledermatology, mobile phone applications,
reflectance confocal microscopy, optical coherence tomography,
computer-assisted diagnosis or artificial intelligence-based tech-
niques, and high-frequency ultrasound (Dinnes 2015a). Evidence
permitting, we will compare the accuracy of available tests in an
overview review, exploiting within-study comparisons of tests and
allowing the analysis and comparison of commonly used diagnos-
tic strategies where tests may be used singly or in combination.
We also considered and excluded a number of tests from review,
including tests used in the context of monitoring people, such as
total body photography of those with large numbers of typical or
atypical naevi, and finally, histopathological confirmation follow-
ing lesion excision. The latter is the established reference standard
for melanoma diagnosis and will be one of the standards against
which we evaluate the index tests in these reviews.
Rationale
Our series of reviews of diagnostic tests used to assist clinical diag-
nosis in either clinical practice or in a research setting aims to iden-
tify the most accurate approaches to diagnosis and to provide clin-
ical and policy decision-makers with the highest possible standard
of evidence on which to base diagnostic and treatment decisions.
With increasing rates of melanoma and a trend to adopt the use of
dermoscopy and other high-resolution image analysis in primary
care, the anxiety around missing early cases needs to be balanced
against the risk of over-referrals, to avoid sending too many peo-
ple with benign lesions for a specialist opinion. It is questionable
whether all skin cancers picked up by sophisticated techniques
contribute to morbidity andmortality or whether newer technolo-
gies run the risk of increasing false-positive diagnoses. It is also
possible that use of some technologies, for example, widespread
use of dermoscopy in primary care with no training, could ac-
tually result in harm by missing melanomas if they are used as
replacement technologies for traditional history-taking and clin-
ical examination of the entire skin. Many branches of medicine
have noted the danger of such “gizmo idolatry” amongst doctors
(Leff 2008). The trend toward remote interpretation of derma-
tology images (whether clinical or dermoscopic images) and the
use of remote technologies that do not involve clinicians without
substantive evidence could further disrupt clinical pathways and
healthcare payments as they may attract custom from the worried
well, leaving an ever decreasing pool of qualified doctors to pick
up any resulting problems.
There are few available systematic reviews in the field. The liter-
ature searches for the most comprehensive systematic reviews of
visual inspection were carried out up to 2007 (Vestergaard 2008)
or are focused on specific clinical questions, for example, spe-
cific healthcare professionals (Corbo 2012 including only direct
comparisons of the accuracy of primary care physicians versus
dermatologists, and Loescher 2011 reviewing the skin cancer de-
tection skills of advanced practice nurses) or settings (Herschorn
2012 including direct comparisons of visual inspection versus der-
moscopy in primary care). More recently, Harrington and col-
leagues (Harrington 2017) published a systematic review of clin-
ical prediction rules (or published algorithms) used to assist the
diagnosis of melanoma; however, the requirement for a clinical
prediction rule does not allow comparison of accuracy with and
without the use of an algorithm.
The critical question about the accuracy of visual inspection alone
and the impact of examiner, prior patient testing, underlying risk
status, and the use of images for diagnosis needs to be answered
before the potential contribution of additional diagnostic tests
can be set in context and appropriately placed in the diagnostic
pathway.
This review follows a generic protocol that covers the full series
of Cochrane DTA reviews for the diagnosis of melanoma (Dinnes
2015a). The Background and Methods sections of this review
therefore use some text that was originally published in the pro-
tocol (Dinnes 2015a) and text that overlaps some of our other
reviews (Dinnes 2018).
O B J E C T I V E S
To determine the diagnostic accuracy of visual inspection for the
detection of cutaneous invasive melanoma and atypical intraepi-
dermal melanocytic variants in adults.
Accuracy was estimated separately according to the prior testing
undergone by study participants:
• those with limited prior testing, that is, primary
presentation; and
• those referred for further evaluation of a suspicious lesion,
that is, referred participants.
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Accuracy was also estimated separately according to whether the
diagnosis was recorded based on a face-to-face (in-person) en-
counter or based on remote (image-based) assessment.
Secondary objectives
For the identificationof cutaneous invasivemelanoma and atypical
intraepidermal melanocytic variants:
• to determine the diagnostic accuracy of individual
algorithms used to assist visual inspection; and
• to determine the effect of observer experience on diagnostic
accuracy.
For the alternative definitions of the target condition:
• to determine the diagnostic accuracy of visual inspection
for the detection of invasive melanoma alone in adults;
• to determine the diagnostic accuracy of visual inspection for
the detection of any skin cancer or skin lesion with a high risk of
progression to melanoma in adults (i.e. requiring excision).
Investigation of sources of heterogeneity
We set out to address a range of potential sources of heterogeneity
for investigation across our series of reviews, as outlined in our
generic protocol (Dinnes 2015a) and described in Appendix 5;
however, our ability to investigate these was necessarily limited by
the available data on each individual test reviewed.
The sources of heterogeneity that we investigated for visual in-
spection were:
• in-person versus image-based evaluations;
• study setting: primary, community or private care versus
secondary versus specialist clinics;
• use of a diagnostic algorithm: no algorithm reported versus
any named algorithm used;
• type of reference standard: histology alone versus histology
plus clinical follow-up or other reference standard; and
• disease prevalence: ≤ 10% versus > 10%. We chose the
10% cut-off based on advice from clinical co-authors (RB, HW).
M E T H O D S
Criteria for considering studies for this review
Types of studies
We included test accuracy studies that allow comparison of the
result of the index test with that of a reference standard, including
the following:
• studies where all participants receive a single index test and
a reference standard;
• studies where all participants receive more than one index
test(s) and reference standard;
• studies where participants are allocated (by any method) to
receive different index tests or combinations of index tests and all
receive a reference standard (between-person comparative studies
(BPC));
• studies that recruit series of participants unselected by true
disease status (referred to as case series for the purposes of this
review);
• diagnostic case-control studies that separately recruit
diseased and non-diseased groups (see Rutjes 2005); however, we
did not include studies that compared results for malignant
lesions to those for healthy skin (i.e. with no lesion present);
• both prospective and retrospective studies; and
• studies where previously acquired clinical or dermoscopic
images were retrieved and prospectively interpreted for study
purposes.
We excluded studies from which we could not extract 2x2 contin-
gency data or if they included fewer than five melanoma cases or
fewer than five benign lesions. The size threshold of five is arbi-
trary. However, such small studies are unlikely to add precision to
the estimate of accuracy.
Studies available only as conference abstracts were excluded; how-
ever, attempts were made to identify full papers for potentially
relevant conference abstracts (Searching other resources).
Participants
We included studies in adults with pigmented skin lesions or le-
sions suspicious for melanoma or those at high risk of developing
melanoma, including those with a family history or previous his-
tory of melanoma skin cancer, atypical or dysplastic naevus syn-
drome, or genetic cancer syndromes.
We excluded studies that recruited only participants with malig-
nant or benign diagnoses.
We excluded studies conducted in children or that clearly reported
inclusion of more than 50% of participants aged 16 and under.
Index tests
Studies reporting accuracy data for visual inspection alone, with
either image-based or in-person diagnosis, were eligible for inclu-
sion. For in-person visual inspection, diagnosis is undertaken in a
clinic setting with the patient present (face-to-face diagnosis). For
these studies we assumed that patient history-taking would have
taken place and is likely to have contributed to lesion diagnosis;
however, we did not specifically extract details of patient history-
taking due to anticipated poor reporting in the primary studies.
For image-based studies, diagnosis is based on clinical or ‘macro’
images (photographs), remotely from the study participant. For
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these studies, we extracted any additional patient information that
was provided to assist diagnosis.
We included all established algorithms or checklists to assist di-
agnosis by visual inspection. We included studies developing new
algorithms or methods of diagnosis (i.e. derivation studies) if they:
• used a separate independent ’test set’ of participants or
images to evaluate the new approach; or
• investigated lesion characteristics that had previously been
suggested as associated with melanoma and the study reported
accuracy based on the presence or absence of particular
combinations of characteristics.
We excluded studies if they:
• used a statistical model to produce a data-driven equation,
or algorithm based on multiple diagnostic features, with no
separate test set;
• used cross-validation approaches such as ’leave-one-out’
cross-validation (Efron 1983);
• evaluated the accuracy of the presence or absence of
individual lesion characteristics or morphological features, with
no overall diagnosis of malignancy;
• reported accuracy data for ‘clinical diagnosis’ with no clear
description as to whether the reported data related to visual
inspection alone;
• were based on the experience of a particular skin cancer
clinic, where dermoscopy may or may not have been used on an
individual patient-basis.
Although primary care clinicians can in practice be specialists in
skin cancer, we considered primary care physicians as generalist
practitioners and dermatologists as specialists. Within each group,
we extracted any reporting of special interest or accreditation in
skin cancer.
Target conditions
We defined the primary target condition as the detection of:
• any form of invasive cutaneous melanoma or atypical
intraepidermal melanocytic variants (i.e. including melanoma in
situ, or lentigo maligna, which has a risk of progression to
invasive melanoma).
We considered two additional definitions of the target condition
in secondary analyses, namely the detection of:
• any form of invasive cutaneous melanoma alone;
• any skin lesion requiring excision. This latter definition
includes melanoma plus other forms of skin cancer, such as BCC
and cSCC, as well as melanoma in situ, lentigo maligna, and
lesions with severe melanocytic dysplasia.
The diagnosis of the keratinocyte skin cancers, BCC, and SCC
as primary target conditions are the subject of a separate series of
reviews (Dinnes 2015b).
Reference standards
The ideal reference standard is histopathological diagnosis in all eli-
gible lesions. A qualified pathologist or dermatopathologist should
perform histopathology. Ideally, reporting should be standardised
detailing a minimum dataset to include the histopathological fea-
tures of melanoma to determine the American Joint Committee
on Cancer (AJCC) Staging System (e.g. Slater 2014). We did not
apply reporting of a minimum dataset as a necessary inclusion cri-
terion, but extracted any pertinent information.
Partial verification (applying the reference test only to a subset of
those undergoing the index test) was of concern given that lesion
excision or biopsy are unlikely to be carried out for all benign-ap-
pearing lesions within a representative population sample. There-
fore, to reflect what happens in reality, we accepted clinical follow-
up of benign-appearing lesions as an eligible reference standard,
whilst recognising the risk of differential verification bias (as mis-
classification rates of histopathology and follow-up will differ).
Additional eligible reference standards included cancer registry
follow-up and ’expert opinion’ with no histology or clinical fol-
low-up. Cancer registry follow-up is considered less desirable than
active clinical follow-up, as follow-up is not carried out within
the control of the study investigators. Furthermore, if participant-
based analyses as opposed to lesion-based analyses are presented,
it may be difficult to determine whether the detection of a ma-
lignant lesion during follow-up is the same lesion that originally
tested negative on the index test.
All of the above were considered eligible reference standards with
the following caveats:
• all study participants with a final diagnosis of the target
disorder must have a histological diagnosis, either subsequent to
the application of the index test or after a period of clinical
follow-up; and
• at least 50% of all participants with benign lesions must
have either a histological diagnosis or clinical follow-up to
confirm benignity.
Search methods for identification of studies
Electronic searches
The Information Specialist (SB) carried out a comprehensive
search for published and unpublished studies. A single large liter-
ature search was conducted to cover all topics in the programme
grant (see Appendix 1 for a summary of reviews included in the
programme grant). This allowed for the screening of search results
for potentially relevant papers for all reviews at the same time.
A search combining disease related terms with terms related to
the test names, using both text words and subject headings was
formulated. The search strategy was designed to capture studies
evaluating tests for the diagnosis or staging of skin cancer. As the
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majority of records were related to the searches for tests for stag-
ing of disease, a filter using terms related to cancer staging and
to accuracy indices was applied to the staging test search, to try
to eliminate irrelevant studies, for example, those using imaging
tests to assess treatment effectiveness. A sample of 300 records that
would be missed by applying this filter was screened and the filter
adjusted to include potentially relevant studies. When piloted on
MEDLINE, inclusion of the filter for the staging tests reduced the
overall numbers by around 6000. The final search strategy, incor-
porating the filter, was subsequently applied to all bibliographic
databases as listed below (Appendix 6). The final search result was
cross-checked against the list of studies included in five systematic
reviews; our search identified all but one of the studies, and this
study was not indexed on MEDLINE. The Information Special-
ist devised the search strategy, with input from the Information
Specialist from Cochrane Skin. No additional limits were used.
We searched the following bibliographic databases to 29 August
2016 for relevant published studies:
• MEDLINE via OVID (from 1946);
• MEDLINE In-Process & Other Non-Indexed Citations via
OVID; and
• Embase via OVID (from 1980).
We searched the following bibliographic databases to 30 August
2016 for relevant published studies:
• the Cochrane Central Register of Controlled Trials
(CENTRAL; 2016, Issue 7) in the Cochrane Library;
• the Cochrane Database of Systematic Reviews (CDSR;
2016, Issue 8) in the Cochrane Library;
• Cochrane Database of Abstracts of Reviews of Effects
(DARE; 2015, Issue 2);
• CRD HTA (Health Technology Assessment) database,
2016, Issue 3; and
• CINAHL (Cumulative Index to Nursing and Allied Health
Literature via EBSCO from 1960).
We searched the followingdatabases for relevant unpublished stud-
ies using a strategy based on the MEDLINE search:
• CPCI (Conference Proceedings Citation Index), via Web of
Science™ (from 1990; searched 28 August 2016); and
• SCI Science Citation Index Expanded™ via Web of
Science™ (from 1900, using the ’Proceedings and Meetings
Abstracts’ Limit function; searched 29 August 2016).
We searched the following trials registers using the search terms
’melanoma’, ’squamous cell’, ’basal cell’ and ’skin cancer’ combined
with ’diagnosis’:
• Zetoc (from 1993; searched 28 August 2016).
• The US National Institutes of Health Ongoing Trials
Register (www.clinicaltrials.gov); searched 29 August 2016.
• NIHR Clinical Research Network Portfolio Database (
www.nihr.ac.uk/research-and-impact/nihr-clinical-research-
network-portfolio/); searched 29 August 2016.
• The World Health Organization International Clinical
Trials Registry Platform ( apps.who.int/trialsearch/); searched 29
August 2016.
We aimed to identify all relevant studies regardless of language
or publication status (published, unpublished, in press, or in
progress) and applied no date limits.
Searching other resources
We have included information about potentially relevant ongoing
studies in the Characteristics of ongoing studies tables. We have
screened relevant systematic reviews identified by the searches for
their included primary studies, and included any missed by our
searches.We have checked the reference lists of all included papers,
and subject experts within the author team reviewed the final list
of included studies. We did not conduct any citation searching.
Data collection and analysis
Selection of studies
At least one review author (JDi or NC) screened titles and ab-
stracts, with any queries discussed and resolved by consensus. A
pilot screen of 539MEDLINE references showed good agreement
(89% with a kappa of 0.77) between screeners. We included at
initial screening primary test accuracy studies and test accuracy
reviews (for scanning of reference lists) of any test used to investi-
gate suspectedmelanoma, BCC, or cSCC. Both a clinical reviewer
(from one of a team of twelve clinician reviewers) and a method-
ologist reviewer (JDi or NC) independently applied Inclusion cri-
teria (Appendix 7) to all full text articles, disagreements were re-
solved by consensus or by a third party (JDe, CD, HW, and RM).
We contacted authors of eligible studies when insufficient data
were presented to allow for the construction of 2x2 contingency
tables.
Data extraction and management
One clinical (as detailed above) and one methodologist reviewer
(JDi,NCor LFR) independently extracted data concerning details
of the study design, participants, index test(s) or test combinations
and criteria for index test positivity, reference standards, and data
required to populate a 2x2 diagnostic contingency table for each
index test using a piloted data extraction form. We extracted data
at all available index test thresholds. We resolved disagreements
by consensus or by consulting a third party (JDe, CD, HW, and
RM).
We contacted authors of included studies where information re-
lated to final lesion diagnoses or diagnostic thresholds were miss-
ing. In particular, invasive cSCC (included as disease-positive for
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one of our secondary objectives) is not always differentiated from
‘in situ’ variants such as Bowen’s disease (which we did not con-
sider as disease-positive for any of our definitions of the target con-
dition). We contacted authors of conference abstracts published
from 2013 to 2015 to ask whether full data were available. If no
full paper was identified, we marked conference abstracts as ’pend-
ing’ and will revisit them in a future review update.
Dealing with multiple publications and companion papers
Where we identified multiple reports of a primary study, we max-
imised yield of information by collating all available data. Where
there were inconsistencies in reporting or overlapping study pop-
ulations, we contacted study authors for clarification in the first
instance. If this contact with authors was unsuccessful, we used
the most complete and up-to-date data source where possible.
Assessment of methodological quality
We assessed risk of bias and applicability of included studies using
the QUADAS-2 checklist (Whiting 2011), tailored to the review
topic (see Appendix 8) and piloted it on a small number of in-
cluded full-text articles. One clinical (as detailed above) and one
methodologist reviewer (JDi, NC or LFR) independently assessed
quality for the remaining studies; we resolved any disagreement
by consensus or by consulting a third party where necessary (JDe,
CD, HW, and RM).
Statistical analysis and data synthesis
We conducted separate analyses according to the point that study
participants reached in the clinical pathway (numbered from 1
to 7 in Figure 3), the clarity with which the pathway could be
determined (clear or unclear), and the evaluation of in-person
versus image-based diagnosis.
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Figure 3. Clinical pathway
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Our unit of analysis was the lesion rather than the participant.
This is because firstly, in skin cancer, initial treatment is directed
to the lesion rather than systemically (thus it is important to be
able to correctly identify cancerous lesions for each person), and
secondly, it is the most common way in which the primary studies
reported data. Although there is a theoretical possibility of correla-
tions of test errors when the same people contribute data for mul-
tiple lesions, most studies include very few people with multiple
lesions and any potential impact on findings is likely to be very
small, particularly in comparison with other concerns regarding
risk of bias and applicability. Where an individual study assessed
multiple algorithms, we selected datasets on the following prefer-
ential basis:
• ‘no algorithm’ reported; data presented for clinician’s overall
diagnosis or management decision;
• pattern analysis or pattern recognition;
• ABCD algorithm (or derivatives of );
• seven-point checklist (also referred to as Glasgow/MacKie
checklist).
Where multiple thresholds per algorithm were reported, we in-
cluded the standard or most commonly used threshold. If data for
multiple observers were reported, we used data for the most expe-
rienced observer, using single observer diagnosis in preference to a
consensus or average across observers. If we were unable to choose
a dataset based on the above ‘rules’, we made a random selection
of one dataset per study. To allow comparisons of tests, we have
included data on the accuracy of dermoscopy in a separate review
in our series (Dinnes 2018).
For each analysis, we plotted estimates of sensitivity and speci-
ficity on coupled forest plots and in receiver operating charac-
teristic (ROC) space. For tests where commonly used thresholds
were reported we estimated summary operating points (summary
sensitivities and specificities) with 95% confidence intervals and
prediction regions using the bivariate hierarchical model (Chu
2006; Reitsma 2005). Where inadequate data were available for
the model to converge the model was simplified, first by assuming
no correlation between estimates of sensitivity and specificity and
secondly by setting estimates of near zero variance terms to zero
(Takwoingi 2015). Where all studies reported 100% sensitivity
(or 100% specificity) we summed the number with disease (or no
disease) across studies and used it to compute a binomial exact
95% confidence interval.
For computation of likely numbers of true-positive, false-positive,
false-negative and true-negative findings in the ’Summary of find-
ings’ tables, we applied these indicative values to lower quartile,
median and upper quartiles of the prevalence observed in the study
groups. We have reported these numbers for the average operating
point on the SROC curve in ’Summary of findings’ tables.
Investigations of heterogeneity
We investigated heterogeneity, and made comparisons between
algorithms and according to observer experience by comparing
summary ROC curves using the hierarchical summary receiver-
operator curves (HSROC) model (Rutter 2001). HSROC curves
allow incorporation of data at different thresholds and from dif-
ferent algorithms or checklists. We used an HSROC model that
assumed a constant SROC shape between tests and subgroups, but
allowed for differences in threshold and accuracy by addition of
covariates. We assessed the significance of the differences between
tests or subgroups by the likelihood ratio test assessing differences
in both accuracy and threshold, and by a Wald test on the param-
eter estimate testing for differences in accuracy alone. We fitted
simpler models when convergence was not achieved due to small
numbers of studies, first assuming symmetric SROC curves (set-
ting the shape term to zero), and then setting random-effects vari-
ance estimates to zero. We have presented estimates of accuracy
fromHSROCmodels as diagnostic odds ratios (DORs) (estimated
where the SROC curve crosses the sensitivity=specificity line) with
95% confidence intervals. We have presented differences between
tests and subgroups from HSROC analyses as relative diagnostic
odds ratios (RDORs) with 95% confidence intervals.
We fitted bivariate models using the xtmelogit command in
STATA 15 and HSROC models using the NLMIXED procedure
in the SAS statistical software package (SAS 2012; version 9.3; SAS
Institute, Cary, NC, USA) and the metadas macro (Takwoingi
2010).
Sensitivity analyses
We planned sensitivity analyses, restricting analyses to studies at
the least risk of bias; however, these were not carried out due to
insufficient study numbers.
Assessment of reporting bias
Because of uncertainty about the determinants of publication bias
for diagnostic accuracy studies and the inadequacy of tests for de-
tecting funnel plot asymmetry (Deeks 2005), we did not perform
tests to detect publication bias.
R E S U L T S
Results of the search
The Information Specialist identified a total of 34,517 unique ref-
erences and we screened them for inclusion. Of these, we reviewed
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1051 full-text papers for eligibility for any one of the suite of re-
views of tests to assist in the diagnosis of melanoma or keratinocyte
skin cancer. Of the 1051 full-text papers assessed, we excluded 848
from all reviews in our series (see Figure 4; PRISMA flow diagram
of search and eligibility results).
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Figure 4. PRISMA flow diagram.
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Of the 232 studies tagged as potentially eligible for this review
of visual inspection, we included 49 publications, reporting 49
individual studies. Exclusions were mainly due to the inability to
construct a 2x2 contingency table based on the data presented
(n = 54); the use of ineligible index tests (n = 39) (for example:
reporting of data for visual inspection and dermoscopy only (n
= 12), reporting of data for ‘clinical diagnosis’ (n = 11), or for
serial use of the index test in a follow-up context (n = 7)); or
not meeting our requirements for an eligible reference standard
(n = 23). Other reasons for exclusion included ineligible study
populations (n = 20) (for example, recruiting only malignant or
only benign lesions (n = 18)), inadequate sample size (n = 14),
ineligible definition of the target condition (n = 14) or with test
interpretation by medical students or laypeople (n = 6). A list of
the 183 publications excluded from this review with reasons for
exclusion is provided in Characteristics of excluded studies, with
a list of all studies excluded from the full series of reviews available
as a separate pdf (please contact skin.cochrane.org for a copy of
the pdf ).
We contacted the authors of 14 publications for the purposes of
this review of visual inspection and, to date, have received re-
sponses about seven publications. One response allowed the in-
clusion of the study in the review (Walter 2012), five provided
clarifications on methods used on studies included (Bono 2006;
Bourne 2012; Rosendahl 2011; Stanganelli 2000; Walter 2012);
one replied with the information needed but the two studies could
not be included due to the evaluation of ‘clinical diagnosis’ (Youl
2007a; Youl 2007b); and five replied but were not able to provide
the information requested in relation to eight study publications,
one of which we could still include (Menzies 2009) and seven we
could not (Fabbrocini 2008; Freeman 1963; Heal 2008; Menzies
2009; Warshaw 2009a; Warshaw 2009b; Warshaw 2010).
The 49 included study publications report on a total of 51 co-
horts of lesions and 134 datasets with 34,351 lesions and 2499
malignancies. The total number of study participants with suspi-
cious lesions cannot be estimated due to lack of reporting in study
publications. Two thirds of studies (n = 32; 65%) also reported
accuracy data for diagnosis using dermoscopy; these comparisons
are reported in Dinnes 2018. Seven studies reported data for ad-
ditional tests including teledermatology (n = 1) and computer-
assisted diagnosis techniques (n = 6).
Methodological quality of included studies
We have summarised the overall methodological quality of all in-
cluded studies (n = 49) in Figure 5 and Figure 6.
Figure 5. Risk of bias and applicability concerns graph: review authors’ judgements about each domain
presented as percentages across included studies
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Figure 6. Risk of bias and applicability concerns summary: review authors’ judgements about each domain
for each included study
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The majority of study reports provided insufficient information
across almost all study quality domains to allow us to judge the
risk of bias, while we scored applicability of study findings as of
‘High’ concern in three of four domains assessed.
Participant selection
We judged only 22% of studies (n = 11) at low risk of bias for par-
ticipant selection and 27% (n = 13) at high risk of bias. Ten studies
(20%) either used a case-control type design with separate selec-
tion of melanoma cases and lesions with benign diagnoses (n = 6)
or did not clearly describe the study design used (n = 5). Over half
(55%; n = 27) reported random or consecutive participant recruit-
ment; the remaining 45% did not describe recruitment methods.
Over half of studies (53%) did not describe whether they had ap-
plied any exclusion criteria and we judged them at unclear risk of
bias. Seven studies (14%) applied inappropriate participant exclu-
sions, excluding ‘difficult to diagnose’ lesions such as awkwardly lo-
cated lesions (Bono 2002a; Morales Callaghan 2008; Unlu 2014);
those with disagreement on histopathology (de Giorgi 2012; Ek
2005; Zaumseil 1983); or dermoscopically ‘peculiar’ lesions (Carli
2003a).
We considered almost all cohorts (96%; n = 47) at high concern for
applicability of participants. In the majority of cases (n = 41), high
concern was due to restricted study populations: inclusion of only
melanocytic (n = 10) or amelanotic (n = 1) lesions; restriction by
lesion diameter (Bono 2002b; Bono 2006; Steiner 1987); or, most
commonly, inclusion of lesions selected for excision based on the
clinical or dermoscopic diagnosis or selected retrospectively from
histopathology databases (n = 37). We judged only four cohorts
to have included a representative patient population (Grimaldi
2009; Menzies 2009; Stanganelli 2000; Walter 2012). Fourteen
cohorts also included multiple lesions per participant, with only
eight clearly including a similar number of participants and lesions
(Bono 2002a; Bono 2002b; Bono 2006; Bourne 2012; Collas
1999; Krahn 1998; Pizzichetta 2004; Unlu 2014).
Index test
For the index test domain, we considered studies separately ac-
cording to whether they reported in-person evaluations of visual
inspection (n = 33) or evaluations based on interpretation of clin-
ical images (image-based evaluations; n = 16). For the in-person
evaluations, we judged 24% (n = 8) at low risk of bias, and 9%
(n = 3) at high risk; 22 (67%) did not provide sufficient infor-
mation to allow us to judge the risk of bias fully. We considered
that all studies made the diagnosis blinded to the reference stan-
dard result: 24% (n = 8) also clearly reported pre-specification of
the diagnostic threshold (five of the eight using named algorithms
(Argenziano 2006; Cristofolini 1994; Stanganelli 2000; Walter
2012; Zaumseil 1983 and three by the same author team (Bono
2002a; Bono 2002b; Bono 2006) describing the process by which
they had reached the diagnosis. Three studies developed new al-
gorithms (Thomas 1998) or evaluated multiple thresholds for test
positivity (Benelli 2001; McGovern 1992). Reporting was poorer
for the image-based evaluations, with over three quarters of stud-
ies (n = 13) not providing sufficient information to allow us to
judge the risk of bias fully, one study (6%) judged at low risk of
bias and two (12%) at high risk. Again, we considered that all the
studies had made the diagnosis blinded to the reference standard
result, with one prospectively testing two pre-specified diagnostic
thresholds (Benelli 2001) and two (de Giorgi 2012; Scope 2008)
testing multiple diagnostic thresholds.
We recorded high concern for the applicability of the index tests
for 85% (n = 28) of in-person evaluations. High concern was pri-
marily due to a lack of description of the diagnostic thresholds used
(n = 24), but also as a result of presentation of average (Argenziano
2006) or consensus diagnoses (Barzegari 2005; Benelli 1999; Carli
2002a; Cristofolini 1997; Morales Callaghan 2008; Steiner 1987)
as opposed to the diagnosis of a single observer. Two studies were
also judged to have reported diagnosis by non-expert observers
(Menzies 2009; Walter 2012), both of which reported diagnoses
by large groups of primary care practitioners. In reality, specific
expertise in diagnosing pigmented lesions does vary amongst ex-
aminers, for example Menzies 2009 requiring a history of excision
or referral of at least 10 pigmented skin lesions over the previous
12-month period but excluding those already using dermoscopy
or digital monitoring of lesions, and Walter 2012 excluding those
with specialist dermatology trainingbut reporting some training in
dermatology for almost a quarter of participating GPs. We judged
almost three quarters of studies (n = 24) to have applied and in-
terpreted the ‘test’ in a clinically applicable manner, nine (27%)
provided sufficient detail of the threshold used and 11 (33%) de-
scribed the observers as expert or experienced. All image-based
studies were of high concern for applicability, due to the image-
based nature of interpretation limiting the clinical applicability of
findings but also the lack of detail on the thresholds used (n =
13). A higher proportion (62%; n = 10) described the observers
as expert or experienced.
Reference standard
Of the 49 included cohorts, we judged 85% at low risk of bias for
the reference standard due to the use of an acceptable reference
standard (n = 42). Six did not meet our criteria for an accept-
able reference standard, with more than 20% of the benign lesions
having only expert diagnosis with no clinical follow-up (Bono
1996; Green 1991; Grimaldi 2009; Menzies 2009; Stanganelli
2000; Walter 2012), three of which were primary care-based stud-
ies (Grimaldi 2009; Menzies 2009; Walter 2012). We recorded
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blinding of the reference standard to the index test (in this case
the pathology referral diagnosis) but it did not contribute to the
overall risk of bias for the reference standard domain. Three stud-
ies implemented no blinding of the reference standard (Menzies
2009 and Walter 2012 referring patients for excision under stan-
dard practice and Thomas 1998 describing a form recording the
presence or absence of each ABCDE criterion to the usual pathol-
ogy form) and the remaining 46 studies did not describe blind-
ing (94%). The applicability of the reference standard was of low
concern in nine studies (18%), high in seven (14%), and unclear
for 33 (67%). In all cases, high concern was due to the use of
expert opinion for classifying the final diagnosis of some lesions.
The majority of studies (n = 40; 82%) did not report histopathol-
ogy interpretation by an experienced histopathologist or by a der-
matopathologist.
Participant flow
In terms of flow and timing, we judged 20 cohorts at high risk
of bias, seven at low risk, and 22 did not provide enough infor-
mation on which to judge this domain. Of those at high risk, 11
cohorts did not use the same reference standard for all participants
(differential verification), and 15 did not include all participants
in the analysis either due to incomplete information (Argenziano
2006; Bono 1996; Ek 2005; McGovern 1992; Menzies 2009;
Pizzichetta 2004; Walter 2012); inadequate images (Chang 2013;
Dolianitis 2005; Green 1994; Lorentzen 1999; Pizzichetta 2004;
Rosendahl 2011; Scope 2008); and exclusion of particular le-
sion groups following recruitment (Bourne 2012; Dummer 1993;
Menzies 2009). A further 37 cohorts were unclear on the interval
between the application of the index test and excision for histology
with 12 reporting consecutive diagnosis and excision or biopsy.
Findings
1. Target condition: invasive melanoma and atypical
intraepidermal melanocytic variants
Thirty-seven studies reported accuracy data for the detection of
invasive melanoma and atypical intraepidermal melanocytic vari-
ants, one of which reported data for three different sets of lesions
(Morton 1998a; Morton 1998b; Morton 1998c), giving a total of
39 datasets; the studies conducted 28 evaluations in person and
11 were image-based.
We have summarised details of the in-person studies in Appendix
9,with quality assessments inAppendix 10. Summary details of the
image-based studies are in Appendix 11 with quality assessments
in Appendix 12. Details of established algorithms used to assist
diagnosis are described in detail in Appendix 4. Results for the
primary analyses are presented inTable 1.We have presented forest
plots of study data for each analysis in Table 1 in Figure 7 and
Figure 8; summary estimates are depicted in Figure 9 and Figure
10. Table 2 reports heterogeneity investigations, Table 3 compares
test algorithms and Table 4 compares observers.
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Figure 7. Forest plot of in-person evaluations of visual inspection for detection of invasive melanoma and
atypical intraepidermal melanocytic variants by point on the clinical pathway where they are diagnosed
Figure 8. Forest plot of image-based evaluations of visual inspection for detection of invasive melanoma and
melanocytic intraepidermal variants by point on the clinical pathway where they are diagnosed
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Figure 9. Summary estimates of accuracy of in-person visual inspection for the detection of invasive
melanoma and melanocytic intraepidermal variants by point on the clinical pathway where they are diagnosed
(confidence regions are not plotted due to small numbers of studies)
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Figure 10. Summary estimates of accuracy of image-based visual inspection for the detection of invasive
melanoma and melanocytic intraepidermal variants by point on the clinical pathway where they are diagnosed
(confidence regions are not plotted due to small numbers of studies)
In-person evaluations
Of the 28 evaluations conducted on an in-person basis, 17 con-
tained enough information to describe where on the clinical path-
way they had assessed participants (coded as ‘clear’ on pathway),
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and we considered 11 not to have provided sufficient informa-
tion to allow us to identify the pathway (coded ‘unclear’ on path-
way). We considered these evaluations according to position on
the pathway and clear versus unclear pathway classification (Table
1). Figure 7 presents the results of the individual studies grouped
by their position on the pathway; Figure 9 depicts the summary
estimates at each point on the pathway.
Studies in participants with limited prior testing
Six in-person evaluations of visual inspection recruited series of
participantswith pigmented lesions, whowere presenting for a first
structured clinical assessment of a suspicious lesion (Collas 1999;
Gachon 2005; Grimaldi 2009; McGovern 1992; Menzies 2009;
Walter 2012) (Appendix 9; Appendix 10). All studies includedpar-
ticipants with pigmented lesions; Gachon 2005 restricted inclu-
sion to melanocytic lesions only. The prevalence of disease ranged
from 4% to 6% in four studies, with Collas 1999 (11%) and
Grimaldi 2009 (20%) reporting higher prevalence of melanoma.
Three studies prospectively included all participants presenting in
primary care within a given time frame and were clearly positioned
on the clinical pathway (Pathway 2-c in Figure 9):
• summary sensitivity was 92.4% (95% CI 26.2% to 99.8%)
and specificity 79.7% (95% CI 73.7% to 84.7%) (1339 lesions
and 55 melanomas; Grimaldi 2009; Menzies 2009; Walter
2012).
The studies supplemented histological diagnosis with clinical fol-
low-up of at least three months for lesions considered benign (all
three studies) and two included expert clinical diagnosis without
follow-up for some benign lesions (Menzies 2009; Walter 2012).
Three studies included only participants with lesions selected for
excision (Pathway 3-c and 3-u in Figure 9): two were conducted in
private dermatology clinics (Collas 1999; Gachon 2005) and one
at an open access veterans’ dermatology clinic (McGovern 1992)
(Appendix 9):
• summary sensitivity was 90.1% (95% CI 70.0% to 97.3%)
and specificity 81.3% (95% CI 67.5% to 90.0%) for two studies
clearly positioned on the clinical pathway (Pathway 3-c; 4228
lesions and 160 melanomas; Gachon 2005; McGovern 1992);
• sensitivity was 78.9% (95% CI 62.75% to 90.4%) and
specificity 94.0% (95% CI 90.7% to 96.3%) (353 lesions and
38 melanomas; Collas 1999) in the single study that could not
be clearly positioned on the clinical pathway (Pathway 3-u).
Diagnosis was recorded by primary care physicians with a range
of experience (Grimaldi 2009; Menzies 2009; Walter 2012) or
by dermatologists (Collas 1999; Gachon 2005; McGovern 1992)
with noobvious differences in sensitivity or specificity. Four studies
reported no formal algorithm to assist diagnosis. Two of these clas-
sified lesions ‘suspicious for malignancy’ as test-positive (Gachon
2005; Grimaldi 2009) and two reported data for ‘correct’ or ‘pri-
mary’ diagnosis ofmelanoma (Collas 1999;Menzies 2009).Walter
2012 reported data for MacKie’s revised seven-point checklist
(MacKie 1990) at a threshold of ≥ 3, and McGovern 1992 used
the BCD algorithm at ≥ 2 characteristics present (this study also
reported data using the original seven-point checklist, see ’Analy-
ses by algorithm’ reported below).
Studies in referred participants
Studies conducted 22 in-person evaluations of visual inspection
in participants referred for specialist assessment. We were able to
position 12 clearly on the clinical pathway (three evaluations from
a single study) and 10 did not provide sufficient information for
us to make a clear assessment (Figure 7; Appendix 9; Appendix
10).
We judged two studies to include all participants referred for fur-
ther assessment (Pathway 4-c in Figure 9) and both were clearly
positioned on the clinical pathway:
• summary sensitivity was 74.6% (95% CI 48.9% to 90.0%)
and specificity 98.6% (95% CI 94.7% to 99.6%) (3494 lesions
and 61 melanomas; Barzegari 2005; Stanganelli 2000).
Fifteen studies providing 17 datasets included only those with any
lesion selected for excision (Pathway 5-c and 5-u in Figure 9):
• summary sensitivity was 76.7% (95% CI 61.7% to 87.1%)
and specificity 95.7% (95% CI 89.7% to 98.3%) (5331 lesions
and 258 melanomas) for six studies (with eight datasets) clearly
positioned on the clinical pathway (Pathway 5-c; Bono 2002a;
Bono 2002b; Bono 2006; Ek 2005; Green 1991; Morton 1998a;
Morton 1998b; Morton 1998c);
• summary sensitivity was 82.8% (95% CI 74.4% to 88.9%)
and specificity 89.2% (95% CI 71.1% to 96.5%) (9611 lesions
and 1015 melanomas) for nine studies that could not be clearly
positioned on the clinical pathway (Pathway 5-u; Benelli 1999;
Carli 2002a; Cristofolini 1994; Cristofolini 1997; Langley 2001;
Morales Callaghan 2008; Thomas 1998; Unlu 2014; Zaumseil
1983).
We considered three studies to report data only for those partic-
ipants with equivocal or difficult-to-diagnose lesions selected for
excision (Pathway 5*-c and 5*-u in Figure 7 and Figure 9):
• summary sensitivity was 84.7% (95% CI 55.5% to 96.1%)
and specificity 89.5% (95% CI 79.5% to 95.0%) (930 lesions
and 88 melanomas) for two studies clearly positioned on the
clinical pathway (Pathway 5*-c; Dummer 1993; Soyer 1995);
• sensitivity was 61.4% (95% CI 49.0% to 72.9%) and
specificity 87.3% (95% CI 82.5% to 91.2%) (318 lesions and
73 melanomas) in one study not clearly positioned on the
clinical pathway (Pathway 5*-u; Steiner 1987).
Studies included pigmented lesions referred for further evaluation
at a dermatology or pigmented lesion clinic, two restricting to
melanocytic lesions only (Morales Callaghan 2008; Unlu 2014)
and four restricting by lesion diameter (≤ 3 mm (Bono 2006),
≤ 6 mm (Bono 2002b), < 10 mm (Steiner 1987), or ≤ 15 mm
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(Barzegari 2005)). The prevalence of disease ranged from 1% (
Ek 2005) to 41% (Soyer 1995). Disease prevalence was generally
lower in studies clearly positioned on the clinical pathway (11% or
less in 7 of 10 datasets) compared to those that could not be clearly
positioned (7 of 9 datasets reporting disease prevalence of 15%
or over (Appendix 9)). The prevalence of melanoma in studies of
equivocal lesions was 3% (Dummer 1993), 23% (Steiner 1987)
and 41% (Soyer 1995).
Diagnoses were recorded by dermatologists or dermatology resi-
dents (or were assumed to be by dermatologists based on study au-
thors’ institutions or study settings), by surgical oncologists or by
plastic surgeons (Appendix 9). Observer experience was poorly re-
ported, with only seven studies referring to ‘experienced’ or ‘expert’
observers; three studies were clearly positioned on the pathway
and four not clearly positioned. All studies reported observer di-
agnosis with no formal algorithm, apart from five using ABCD or
ABCDE algorithms (Benelli 1999; Cristofolini 1994; Cristofolini
1997; Thomas 1998; Stanganelli 2000). Diagnosis was more often
based on the opinion of a single observer as opposed to a consensus
or average decision in studies clearly positioned on the pathway
(10 of 12 datasets; Stanganelli 2000; Bono 2002a; Bono 2002b;
Bono 2006; Green 1991;Morton 1998a; Morton 1998b; Morton
1998c; Dummer 1993; Soyer 1995) compared to those not clearly
positioned (3 of 10 datasets; Thomas 1998; Unlu 2014; Zaumseil
1983).
Image-based evaluations
Of the 11 image-based evaluations, two contained enough infor-
mation to describe where on the clinical pathway they had assessed
participants (coded as ‘clear’ on pathway), and we considered nine
to have provided insufficient information to allow us to identify
the pathway (coded ‘unclear’ on pathway) (Appendix 11 Appendix
12).We have presented the results in Table 1. Figure 8 presents the
results of the individual studies grouped by their position on the
pathway; Figure 10 depicts the summary estimates at each point
on the pathway.
Studies in participants with limited prior testing
Two studies retrospectively reviewed clinical images from partic-
ipants with lesions excised in primary care settings (Pathway 3-c
and 3-u in Figure 10):
• sensitivity was 22.2% (95% CI 2.8% to 60.0%) and
specificity 70.7% (95% CI 54.4% to 83.9%) (50 lesions and 9
melanomas) in one study clearly positioned on the clinical
pathway (Pathway 3-c; Bourne 2012);
• sensitivity was 20.7% (95% CI 8.0% to 39.7%) and
specificity 96.8% (95% CI 94.6% to 98.2%) (463 lesions and
29 melanomas) in the study not clearly positioned on the clinical
pathway (Pathway 3-u) (Rosendahl 2011). The study report was
unclear as to whether the excisions were undertaken at the
primary care practice or in a referral setting.
The prevalence of melanoma was 6% (Rosendahl 2011) and 20%
(Bourne 2012) and both studies included a range of different
types of lesions. Three GPs and a clinical nurse, with varying
levels of dermoscopy experience, reviewed the lesion images in
Bourne 2012 and an expert dermatologist reviewed the images in
Rosendahl 2011. They made their diagnoses without the aid of a
published algorithm.
Studies in referred participants
Nine evaluations of clinical images were conducted in participants
referred for specialist assessment; we could clearly position one on
the clinical pathway and eight did not provide sufficient informa-
tion for us to make a clear assessment.
We considered the one study clearly positioned on the clinical
pathway to have included all participants referred for further as-
sessment (Pathway 4-c in Figure 10):
• sensitivity was 74.2% (95% CI 55.4% to 88.1%) and
specificity 82.5% (95% CI 73.8% to 89.3%) (134 lesions and
31 melanomas; Stanganelli 2005).
Although the remaining eight studies did not provide sufficient
information to allow us to clearly position them on the clinical
pathway, we assumed that they had obtained lesion images from
referral settings (Pathway 5-u and 5*-u in Figure 10):
• summary sensitivity was 60.3% (95% CI 49.2% to 70.5%)
and specificity 77.0% (95% CI 63.9% to 86.4%) (293 lesions
and 96 melanomas) for six studies that included all lesions
selected for excision (Pathway 5-u) (Benelli 2001; Carli 2002b;
Dolianitis 2005; Pizzichetta 2004; Stanganelli 1998a;
Winkelmann 2016);
• summary sensitivity was 61.9% (95% CI 46.7% to 75.0%)
and specificity 81.8% (95% CI 75.2% to 87.0%) (303 lesions
and 98 melanomas) across two studies that included participants
with equivocal lesions selected for excision (Pathway 5*-u) (Carli
2003a; de Giorgi 2012).
Studies were retrospective case series apart from two case-control
type studies (Dolianitis 2005; Winkelmann 2016) and one with
an unclear design (Benelli 2001). Three studies (Benelli 2001;
Dolianitis 2005; Stanganelli 1998a) evaluated observer accuracy
before and after dermoscopy training. All the studies reviewed
images of pigmented or melanocytic lesions apart from one that
focused on hypomelanotic (≤ 30% pigmentation) or amelanotic
lesions (Pizzichetta 2004). The prevalence of melanoma ranged
from 19% (Carli 2002b) to 50% (Dolianitis 2005); four studies
included only melanomas (including in situ) and benign naevi
(Carli 2003a; de Giorgi 2012; Stanganelli 2005; Winkelmann
2016).
Dermatologists or observers with mixed qualifications under-
took lesion diagnosis; observer experience was poorly reported
(Appendix 11). Stanganelli 2005 also provided accuracy data for
the average of three GPs (data reported in section 1.3.2). Most
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studies presented average accuracy across observers; only two re-
ported accuracy for a single observer (Benelli 2001; Pizzichetta
2004). All studies except Benelli 2001 (ABCDE algorithm) and
de Giorgi 2012 (ABCD) made diagnoses without the use of diag-
nostic algorithms.
Secondary analyses
We conducted secondary analyses for the detection of invasive
melanoma and atypical intraepidermal melanocytic variants, re-
gardless of classification by clinical pathway.
Covariate investigations
A preliminary analysis across the 39 datasets contributing to the
primary analyses described above found a large difference in ac-
curacy for in-person evaluations compared to those based on the
assessment of clinical images (RDOR 8.54, 95% CI 2.89 to 25.3,
P < 0.001; Table 2; Figure 11). The magnitude and importance of
the observed difference is so large, raising serious concerns about
the applicability of visual inspection studies done via image obser-
vation only, that we elected to undertake all subsequent covariate
investigations based on in-person evaluations only (n = 28).
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Figure 11. Summary ROC comparing in-person and image-based evaluations of visual inspection for
detection of invasive melanoma or atypical intraepidermal melanocytic variants (MEL)
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For the 28 in-person evaluations, only one of the four covari-
ate investigations approached statistical significance (Table 2); ob-
served accuracy was lower in studies where disease prevalence of
melanoma (percentage of cases in the study that tested positive
for the reference standard) was over 10% compared to those with
disease prevalence of 10% or less (RDOR 0.31, 95% CI 0.09 to
1.00; P = 0.05). The RDOR for study setting (secondary care or
specialist clinic compared to primary care) was 1.51 (95%CI 0.32
to 7.09; P = 0.59; Figure 12), for use of a named algorithm to
aid diagnosis compared to no algorithm reported was 1.03 (95%
CI 0.25 to 4.34; P = 0.96; Figure 13), and for use of histology
plus clinical follow-up or other reference standard compared to
histology alone was 0.76 (95% CI 0.14 to 4.02; P = 0.74; Figure
14).
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Figure 12. Summary ROC plot of in-person visual inspection evaluations stratified by study setting for
detection of invasive melanoma and atypical intraepidermal melanocytic variants (MEL)
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Figure 13. Summary ROC Plot of in-person visual inspection evaluations stratified by use of a published
algorithm for detection of invasive melanoma and atypical intraepidermal melanocytic variants (MEL)
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Figure 14. Summary ROC plot of in-person visual inspection evaluations stratified by reference standard for
detection of invasive melanoma and atypical intraepidermal melanocytic variants (MEL)
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Analyses by algorithms used to assist visual inspection
Of the 28 in-person evaluations only seven reported using an al-
gorithm to assist visual inspection, limiting our ability to make
meaningful comparisons between algorithms (Table 3). Observer
diagnosis without the use of a formal algorithm (n = 21 datasets)
had the highest diagnostic accuracy (DOR 46.2, 95% CI 21.9
to 97.5), with an average sensitivity of 78% (95% CI 68% to
85%) and average specificity of 93% (95% CI 88% to 96%).
Pooled sensitivity was slightly higher and specificity slightly lower
for variations on the (A)BCD(E) algorithm (n = 6 datasets), but
with overlapping confidence intervals (summary sensitivity 83%
(95% CI 75% to 88%); summary specificity 88% (95% CI 64%
to 97%)). Two datasets reported data for either the original seven-
point checklist at a number of thresholds (McGovern 1992) or for
the revised seven-point checklist (Walter 2012). At the standard
threshold of 3 or above for both algorithms, the highest observed
sensitivity and specificity was 94% (95% CI 73% to 100%) and
80% (95%CI 77% to 83%) for the revised version (Walter 2012).
The image-based evaluations reported data for either no algorithm
or for variations of ABCD(E); we observed a similar pattern with
much lower levels of overall accuracy (Table 3).
Analyses by observer experience
Analyses by observer expertise were restricted by the limited
amount of information provided in the study reports (Table 4;
Appendix 9; Appendix 11). Our analyses are therefore based pri-
marily on study subgroups by observer qualifications (consultant/
registrar/mixed qualifications/primary care practitioners), with the
‘consultant’ category separated into ‘Expert consultant’ (for any
study describing observers as expert or experienced) and ‘Con-
sultant’ where experience or expertise was not otherwise reported
(for example, for those that described observers as dermatologists)
(Table 4).
No clear pattern according to observer experience could be dis-
cerned for in-person evaluations. RDORs in comparison to the
‘Expert consultant’ group (9 studies) ranged from 0.45 (95% CI
0.05 to 3.67; P = 0.44) for observers at resident/registrar level (2
studies) to 7.28 (95% CI 0.69 to 76.3; P = 0.09) for GPs (3 stud-
ies).
For image-based evaluations, accuracy was highest for the ‘Expert
consultant’ group (DOR 20.5, 95% CI 4.82 to 86.9); RDORs
in comparison to the ‘expert’ group ranged from 0.18 (95% CI
0.04 to 0.90; P = 0.04) for observers described as ‘dermatologists’
(4 studies) to 0.56 (95% CI 0.04 to 7.51; P = 0.63) for mixed
secondary and primary care observers (1 study).
Across all definitions of the target condition, seven studies pro-
vided comparative data according to observer qualifications or ex-
perience (Table 5). Most were image-based assessments, using no
prescribed algorithm to aid diagnosis and reporting average results
across groups of observers.We observed some evidence of increased
sensitivity and smaller increases in specificity with increasing expe-
rience; however, wide variations in accuracy remained, with sen-
sitivity ranging from 58% to 91% for expert dermatologists and
specificities from 53% to 99%.
2. Target condition: invasive melanoma only
In this section,we present the results for studies of visual inspection
for the identification of invasive melanoma, according to the ap-
proach taken for diagnosis: in-person or image-based evaluations.
We have presented summary characteristics of studies in Appendix
13 and results of meta-analyses in Table 6. Table 7 compares re-
sults in studies reporting data for invasive melanoma alone and
for invasive melanoma plus atypical intraepidermal melanocytic
variants.
Seven datasets evaluated the accuracy of in-person visual inspec-
tion for the detection of invasive melanoma (Bono 1996; Green
1994; Kopf 1975; Krahn 1998; McGovern 1992; Viglizzo 2004;
Walter 2012), only two of which also reported data for the primary
target condition (McGovern 1992; Walter 2012). All studies were
based in secondary care or specialist units apart fromWalter 2012
(primary care) and McGovern 1992 (army medical centre derma-
tology clinic). Studies used amodified version of the ABCDcheck-
list (McGovern 1992), the revised seven-point-checklist (Walter
2012), or no algorithm (n = 5; 71%) to assist diagnosis. The preva-
lence of melanoma ranged from 2% (Kopf 1975; Walter 2012) to
49% (Krahn 1998). Two studies supplemented a histological ref-
erence standard with clinical follow-up (Walter 2012) and expert
diagnosis of some benign lesions (Bono 1996; Walter 2012).
Sensitivities ranged from 67% to 100% and specificities ranged
from 76% to 100%. In meta-analysis the DOR was 62.4 (95%
CI 17.6 to 222) (6857 lesions and 208 melanoma cases). Sensi-
tivity and specificity at the average operating point on the SROC
curve were 86% (95% CI 68% to 94%) and 91% (95% CI 81%
to 96%) respectively. For the two in-person evaluations that also
reported data for the primary target condition (Table 7), speci-
ficity estimates were hardly affected due to small numbers of in-
cluded melanoma in situ lesions (five in McGovern 1992 and
two in Walter 2012). Sensitivity however, was higher for detec-
tion of invasive melanoma alone in McGovern 1992 (100% ver-
sus 73% for detection of invasive melanoma or atypical intraepi-
dermal melanocytic variants) due to correct diagnosis of only two
of five in situ melanomas, and was marginally lower in Walter
2012 (93.8% versus 94.4% for detection of invasive melanoma or
atypical intraepidermal melanocytic variants) due to correct iden-
tification of both in situ melanomas with one invasive melanoma
missed.
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Five datasets reported the accuracy of image-based visual inspec-
tion for the detection of invasive melanoma (Lorentzen 1999;
Rao 1997; Scope 2008; Troyanova 2003; Westerhoff 2000), but
none of them reported data for the primary target condition. Only
two studies used images from normal practice settings (Lorentzen
1999; Rao 1997); one obtained images from a teledermatology
company (Scope 2008) and two selected images ofmelanoma cases
and controls for use in dermoscopy training studies (Troyanova
2003; Westerhoff 2000). The prevalence of melanoma ranged
from 3% (Scope 2008) to 50% (Troyanova 2003; Westerhoff
2000). Studies used the ABCD checklist (Rao 1997), the ugly
duckling approach (Scope 2008), or no algorithm (n = 3) to as-
sist diagnosis. Four evaluations clearly presented only the clinical
image with no further patient information (80%), and one (Rao
1997) may have presented observers with a concurrent dermo-
scopic image of the lesion, as blinding between images was not
clearly described.
Sensitivities ranged from 62% to 86%; specificities ranged from
54% to 95%. In meta-analysis the DOR was 14.8 (95% CI 3.56
to 61.9) (599 lesions and 150 melanoma cases). Sensitivity and
specificity at the average operating point on the SROC curve were
76% (95% CI 50% to 91%) and 83% (95% CI 62% to 93%)
respectively.
Accuracy was non-significantly higher for in-person compared to
image-based evaluations (RDOR 4.21; 95% CI 0.62 to 28.6; P =
0.13).
3. Target condition: any skin lesion requiring excision
In this section,we present the results for studies of visual inspection
for the identification of any skin lesion requiring excision (for each
study, we could only extract data for the detection of any skin
cancer), according to the approach taken for diagnosis: in-person
or image-based evaluations. Summary characteristics of studies are
presented in Appendix 14 and results of meta-analyses in Table
6 and Figure 15. Table 7 compares results in studies reporting
data for invasive melanoma alone and for invasive melanoma plus
atypical intraepidermal melanocytic variants.
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Figure 15. Summary ROC comparing in-person and image-based evaluations of visual inspection for
detection of any skin lesion requiring excision (any)
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Seven datasets evaluated the accuracy of in-person visual in-
spection for the detection of any skin lesion requiring excision
(Argenziano 2006; Chang 2013; Ek 2005; McGovern 1992;
Stanganelli 2000; Steiner 1987;Walter 2012). Five of these also re-
ported data for the primary target condition (Ek 2005;McGovern
1992; Stanganelli 2000; Steiner 1987; Walter 2012). Three stud-
ies were based in primary care (Argenziano 2006; Walter 2012)
or community dermatology clinics (McGovern 1992), the oth-
ers were based in secondary care or specialist referral clinics.
The prevalence of skin cancer ranged from 3% (Walter 2012) to
68% (Ek 2005). Studies used the ABCD algorithm (Argenziano
2006; McGovern 1992; Stanganelli 2000), the revised seven-
point-checklist (Walter 2012), or no algorithm (n = 3) to assist
diagnosis. Two studies supplemented a histological reference stan-
dard with clinical follow-up (Stanganelli 2000; Walter 2012) and
expert diagnosis of some benign lesions (Walter 2012).
Sensitivities ranged from 57% to 98%; specificities ranged from
13% to 99%. In meta-analysis the DOR was 20.5 (95% CI 7.11
to 59.3; 8091 lesions and 2187 skin cancer cases). Sensitivity and
specificity at the average operating point on the SROC curve were
81% (95% CI 68% to 90%) and 81% (95% CI 56% to 93%)
respectively. For the in-person evaluations that also reported data
for the primary target condition (Table 7), specificity estimates
were not affected in four of the five studies due to the relatively
small percentage of other skin cancers in the study populations
(BCCs making up 2% of all lesions in McGovern 1992; 1% in
Stanganelli 2000 andWalter 2012; and 6% in Steiner 1987). Sen-
sitivities increased in two studies due to a majority of BCCs cor-
rectly identified (Stanganelli 2000; Steiner 1987); sensitivity fell
in Walter 2012 due to three of four BCCs not being picked up
by the revised seven-point checklist; and remained the same in
McGovern 1992. We observed a large increase in sensitivity and
fall in specificity in Ek 2005, however, as BCCs made up 47%
of the total study population and invasive SCCs comprised 20%.
When these two lesion groups were considered as disease-positive,
sensitivity increased from 48% to 98% and specificity fell from
99% to 13% due to the largely correct identification of BCC and
SCC as malignant and high false-positives in the remaining group
of lesions considered disease-negative (including large proportions
with Bowen’s disease, solar keratoses, or seborrhoeic keratoses).
Three datasets reported the accuracy of image-based visual inspec-
tion for the detection of any skin lesion requiring excision (Carli
2002b; Rosendahl 2011; Stanganelli 1998a), all of which also re-
ported data for the primary condition. All studies selected im-
ages from normal practice settings, two in secondary care (Carli
2002b; Stanganelli 1998a) and one from a primary care prac-
tice (Rosendahl 2011). The prevalence of lesions suitable for ex-
cision ranged from 22% (Rosendahl 2011) to 47% (Stanganelli
1998a); the latter selecting images for use in a dermoscopy training
study. Rosendahl 2011 presented data for a single dermatologist,
Carli 2002b for a consensus of two dermatologists, and Stanganelli
1998a presented the average across 20 dermatologists. None of
these studies used an algorithm to assist diagnosis (n = 3) and none
presented any further participant information to assist diagnosis.
Sensitivities ranged from 64% to 80%; specificities ranged from
74% to 85%. In meta-analysis the DOR was 11.9 (95% CI 2.22
to 65.3; 547 lesions and 138 skin cancer cases). Sensitivity and
specificity at the average operating point on the SROC curve were
75% (95% CI 49% to 90%) and 79% (95% CI 38% to 96%) re-
spectively. For the three studies that also reported data for the pri-
mary target condition (Table 7), sensitivities increased in two due
to correct identification of BCCs (Rosendahl 2011; Stanganelli
1998a). Specificity decreased in Carli 2002b due to small sample
size and high prevalence of malignancy (20 of 53; 38%) and de-
creased in Rosendahl 2011 due to the use of a different threshold
for the primary target condition ’is this lesion a melanoma?’ com-
pared to ‘should this lesion be excised?’ for the target condition of
any lesion requiring excision.
We did not identify any significant difference in accuracy between
in-person and image-based evaluations (RDOR 1.70; 95% CI
0.24 to 12.3; P = 0.55).
D I S C U S S I O N
Summary of main results
The included studies evaluated visual inspection in a range of study
populations, on an in-person basis and using clinical images, and
both with and without the use of published algorithms to assist
diagnosis.We observedwide variations in sensitivity and specificity
for all definitions of the target condition.
There are five main findings from our review:
1) There is an almost universal problem with poor reporting in the
primary studies, hindering attempts to analyse studies according
to their position on the clinical pathway and to fully assess sources
of heterogeneity and methodological quality.
Fewer than two thirds of in-person evaluations of visual inspection
contained enough information to describe where on the clinical
pathway participants were assessed. This was particularly the case
for studies apparently conducted in referred populations, where
almost half of studies neither described participants as ‘referred’,
nor provided any description of participants’ prior testing or path-
way followed prior to presentation for specialist review. Observer
experience and expertise in pigmented lesion diagnosis is likely
to affect test accuracy; however, this information was rarely pro-
vided in any detail making it difficult to assess any differences in
accuracy according to clinician experience. Analyses by reported
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observer qualifications and descriptions of observers as ‘expert’ or
‘experienced’ showed no significant differences between groups.
In terms of methodological quality, studies were at unclear risk of
bias due to poor reporting of key items around participant selec-
tion, pre-specification of thresholds used, and timing of diagnosis
in relation to reference standard diagnosis. Concern around appli-
cability of studies was almost universally poor due to restricted in-
clusion of lesions and lack of reproducibility of diagnostic thresh-
olds. Given these limitations and the heterogeneity in various as-
pects of the primary studies, our results cannot be considered con-
clusive regarding the accuracy of visual inspection for melanoma
diagnosis.
2) Prior testing of participants or study position on the clinical
pathway does appear to matter.
Focusing on in-person evaluations that could be clearly positioned
on the clinical pathway (Summary of findings), we observed the
highest sensitivity (92.4%, 95% CI 26.2% to 99.8%) and low-
est specificity (79.7%, 95% CI 73.7% to 84.7%) for the primary
target condition of invasive melanoma or atypical intraepidermal
melanocytic variants in three datasets from participants with lim-
ited prior testing; however, confidence intervals were wide and
heterogeneity high, particularly for sensitivity. Data for referred
participants suggest that summary sensitivities fall to around 75%,
but with much higher specificities (e.g. sensitivity 76.7% (95%
CI 61.7% to 87.1%) and specificity 95.7% (95% CI 89.7% to
98.3%) for lesions selected for excision, n = 8 datasets). Sensitivity
was higher for equivocal lesion populations but with very wide
confidence intervals (84.7%, 95%CI 55.5% to 96.1%) with sum-
mary specificity of 89.5% (95% CI 79.5% to 95.0%; 2 datasets).
The general trade-off between sensitivity and specificity along the
pathway could be due to differences in the spectrum or ‘case mix’
of included lesions, differences in the definition of a positive test
result, or may be linked to variations in observer expertise. Spec-
trum effects can be observed when tests that are developed further
down the referral pathway have lower sensitivity and higher speci-
ficity when applied in settings with participants with limited prior
testing (Usher-Smith 2016). Classic examples include the use of
dipstick tests for detection of urinary tract infection (UTI) (Lachs
1992) and the D-dimer test to detect pulmonary embolism (PE)
(Ginsberg 1993). In both studies, as the prior probability of hav-
ing UTI or PE increases (and so prevalence of disease increased),
test sensitivity increased (from 79% to 93% in Ginsberg 1993,
and from 58% to 92% in Lachs 1992) while specificities decreased
(from 76% to 45% in Ginsberg 1993 and from 77% to 42% in
Lachs 1992). However, this direction of effect is not consistent
across tests and diseases as Leeflang 2013 clearly demonstrates;
the mechanisms in action are often more complex than prevalence
alone and can be difficult to identify.
Using disease prevalence as a proxy for disease spectrum, our classi-
fication of studies did result in a somewhat lower prevalence of dis-
ease (suggesting a wider spectrum of lesion types) in limited prior
testing studies (median prevalence 5%, interquartile range (IQR)
3% to 9%) compared to referral settings (median prevalence 15%,
IQR 10% to 21%), but with overlapping ranges (2% to 11%, and
1% to 41%, respectively). The lower specificity observed in lim-
ited prior testing studies is likely related to the presence of a wider
range of benign lesions with similar characteristics to melanoma,
leading to more referrals. Observers in primary care are also likely
to have a lower threshold for considering benign lesions as possi-
bly malignant due to the risk of missing true cases of melanoma,
contributing both to higher sensitivity and a higher false-positive
rate. Referred populations on the other hand may have a higher
proportion of equivocal or ‘difficult-to-diagnose’ melanomas that
are difficult to identify.
In terms of eligibility criteria, the studies required varying degrees
of clinical suspicion of malignancy to include lesions in limited
prior-testing populations, ranging from lesions that could not im-
mediately be diagnosed as benign to there being a requirement for
a teledermatology second opinion. In referral populations, eligi-
bility was frequently based on lesion excision, the basis or rationale
for which was not described. The restriction to lesions deemed
to be suitable for excision would decrease specificity, as more ob-
viously benign lesions would be excluded. The spectrum of le-
sion types in the disease-negative groups also varied across stud-
ies, with a number of studies restricting inclusion only to those
with melanocytic lesions (such that all benign lesions were benign
melanocytic naevi) and others reporting high proportions of other
types of skin cancers (BCC or SCC), or of benign keratotic lesions,
such as seborrhoeic or actinic keratoses, or of Spitz naevi, which
may be difficult to differentiate from melanoma.
3) Visual inspection alone is not sufficiently sensitive for the de-
tection of melanoma, and there is no clear evidence that accuracy
is improved by the use of any named or published algorithm to
assist diagnosis in all settings.
Test sensitivity was greater than 90% (i.e. fewer than 1 in 10
melanomas missed) in only six of the 28 in-person-based eval-
uations of the primary target condition, and confidence inter-
vals for the pooled estimates were wide, raising the question of
whether visual inspection can be relied on to rule out the presence
of melanoma. Applying the sensitivity and specificity estimates
for the limited prior testing studies cited above to a hypothetical
cohort of 1000 lesions at disease prevalence of 4%, 9%, and 16%
(see Summary of findings) shows that on average, visual inspection
would miss 3, 7 or 12 melanomas, with 195, 185 and 171 false-
positive results (potentially leading to unnecessary excisions or le-
sion referral or follow-up depending on the anticipated clinical
action following a positive result). The wide confidence intervals
however mean that the number of melanomas missed could range
from between 0 and 118, with false-positives from 129 to 252.
For a cohort of 1000 lesions in a referred population at prevalence
of 4%, 9%, and 16% (Summary of findings), the pooled sensi-
tivity of 76.7% and specificity 95.7% translate to 9, 21, and 37
melanomas missed on average (range: 5 to 61) and 41, 39, and 36
false-positive results (range: 14 to 99).
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The evidence to support the use of available algorithms to assist vi-
sual inspection was limited, and results are likely to be confounded
by patient spectrum and observer experience. We also observed
considerable variation in definitions of test positivity across studies
that did not report using any algorithm, that is, where observer di-
agnosis was based on observers’ own interpretation of lesion char-
acteristics. Where reported, visual inspection was considered to be
positive for observers ‘correct diagnosis of melanoma’, ‘suspicion
of malignancy’, or ‘selection for excision’, each of which is likely
to result in varying proportions of test-positive or test-negative for
any given population.
Nevertheless, covariate investigations for the primary analysis
across all study settings suggested no difference in accuracy accord-
ing to the reported use of any named or published algorithm to as-
sist diagnosis. This result was supported by limited subgroup anal-
ysis according to algorithm used. Only one eligible study directly
compared the accuracy of visual inspection with and without the
use of an algorithm (Collas 1999); however, the study authors de-
veloped their own new algorithm for the study and found sensitiv-
ity to be higher without the use of the algorithm. Comparing dif-
ferent algorithms, McGovern 1992 reported highest sensitivities
from the BCD algorithm (any one characteristic present) and the
original seven-point checklist (at least two characteristics present).
Current guidelines in the UK support the use of the revised seven-
point checklist in primary care (NICE 2015a). A number of studies
assessing the revised seven-point checklist algorithm did not meet
the stringent inclusion criteria for our review (Healsmith 1994;
Higgins 1992; Osborne 1999; Walter 2013); however, the single
eligible study using the revised seven-point checklist as part of a
large randomised controlled trial reported high sensitivity (94%)
when used by GPs (Walter 2012).
4) The definition of the target condition has an effect on diagnostic
accuracy.
Results from studies reporting data for more than one definition
of the target condition show that sensitivity in particular is af-
fected by the inclusion of, and percentage of, melanoma in situ
and BCC lesions considered disease-positive. The direction of ef-
fect depends on observers’ ability to correctly identify these lesions
as malignant. It is likely that similar effects have an impact on
results observed across all included studies. Clear identification of
the target condition was not provided in 11 of the 28 datasets in-
cluded in our primary analyses, so that the inclusion of melanoma
in situ lesions as disease-positive was assumed on the basis that the
disease-positive group was described as ‘melanoma’ and not as ‘in-
vasive melanoma’ or ‘malignant melanoma’. Of those studies that
clearly reported including in situ lesions, the percentage of the dis-
ease-positive group (invasive melanoma and atypical intraepider-
mal melanocytic variants) described as being in situ ranged from
10% to 50%. Where studies included other invasive skin cancers
(mainly BCCs or SCCs) in the study population (lesions consid-
ered disease-negative for detection of the primary target), we at-
tempted to class any that were correctly identified by observers
as malignant as ‘true negative’ results as opposed to ‘false-posi-
tive’ (thereby increasing observed specificities), on the basis that
removal of any skin cancer in the attempt to identify melanomas
would not be a negative consequence of the test. Our ability to re-
classify lesions relied on studies providing a disaggregation of test
results according to final lesion classification and was not always
possible, particularly when invasive SCCs were not separated from
‘in situ’ lesions such as Bowen’s disease.
5) There are substantial differences in diagnostic accuracy between
in-person and image-based assessments.
Accuracy was much lower and reporting was poorer for evalua-
tions of a diagnosis based on the interpretation of clinical images as
opposed to in-person evaluations. Other than possible differences
in patient spectrum between in-person and image-based studies,
one possible explanation for the observed difference is that even
using the highest quality clinical image, a remote assessment is
not equivalent to a physical, face-to-face, patient-to-clinician in-
teraction, which will include patient history-taking as well as a
total body examination. We were unable to examine any impact
from history-taking over and above inspection of the lesion it-
self; however, history-taking and in particular, assessment of and
knowledge of patients’ other lesions could have a significant im-
pact on the decision as to whether or not a patient has melanoma
(Aldridge 2013; Grob 1998). Subtle differences in assessing the
lesion shape and colour can be done in an in-person consultation,
for example, by stretching the lesion in the axis perpendicular to
the skin creases, which may distort the lesion shape, and by alter-
ing the light intensity and direction used during lesion inspection.
Palpation of the lesion (and regional lymph nodes) is also possi-
ble during in-person examination. The fact that image quality is
likely to vary between studies, the time taken to review each image
is likely to vary, and the considerable variation in supplementary
information provided to observers (ranging from no clinical infor-
mation, to clinical details regarding patient age, gender or lesion
site and information on lesion change over time) will have further
contributed to variation in accuracy and lower accuracy estimates
in comparison to in-person evaluations. Furthermore, the diag-
nostic context may have a key influence on observer decisions.
In a face-to-face diagnostic encounter and for the examination of
lesion images for a teledermatology consultation, the clinicians
concerned know that their assessment has a direct consequence
on patient management and potentially on patient outcomes. The
image-based evaluations included in our primary analysis how-
ever were not conducted for teledermatology purposes, but were
studies using lesion images to compare accuracy between clinical-
image diagnosis and dermoscopic-image diagnosis, or to compare
observer or algorithm performance, for example. Observers would
have been aware that their assessment of the lesion image was done
in an experimental setting, and would not have an impact on pa-
tients; this could potentially have affected interpretation.
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Strengths and weaknesses of the review
The strengths of our review include an in-depth and comprehen-
sive electronic literature search, systematic reviewmethods includ-
ing double extraction of papers by both clinicians and methodol-
ogists, and contact with study authors to allow study inclusion or
clarify data. In order to estimate test accuracy in different study
populations, we adopted a clear analysis structure according to ap-
proach to diagnosis, the definition of the target condition, and the
patient pathway. We undertook a detailed and replicable analysis
of methodologic quality.
In comparison to other available systematic reviews, our review
extends the time period searched for eligible studies to August
2016 (from 2007 in Vestergaard 2008 and from March 2015 in
Harrington 2017), and we include all eligible studies regardless of
availability of a direct comparison with dermoscopic examination
(as required in Vestergaard 2008) or requirement for an algorithm
or clinical prediction rule to be included (Harrington 2017). Our
stringent application of review inclusion criteria meant that we
excluded several otherwise eligible studies. For example, we ex-
cluded those reporting accuracy data for ‘clinical diagnosis’, where
dermoscopy may or may not have been used to assist diagnosis,
on the basis that the contribution of visual inspection of the lesion
could not be discerned.
We also excluded from our review studies evaluating eligible al-
gorithms (that were included in Harrington 2017), due to lack
of data to construct a 2x2 contingency table, the serial use of the
algorithm in the context of lesion follow-up, or use of inadequate
reference standards. Without these restrictions, the observed data
would likely have been considerably more heterogeneous and of
poorer methodological quality. At the same time, our inclusion of
all studies reporting data for visual inspection meant that we were
able to make an overall assessment of observer accuracy, regardless
of the use of a named algorithm.Harrington and colleagues rightly
point out that lower sensitivity associated with the use of a clinical
prediction rule “should not prevent [its] use unless usual decisions,
made without the rule, are demonstrably better”; however, unless
the accuracy of ‘usual decisions’ is examined, any benefit from the
use of an algorithm cannot be established.
The main concerns for the review are a result of the poor reporting
of primary studies, in particular forcing some assumptions to be
made to allow studies to be split by pathway and in separating
studies by the different definitions of the target condition. Our
inability to clearly separate studies by pathway is of real concern
given the evidence for the effect on accuracy according to the spec-
trum or case-mix of included participants (Lachs 1992; Leeflang
2013; Moons 1997).
Finally, observer expertise is key for any diagnostic process based
on visual inspection, with both non-analytical pattern recognition
(implicit identification) and analytical pattern recognition (using
more explicit ‘rules’ based on conscious analytical reasoning) em-
ployed to varying extents between clinicians, according to factors
such as experience and familiarity with the diagnostic question
(Norman 2009). A lack of clear reporting of observer training and
experience made analysis difficult.
Applicability of findings to the review question
Varying definitions of the eligible study populations and lack of
clarity regarding the patient pathway and any prior testing may
restrict the extent to which our findings are applicable to the clini-
cal setting. Varying definitions of test positivity and lack of repro-
ducibility of diagnostic thresholds, variability in the use of pub-
lished algorithms, and in observer qualifications and experience,
further restrict the transferability of results to a clinical setting.
A U T H O R S ’ C O N C L U S I O N S
Implications for practice
Visual inspection is an essential, fundamental component of the
assessment of a suspicious skin lesion; however, the evidence sug-
gests that melanomas will be missed if visual inspection is used
on its own. The evidence to support its accuracy in the range of
settings in which it is used is both flawed and poorly reported,
resulting in an inability to produce meaningful summary results
and clear pointers as to where visual inspection is most useful.
Overall, the use of published algorithms to assist diagnosis does
not appear to improve accuracy; however, neither is there suffi-
cient evidence to suggest that the ‘no algorithm’ approach should
be preferred in all settings, for example, for training junior staff.
Further investigation may lend support to the theory that expert
observers are more reliant on non-analytical pattern recognition,
while attempts to assist analytical pattern recognition are of more
benefit for less experienced or more generalist observers.
Implications for research
Despite the vast volume of research that has been funded to eval-
uate visual inspection, further prospective evaluation of the added
value of established algorithms according to the prior testing or
diagnostic difficulty of lesions may be warranted. Prospective re-
cruitment of consecutive series of participants and with systematic
follow-up of non-excised lesions to avoid over-reliance on a histo-
logical reference standard would allow results to bemore generalis-
able to routine practice. A clear identification of the level of train-
ing and experience required to achieve good results is also required.
Any future research study needs to be clear about the diagnostic
pathway followed by study participants prior to study enrolment,
and should conform to the updated Standards for Reporting of
Diagnostic Accuracy (STARD) guideline (Bossuyt 2015).
A C K N OW L E D G E M E N T S
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C H A R A C T E R I S T I C S O F S T U D I E S
Characteristics of included studies [ordered by study ID]
Argenziano 2006
Study characteristics
Patient sampling Study design: RCT allocating primary care physicians to use either VI alone or VI plus dermoscopy
(only excised lesions can be included for each arm)
Data collection: prospective
Period of data collection: May 2003-September 2004
Country: Italy and Spain
Patient characteristics and set-
ting
Inclusion criteria: patients asking for screening or exhibiting ≥ 1 skin tumours as seen during
routine physical examination (patient-finding screening) were considered for inclusion; those un-
dergoing excision were included in this review (i.e. those deemed sufficiently suspicious by the ex-
pert evaluation). PCPs were invited to participate in the trial; only those who attended the training
sessions and who then screened patients and referred them to the PLCs were randomised
Setting: primary
Prior testing: no prior testing
Setting for prior testing: N/A
Exclusion criteria: NR
Sample size (participants): number eligible: 3271 screened; 1325 participants allocated to ’naked
eye’ observation and 1197 participants allocated to dermoscopy observation; number included: 162
received histology after expert evaluation at the PLC
Sample size (lesions): 85 in VI arm and 77 in dermoscopy arm underwent excision
Participant characteristics: based on full sample: mean age 40, range 2-90 (VI group)/ 41, range
3-94 (dermoscopy group). Male 498 (38%): VI group/451 (38%) dermoscopy
Lesion characteristics: NR
Index tests VI: ABCD (control arm of RCT comparing naked eye examination to naked eye plus dermoscopy)
Method of diagnosis: in-person diagnosis
Prior test data: N/A in-person diagnosis
Diagnostic threshold: qualitative NR; described in intro as: simple morphologic features summa-
rized by the asymmetry, border irregularity, colour variegation, and diameter 5 mm (ABCD)
Diagnosis based on: average (n = 37)
Observer qualifications: primary care physicians
Experience in practice: not described
Experience with index test: not described
Other detail: pre-randomisation all participating PCPs underwent training in ABCD rule for
clinical diagnosis and 3-point checklist for dermoscopy
Dermoscopy: evaluated in intervention arm of trial only
Target condition and reference
standard(s)
Reference standard: histological diagnosis alone
Details: all lesions considered suggestive of skin cancer at the PLC were excised and subsequently
diagnosed histopathologically. Equivocal lesions by histopathologic examination were reviewed by
a second independent pathologist and a final diagnosis made.
Disease positive: 92 malignant tumours; disease negative: 70 benign tumours
Target condition (final diagnoses)
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Melanoma (in situ and invasive, or NR): 12; BCC: 66; cSCC: 14
SK: 13; MN 51; other: 6
Flow and timing Excluded participants: data can only be extracted for those with histology (i.e. participants con-
sidered to have lesions suggestive of skin cancer); remainder had expert diagnosis (not included in
the final 2x2 data extracted)
Time interval to reference test: NR
Comparative RCT examining effect of making dermoscopy available to primary care practitioners
Notes -
Methodological quality
Item Authors’ judgement Risk of bias Applicability concerns
DOMAIN 1: Patient Selection
Was a consecutive or random
sample of patients enrolled?
Yes
Was a case-control design
avoided?
Yes
Did the study avoid inappropri-
ate exclusions?
Unclear
Are the included patients and
chosen study setting appropri-
ate?
No
Did the study avoid including
participants with multiple le-
sions?
Unclear
Unclear High
DOMAIN 2: Index Test Visual Inspection - in-person
Were the index test results in-
terpreted without knowledge of
the results of the reference stan-
dard?
Yes
If a threshold was used, was it
pre-specified?
Yes
For studies reporting the ac-
curacy of multiple diagnostic
thresholds, was each threshold
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or algorithm interpreted with-
out knowledge of the results of
the others?
Was the test applied and inter-
preted in a clinically applicable
manner?
No
Were thresholds or criteria for
diagnosis reported in sufficient
detail to allow replication?
Yes
Was the test interpretation car-
ried out by an experienced ex-
aminer?
Unclear
Low High
DOMAIN 3: Reference Standard
Is the reference standards likely
to correctly classify the target
condition?
Yes
Were the reference standard re-
sults
interpreted without knowledge
of the results of the index tests?
Unclear
Expert opinion (with no his-
tological confirmation) was not
used as a reference standard
Yes
Was histology interpretation
carried out by an experienced
histopathologist or by a der-
matopathologist?
Yes
Low Low
DOMAIN 4: Flow and Timing
Was there an appropriate inter-
val between index test and ref-
erence standard?
Unclear
Did all patients receive the same
reference standard?
Yes
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Were all patients included in the
analysis?
No
If the reference standard in-
cludes clinical follow-up of
borderline/benign appearing le-
sions, was there a minimum
follow-up following application
of index test(s) of at least: 3
months for melanoma or cSCC
or 6 months for BCC?
If more than one algorithm was
evaluated for the same test, was
the interval between applica-
tion of the different algorithms
1 month or less?
High
Barzegari 2005
Study characteristics
Patient sampling Study design: CS
Data collection: NR
Period of data collection: NR
Country: Iran
Patient characteristics and set-
ting
Inclusion criteria: PSLs with a clinical diagnosis of melanocytic lesion≤ 15 mm diameter referred
to dermatology clinic for diagnostic evaluation or cosmetic reasons
Setting: secondary (general dermatology)
Prior testing: clinical suspicion of malignancy without dermatoscopic suspicion; patient request
for evaluation/excision
Setting for prior testing: NR
Exclusion criteria: none reported
Sample size (participants): number included: 91
Sample size (lesions): number included: 122
Participant characteristics: mean age 32.3 (6-94 years); male: 30; 33%
Lesion characteristics: NR
Index tests VI: no algorithm
Method of diagnosis: in-person diagnosis
Prior test data: N/A in-person diagnosis
Diagnostic threshold: qualitative melanoma likely (i.e. melanoma first in list of considered diag-
noses)/ melanoma possible (melanoma one of a number of diagnoses)
Diagnosis based on: consensus (2 observers); n = 2
Observer qualifications: dermatology registrar (dermatology resident (3rd year)); dermatologist
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Experience in practice: mixed experience (low and high experience combined)
Experience with index test: mixed (low and high experience combined)
Target condition and reference
standard(s)
Reference standard: histological diagnosis alone
Disease positive: 6; disease negative: 116
Target condition (final diagnoses)
Melanoma (invasive): 3; melanoma (in situ): 3
SK: 2; benign naevus: 104; dysplastic naevus 7 DF, 1 AK
Flow and timing Excluded participants: none
Time interval between index and reference: unclear
Time interval between index test(s): consecutive
Comparative
Notes -
Methodological quality
Item Authors’ judgement Risk of bias Applicability concerns
DOMAIN 1: Patient Selection
Was a consecutive or random
sample of patients enrolled?
Yes
Was a case-control design
avoided?
Yes
Did the study avoid inappropri-
ate exclusions?
Yes
Are the included patients and
chosen study setting appropri-
ate?
Unclear
Did the study avoid including
participants with multiple le-
sions?
No
Low High
DOMAIN 2: Index Test Visual Inspection - in-person
Were the index test results in-
terpreted without knowledge of
the results of the reference stan-
dard?
Yes
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If a threshold was used, was it
pre-specified?
Unclear
For studies reporting the ac-
curacy of multiple diagnostic
thresholds, was each threshold
or algorithm interpreted with-
out knowledge of the results of
the others?
Was the test applied and inter-
preted in a clinically applicable
manner?
No
Were thresholds or criteria for
diagnosis reported in sufficient
detail to allow replication?
No
Was the test interpretation car-
ried out by an experienced ex-
aminer?
Unclear
Unclear High
DOMAIN 3: Reference Standard
Is the reference standards likely
to correctly classify the target
condition?
Yes
Were the reference standard re-
sults
interpreted without knowledge
of the results of the index tests?
Unclear
Expert opinion (with no his-
tological confirmation) was not
used as a reference standard
Yes
Was histology interpretation
carried out by an experienced
histopathologist or by a der-
matopathologist?
Unclear
Low Unclear
DOMAIN 4: Flow and Timing
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Was there an appropriate inter-
val between index test and ref-
erence standard?
Unclear
Did all patients receive the same
reference standard?
Yes
Were all patients included in the
analysis?
Yes
If the reference standard in-
cludes clinical follow-up of
borderline/benign appearing le-
sions, was there a minimum
follow-up following application
of index test(s) of at least: 3
months for melanoma or cSCC
or 6 months for BCC?
If more than one algorithm was
evaluated for the same test, was
the interval between applica-
tion of the different algorithms
1 month or less?
No
Unclear
Benelli 1999
Study characteristics
Patient sampling Study design: CS
Data collection: prospective
Period of data collection: 1 September1997-30 September 1998
Country: Italy
Patient characteristics and set-
ting
Inclusion criteria: all PSLs observed and excised at the dermatologic surgery department
Setting: dermatologic surgery department
Prior testing: selected for excision (no further detail)
Setting for prior testing: dermatologic surgery department
Exclusion criteria: none reported
Sample size (participants): NR
Sample size (lesions): number included: 401
Participant characteristics: NR
Lesion characteristics: melanoma thickness: 6 in situ; 42 < 0.75 mm thick, 80 0.76-1.5 mm thick,
4 1.5-4 mm thick (mean 0.60 mm, median 0.55 mm, max 1.9 mm, min 0.10 mm, SD 0.45)
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Index tests VI: ABCDE
Method of diagnosis: in-person diagnosis
Prior test data: lesions assessed by both dermatologists clinically and dermoscopically
Diagnostic threshold: data given for accuracy of each potential score (1-5); score estimation de-
scribed in detail
Diagnosis based on: consensus (2 observers); n = 2
Observer qualifications: dermatologist
Experience in practice: not described
Experience with index test: not described
Dermoscopy 7FFM also assessed by same observers
Target condition and reference
standard(s)
Reference standard: histological diagnosis alone
Disease positive: 60 (15%) lesions; disease negative: 340 (non melanoma) + 1 BCC
Target condition (final diagnoses)
Melanoma (invasive): 54 (13.5%); melanoma (in situ): 6 (1.5%); BCC: 1 (0.4%)
SK: 1 (0.4%); MN: 316; epithelioid and/or spindle cell naevi: 18 (4.5%); LS: 5 (1.2%)
Flow and timing Excluded participants: NR
Time interval to reference test: same day
Comparative Blinding between tests: Clinical and dermoscopic evaluations made in-person by 2 dermatologists
prior to excision
Time interval between index test(s): same day
Notes -
Methodological quality
Item Authors’ judgement Risk of bias Applicability concerns
DOMAIN 1: Patient Selection
Was a consecutive or random
sample of patients enrolled?
Yes
Was a case-control design
avoided?
Yes
Did the study avoid inappropri-
ate exclusions?
Unclear
Are the included patients and
chosen study setting appropri-
ate?
No
Did the study avoid including
participants with multiple le-
sions?
Unclear
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Unclear High
DOMAIN 2: Index Test Visual Inspection - in-person
Were the index test results in-
terpreted without knowledge of
the results of the reference stan-
dard?
Yes
If a threshold was used, was it
pre-specified?
No
For studies reporting the ac-
curacy of multiple diagnostic
thresholds, was each threshold
or algorithm interpreted with-
out knowledge of the results of
the others?
Was the test applied and inter-
preted in a clinically applicable
manner?
No
Were thresholds or criteria for
diagnosis reported in sufficient
detail to allow replication?
Yes
Was the test interpretation car-
ried out by an experienced ex-
aminer?
Unclear
High High
DOMAIN 3: Reference Standard
Is the reference standards likely
to correctly classify the target
condition?
Yes
Were the reference standard re-
sults
interpreted without knowledge
of the results of the index tests?
Unclear
Expert opinion (with no his-
tological confirmation) was not
used as a reference standard
Yes
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Was histology interpretation
carried out by an experienced
histopathologist or by a der-
matopathologist?
Unclear
Low Unclear
DOMAIN 4: Flow and Timing
Was there an appropriate inter-
val between index test and ref-
erence standard?
Yes
Did all patients receive the same
reference standard?
Yes
Were all patients included in the
analysis?
Yes
If the reference standard in-
cludes clinical follow-up of
borderline/benign appearing le-
sions, was there a minimum
follow-up following application
of index test(s) of at least: 3
months for melanoma or cSCC
or 6 months for BCC?
If more than one algorithm was
evaluated for the same test, was
the interval between applica-
tion of the different algorithms
1 month or less?
Low
Benelli 2001
Study characteristics
Patient sampling Study design: unclear
Data collection: retrospective image selection/prospective interpretation
Period of data collection: NR - only dates of training course and agreement study given (April-
May 1999)
Country: Italy
Patient characteristics and set-
ting
Inclusion criteria: slides of pigmented skin tumours were selected for evaluation during a training
course on dermoscopy. Lesions not located on head, palms or soles; histological slide available
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Setting: training images; study authors’ institution. Institute of Dermatologic Sciences, University
of Milan
Prior testing: slides of pigmented skin tumours were selected for evaluation during a training course
on dermoscopy
Setting for prior testing: unspecified
Exclusion criteria: none reported
Sample size (participants): NR
Sample size (lesions): number included: 49 (paper reports 50 but only 49 accounted for in text)
Participant characteristics: none reported
Lesion characteristics: none reported
Index tests VI: ABCDE
Method of diagnosis: clinical photographs
Prior test data: no further information used
Diagnostic threshold: ABCDE Score ≥ 2; presence of 2 criteria; ABCDE score ≥ 3; presence of
3 criteria. All criteria described in full
Diagnosis based on: single (n = 1); average (n = 65; attending 1/3 courses in dermoscopy held to
inform dermatologists about a new dermatoscopic diagnostic method (7FFM))
Observer qualifications: dermatologists
Experience in practice: expert author; not described for participating dermatologists
Experience with dermoscopy: expert author; prior experience not described for participating der-
matologists; all underwent dermoscopy training for study purposes
Dermoscopy: 7FFM; ABCDE also evaluated in study
Target condition and reference
standard(s)
Reference standard: histological diagnosis alone
Disease positive: 12/49 melanomas (paper reports 50 but only 49 accounted for in text)
Target condition (final diagnoses)
Melanoma (invasive): 10; melanoma (in situ): 2; BCC: 2 pigmented BCC
3 seborrhoeic keratoses: 2; pigmented BCC: 1; blue nevus: 2; angiokeratoma: 5; Spitz nevus: 5;
junctional naevi 9 compound naevi, 10 naevi undergoing regression
Flow and timing Excluded participants: none reported
Time interval to reference test: unclear
Comparative Blinding between tests: Clinical images interpreted in the morning and dermoscopic images in the
afternoon
Time interval between index test(s): image capture NR
Notes -
Methodological quality
Item Authors’ judgement Risk of bias Applicability concerns
DOMAIN 1: Patient Selection
Was a consecutive or random
sample of patients enrolled?
Unclear
74Visual inspection for diagnosing cutaneous melanoma in adults (Review)
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Benelli 2001 (Continued)
Was a case-control design
avoided?
Unclear
Did the study avoid inappropri-
ate exclusions?
Unclear
Are the included patients and
chosen study setting appropri-
ate?
No
Did the study avoid including
participants with multiple le-
sions?
Unclear
Unclear High
DOMAIN 2: Index Test Visual inspection - image-based
Were the index test results in-
terpreted without knowledge of
the results of the reference stan-
dard?
Yes
If a threshold was used, was it
pre-specified?
Yes
For studies reporting the ac-
curacy of multiple diagnostic
thresholds, was each threshold
or algorithm interpreted with-
out knowledge of the results of
the others?
Was the test applied and inter-
preted in a clinically applicable
manner?
No
Were thresholds or criteria for
diagnosis reported in sufficient
detail to allow replication?
Yes
Was the test interpretation car-
ried out by an experienced ex-
aminer?
Yes
Low High
DOMAIN 3: Reference Standard
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Is the reference standards likely
to correctly classify the target
condition?
Yes
Were the reference standard re-
sults
interpreted without knowledge
of the results of the index tests?
Unclear
Expert opinion (with no his-
tological confirmation) was not
used as a reference standard
Yes
Was histology interpretation
carried out by an experienced
histopathologist or by a der-
matopathologist?
Unclear
Low Unclear
DOMAIN 4: Flow and Timing
Was there an appropriate inter-
val between index test and ref-
erence standard?
Unclear
Did all patients receive the same
reference standard?
Yes
Were all patients included in the
analysis?
Yes
If the reference standard in-
cludes clinical follow-up of
borderline/benign appearing le-
sions, was there a minimum
follow-up following application
of index test(s) of at least: 3
months for melanoma or cSCC
or 6 months for BCC?
If more than one algorithm was
evaluated for the same test, was
the interval between applica-
tion of the different algorithms
1 month or less?
Unclear
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Study characteristics
Patient sampling Study design: unclear
Data collection: NR
Period of data collection: March 1993-October 1994
Country: Italy
Patient characteristics and set-
ting
Inclusion criteria: PSLs at the Instituto Nazionale Tumori of Milan
Setting: specialist unit (skin cancer clinic/PLC) Instituto Nazionale Tumori of Milan
Prior testing: NR
Setting for prior testing: NR
Exclusion criteria: none reported
Sample size (participants): number eligible: 45
Sample size (lesions): number eligible: 54/ number included: 43
Participant characteristics: NR
Lesion characteristics: site - face/ears: 3 (6%)/trunk: 39 (72%)/limbs: 12 (22%); 10MM≤ 1 mm
depth; median size: 10 mm (4 mm-40 mm)
Index tests VI: no algorithm
Method of diagnosis: in-person diagnosis
Prior test data: N/A in-person diagnosis
Diagnostic threshold: NR; ’clinical diagnosis’
Diagnosis based on: single observer; n = NR
Observer qualifications: treating surgeon
Experience in practice: not described
Experience with index test: not described
Target condition and reference
standard(s)
Reference standard: histological diagnosis
Disease positive: 18; disease negative: 25
Expert opinion: disease negative: 11
Target condition (final diagnoses)
Melanoma (in situ and invasive, or NR): 18
Mild/moderate dysplasia: 8 dysplastic naevi
Benign naevus: 17 common MN
Flow and timing Excluded participants: only 43 lesions had complete clinical and histological information. 11
lesions not surgically removed had only clinical diagnosis (benign) and were not included in the
final accuracy analysis
Time interval to reference test: NR
Time interval between index test(s): NR
Comparative
Notes -
Methodological quality
Item Authors’ judgement Risk of bias Applicability concerns
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DOMAIN 1: Patient Selection
Was a consecutive or random
sample of patients enrolled?
Unclear
Was a case-control design
avoided?
Unclear
Did the study avoid inappropri-
ate exclusions?
Unclear
Are the included patients and
chosen study setting appropri-
ate?
Unclear
Did the study avoid including
participants with multiple le-
sions?
No
Unclear High
DOMAIN 2: Index Test Visual Inspection - in-person
Were the index test results in-
terpreted without knowledge of
the results of the reference stan-
dard?
Yes
If a threshold was used, was it
pre-specified?
Unclear
For studies reporting the ac-
curacy of multiple diagnostic
thresholds, was each threshold
or algorithm interpreted with-
out knowledge of the results of
the others?
Was the test applied and inter-
preted in a clinically applicable
manner?
Yes
Were thresholds or criteria for
diagnosis reported in sufficient
detail to allow replication?
No
Was the test interpretation car-
ried out by an experienced ex-
aminer?
Unclear
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Unclear High
DOMAIN 3: Reference Standard
Is the reference standards likely
to correctly classify the target
condition?
No
Were the reference standard re-
sults
interpreted without knowledge
of the results of the index tests?
Unclear
Expert opinion (with no his-
tological confirmation) was not
used as a reference standard
No
Was histology interpretation
carried out by an experienced
histopathologist or by a der-
matopathologist?
Unclear
High High
DOMAIN 4: Flow and Timing
Was there an appropriate inter-
val between index test and ref-
erence standard?
Unclear
Did all patients receive the same
reference standard?
No
Were all patients included in the
analysis?
No
If the reference standard in-
cludes clinical follow-up of
borderline/benign appearing le-
sions, was there a minimum
follow-up following application
of index test(s) of at least: 3
months for melanoma or cSCC
or 6 months for BCC?
Yes
If more than one algorithm was
evaluated for the same test, was
the interval between applica-
tion of the different algorithms
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1 month or less?
High
Bono 2002a
Study characteristics
Patient sampling Study design: CS
Data collection: prospective
Period of data collection: June 1998-March 2000
Country: Italy
Test set derived: a training set was separately derived using data obtained from 237 previously
studied lesions (Farina 2000)
Patient characteristics and set-
ting
Inclusion criteria: cutaneous pigmented lesions with clinical and/or dermatoscopic features that
suggested a more or less important suspicion for CM
Setting: specialist unit (skin cancer clinic/PLC)
Prior testing: clinical and/or dermatoscopic suspicion
Setting for prior testing: specialist unit (skin cancer clinic/PLC)
Exclusion criteria: location/site of lesion. Awkwardly situated lesions, e.g. interdigital space, ears,
nose or eyelids. Lesions on scalp excluded due to hair interference with reflectance. Lesion size,
obvious large, thick melanomas
Sample size (participants): number included: 298
Sample size (lesions): number included: 313
Participant characteristics: mean age: 40 years (10-86 years); male: 122; 41%
Lesion characteristics: lesion site: head/neck: 3%; trunk: 61%; limbs: 36%; thickness ≤ 1 mm:
70% (46/66); for 55 invasive MM: median thickness 0.64 mm, range 0.17-3.24 mm. Median
diameter: 11 mm (3-31 mm)
Index tests VI: no algorithm (training in the unit based on ABCD but subjective experience of the clinician
used for diagnosis)
Method of diagnosis: in-person diagnosis
Prior test data: same clinician undertook clinical diagnosis and diagnosis using dermoscopy
Diagnostic threshold: clinical diagnostic criteria based on subjective experience; emphasised lesion
colour over dimensions. Diagnosis of suspect CM made when the level of suspicion was “roughly
50% or more”. ABCD criteria have been the basis of training at the unit, but is not implemented
in diagnosis; preferred emphasis on colour rather than dimensional character
Diagnosis based on: single observer; (n = 1)
Observer qualifications: surgical oncologists
Experience in practice: high experience or ’Expert’; over 5 years
Dermoscopy: also evaluated in same study (no algorithm)
Target condition and reference
standard(s)
Reference standard: histological diagnosis alone
Target condition (final diagnoses)
Melanoma (invasive): 55; Melanoma (in situ): 11; BCC: 6
’Benign’ diagnoses: 241; 151 compound naevus, 24 junctional naevus, 12 dermal naevus, 12 LS,
10 dysplastic naevus, 8 spindle-cell naevus, 8 SK, 5 blue naevus, 3 Spitz naevus, 8 other
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Flow and timing Excluded participants: NR
Interval between index and reference: NR
Comparative Same clinician undertook both diagnoses (in-person)
Time interval between index test(s): Appears consecutive but not fully clear
Notes -
Methodological quality
Item Authors’ judgement Risk of bias Applicability concerns
DOMAIN 1: Patient Selection
Was a consecutive or random
sample of patients enrolled?
Yes
Was a case-control design
avoided?
Yes
Did the study avoid inappropri-
ate exclusions?
No
Are the included patients and
chosen study setting appropri-
ate?
No
Did the study avoid including
participants with multiple le-
sions?
Yes
High High
DOMAIN 2: Index Test Visual Inspection - in-person
Were the index test results in-
terpreted without knowledge of
the results of the reference stan-
dard?
Yes
If a threshold was used, was it
pre-specified?
Yes
For studies reporting the ac-
curacy of multiple diagnostic
thresholds, was each threshold
or algorithm interpreted with-
out knowledge of the results of
the others?
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Was the test applied and inter-
preted in a clinically applicable
manner?
Yes
Were thresholds or criteria for
diagnosis reported in sufficient
detail to allow replication?
No
Was the test interpretation car-
ried out by an experienced ex-
aminer?
Yes
Low High
DOMAIN 3: Reference Standard
Is the reference standards likely
to correctly classify the target
condition?
Yes
Were the reference standard re-
sults
interpreted without knowledge
of the results of the index tests?
Unclear
Expert opinion (with no his-
tological confirmation) was not
used as a reference standard
Yes
Was histology interpretation
carried out by an experienced
histopathologist or by a der-
matopathologist?
Unclear
Low Unclear
DOMAIN 4: Flow and Timing
Was there an appropriate inter-
val between index test and ref-
erence standard?
Unclear
Did all patients receive the same
reference standard?
Yes
Were all patients included in the
analysis?
Yes
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If the reference standard in-
cludes clinical follow-up of
borderline/benign appearing le-
sions, was there a minimum
follow-up following application
of index test(s) of at least: 3
months for melanoma or cSCC
or 6 months for BCC?
If more than one algorithm was
evaluated for the same test, was
the interval between applica-
tion of the different algorithms
1 month or less?
Unclear
Bono 2002b
Study characteristics
Patient sampling Study design: CS
Data collection: prospective
Period of data collection: December 2000 and August 2001
Country: Italy
Patient characteristics and set-
ting
Inclusion criteria: consecutive cutaneous pigmented lesions that were ≤ 6 mm in diameter and
required surgical biopsy for diagnosis based on clinical or dermoscopic suspicion of CMM
Setting: specialist unit (skin cancer clinic/PLC)
Prior testing: clinical and/or dermatoscopic suspicion
Setting for prior testing: NR
Exclusion criteria: lesion size > 6 mm; non-pigmented
Sample size (participants): number eligible: 349/number included: 157
Sample size (lesions): number eligible: 375/number included: 161
Participant characteristics: mean age 38 years (14-82); male: 61 (39%)
Lesion characteristics: site: head/neck: 14 (9%); trunk: 88 (55%); limbs: 59 (36%)
Lesion size: median: 5 mm (1 mm-6 mm)
Index tests VI: no algorithm (ABCD criteria have been the basis of training at the unit, but is not implemented
in diagnosis; preferred emphasis on colour rather than dimensional character)
Method of diagnosis: in-person diagnosis
Prior test data: N/A, in-person diagnosis
Other test data: dermoscopy evaluated in same study by same observer(s)
Diagnostic threshold: a diagnosis of suspect CM is made when the level of suspicion is roughly
50% or more; lesions at a lower index of suspicion were considered benign for the purposes of this
study
Diagnosis based on: single observer diagnostic criteria based on the subjective experience of the
single clinician examining the pigmented lesion (n = 2)
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Observer qualifications: surgical oncologists
Experience in practice: high experience or ‘Expert’; observers described as “expert in the recognition
of pigmented lesions”
Other detail: diagnostic criteria were based on the subjective experience of the single clinician
examining the pigmented lesion, although the ABCD criteria have been the basis of training at the
unit, they did not consider the ABCD mnemonic an essential formula for diagnosis of CM. They
did not take into consideration the dimensional character and attributed great importance to the
colour of a given lesion
Dermoscopy: performed by the same 2 clinicians who firstly made and registered the clinical
diagnosis
Target condition and reference
standard(s)
Reference standard: histological diagnosis alone
Disease positive: 13 CM; disease negative: 148
Target condition (final diagnoses)
Melanoma (invasive): 10; melanoma (in situ): 3; BCC: 2 (1.2%)
Mild/moderate dysplasia: 26 (16.1%); SK: 4 (2.5%); benign naevus: compound nevus 57 (35.4%)
, junctional nevus 38 (23.6%), spindle-cell nevus 6 (3.7%), Spitz nevus 5 (3.1%), blue nevus 2 (1.
2%), other 6 (3.7%), LS 2 (1.2%)
Flow and timing Excluded participants: none reported
Time interval to reference test: NR
Comparative Dermoscopy performed by the same two clinicians who firstly made and registered the clinical
diagnosis
Time interval between index test(s): appears consecutive
Notes -
Methodological quality
Item Authors’ judgement Risk of bias Applicability concerns
DOMAIN 1: Patient Selection
Was a consecutive or random
sample of patients enrolled?
Yes
Was a case-control design
avoided?
Yes
Did the study avoid inappropri-
ate exclusions?
Yes
Are the included patients and
chosen study setting appropri-
ate?
No
Did the study avoid including
participants with multiple le-
sions?
Yes
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Low High
DOMAIN 2: Index Test Visual Inspection - in-person
Were the index test results in-
terpreted without knowledge of
the results of the reference stan-
dard?
Yes
If a threshold was used, was it
pre-specified?
Yes
For studies reporting the ac-
curacy of multiple diagnostic
thresholds, was each threshold
or algorithm interpreted with-
out knowledge of the results of
the others?
Was the test applied and inter-
preted in a clinically applicable
manner?
Yes
Were thresholds or criteria for
diagnosis reported in sufficient
detail to allow replication?
No
Was the test interpretation car-
ried out by an experienced ex-
aminer?
Yes
Low High
DOMAIN 3: Reference Standard
Is the reference standards likely
to correctly classify the target
condition?
Yes
Were the reference standard re-
sults
interpreted without knowledge
of the results of the index tests?
Unclear
Expert opinion (with no his-
tological confirmation) was not
used as a reference standard
Yes
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Was histology interpretation
carried out by an experienced
histopathologist or by a der-
matopathologist?
Unclear
Low Unclear
DOMAIN 4: Flow and Timing
Was there an appropriate inter-
val between index test and ref-
erence standard?
Unclear
Did all patients receive the same
reference standard?
Yes
Were all patients included in the
analysis?
Yes
If the reference standard in-
cludes clinical follow-up of
borderline/benign appearing le-
sions, was there a minimum
follow-up following application
of index test(s) of at least: 3
months for melanoma or cSCC
or 6 months for BCC?
If more than one algorithm was
evaluated for the same test, was
the interval between applica-
tion of the different algorithms
1 month or less?
Unclear
Bono 2006
Study characteristics
Patient sampling Study design: CS
Data collection: retrospective
Period of data collection: January 2003-December 2004
Country: Italy
Patient characteristics and set-
ting
Inclusion criteria: consecutive patientswith PSLswith amaximumdiameter of≤ 3mmundergoing
excision. The decision for diagnostic excision was based on clinical and/or dermoscopic features
suggesting a more or less important suspicion for CM
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Setting: specialist unit (skin cancer clinic/PLC) Istituto Nazionale Tumori of Milan
Prior testing: clinical and/or dermatoscopic suspicion
Setting for prior testing: specialist unit (skin cancer clinic/PLC)
Exclusion criteria: lesion size > 3 mm
Sample size (participants): number eligible: 204/number included: 204
Sample size (lesions): number eligible: 206/number included: 206
Participant characteristics: median age: 40 (6-74); male: 71 (35%)
Lesion characteristics: head/neck: 8 (4%); trunk: 84 (41%); limbs: 114 (55%). Median size: 2
mm (1 mm-3 mm)
Index tests VI: no algorithm
Method of diagnosis: in-person diagnosis
Prior test data: N/A, in-person diagnosis
Other test data: dermoscopy evaluated in same study by same observer(s)
Diagnostic threshold: a diagnosis of suspicious CM is made when the level of suspicion is roughly
50% or more; lesions at a lower index of suspicion were considered not CM
Diagnosis based on: single observer; n = 1
Observer qualifications: NR (assumed Oncologist as per Bono 2002a and Bono 2002b); “single
clinician examining the pigmented lesion”
Experience in practice: not described
Experience with dermoscopy: not described
Dermoscopy: evaluated in same study; Menzies criteria
Any other detail: ABCD criteria have been the basis of training at the unit, but is not implemented
in diagnosis; preferred emphasis on colour rather than dimensional character
Target condition and reference
standard(s)
Reference standard: histological diagnosis alone
Details: the slides were evaluated according to widely accepted criteria for the histopathological
diagnosis of the various pigmented lesions.
Disease positive: 23; disease negative: 183
Target condition (final diagnoses)
Melanoma (invasive): 19 (9.2%); melanoma (in situ): 4 (2.0%)
Mild/moderate dysplasia: dysplastic naevus 10 (4.9%); junctional naevus 76 (36.9%); compound
naevus 50 (24.3%); dermal naevus 12 (5.8%); blue naevus 11 (5.3%); reed naevus 7 (3.4%); Spitz
naevus 3 (1.5%); halo naevus 3 (1.5%); LS 7 (3.4%); other 4 (1.9%)
Flow and timing Excluded participants: none
Time interval to reference test: NR
Comparative Sibngle observer performed both tests
Time interval between index test(s): not reported
Notes -
Methodological quality
Item Authors’ judgement Risk of bias Applicability concerns
DOMAIN 1: Patient Selection
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Was a consecutive or random
sample of patients enrolled?
Yes
Was a case-control design
avoided?
Yes
Did the study avoid inappropri-
ate exclusions?
Yes
Are the included patients and
chosen study setting appropri-
ate?
No
Did the study avoid including
participants with multiple le-
sions?
Yes
Low High
DOMAIN 2: Index Test Visual Inspection - in-person
Were the index test results in-
terpreted without knowledge of
the results of the reference stan-
dard?
Yes
If a threshold was used, was it
pre-specified?
Yes
For studies reporting the ac-
curacy of multiple diagnostic
thresholds, was each threshold
or algorithm interpreted with-
out knowledge of the results of
the others?
Was the test applied and inter-
preted in a clinically applicable
manner?
Yes
Were thresholds or criteria for
diagnosis reported in sufficient
detail to allow replication?
No
Was the test interpretation car-
ried out by an experienced ex-
aminer?
Unclear
Low High
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DOMAIN 3: Reference Standard
Is the reference standards likely
to correctly classify the target
condition?
Yes
Were the reference standard re-
sults
interpreted without knowledge
of the results of the index tests?
Unclear
Expert opinion (with no his-
tological confirmation) was not
used as a reference standard
Yes
Was histology interpretation
carried out by an experienced
histopathologist or by a der-
matopathologist?
Unclear
Low Unclear
DOMAIN 4: Flow and Timing
Was there an appropriate inter-
val between index test and ref-
erence standard?
Unclear
Did all patients receive the same
reference standard?
Yes
Were all patients included in the
analysis?
Yes
If the reference standard in-
cludes clinical follow-up of
borderline/benign appearing le-
sions, was there a minimum
follow-up following application
of index test(s) of at least: 3
months for melanoma or cSCC
or 6 months for BCC?
If more than one algorithm was
evaluated for the same test, was
the interval between applica-
tion of the different algorithms
1 month or less?
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Unclear
Bourne 2012
Study characteristics
Patient sampling Study design: CS
Data collection: retrospective image selection/prospective interpretation
Period of data collection: 1 June-6 July 2009
Country: Australia
Patient characteristics and set-
ting
Inclusion criteria: all skin lesions consecutively excised at a skin cancer practice to exclude skin
cancer and common lesions assessed as clearly benign and not biopsied were included
Setting: primary
Prior testing: clinical and/or dermatoscopic suspicion. Prior testing to assemble the test set occurs
in secondary care by an experienced skin cancer doctor, then the images are tested on primary care
professionals
Setting for prior testing: specialist unit (skin cancer clinic/PLC)
Exclusion criteria: clinically obvious BCCs that could be easily diagnosed without dermoscopy
were not included in the collection set
Sample size (participants): number eligible: 46/number included: 46
Sample size (lesions): number eligible: 50/number included: 50
Participant characteristics: mean age: 58 (30-60); male: 22
Lesion characteristics: face = 8; neck = 1; chest = 3; back = 21; shoulder = 2; arm = 3; thigh = 4;
leg = 7; foot plantar = 1
Index tests VI: no algorithm
Method of diagnosis: clinical photographs
Prior test data: no further information used; image assessments were done on 4 occasions, each
time using a different diagnostic approach
Diagnostic threshold: NR, clinicians provided with Excel answer sheets for each method listing
the various criteria used in that algorithm but no algorithm was cited for VI
Diagnosis based on: average (n = 4)
Observer qualifications: 3 GPs and 1 clinical nurse
Experience in practice: mixed; described as varying levels of dermatoscopic experience
Dermoscopy: evaluated in same study; 3-point rule; Menzies criteria
Target condition and reference
standard(s)
Reference standard: histological diagnosis plus other
Histopathological examination (n = 46); expert diagnosis as benign (n = 3); digital follow-up (n =
1)
Target condition (final diagnoses)
Melanoma (invasive): 1; melanoma (in situ): 7; BCC: 6; lentigo maligna 1
SK: 5. ’Benign’ diagnoses: banal nevus 10, blue naevus 1, nevus and SK/solar lentigo collision 3,
solar lentigo 4, LPLK 4, DF 1, psoriasis 1, solar keratosis 2, intraepidermal carcinoma 3, regressed
keratoacanthoma 1
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Flow and timing Excluded participants: as 2 of themethods (Menzies and 3-point checklist) related to only pigmented
lesions, we excluded the 5 non-pigmented specimens in the set of 50 from the contingency tables
for these methods
Time interval to reference test, quote: “all skin lesions consecutively excised to exclude skin cancer
were recorded”
Comparative
Notes -
Methodological quality
Item Authors’ judgement Risk of bias Applicability concerns
DOMAIN 1: Patient Selection
Was a consecutive or random
sample of patients enrolled?
Yes
Was a case-control design
avoided?
Yes
Did the study avoid inappropri-
ate exclusions?
Unclear
Are the included patients and
chosen study setting appropri-
ate?
No
Did the study avoid including
participants with multiple le-
sions?
Yes
Unclear High
DOMAIN 2: Index Test Visual inspection - image-based
Were the index test results in-
terpreted without knowledge of
the results of the reference stan-
dard?
Yes
If a threshold was used, was it
pre-specified?
Unclear
For studies reporting the ac-
curacy of multiple diagnostic
thresholds, was each threshold
or algorithm interpreted with-
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out knowledge of the results of
the others?
Was the test applied and inter-
preted in a clinically applicable
manner?
No
Were thresholds or criteria for
diagnosis reported in sufficient
detail to allow replication?
No
Was the test interpretation car-
ried out by an experienced ex-
aminer?
Unclear
Unclear High
DOMAIN 3: Reference Standard
Is the reference standards likely
to correctly classify the target
condition?
Yes
Were the reference standard re-
sults
interpreted without knowledge
of the results of the index tests?
Yes
Expert opinion (with no his-
tological confirmation) was not
used as a reference standard
No
Was histology interpretation
carried out by an experienced
histopathologist or by a der-
matopathologist?
Unclear
Low High
DOMAIN 4: Flow and Timing
Was there an appropriate inter-
val between index test and ref-
erence standard?
Yes
Did all patients receive the same
reference standard?
No
Were all patients included in the
analysis?
No
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If the reference standard in-
cludes clinical follow-up of
borderline/benign appearing le-
sions, was there a minimum
follow-up following application
of index test(s) of at least: 3
months for melanoma or cSCC
or 6 months for BCC?
Unclear
If more than one algorithm was
evaluated for the same test, was
the interval between applica-
tion of the different algorithms
1 month or less?
Yes
High
Carli 2002a
Study characteristics
Patient sampling Study design: CS
Data collection: prospective for clinical examination and in vivo dermoscopy; retrospective image
selection/prospective interpretation for ex vivo dermoscopic evaluation
Period of data collection: June 1997-December 1998
Country: Italy
Patient characteristics and set-
ting
Inclusion criteria: clinically equivocal and suspicious PSLs subjected to excisional biopsy at the
Institute of Dermatology
Setting: secondary (not further specified)
Prior testing: clinical and/or dermatoscopic suspicion
Setting for prior testing: secondary
Exclusion criteria: none reported
Sample size (participants): NR
Sample size (lesions): 256
Participant characteristics: none reported
Lesion characteristics: of the CMs, 14 (25.9%) were in situ melanoma (Clark level I), 18 (33.
3%) were invasive with < 0.75 mm thickness, 19 (35.3%) were of intermediate thickness (0.76-1.
50 mm) and 3 (5.5%) were > 1.5 mm. The median thickness of invasive melanomas was 0.94 mm
± 0.5 (SD) (range 0.2-2.6)
Index tests VI: no algorithm
Method of diagnosis: in-person diagnosis
Prior test data: unclear
Other test data: clinical examination and in vivo dermoscopy were performed before excision by 2
trained dermatologists and diagnosis reached
Diagnostic threshold: NR
Diagnosis based on: consensus (2 observers); final clinical diagnosis was based on agreement
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between the 2 observers. In case of disagreement, the opinion of a 3rd observer (B.G.) was considered
to be the judge for the diagnosis
Observer qualifications: dermatologist
Experience in practice: high experience or ‘Expert’; described as “dermatologists with extensive
experience in both clinical and dermoscopic diagnosis of pigmented skin lesions”
Dermoscopy: evaluated in same study; pattern analysis
Target condition and reference
standard(s)
Reference standard: histological diagnosis alone
Target condition (final diagnoses)
Melanoma (invasive): 40; melanoma (in situ): 14
BCC: 5
SK: 4; benign naevus: 90 common MN; 78 MN; 9 blue naevi; 16 Spitz reed naevi
Flow and timing Excluded participants: none reported
Time interval to reference test: NR
Comparative In person clinical examination and dermoscopy
Time interval between index test(s): the interval between the time in-vivo dermoscopy and re-
evaluation of dermoscopic images was reported as 1 year
Notes -
Methodological quality
Item Authors’ judgement Risk of bias Applicability concerns
DOMAIN 1: Patient Selection
Was a consecutive or random
sample of patients enrolled?
Yes
Was a case-control design
avoided?
Yes
Did the study avoid inappropri-
ate exclusions?
Unclear
Are the included patients and
chosen study setting appropri-
ate?
No
Did the study avoid including
participants with multiple le-
sions?
Unclear
Unclear High
DOMAIN 2: Index Test Visual Inspection - in-person
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Were the index test results in-
terpreted without knowledge of
the results of the reference stan-
dard?
Yes
If a threshold was used, was it
pre-specified?
Unclear
For studies reporting the ac-
curacy of multiple diagnostic
thresholds, was each threshold
or algorithm interpreted with-
out knowledge of the results of
the others?
Was the test applied and inter-
preted in a clinically applicable
manner?
No
Were thresholds or criteria for
diagnosis reported in sufficient
detail to allow replication?
Yes
Was the test interpretation car-
ried out by an experienced ex-
aminer?
Yes
Unclear High
DOMAIN 3: Reference Standard
Is the reference standards likely
to correctly classify the target
condition?
Yes
Were the reference standard re-
sults
interpreted without knowledge
of the results of the index tests?
Unclear
Expert opinion (with no his-
tological confirmation) was not
used as a reference standard
Yes
Was histology interpretation
carried out by an experienced
histopathologist or by a der-
matopathologist?
Unclear
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Low Unclear
DOMAIN 4: Flow and Timing
Was there an appropriate inter-
val between index test and ref-
erence standard?
Unclear
Did all patients receive the same
reference standard?
Yes
Were all patients included in the
analysis?
Yes
If the reference standard in-
cludes clinical follow-up of
borderline/benign appearing le-
sions, was there a minimum
follow-up following application
of index test(s) of at least: 3
months for melanoma or cSCC
or 6 months for BCC?
If more than one algorithm was
evaluated for the same test, was
the interval between applica-
tion of the different algorithms
1 month or less?
Unclear
Carli 2002b
Study characteristics
Patient sampling Study design: CS
Data collection: NR
Period of data collection: NR
Country: Italy
Patient characteristics and set-
ting
Inclusion criteria: clinically suspicious or equivocal PSLs undergoing excision for diagnostic pur-
poses; only lesions with a diameter of ≤ 14 mm were included
Setting: secondary (general dermatology)
Prior testing: clinical suspicion of malignancy without dermatoscopic suspicion
Setting for prior testing: secondary (general dermatology)
Exclusion criteria: none reported
Sample size (participants): number included: NR
Sample size (lesions): number included: 57
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Participant characteristics: none reported
Lesion characteristics: thickness ≤ 1 mm: 11 cases (5 in situ 6 invasive); All ≤ 14 mm diameter
Index tests VI: no algorithm
Method of diagnosis: clinical photographs; fixed focus distance of 10 cm; images observed using
a viewer in 2 separate diagnostic sessions
Prior test data: no further information used; contact (dermoscopic) images viewed first and then
distant images (clinical), without knowing the classification of the contact image of the individual
lesions
Diagnostic threshold: NR
Diagnosis based on: consensus (2 observers); n = 2
Observer qualifications: dermatologist
Experience in practice: high experience or ‘Expert’; states “with experience in the field of PSL”
Other detail: used an AF micro Nikkor 60 lens objective mounted on a NIKON f50 camera, with
a fixed focus distance of 10 cm
Dermoscopy: evaluated in same study; no algorithm
Target condition and reference
standard(s)
Reference standard: histology (not further described)
Disease positive: 21; disease negative: 36
Target condition (final diagnoses)
Melanoma (invasive): 6; melanoma (in situ): 5; BCC: 10
’Benign’ diagnoses: 36
Flow and timing Excluded participants: no exclusions reported
Time interval to reference test: photographic procedures performed consecutively prior to surgery
Comparative Photographic procedures performed consecutively prior to surgery
Notes -
Methodological quality
Item Authors’ judgement Risk of bias Applicability concerns
DOMAIN 1: Patient Selection
Was a consecutive or random
sample of patients enrolled?
Unclear
Was a case-control design
avoided?
Yes
Did the study avoid inappropri-
ate exclusions?
Unclear
Are the included patients and
chosen study setting appropri-
ate?
No
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Did the study avoid including
participants with multiple le-
sions?
Unclear
Unclear High
DOMAIN 2: Index Test Visual inspection - image-based
Were the index test results in-
terpreted without knowledge of
the results of the reference stan-
dard?
Yes
If a threshold was used, was it
pre-specified?
Unclear
For studies reporting the ac-
curacy of multiple diagnostic
thresholds, was each threshold
or algorithm interpreted with-
out knowledge of the results of
the others?
Was the test applied and inter-
preted in a clinically applicable
manner?
No
Were thresholds or criteria for
diagnosis reported in sufficient
detail to allow replication?
No
Was the test interpretation car-
ried out by an experienced ex-
aminer?
Yes
Unclear High
DOMAIN 3: Reference Standard
Is the reference standards likely
to correctly classify the target
condition?
Yes
Were the reference standard re-
sults
interpreted without knowledge
of the results of the index tests?
Unclear
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Expert opinion (with no his-
tological confirmation) was not
used as a reference standard
Yes
Was histology interpretation
carried out by an experienced
histopathologist or by a der-
matopathologist?
Unclear
Low Unclear
DOMAIN 4: Flow and Timing
Was there an appropriate inter-
val between index test and ref-
erence standard?
Yes
Did all patients receive the same
reference standard?
Yes
Were all patients included in the
analysis?
Yes
If the reference standard in-
cludes clinical follow-up of
borderline/benign appearing le-
sions, was there a minimum
follow-up following application
of index test(s) of at least: 3
months for melanoma or cSCC
or 6 months for BCC?
If more than one algorithm was
evaluated for the same test, was
the interval between applica-
tion of the different algorithms
1 month or less?
Low
Carli 2003a
Study characteristics
Patient sampling Study design: CS
Data collection: retrospective image selection/prospective interpretation
Period of data collection: 1999-2001
Country: Italy
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Patient characteristics and set-
ting
Inclusion criteria: clinically difficult to diagnose or equivocalmelanocytic lesions randomly selected
from image database; all melanomas < 1 mm thickness
Setting: secondary (general dermatology)
Prior testing: clinical suspicion of malignancy without dermatoscopic suspicion
Setting for prior testing: secondary (general dermatology)
Exclusion criteria: ≥ 1 mm thick melanomas, dermoscopically peculiar lesions (e.g. blue naevi or
Spitz naevi)
Sample size (participants): NR
Sample size (lesions): number included: 200
Participant characteristics: none reported
Lesion characteristics: diameter < 6 mm, 58; 6-10 mm, 87; ≥ 10 mm, 55 (results reported per
subgroup) Lesions ≤ 1 mm thickness: 64; median thickness 0.3 mm, 25th-75th centile 0.00-0.58
mm; mean diameter 7.4 (SD2.79) mm; median: 7 mm (2-16 mm)
Any other detail: same lesions appear to be reported in De Giorgi 2011 but with a different set of
8 observers (De Giorgi 2011 excluded from review on this basis)
Index tests VI: no algorithm
Method of diagnosis: clinical photographs
Prior test data: no further information used; dermoscopic images interpreted subsequent to clinical
images
Diagnostic threshold: NR
Diagnosis based on: average; n = 8
Observer qualifications: dermatology registrar; 2 final year residents. Dermatologist 6
Experience in practice: mixed - 2 senior experts, 4 practicing dermatologists, 2 last year resident
dermatologists. Classified as ’high’ due to expertise/training in dermoscopy use
Other detail: clinical photos using Nikon F40 with macro lens at 15 cm
Dermoscopy: evaluated in same study; no algorithm (own choice)
Target condition and reference
standard(s)
Reference standard: histological diagnosis alone
Disease positive: 64; disease negative: 136
Target condition (final diagnoses)
Melanoma (invasive): 40; melanoma (in situ): 24
Other: 136 MN
Flow and timing Excluded participants: no exclusions reported
Time interval to reference test: interval not described
Comparative
Notes -
Methodological quality
Item Authors’ judgement Risk of bias Applicability concerns
DOMAIN 1: Patient Selection
Was a consecutive or random
sample of patients enrolled?
Yes
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Was a case-control design
avoided?
Yes
Did the study avoid inappropri-
ate exclusions?
No
Are the included patients and
chosen study setting appropri-
ate?
No
Did the study avoid including
participants with multiple le-
sions?
Unclear
High High
DOMAIN 2: Index Test Visual inspection - image-based
Were the index test results in-
terpreted without knowledge of
the results of the reference stan-
dard?
Yes
If a threshold was used, was it
pre-specified?
Unclear
For studies reporting the ac-
curacy of multiple diagnostic
thresholds, was each threshold
or algorithm interpreted with-
out knowledge of the results of
the others?
Was the test applied and inter-
preted in a clinically applicable
manner?
No
Were thresholds or criteria for
diagnosis reported in sufficient
detail to allow replication?
No
Was the test interpretation car-
ried out by an experienced ex-
aminer?
Yes
Unclear High
DOMAIN 3: Reference Standard
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Is the reference standards likely
to correctly classify the target
condition?
Yes
Were the reference standard re-
sults
interpreted without knowledge
of the results of the index tests?
Unclear
Expert opinion (with no his-
tological confirmation) was not
used as a reference standard
Yes
Was histology interpretation
carried out by an experienced
histopathologist or by a der-
matopathologist?
Yes
Low Low
DOMAIN 4: Flow and Timing
Was there an appropriate inter-
val between index test and ref-
erence standard?
Unclear
Did all patients receive the same
reference standard?
Yes
Were all patients included in the
analysis?
Yes
If the reference standard in-
cludes clinical follow-up of
borderline/benign appearing le-
sions, was there a minimum
follow-up following application
of index test(s) of at least: 3
months for melanoma or cSCC
or 6 months for BCC?
If more than one algorithm was
evaluated for the same test, was
the interval between applica-
tion of the different algorithms
1 month or less?
Unclear
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Study characteristics
Patient sampling Study design: CS
Data collection: retrospective
Period of data collection: January 2006-July 2009
Country: Taiwan
Patient characteristics and set-
ting
Inclusion criteria: potentially malignant biopsied or excised skin lesions (non-tumour specimens
excluded)
Setting: secondary (general dermatology)
Prior testing: selected for excision (no further detail)
Setting for prior testing: secondary (general dermatology)
Exclusion criteria: prior surgery; image misregistered or poor-quality images (unfocused or con-
taining a motion artefact) (considered under ’Flow and timing’)
Sample size (participants): number eligible: 3964; number included: 676
Sample size (lesions): number eligible: 4192; number included: 769
Participant characteristics: mean age: 47.6 (SD 21.0); male: 296; 43.8%
Lesion characteristics: none reported
Index tests VI: no algorithm
Method of diagnosis: in-person diagnosis
Prior test data: N/A, in-person diagnosis
Diagnostic threshold: NR; clinicians’ impressions prior to biopsy were classified as “benign”,
“malignant”, or “indeterminate”. When the clinicians were not confident enough to make a definite
benign or malignant diagnosis, the clinical impression was considered as “indeterminate”. Data
extracted for malignant vs rest and malignant/indeterminate vs rest
Diagnosis based on: single observer; board-certified staff dermatologists from institute; n = 25
Observer qualifications: dermatologist
Experience in practice: board certified; ’High’
Target condition and reference
standard(s)
Reference standard: histology (not further described)
Disease positive: 174; disease negative: 595
Target condition (final diagnoses)
Melanoma (invasive): 4; melanoma (in situ): 4; BCC: 110; cSCC: 20
’Benign’ diagnoses: 595
Flow and timing Excluded participants: misregistered or poor-quality images (unfocused or containing a motion
artifact) as a study inclusion criterion
Time interval to reference test: not described
Comparative
Notes -
Methodological quality
Item Authors’ judgement Risk of bias Applicability concerns
DOMAIN 1: Patient Selection
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Was a consecutive or random
sample of patients enrolled?
Yes
Was a case-control design
avoided?
Yes
Did the study avoid inappropri-
ate exclusions?
Yes
Are the included patients and
chosen study setting appropri-
ate?
No
Did the study avoid including
participants with multiple le-
sions?
No
Low High
DOMAIN 2: Index Test Visual Inspection - in-person
Were the index test results in-
terpreted without knowledge of
the results of the reference stan-
dard?
Yes
If a threshold was used, was it
pre-specified?
Unclear
For studies reporting the ac-
curacy of multiple diagnostic
thresholds, was each threshold
or algorithm interpreted with-
out knowledge of the results of
the others?
Was the test applied and inter-
preted in a clinically applicable
manner?
Yes
Were thresholds or criteria for
diagnosis reported in sufficient
detail to allow replication?
No
Was the test interpretation car-
ried out by an experienced ex-
aminer?
Yes
Unclear High
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DOMAIN 3: Reference Standard
Is the reference standards likely
to correctly classify the target
condition?
Yes
Were the reference standard re-
sults
interpreted without knowledge
of the results of the index tests?
Unclear
Expert opinion (with no his-
tological confirmation) was not
used as a reference standard
Yes
Was histology interpretation
carried out by an experienced
histopathologist or by a der-
matopathologist?
Unclear
Low Unclear
DOMAIN 4: Flow and Timing
Was there an appropriate inter-
val between index test and ref-
erence standard?
Unclear
Did all patients receive the same
reference standard?
Yes
Were all patients included in the
analysis?
No
If the reference standard in-
cludes clinical follow-up of
borderline/benign appearing le-
sions, was there a minimum
follow-up following application
of index test(s) of at least: 3
months for melanoma or cSCC
or 6 months for BCC?
If more than one algorithm was
evaluated for the same test, was
the interval between applica-
tion of the different algorithms
1 month or less?
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High
Collas 1999
Study characteristics
Patient sampling Study design: CS
Data collection: prospective
Period of data collection: January 1996 and August 1997
Country: France
Patient characteristics and set-
ting
Inclusion criteria: PSLs undergoing excision by dermatologists in private practice, and by hospital
dermatologists
Setting: secondary (general dermatology); private care
Prior testing: selected for excision (no further detail)
Setting for prior testing: secondary (general dermatology); private care
Exclusion criteria: none reported
Sample size (participants): number included: 353
Sample size (lesions): number included: 353
Participant characteristics: male: 46%; 162
Lesion characteristics: none reported
Index tests VI: no algorithm. Own new algorithm
Diagnosis based on features from ABCD and 7-point checklist but neither one specifically followed
Study authors selected own combination of lesion characteristics based on observed data
Method of diagnosis: in-person diagnosis
Prior test data: unclear
Diagnostic threshold: data can be extracted at a number of thresholds.
1. primary diagnosis of melanoma; 2. certainty of melanoma diagnosis; 3. various combinations of
assessed features (based on logistic regression)
Recorded: most likely clinical diagnosis; degree of melanoma suspicion and clinical sign(s) that led
to the removal decision based on ABCD rule (McCarthy 1995) and the 7-point checklist (Healsmith
1994)
Diagnosis based on: single observer; n = NR
Observer qualifications: dermatologist
Experience in practice: not described
Experience with index test: not described
Other detail: most predictive features derived by logistic regression from the following list: irregular
contours; abnormal pigmentation; blurred; frank tumor appearance; erosion, ulceration or bleeding;
regression signs; lesion recently amended; lesion appeared recently; pruritic lesion; other
Target condition and reference
standard(s)
Reference standard: histology (not further described)
Disease positive: 38; disease negative: 315
Target condition (final diagnoses)
Melanoma (in situ and invasive, or NR): 38
Other: 160
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Collas 1999 (Continued)
Flow and timing Excluded participants: no exclusions reported
Time interval to reference test: consecutive; quote: “When the dermatologist decided to resection
a pigmented lesion, he fulfilled a pre-printed sheet”
Comparative
Notes -
Methodological quality
Item Authors’ judgement Risk of bias Applicability concerns
DOMAIN 1: Patient Selection
Was a consecutive or random
sample of patients enrolled?
Unclear
Was a case-control design
avoided?
Yes
Did the study avoid inappropri-
ate exclusions?
Unclear
Are the included patients and
chosen study setting appropri-
ate?
No
Did the study avoid including
participants with multiple le-
sions?
Yes
Unclear High
DOMAIN 2: Index Test Visual Inspection - in-person
Were the index test results in-
terpreted without knowledge of
the results of the reference stan-
dard?
Yes
If a threshold was used, was it
pre-specified?
Unclear
For studies reporting the ac-
curacy of multiple diagnostic
thresholds, was each threshold
or algorithm interpreted with-
out knowledge of the results of
the others?
No
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Collas 1999 (Continued)
Was the test applied and inter-
preted in a clinically applicable
manner?
Yes
Were thresholds or criteria for
diagnosis reported in sufficient
detail to allow replication?
Yes
Was the test interpretation car-
ried out by an experienced ex-
aminer?
Unclear
Unclear Unclear
DOMAIN 3: Reference Standard
Is the reference standards likely
to correctly classify the target
condition?
Yes
Were the reference standard re-
sults
interpreted without knowledge
of the results of the index tests?
Unclear
Expert opinion (with no his-
tological confirmation) was not
used as a reference standard
Yes
Was histology interpretation
carried out by an experienced
histopathologist or by a der-
matopathologist?
Unclear
Low Unclear
DOMAIN 4: Flow and Timing
Was there an appropriate inter-
val between index test and ref-
erence standard?
Yes
Did all patients receive the same
reference standard?
Yes
Were all patients included in the
analysis?
Yes
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Collas 1999 (Continued)
If the reference standard in-
cludes clinical follow-up of
borderline/benign appearing le-
sions, was there a minimum
follow-up following application
of index test(s) of at least: 3
months for melanoma or cSCC
or 6 months for BCC?
If more than one algorithm was
evaluated for the same test, was
the interval between applica-
tion of the different algorithms
1 month or less?
Yes
Low
Cristofolini 1994
Study characteristics
Patient sampling Study design: CS
Data collection: prospective
Period of data collection: October 1990-June 1991
Country: Italy
Patient characteristics and set-
ting
Inclusion criteria: patients with pigmented lesions presenting during a campaign for the early
diagnosis of CM at the Dermatology Department in Trento
Setting: secondary (general dermatology)
Prior testing: NR
Setting for prior testing: NR
Exclusion criteria: lesions that were not taken into consideration included benign lesions, naevi
of Unna and Miescher types and naevi that showed no inclusion criteria at the ABCDE clinical
examination
Sample size (participants): number eligible: 700 people; number included: NR
Sample size (lesions): number eligible: 220; number included: 220
Participant characteristics: none reported
Lesion characteristics: none reported
Index tests VI: ABCDE
Method of diagnosis: in-person diagnosis
Prior test data: N/A, in-person diagnosis
Other test data: dermoscopy undertaken by same clinician(s) subsequent to clinical evaluation
Diagnostic threshold: lesions showing ≥ 2 of the ABCDE criteria all of which were shown the
same diagnostic importance, were considered positive
Diagnosis based on: unclear; n = 4
Observer qualifications: dermatologist
Experience in practice: high experience or ‘Expert’; all trained in the recognition of pigmented
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Cristofolini 1994 (Continued)
lesions during a training course about the clinical diagnosis of naevi and melanomas; all working in
a department where the early diagnosis of melanoma had been dealt with for over 10 years
Experience with dermoscopy: high experience/‘Expert’ users
Other detail: ABCDE criteria are (asymmetry in shape, border irregular and notched, colour
mottled-haphazard display, dimension > 6 mm, evolution changes in pigmentation)
Dermoscopy: evaluated in same study; pattern analysis
Target condition and reference
standard(s)
Reference standard: histological diagnosis alone
Target condition (final diagnoses)
Melanoma (in situ and invasive, or NR): 33
Mild//moderate dysplasia: 23 dysplastic naevi; SK: 4; benign naevus: 158 common naevus
Other: 2 thrombosed angiomas
Flow and timing Excluded participants: no exclusions reported
Time interval to reference test: not described
Time interval between index tests: clinical evaluation directly followed by dermoscopy
Comparative Clinical evaluation directly followed by dermoscopy
Notes -
Methodological quality
Item Authors’ judgement Risk of bias Applicability concerns
DOMAIN 1: Patient Selection
Was a consecutive or random
sample of patients enrolled?
Unclear
Was a case-control design
avoided?
Yes
Did the study avoid inappropri-
ate exclusions?
Yes
Are the included patients and
chosen study setting appropri-
ate?
No
Did the study avoid including
participants with multiple le-
sions?
Unclear
Unclear High
DOMAIN 2: Index Test Visual Inspection - in-person
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Cristofolini 1994 (Continued)
Were the index test results in-
terpreted without knowledge of
the results of the reference stan-
dard?
Yes
If a threshold was used, was it
pre-specified?
Yes
For studies reporting the ac-
curacy of multiple diagnostic
thresholds, was each threshold
or algorithm interpreted with-
out knowledge of the results of
the others?
Was the test applied and inter-
preted in a clinically applicable
manner?
Unclear
Were thresholds or criteria for
diagnosis reported in sufficient
detail to allow replication?
Yes
Was the test interpretation car-
ried out by an experienced ex-
aminer?
Yes
Low Unclear
DOMAIN 3: Reference Standard
Is the reference standards likely
to correctly classify the target
condition?
Yes
Were the reference standard re-
sults
interpreted without knowledge
of the results of the index tests?
Unclear
Expert opinion (with no his-
tological confirmation) was not
used as a reference standard
Yes
Was histology interpretation
carried out by an experienced
histopathologist or by a der-
matopathologist?
Unclear
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Cristofolini 1994 (Continued)
Low Unclear
DOMAIN 4: Flow and Timing
Was there an appropriate inter-
val between index test and ref-
erence standard?
Unclear
Did all patients receive the same
reference standard?
Yes
Were all patients included in the
analysis?
Yes
If the reference standard in-
cludes clinical follow-up of
borderline/benign appearing le-
sions, was there a minimum
follow-up following application
of index test(s) of at least: 3
months for melanoma or cSCC
or 6 months for BCC?
If more than one algorithm was
evaluated for the same test, was
the interval between applica-
tion of the different algorithms
1 month or less?
Unclear
Cristofolini 1997
Study characteristics
Patient sampling Study design: CS
Data collection: prospective
Period of data collection: November 1992-September 1993
Country: Italy
Patient characteristics and set-
ting
Inclusion criteria: patients with small and flat common and atypical PSLs recruited during a health
campaign for the early diagnosis of CM underwent clinical diagnosis, computerised analysis by SVS
and subsequent skin biopsy
Setting: secondary (general dermatology)
Prior testing: no prior testing
Setting for prior testing: secondary (general dermatology)
Exclusion criteria: none reported
Sample size (participants): 176
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Cristofolini 1997 (Continued)
Sample size (lesions): 176
Participant characteristics: none reported
Lesion characteristics: none reported
Index tests VI: ABCD
Method of diagnosis: in-person diagnosis
Prior test data: clinical examination and/or case notes
Diagnostic threshold: NR; examined individual ABCD characteristics but no ’rule’ as to when to
diagnose melanoma; appears to be subjective diagnosis
Diagnosis based on: consensus (3 observers) (n = 3)
Observer qualifications: dermatologist
Experience in practice: not described in paper but judged as ’High’; states that, quote: “All lesions
were examined by three dermatologists according to the ABCD system, if they disagreed a fourth
dermatologist an expert in the diagnosis of pigmented lesions was consulted.” Cristofolini 1994
describes 4 dermatologists “trained in the recognition of pigmented lesions”, 3/4 are in common
with Cristofolini 1997.
Target condition and reference
standard(s)
Reference standard: histological diagnosis alone
Target condition (final diagnoses)
Melanoma (in situ and invasive, or NR): 35
Other: 141 MN
Flow and timing Excluded participants: NR
Time interval to reference test: quote: “subsequent skin biopsy”
Time interval between index test(s): NR, appears to be simultaneous
Comparative
Notes -
Methodological quality
Item Authors’ judgement Risk of bias Applicability concerns
DOMAIN 1: Patient Selection
Was a consecutive or random
sample of patients enrolled?
Unclear
Was a case-control design
avoided?
Yes
Did the study avoid inappropri-
ate exclusions?
Unclear
Are the included patients and
chosen study setting appropri-
ate?
No
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Cristofolini 1997 (Continued)
Did the study avoid including
participants with multiple le-
sions?
Unclear
Unclear High
DOMAIN 2: Index Test Visual Inspection - in-person
Were the index test results in-
terpreted without knowledge of
the results of the reference stan-
dard?
Yes
If a threshold was used, was it
pre-specified?
Unclear
For studies reporting the ac-
curacy of multiple diagnostic
thresholds, was each threshold
or algorithm interpreted with-
out knowledge of the results of
the others?
Was the test applied and inter-
preted in a clinically applicable
manner?
No
Were thresholds or criteria for
diagnosis reported in sufficient
detail to allow replication?
Yes
Was the test interpretation car-
ried out by an experienced ex-
aminer?
Yes
Unclear High
DOMAIN 3: Reference Standard
Is the reference standards likely
to correctly classify the target
condition?
Yes
Were the reference standard re-
sults
interpreted without knowledge
of the results of the index tests?
Unclear
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Cristofolini 1997 (Continued)
Expert opinion (with no his-
tological confirmation) was not
used as a reference standard
Yes
Was histology interpretation
carried out by an experienced
histopathologist or by a der-
matopathologist?
Unclear
Low Unclear
DOMAIN 4: Flow and Timing
Was there an appropriate inter-
val between index test and ref-
erence standard?
Yes
Did all patients receive the same
reference standard?
Yes
Were all patients included in the
analysis?
Yes
If the reference standard in-
cludes clinical follow-up of
borderline/benign appearing le-
sions, was there a minimum
follow-up following application
of index test(s) of at least: 3
months for melanoma or cSCC
or 6 months for BCC?
If more than one algorithm was
evaluated for the same test, was
the interval between applica-
tion of the different algorithms
1 month or less?
Low
de Giorgi 2012
Study characteristics
Patient sampling Study design: CS
Data collection: retrospective image selection/prospective interpretation
Period of data collection: October 2006-September 2010
Country: Italy
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de Giorgi 2012 (Continued)
Patient characteristics and set-
ting
Inclusion criteria: pigmented melanocytic skin lesions with a maximum diameter of 6 mm excised
at Deptartment of Dermatology
Setting: secondary (general dermatology)
Prior testing: NR
Setting for prior testing: NR
Exclusion criteria: location/site of lesion - palmar and plantar regions, mucosal lesions and pig-
mented melanocytic lesions of the nails excluded
Sample size (participants): NR
Sample size (lesions): number included: 103
Participant characteristics: mean age: melanoma group male (50.4 years) female (48.4 years);
benign group male (36 years) female (36.8 years)
Lesion characteristics: head/neck: 3; trunk: 21; upper limbs/shoulder: 16; lower limbs/hip: 26;
back = 34; dorsal acral = 3. Thickness: ≤ 1 mm 15; > 1 mm = 1 MM
Index tests VI: ABCD
Method of diagnosis: clinical photographs
Prior test data: unclear
Other test data: dermoscopic images also presented separately to observer (only presence/absence
of particular dermoscopic features recorded; not an overall diagnostic assessment)
Diagnostic threshold: ABCD criteria ≥ 2 criteria present
Diagnosis based on: consensus (3 observers); n = 3
Observer qualifications: dermatologist
Experience in practice: high experience or ‘Expert’; quote: “the four dermatologists had the same
level of training and experience in dermatology, with more than 5 years of practice in dermoscopy”
Target condition and reference
standard(s)
Reference standard: histological diagnosis alone
Disease positive: 34; disease negative: 69
Target condition (final diagnoses)
Melanoma (in situ and invasive, or NR): 34
’Benign’ diagnoses: 69 benign melanocytic nevus
Flow and timing Excluded participants: none reported
Time interval to reference test: NR
Comparative
Notes -
Methodological quality
Item Authors’ judgement Risk of bias Applicability concerns
DOMAIN 1: Patient Selection
Was a consecutive or random
sample of patients enrolled?
Yes
Was a case-control design
avoided?
Yes
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de Giorgi 2012 (Continued)
Did the study avoid inappropri-
ate exclusions?
No
Are the included patients and
chosen study setting appropri-
ate?
No
Did the study avoid including
participants with multiple le-
sions?
Unclear
High High
DOMAIN 2: Index Test Visual inspection - image-based
Were the index test results in-
terpreted without knowledge of
the results of the reference stan-
dard?
Yes
If a threshold was used, was it
pre-specified?
No
For studies reporting the ac-
curacy of multiple diagnostic
thresholds, was each threshold
or algorithm interpreted with-
out knowledge of the results of
the others?
Was the test applied and inter-
preted in a clinically applicable
manner?
No
Were thresholds or criteria for
diagnosis reported in sufficient
detail to allow replication?
Yes
Was the test interpretation car-
ried out by an experienced ex-
aminer?
Yes
High High
DOMAIN 3: Reference Standard
Is the reference standards likely
to correctly classify the target
condition?
Yes
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de Giorgi 2012 (Continued)
Were the reference standard re-
sults
interpreted without knowledge
of the results of the index tests?
Unclear
Expert opinion (with no his-
tological confirmation) was not
used as a reference standard
Yes
Was histology interpretation
carried out by an experienced
histopathologist or by a der-
matopathologist?
Yes
Low Low
DOMAIN 4: Flow and Timing
Was there an appropriate inter-
val between index test and ref-
erence standard?
Unclear
Did all patients receive the same
reference standard?
Yes
Were all patients included in the
analysis?
Yes
If the reference standard in-
cludes clinical follow-up of
borderline/benign appearing le-
sions, was there a minimum
follow-up following application
of index test(s) of at least: 3
months for melanoma or cSCC
or 6 months for BCC?
If more than one algorithm was
evaluated for the same test, was
the interval between applica-
tion of the different algorithms
1 month or less?
Unclear
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Dolianitis 2005
Study characteristics
Patient sampling Study design: CCS
Data collection: retrospective image selection/prospective interpretation
Period of data collection: July 2001-June 2002
Country: Australia
Patient characteristics and set-
ting
Inclusion criteria: dermoscopy training study using a CD with 5 test sets of images, each with 40
images of melanocytic skin lesions. Only good-quality macroscopic and dermoscopic images were
included
Setting: training images; study author’s institute, Deptartment of Dermatology, University of Mel-
bourne
Prior testing: unclear
Setting for prior testing: NR
Exclusion criteria: nonmelanocytic lesions; poor-quality index test image, only good-qualitymacro-
scopic and dermoscopic images were included, where the whole lesion was visible, including the
entire periphery (considered under ’Flow and timing’)
Sample size (participants): NR
Sample size (lesions): number eligible: 40; number included: 40
Participant characteristics: NR
Lesion characteristics: ≤ 1 mm thickness: 14 invasive melanomas; median 0.50 mm
Index tests VI: no algorithm
Method of diagnosis: clinical photographs alone
Prior test data: no further information used
Other test data: dermoscopic images presented to observer subsequent to diagnosis using clinical
images alone
Diagnostic threshold: NR
Diagnosis based on: average; 61 participants (invited to participate in a study comparing dermo-
scopic algorithms; advertised at several medical meetings and on a Website for primary care physi-
cians)
Observer qualifications: 10 dermatologists, 16 dermatology trainees, 35 GPs
Experience in practice: mixed. Participant (volunteers), quote: ”had a range of experience levels
with assessment of skin lesions [outlined in detail in the paper]... and a significant number were
novices in dermoscopy”. Paper reports 82% of participants responded that they assessed at least 2-4
PSL per week. Participants were given explanatory writtenmaterial and CDs containing educational
material on dermoscopy and test images
Dermoscopy: evaluated in same study based on dermoscopic images alone; pattern analysis; 7-point
checklist; ABCD; Menzies criteria
Target condition and reference
standard(s)
Reference standard: histological diagnosis plus other (1 lesion described as having no biopsy per-
formed)
Histology (not further described). Disease positive: 20; disease negative: 19
Expert diagnosis: 1
Target condition (final diagnoses)
Melanoma (invasive): 18; lentigo maligna 2
Benign naevus: 7 dysplastic naevi; 3 Spitz naevi; 3 junctional naevi; 2 compound naevi; 4 other
(ink-spot lentigo, blue naevus, solar lentigo, ephelis)
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Dolianitis 2005 (Continued)
Flow and timing Excluded participants: none reported
Time interval to reference test: NR
Time interval between index test(s): NR
Comparative
Notes -
Methodological quality
Item Authors’ judgement Risk of bias Applicability concerns
DOMAIN 1: Patient Selection
Was a consecutive or random
sample of patients enrolled?
Yes
Was a case-control design
avoided?
No
Did the study avoid inappropri-
ate exclusions?
Unclear
Are the included patients and
chosen study setting appropri-
ate?
No
Did the study avoid including
participants with multiple le-
sions?
Unclear
High High
DOMAIN 2: Index Test Visual inspection - image-based
Were the index test results in-
terpreted without knowledge of
the results of the reference stan-
dard?
Yes
If a threshold was used, was it
pre-specified?
Unclear
For studies reporting the ac-
curacy of multiple diagnostic
thresholds, was each threshold
or algorithm interpreted with-
out knowledge of the results of
the others?
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Dolianitis 2005 (Continued)
Was the test applied and inter-
preted in a clinically applicable
manner?
No
Were thresholds or criteria for
diagnosis reported in sufficient
detail to allow replication?
No
Was the test interpretation car-
ried out by an experienced ex-
aminer?
Unclear
Unclear High
DOMAIN 3: Reference Standard
Is the reference standards likely
to correctly classify the target
condition?
Yes
Were the reference standard re-
sults
interpreted without knowledge
of the results of the index tests?
Unclear
Expert opinion (with no his-
tological confirmation) was not
used as a reference standard
No
Was histology interpretation
carried out by an experienced
histopathologist or by a der-
matopathologist?
Unclear
Low High
DOMAIN 4: Flow and Timing
Was there an appropriate inter-
val between index test and ref-
erence standard?
Unclear
Did all patients receive the same
reference standard?
No
Were all patients included in the
analysis?
Yes
121Visual inspection for diagnosing cutaneous melanoma in adults (Review)
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Dolianitis 2005 (Continued)
If the reference standard in-
cludes clinical follow-up of
borderline/benign appearing le-
sions, was there a minimum
follow-up following application
of index test(s) of at least: 3
months for melanoma or cSCC
or 6 months for BCC?
Unclear
If more than one algorithm was
evaluated for the same test, was
the interval between applica-
tion of the different algorithms
1 month or less?
High
Dummer 1993
Study characteristics
Patient sampling Study design: CS
Data collection: prospective
Period of data collection: 12-month period (year/dates NR)
Country: Germany
Patient characteristics and set-
ting
Inclusion criteria: patients with skin lesions difficult to diagnose clinically
Setting: specialist unit (skin cancer clinic/PLC)
Prior testing: clinical suspicion of malignancy without dermatoscopic suspicion
Setting for prior testing: specialist unit (skin cancer clinic/PLC). A type of specialist-care-derma-
tology-based clinic
Exclusion criteria: patients who had excisions performed in individual practices or where there was
no histology or cases that were so obvious they did not need to have further investigation (clearly
benign)
Sample size (participants): NR
Sample size (lesions): number eligible: 824; number included: 771
Participant characteristics: NR
Lesion characteristics: NR
Index tests VI: no algorithm
Method of diagnosis: in person
Prior test data: in person
Other test data: dermoscopic images viewed separately
Diagnostic threshold: NR
Diagnosis based on: single observer; (n = 2 or 3)
Observer qualifications: unclear; clinician based in dermatology clinic
Experience in practice: unclear
Experience with index test: unclear
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Dummer 1993 (Continued)
Target condition and reference
standard(s)
Reference standard: histological diagnosis alone
Disease positive: 23 MM; disease negative: 748 benign
Target condition (final diagnoses)
Invasive melanoma: 23
Benign naevus 706; SK 4; benign non-melanocytic naevus 32
Flow and timing Excluded participants: 53 NML not included in the final analysis (no melanomas present in this
group)
Time interval to reference test: NR
Time interval between index test(s): NR
Comparative
Notes -
Methodological quality
Item Authors’ judgement Risk of bias Applicability concerns
DOMAIN 1: Patient Selection
Was a consecutive or random
sample of patients enrolled?
Unclear
Was a case-control design
avoided?
Yes
Did the study avoid inappropri-
ate exclusions?
Yes
Are the included patients and
chosen study setting appropri-
ate?
No
Did the study avoid including
participants with multiple le-
sions?
Unclear
Unclear High
DOMAIN 2: Index Test Visual Inspection - in-person
Were the index test results in-
terpreted without knowledge of
the results of the reference stan-
dard?
Yes
If a threshold was used, was it
pre-specified?
Unclear
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Dummer 1993 (Continued)
For studies reporting the ac-
curacy of multiple diagnostic
thresholds, was each threshold
or algorithm interpreted with-
out knowledge of the results of
the others?
Was the test applied and inter-
preted in a clinically applicable
manner?
Yes
Were thresholds or criteria for
diagnosis reported in sufficient
detail to allow replication?
No
Was the test interpretation car-
ried out by an experienced ex-
aminer?
Unclear
Unclear High
DOMAIN 3: Reference Standard
Is the reference standards likely
to correctly classify the target
condition?
Yes
Were the reference standard re-
sults
interpreted without knowledge
of the results of the index tests?
Unclear
Expert opinion (with no his-
tological confirmation) was not
used as a reference standard
Yes
Was histology interpretation
carried out by an experienced
histopathologist or by a der-
matopathologist?
Unclear
Low Unclear
DOMAIN 4: Flow and Timing
Was there an appropriate inter-
val between index test and ref-
erence standard?
Unclear
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Dummer 1993 (Continued)
Did all patients receive the same
reference standard?
Yes
Were all patients included in the
analysis?
No
If the reference standard in-
cludes clinical follow-up of
borderline/benign appearing le-
sions, was there a minimum
follow-up following application
of index test(s) of at least: 3
months for melanoma or cSCC
or 6 months for BCC?
If more than one algorithm was
evaluated for the same test, was
the interval between applica-
tion of the different algorithms
1 month or less?
High
Ek 2005
Study characteristics
Patient sampling Study design: CS
Data collection: prospective
Period of data collection: January 2001-December 2002
Country: Australia
Patient characteristics and set-
ting
Inclusion criteria: lesions excised at tertiary referral centre for the management of cancers; only
those lesions in which malignancy could not be excluded were included
Setting: specialist unit (skin cancer clinic/PLC)
Prior testing: selected for excision (no further detail)
Setting for prior testing: specialist unit (skin cancer clinic/PLC)
Exclusion criteria: punch, shave or incisional biopsies and palliative excisions. Equivocal pathology
report (n = 56)
Sample size (participants): number eligible: 1302; number included: 1223
Sample size (lesions): number eligible: 2678; number included: 2582
Participant characteristics: mean age: 73.6 years (16-102 years); male: 784 (64.1%); history of
melanoma/skin cancer (%) 224; 8.7% recurrent lesions
Lesion characteristics: head/neck: 61%; trunk: 14.4%; limbs: 24.6%
Index tests VI: no algorithm
Method of diagnosis: in-person diagnosis
Prior test data: N/A, in-person diagnosis
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Ek 2005 (Continued)
Diagnostic threshold: NR, pre-operative diagnosis
Diagnosis based on: unclear; likely single (n = 5)
Observer qualifications: 3 consultants, a plastic surgery trainee and a clinical assistant
Experience in practice: mixed (low and high experience combined); plastic surgery trainee usually
1st year, on 6-month rotation; clinical assistant described as having “many years of experience”
Other detail: some results are presented for consultant, senior registrar and registrar but underlying
patient numbers are not provided per observer to allow separate 2x2 estimation. The discussion
does describe the “six MM misdiagnosed as benign … as .. assessed by non-consultants”
Target condition and reference
standard(s)
Reference standard: histological diagnosis alone
Target condition (final diagnoses)
Melanoma (in situ and invasive, or NR): 23
BCC: 1214; cSCC: 517
’Benign’ diagnoses: 188 (7.3%) SCC in situ (Bowen’s disease), 330 (12.8%) solar keratoses, 63 (2.
4%) seborrhoeic keratoses 247 (9.6%) were other benign lesions
Flow and timing Excluded participants: lesions with incomplete or incorrectly entered proformas were excluded (n
= 40)
Index to reference interval: consecutive; used pre-operative clinical diagnosis of lesions undergoing
biopsy
Comparative
Notes -
Methodological quality
Item Authors’ judgement Risk of bias Applicability concerns
DOMAIN 1: Patient Selection
Was a consecutive or random
sample of patients enrolled?
Yes
Was a case-control design
avoided?
Yes
Did the study avoid inappropri-
ate exclusions?
No
Are the included patients and
chosen study setting appropri-
ate?
Unclear
Did the study avoid including
participants with multiple le-
sions?
No
High High
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Ek 2005 (Continued)
DOMAIN 2: Index Test Visual Inspection - in-person
Were the index test results in-
terpreted without knowledge of
the results of the reference stan-
dard?
Yes
If a threshold was used, was it
pre-specified?
Unclear
For studies reporting the ac-
curacy of multiple diagnostic
thresholds, was each threshold
or algorithm interpreted with-
out knowledge of the results of
the others?
Was the test applied and inter-
preted in a clinically applicable
manner?
Yes
Were thresholds or criteria for
diagnosis reported in sufficient
detail to allow replication?
No
Was the test interpretation car-
ried out by an experienced ex-
aminer?
Unclear
Unclear High
DOMAIN 3: Reference Standard
Is the reference standards likely
to correctly classify the target
condition?
Yes
Were the reference standard re-
sults
interpreted without knowledge
of the results of the index tests?
Unclear
Expert opinion (with no his-
tological confirmation) was not
used as a reference standard
Yes
Was histology interpretation
carried out by an experienced
histopathologist or by a der-
Unclear
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matopathologist?
Low Unclear
DOMAIN 4: Flow and Timing
Was there an appropriate inter-
val between index test and ref-
erence standard?
Yes
Did all patients receive the same
reference standard?
Yes
Were all patients included in the
analysis?
No
If the reference standard in-
cludes clinical follow-up of
borderline/benign appearing le-
sions, was there a minimum
follow-up following application
of index test(s) of at least: 3
months for melanoma or cSCC
or 6 months for BCC?
If more than one algorithm was
evaluated for the same test, was
the interval between applica-
tion of the different algorithms
1 month or less?
High
Gachon 2005
Study characteristics
Patient sampling Study design: CS (dermatologists recruited and asked to use standardised questionnaire formwhen-
ever he or she decided to remove a nevus or MM for any reason, e.g. suspicion of MM, aesthetics,
comfort, prevention)
Data collection: prospective
Period of data collection: NR
Country: France
Patient characteristics and set-
ting
Inclusion criteria: melanocytic skin lesions removed for any reason (e.g. suspicion of melanoma,
aesthetics, comfort, prevention) by volunteer dermatologists
Setting: secondary (general dermatology) and private care; mostly ”community dermatologists
working in a private setting, and only 2 were academic dermatologists“
Prior testing: clinical suspicion of malignancy without dermatoscopic suspicion/patient request for
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Gachon 2005 (Continued)
evaluation/excision; 1199 (29.7%) excised because they were considered suspicious by the derma-
tologist, and 869 (21.5%) because they were considered as precursors by the dermatologist; 1634
(40.7%) removed due to aesthetic or functional reasons, and 535 (13.3%) “only to reassure the
patient”
Setting for prior testing: N/A
Exclusion criteria: none reported
Sample size (participants): NR
Sample size (lesions): number included: 4036
Participant characteristics: none reported
Lesion characteristics: 36 (24.1%) of 149 melanoma were in situ or other invasive lesions with a
median Breslow thickness of 0.60 mm
Index tests VI: no algorithm. Accuracy presented only for clinician’s first clinical impression of lesions; after
recording likelihood of melanoma, assessments were made as to the contributions of pattern recog-
nition, ABCD criteria and ugly duckling (differential recognition)
Method of diagnosis: in-person diagnosis
Prior test data: N/A, in-person diagnosis
Diagnostic threshold: ’considered suspicious’ by dermatologist
Diagnosis based on: single observer; (n = 135 of 200 volunteers)
Observer qualifications: dermatologist
Experience in practice: not described; most were community dermatologists working in a private
setting, and 2 were academic dermatologists
Experience with index test: not described
Target condition and reference
standard(s)
Reference standard: histological diagnosis alone
Disease positive: 149; disease negative: 3887
Target condition (final diagnoses)
Melanoma (in situ and invasive, or NR): 149 (36 were in situ or other invasive lesions with a median
Breslow thickness of 0.60 mm)
’Benign’ diagnoses: 3629 naevi (89.9%); 4 uncertain MMs/naevi (0.1%); and 254 NML clinically
considered to be naevi or MMs (6.3%)
Flow and timing Excluded participants: none reported
Time interval to reference test: NR
Comparative
Notes -
Methodological quality
Item Authors’ judgement Risk of bias Applicability concerns
DOMAIN 1: Patient Selection
Was a consecutive or random
sample of patients enrolled?
Yes
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Gachon 2005 (Continued)
Was a case-control design
avoided?
Yes
Did the study avoid inappropri-
ate exclusions?
Unclear
Are the included patients and
chosen study setting appropri-
ate?
No
Did the study avoid including
participants with multiple le-
sions?
Unclear
Unclear High
DOMAIN 2: Index Test Visual Inspection - in-person
Were the index test results in-
terpreted without knowledge of
the results of the reference stan-
dard?
Yes
If a threshold was used, was it
pre-specified?
Unclear
For studies reporting the ac-
curacy of multiple diagnostic
thresholds, was each threshold
or algorithm interpreted with-
out knowledge of the results of
the others?
Was the test applied and inter-
preted in a clinically applicable
manner?
Yes
Were thresholds or criteria for
diagnosis reported in sufficient
detail to allow replication?
No
Was the test interpretation car-
ried out by an experienced ex-
aminer?
Unclear
Unclear High
DOMAIN 3: Reference Standard
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Gachon 2005 (Continued)
Is the reference standards likely
to correctly classify the target
condition?
Yes
Were the reference standard re-
sults
interpreted without knowledge
of the results of the index tests?
Unclear
Expert opinion (with no his-
tological confirmation) was not
used as a reference standard
Yes
Was histology interpretation
carried out by an experienced
histopathologist or by a der-
matopathologist?
Unclear
Low Unclear
DOMAIN 4: Flow and Timing
Was there an appropriate inter-
val between index test and ref-
erence standard?
Unclear
Did all patients receive the same
reference standard?
Yes
Were all patients included in the
analysis?
Yes
If the reference standard in-
cludes clinical follow-up of
borderline/benign appearing le-
sions, was there a minimum
follow-up following application
of index test(s) of at least: 3
months for melanoma or cSCC
or 6 months for BCC?
If more than one algorithm was
evaluated for the same test, was
the interval between applica-
tion of the different algorithms
1 month or less?
Unclear
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Green 1991
Study characteristics
Patient sampling Study design: CS
Data collection: prospective
Period of data collection: February 1989-August 1990
Country: Australia
Patient characteristics and set-
ting
Inclusion criteria: pigmented lesions with complete clinical and histological data
Setting: secondary (referred from surgery, dermatology, casualty)
Prior testing: NR
Setting for prior testing: surgery, dermatology and casualty departments
Exclusion criteria: none reported
Sample size (participants): number eligible: 81/number included: unclear
Sample size (lesions): number eligible: 89; number included: 70
Participant characteristics: median age 32 years; male 36 (44%)
Lesion characteristics: site trunk: 80%; limbs: 10%; face and neck 10%
Index tests VI: no algorithm
Method of diagnosis: in-person
Prior test data: in-person
Diagnostic threshold:NR, clinical diagnosis recordedplus assessment of diameter, colour, regularity
of outline, diffuseness of edge and palpability
Diagnosis based on: single observer; (n = NR)
Observer qualifications: mixed; “in the majority of cases a surgeon or a dermatologist”
Experience in practice: not described
Target condition and reference
standard(s)
Reference standard; histological diagnosis and expert diagnosis
Histology: 62/70 lesions
Expert diagnosis: 8/70 lesions; 8 lesions had clinical diagnoses assigned (all benign) in the absence
of available histology reports
Target condition (final diagnoses)
Melanoma (in situ and invasive, or NR): 5
BCC: 2; SK: 7; benign naevus: 53 oOther: 2 skin tags, 1 ’lentigo’
Flow and timing Excluded participants: 19/89 lesions excluded due to incomplete clinical and histology records
Time interval to reference test: assumed consecutive; pathology referral form used to ascertain
clinical diagnosis
Comparative
Notes -
Methodological quality
Item Authors’ judgement Risk of bias Applicability concerns
DOMAIN 1: Patient Selection
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Green 1991 (Continued)
Was a consecutive or random
sample of patients enrolled?
Unclear
Was a case-control design
avoided?
Yes
Did the study avoid inappropri-
ate exclusions?
Unclear
Are the included patients and
chosen study setting appropri-
ate?
No
Did the study avoid including
participants with multiple le-
sions?
Unclear
Unclear High
DOMAIN 2: Index Test Visual Inspection - in-person
Were the index test results in-
terpreted without knowledge of
the results of the reference stan-
dard?
Yes
If a threshold was used, was it
pre-specified?
Unclear
For studies reporting the ac-
curacy of multiple diagnostic
thresholds, was each threshold
or algorithm interpreted with-
out knowledge of the results of
the others?
Was the test applied and inter-
preted in a clinically applicable
manner?
Yes
Were thresholds or criteria for
diagnosis reported in sufficient
detail to allow replication?
No
Was the test interpretation car-
ried out by an experienced ex-
aminer?
Unclear
Unclear High
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Green 1991 (Continued)
DOMAIN 3: Reference Standard
Is the reference standards likely
to correctly classify the target
condition?
No
Were the reference standard re-
sults
interpreted without knowledge
of the results of the index tests?
Unclear
Expert opinion (with no his-
tological confirmation) was not
used as a reference standard
No
Was histology interpretation
carried out by an experienced
histopathologist or by a der-
matopathologist?
Unclear
High High
DOMAIN 4: Flow and Timing
Was there an appropriate inter-
val between index test and ref-
erence standard?
Yes
Did all patients receive the same
reference standard?
No
Were all patients included in the
analysis?
No
If the reference standard in-
cludes clinical follow-up of
borderline/benign appearing le-
sions, was there a minimum
follow-up following application
of index test(s) of at least: 3
months for melanoma or cSCC
or 6 months for BCC?
If more than one algorithm was
evaluated for the same test, was
the interval between applica-
tion of the different algorithms
1 month or less?
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Green 1991 (Continued)
High
Green 1994
Study characteristics
Patient sampling Study design: CS
Data collection: NR; appears to use previously acquired images to develop a new CAD classifier
(not included as derivation), and compare results to clinical diagnosis of clinicians as recorded in
notes. Unclear whether set up prospectively or was retrospective assessment
Period of data collection: August 1990-April 1992
Country: Australia
Patient characteristics and set-
ting
Inclusion criteria: pigmented lesions for excision
Setting: secondary (Deptartment of Surgery)
Prior testing: selected for excision (no further detail)
Setting for prior testing: NR
Exclusion criteria: none reported
Sample size (participants): number included: 129
Sample size (lesions): number eligible: 204; number included: 164
Participant characteristics: mean age 36 years, range 6-87 years; male: 42.6%
Lesion characteristics: site face/neck: 10%, trunk: 66%, limbs: 24%
Index tests VI: no algorithm
Method of diagnosis: in-person diagnosis
Prior test data: no further information used
Diagnostic threshold:NR; clinical diagnosis recordedplus assessment of diameter, colour, regularity
of outline, diffuseness of edge and palpability (same as for Green 1991)
Diagnosis based on: single observer; (n = NR)
Observer qualifications: NR
Experience in practice: not described
Target condition and reference
standard(s)
Reference standard: histology (not further described)
Disease positive: 18; disease negative: 146
Target condition (final diagnoses)
Melanoma (invasive): 18; melanoma (in situ): 3
128MN; 15miscellaneous pigmented lesions including seborrhoeic keratoses, BCCs, and lentigines
Flow and timing Excluded participants: 33 lesions excluded due to problems using the images with the CAD
software, e.g. lesion “too big”; image “obscured by hairs or surgeons pen marks” or “software was
unable to contend with the lesion characteristics, mainly because the lesion was too light or too
fragmented” or “avoidable operator error”
Time interval to reference test: NR
Comparative
Notes -
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Green 1994 (Continued)
Methodological quality
Item Authors’ judgement Risk of bias Applicability concerns
DOMAIN 1: Patient Selection
Was a consecutive or random
sample of patients enrolled?
Unclear
Was a case-control design
avoided?
Yes
Did the study avoid inappropri-
ate exclusions?
Unclear
Are the included patients and
chosen study setting appropri-
ate?
No
Did the study avoid including
participants with multiple le-
sions?
No
Unclear High
DOMAIN 2: Index Test Visual Inspection - in-person
Were the index test results in-
terpreted without knowledge of
the results of the reference stan-
dard?
Yes
If a threshold was used, was it
pre-specified?
Unclear
For studies reporting the ac-
curacy of multiple diagnostic
thresholds, was each threshold
or algorithm interpreted with-
out knowledge of the results of
the others?
Was the test applied and inter-
preted in a clinically applicable
manner?
Yes
Were thresholds or criteria for
diagnosis reported in sufficient
detail to allow replication?
No
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Green 1994 (Continued)
Was the test interpretation car-
ried out by an experienced ex-
aminer?
Unclear
Unclear High
DOMAIN 3: Reference Standard
Is the reference standards likely
to correctly classify the target
condition?
Yes
Were the reference standard re-
sults
interpreted without knowledge
of the results of the index tests?
Unclear
Expert opinion (with no his-
tological confirmation) was not
used as a reference standard
Yes
Was histology interpretation
carried out by an experienced
histopathologist or by a der-
matopathologist?
Unclear
Low Unclear
DOMAIN 4: Flow and Timing
Was there an appropriate inter-
val between index test and ref-
erence standard?
Unclear
Did all patients receive the same
reference standard?
Yes
Were all patients included in the
analysis?
No
If the reference standard in-
cludes clinical follow-up of
borderline/benign appearing le-
sions, was there a minimum
follow-up following application
of index test(s) of at least: 3
months for melanoma or cSCC
or 6 months for BCC?
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Green 1994 (Continued)
If more than one algorithm was
evaluated for the same test, was
the interval between applica-
tion of the different algorithms
1 month or less?
High
Grimaldi 2009
Study characteristics
Patient sampling Study design: CS
Data collection: prospective
Period of data collection: October 2005-March 2006
Country: Italy
Patient characteristics and set-
ting
Inclusion criteria: cutaneous pigmented lesions with digital images forwarded by primary care
physicians to a referral centre for confirmation of diagnosis
Setting: primary; lesions selected for referral by GPs; accuracy of GP diagnosis assessed
Prior testing: NR
Setting for prior testing: NR
Exclusion criteria: lesions whose removal had been explicitly demanded by the patients for aesthetic
reasons, as well as those irritated or subjected to trauma
Sample size (participants): number included: 197
Sample size (lesions): number included: 235
Participant characteristics: none reported
Lesion characteristics: none reported
Index tests VI: no algorithm
Method of diagnosis: in-person diagnosis
Prior test data: N/A, in-person diagnosis
Other test data: “two-step judgment (before and after dermoscopy) formulated by the sending
physician, who labelled each lesion as ‘benign’ or ‘suspicious for malignancy’.”
Diagnostic threshold: NR, quote, “Each physician was asked to formulate a written first judgment
of every lesion before digital acquisition and to re-evaluate it after dermoscopy”
Diagnosis based on: single observer; (n = 13)
Observer qualifications: GP; from approximately 250 primary care clinicians attending a confer-
ence, 13 volunteered to participate
Experience in practice: not clearly described; assumed to be low experience with pigmented lesions
Experience in dermoscopy: unclear; classified as ’trained’, “simple protocols for diagnosis were
made up and given to the participants via e-learning courses, direct meetings, and involving self
assessment procedures”
Dermoscopy: evaluated in same study; no algorithm (ABCD used for telediagnosis at reference
centre)
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Grimaldi 2009 (Continued)
Target condition and reference
standard(s)
Reference standard: histological diagnosis plus follow-up (reference is expert diagnosis for teleder-
matology component of study)
Histology (not further described): n = 16;disease positive: 5; disease negative: 11
Clinical follow-up (6 months) plus histology of suspicious lesions: n = 219; disease positive: 0;
disease negative: 208
Target condition (final diagnoses)
Melanoma (in situ and invasive, or NR): 5
Other: 230 benign
Flow and timing Excluded participants: NR
Time interval to reference test: NR
Time interval between index test(s): NR
Comparative
Notes -
Methodological quality
Item Authors’ judgement Risk of bias Applicability concerns
DOMAIN 1: Patient Selection
Was a consecutive or random
sample of patients enrolled?
Yes
Was a case-control design
avoided?
Yes
Did the study avoid inappropri-
ate exclusions?
Yes
Are the included patients and
chosen study setting appropri-
ate?
Yes
Did the study avoid including
participants with multiple le-
sions?
No
Low High
DOMAIN 2: Index Test Visual Inspection - in-person
Were the index test results in-
terpreted without knowledge of
the results of the reference stan-
dard?
Yes
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Grimaldi 2009 (Continued)
If a threshold was used, was it
pre-specified?
Unclear
For studies reporting the ac-
curacy of multiple diagnostic
thresholds, was each threshold
or algorithm interpreted with-
out knowledge of the results of
the others?
Was the test applied and inter-
preted in a clinically applicable
manner?
Yes
Were thresholds or criteria for
diagnosis reported in sufficient
detail to allow replication?
No
Was the test interpretation car-
ried out by an experienced ex-
aminer?
No
Unclear High
DOMAIN 3: Reference Standard
Is the reference standards likely
to correctly classify the target
condition?
No
Were the reference standard re-
sults
interpreted without knowledge
of the results of the index tests?
Unclear
Expert opinion (with no his-
tological confirmation) was not
used as a reference standard
Yes
Was histology interpretation
carried out by an experienced
histopathologist or by a der-
matopathologist?
Unclear
High Unclear
DOMAIN 4: Flow and Timing
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Grimaldi 2009 (Continued)
Was there an appropriate inter-
val between index test and ref-
erence standard?
Unclear
Did all patients receive the same
reference standard?
No
Were all patients included in the
analysis?
Yes
If the reference standard in-
cludes clinical follow-up of
borderline/benign appearing le-
sions, was there a minimum
follow-up following application
of index test(s) of at least: 3
months for melanoma or cSCC
or 6 months for BCC?
Yes
If more than one algorithm was
evaluated for the same test, was
the interval between applica-
tion of the different algorithms
1 month or less?
High
Kopf 1975
Study characteristics
Patient sampling Study design: CS
Data collection: retrospective
Period of data collection: 1955-1967
Country: USA
Patient characteristics and set-
ting
Inclusion criteria: all lesions subject to biopsy at the Oncology Section of the Skin and Cancer
Unit
Setting: specialist unit (skin cancer clinic/PLC)
Prior testing: NR
Setting for prior testing: NR
Exclusion criteria: none reported
Sample size (participants): number included: NR
Sample size (lesions): number included: 5538
Participant characteristics: none reported
Lesion characteristics: none reported
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Kopf 1975 (Continued)
Index tests VI: no algorithm
Method of diagnosis: in-person diagnosis
Prior test data: unclear
Diagnostic threshold: NR; clinical diagnosis
Diagnosis based on: single observer; in-clinic diagnosis (n = NR)
Observer qualifications: oncologist
Experience in practice: not described
Experience with index test: not described
Target condition and reference
standard(s)
Reference standard: histological diagnosis alone
Disease positive: 99; disease negative: 5439
Target condition (final diagnoses)
Melanoma (invasive): 99 (described as “malignant melanoma”)
Diagnoses listed only for false-positives; included: 3 pigmented BCC, 3 DFs, 2 junction naevi, 2
compound naevi, and 1 each of: Kaposi sarcoma, hemangioma, SK, leiomyoma, cellular blue nevus,
sclerosing hemangioma, SCC, verrucous nevus, and intradermal nevus FNs included: 6 clinically
diagnosed as pigmented BCC; 2 “other forms” of BCC; 3 junction naevi; 3 pyogenic granulomas;
2 compound naevi; 2 SCCs; 2 halo naevi; 1 Bowen disease; 1 SK; and 1 lentigo. 17 of these lesions
were pigmented and 6 were not
Flow and timing Excluded participants: none reported
Time interval to reference test: NR
Comparative
Notes -
Methodological quality
Item Authors’ judgement Risk of bias Applicability concerns
DOMAIN 1: Patient Selection
Was a consecutive or random
sample of patients enrolled?
Yes
Was a case-control design
avoided?
Yes
Did the study avoid inappropri-
ate exclusions?
Yes
Are the included patients and
chosen study setting appropri-
ate?
No
Did the study avoid including
participants with multiple le-
sions?
Unclear
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Kopf 1975 (Continued)
Low High
DOMAIN 2: Index Test Visual Inspection - in-person
Were the index test results in-
terpreted without knowledge of
the results of the reference stan-
dard?
Yes
If a threshold was used, was it
pre-specified?
Unclear
For studies reporting the ac-
curacy of multiple diagnostic
thresholds, was each threshold
or algorithm interpreted with-
out knowledge of the results of
the others?
Was the test applied and inter-
preted in a clinically applicable
manner?
Yes
Were thresholds or criteria for
diagnosis reported in sufficient
detail to allow replication?
No
Was the test interpretation car-
ried out by an experienced ex-
aminer?
Unclear
Unclear High
DOMAIN 3: Reference Standard
Is the reference standards likely
to correctly classify the target
condition?
Yes
Were the reference standard re-
sults
interpreted without knowledge
of the results of the index tests?
Unclear
Expert opinion (with no his-
tological confirmation) was not
used as a reference standard
Yes
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Kopf 1975 (Continued)
Was histology interpretation
carried out by an experienced
histopathologist or by a der-
matopathologist?
Unclear
Low Unclear
DOMAIN 4: Flow and Timing
Was there an appropriate inter-
val between index test and ref-
erence standard?
Unclear
Did all patients receive the same
reference standard?
Yes
Were all patients included in the
analysis?
Yes
If the reference standard in-
cludes clinical follow-up of
borderline/benign appearing le-
sions, was there a minimum
follow-up following application
of index test(s) of at least: 3
months for melanoma or cSCC
or 6 months for BCC?
If more than one algorithm was
evaluated for the same test, was
the interval between applica-
tion of the different algorithms
1 month or less?
Unclear
Krahn 1998
Study characteristics
Patient sampling Study design: CS
Data collection: prospective
Period of data collection: NR
Country: Germany
Patient characteristics and set-
ting
Inclusion criteria: excised PSLs
Setting: secondary (general dermatology)
Prior testing: NR
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Krahn 1998 (Continued)
Setting for prior testing: NR
Exclusion criteria: none reported
Sample size (participants): number included: 80
Sample size (lesions): number included: 80
Participant characteristics: none reported
Lesion characteristics range in thickness (melanomas) 0.18-1.9 mm; 29/39 < 0.76 mm; 7/39 0.
76-1.5 mm; 3/39 > 1.5 mm
Index tests VI: no algorithm reported
Method of diagnosis: in-person diagnosis
Prior test data: unclear
Other test data: dermoscopy undertaken by same clinician(s) subsequent to clinical evaluation
Diagnostic threshold: NR; no details
Diagnosis based on: single observer (n = 1)
Observer qualifications: NR, likely dermatologist
Experience in practice: not described
Experience with index test: not described
Dermoscopy: evaluated in same study; no algorithm
Target condition and reference
standard(s)
Reference standard: histological diagnosis alone including histometrics
Disease positive: 39; disease negative: 41
Target condition (final diagnoses)
Melanoma (invasive): 39 (SSM, lentigo MM, nodular M)
Benign naevus: 37 common naevus; 3 dysplastic nevus, 1 Spitz naevus
Flow and timing Excluded participants: none reported
Time interval to reference test: NR
Time interval between index test(s): NR
Comparative
Notes -
Methodological quality
Item Authors’ judgement Risk of bias Applicability concerns
DOMAIN 1: Patient Selection
Was a consecutive or random
sample of patients enrolled?
Unclear
Was a case-control design
avoided?
Yes
Did the study avoid inappropri-
ate exclusions?
Unclear
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Krahn 1998 (Continued)
Are the included patients and
chosen study setting appropri-
ate?
No
Did the study avoid including
participants with multiple le-
sions?
Yes
Unclear High
DOMAIN 2: Index Test Visual Inspection - in-person
Were the index test results in-
terpreted without knowledge of
the results of the reference stan-
dard?
Yes
If a threshold was used, was it
pre-specified?
Unclear
For studies reporting the ac-
curacy of multiple diagnostic
thresholds, was each threshold
or algorithm interpreted with-
out knowledge of the results of
the others?
Was the test applied and inter-
preted in a clinically applicable
manner?
Yes
Were thresholds or criteria for
diagnosis reported in sufficient
detail to allow replication?
No
Was the test interpretation car-
ried out by an experienced ex-
aminer?
Unclear
Unclear High
DOMAIN 3: Reference Standard
Is the reference standards likely
to correctly classify the target
condition?
Yes
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Krahn 1998 (Continued)
Were the reference standard re-
sults
interpreted without knowledge
of the results of the index tests?
Unclear
Expert opinion (with no his-
tological confirmation) was not
used as a reference standard
Yes
Was histology interpretation
carried out by an experienced
histopathologist or by a der-
matopathologist?
Yes
Low Low
DOMAIN 4: Flow and Timing
Was there an appropriate inter-
val between index test and ref-
erence standard?
Unclear
Did all patients receive the same
reference standard?
Yes
Were all patients included in the
analysis?
Yes
If the reference standard in-
cludes clinical follow-up of
borderline/benign appearing le-
sions, was there a minimum
follow-up following application
of index test(s) of at least: 3
months for melanoma or cSCC
or 6 months for BCC?
If more than one algorithm was
evaluated for the same test, was
the interval between applica-
tion of the different algorithms
1 month or less?
Unclear
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Langley 2001
Study characteristics
Patient sampling Study design: CS
Data collection: prospective
Period of data collection: NR
Country: USA
Patient characteristics and set-
ting
Inclusion criteria: patients with lesions scheduled for excision at the PLC to either remove atypical
naevi or to rule out melanoma or for cosmetic reasons
Setting: specialist unit (skin cancer clinic/PLC)
Prior testing: selected for excision; to remove atypical naevi or rule out melanoma or for cosmetic
reasons
Setting for prior testing: NR
Exclusion criteria: none reported
Sample size (participants): number included: 29
Sample size (lesions): number eligible: 40; number included: 38
Participant characteristics: mean age 39 years, range 19-95 years; male: 14 (48%)
Lesion characteristics: none reported
Index tests VI: no algorithm
Method of diagnosis: in-person diagnosis
Prior test data: N/A, in-person diagnosis
Diagnostic threshold: NR; clinical diagnosis
Diagnosis based on: unclear likely in clinic diagnoses (n = NR)
Observer qualifications: NR, likely dermatologists
Experience in practice: not described
Experience with index test: not described
Target condition and reference
standard(s)
Reference standard: histological diagnosis plus other
Histology details (n = 38):“After excision, the samples were processed in paraffin and stained with
H&E for routine light microscopy. Correlation was performed by examining the confocal images
and the pathology sections to compare nuclear, cellular, and morphologic detail and to identify
potential significance of the in vivo CSLM observations. For the histologic diagnosis of dysplastic
naevi, we used the criteria that are defined in the World Health Organization consensus study.”
Expert diagnosis (n = 2): 2 lesions did not undergo histology; expert diagnosis only (both benign)
Target condition (final diagnoses)
Melanoma (invasive): 3; melanoma (in situ): 1; lentigo maligna 2
Dysplastic naevi: 17; benign naevus: 15
Flow and timing Excluded participants: none reported
Time interval to reference test: NR
Time interval between index test(s): NR
Comparative
Notes -
Methodological quality
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Langley 2001 (Continued)
Item Authors’ judgement Risk of bias Applicability concerns
DOMAIN 1: Patient Selection
Was a consecutive or random
sample of patients enrolled?
Unclear
Was a case-control design
avoided?
Yes
Did the study avoid inappropri-
ate exclusions?
Unclear
Are the included patients and
chosen study setting appropri-
ate?
Unclear
Did the study avoid including
participants with multiple le-
sions?
No
Unclear High
DOMAIN 2: Index Test Visual Inspection - in-person
Were the index test results in-
terpreted without knowledge of
the results of the reference stan-
dard?
Yes
If a threshold was used, was it
pre-specified?
Unclear
For studies reporting the ac-
curacy of multiple diagnostic
thresholds, was each threshold
or algorithm interpreted with-
out knowledge of the results of
the others?
Was the test applied and inter-
preted in a clinically applicable
manner?
Unclear
Were thresholds or criteria for
diagnosis reported in sufficient
detail to allow replication?
No
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Langley 2001 (Continued)
Was the test interpretation car-
ried out by an experienced ex-
aminer?
Unclear
Unclear High
DOMAIN 3: Reference Standard
Is the reference standards likely
to correctly classify the target
condition?
Yes
Were the reference standard re-
sults
interpreted without knowledge
of the results of the index tests?
Unclear
Expert opinion (with no his-
tological confirmation) was not
used as a reference standard
No
Was histology interpretation
carried out by an experienced
histopathologist or by a der-
matopathologist?
Unclear
Low High
DOMAIN 4: Flow and Timing
Was there an appropriate inter-
val between index test and ref-
erence standard?
Unclear
Did all patients receive the same
reference standard?
Yes
Were all patients included in the
analysis?
Yes
If the reference standard in-
cludes clinical follow-up of
borderline/benign appearing le-
sions, was there a minimum
follow-up following application
of index test(s) of at least: 3
months for melanoma or cSCC
or 6 months for BCC?
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Langley 2001 (Continued)
If more than one algorithm was
evaluated for the same test, was
the interval between applica-
tion of the different algorithms
1 month or less?
Unclear
Lorentzen 1999
Study characteristics
Patient sampling Study design: CS
Data collection: prospective
Period of data collection: 1994-1997
Country: Denmark
Patient characteristics and set-
ting
Inclusion criteria: patients with lesions suspicious for CMM referred to outpatients clinic
Excluded participants: none reported
Time interval to reference test: NR
Setting: NR
Prior testing: clinical suspicion of malignancy without dermatoscopic suspicion
Setting for prior testing: NR
Exclusion criteria: poor-quality index test image (considered under flow/timing)
Sample size (participants): number eligible: 242; number included: 232
Sample size (lesions): number eligible: 242; number included: 232*
Participant characteristics: none reported
Lesion characteristics: none reported
*NBNot all cases were assessed by all observers; 2x2 are based on presented sensitivity and specificity
estimates for full dataset of lesions; “the dermatoscopy experts assessed almost all cases (98 ± 100%)
, whereas the non-expert group completed fewer assessments, from 76 to 98%.”
Index tests VI: no algorithm
Method of diagnosis: clinical photographs
Prior test data: no further information used; no option to change clinical diagnosis after viewing
dermoscopic image
Other test data: dermoscopic images presented to observer subsequent to diagnosis using clinical
images alone; clinical images presented before dermoscopic images
Diagnostic threshold: NR; clinical diagnosis
Diagnosis based on: average; n = 9
Observer qualifications: dermatologist
Experience in practice: high; moderate; mixed (average reported); 4 “experienced dermatologists”
(4-5 years daily experience) and 5 “non-expert dermatology residents” (1-2 years’ interest and formal
training in dermatoscopy)
Experience with index test: high; moderate; mixed
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Target condition and reference
standard(s)
Reference standard: histological diagnosis alone
Disease positive: 65 ; disease negative: 167
Target condition (final diagnoses)
Melanoma (invasive): 49 “malignant melanoma”
BCC: 16
SK: 12; benign naevus: 137 (pigmented naevi = 116; blue naevi = 16; atypical naevi = 5); Other:
18 (Spitz naevi, Bowen’s disease, sarcoid, nevus spilus, hemangioma, and others)
Flow and timing Excluded participants: 10 cases were “considered unfit for evaluation” due to poor-quality image
Reference interval: “biopsy specimens...were obtained after the clinical and dermatoscopic pho-
tographs had been performed”
Comparative
Notes -
Methodological quality
Item Authors’ judgement Risk of bias Applicability concerns
DOMAIN 1: Patient Selection
Was a consecutive or random
sample of patients enrolled?
Unclear
Was a case-control design
avoided?
Yes
Did the study avoid inappropri-
ate exclusions?
Yes
Are the included patients and
chosen study setting appropri-
ate?
No
Did the study avoid including
participants with multiple le-
sions?
Unclear
Unclear High
DOMAIN 2: Index Test Visual inspection - image-based
Were the index test results in-
terpreted without knowledge of
the results of the reference stan-
dard?
Yes
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Lorentzen 1999 (Continued)
If a threshold was used, was it
pre-specified?
Unclear
For studies reporting the ac-
curacy of multiple diagnostic
thresholds, was each threshold
or algorithm interpreted with-
out knowledge of the results of
the others?
Was the test applied and inter-
preted in a clinically applicable
manner?
No
Were thresholds or criteria for
diagnosis reported in sufficient
detail to allow replication?
No
Was the test interpretation car-
ried out by an experienced ex-
aminer?
Yes
Unclear High
DOMAIN 3: Reference Standard
Is the reference standards likely
to correctly classify the target
condition?
Yes
Were the reference standard re-
sults
interpreted without knowledge
of the results of the index tests?
Unclear
Expert opinion (with no his-
tological confirmation) was not
used as a reference standard
Yes
Was histology interpretation
carried out by an experienced
histopathologist or by a der-
matopathologist?
Unclear
Low Unclear
DOMAIN 4: Flow and Timing
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Lorentzen 1999 (Continued)
Was there an appropriate inter-
val between index test and ref-
erence standard?
Yes
Did all patients receive the same
reference standard?
Yes
Were all patients included in the
analysis?
No
If the reference standard in-
cludes clinical follow-up of
borderline/benign appearing le-
sions, was there a minimum
follow-up following application
of index test(s) of at least: 3
months for melanoma or cSCC
or 6 months for BCC?
If more than one algorithm was
evaluated for the same test, was
the interval between applica-
tion of the different algorithms
1 month or less?
High
McGovern 1992
Study characteristics
Patient sampling Study design: CS
Data collection: prospective
Period of data collection: 1 November 1989-31 October 1990
Country: USA
Patient characteristics and set-
ting
Inclusion criteria: pigmented lesions excised to rule out dysplasia, lentigo maligna or MM
Setting: secondary (general dermatology); army dermatology clinic - appears to be open access
Prior testing: no prior testing. Multiple reasons given for seeking dermatological consultation,
including (in descending order): increasing size, “mole check”, inflammation, colour change, itch,
follow-up, variegation, cosmetic, referral, irregular border, seen for other lesion, unknown, large size
Setting for prior testing: N/A
Exclusion criteria: none reported
Sample size (participants): number eligible: 179; number included: NR
Sample size (lesions): number eligible: 237; number included: 13 lesions excluded and 32 lesions
unaccounted for
Participant characteristics: mean age: 44 (SD 18); range: 3 months to 86 years; male: 89 (49%)
Lesion characteristics: lesion site: head/neck: 71 (30%); trunk: 52 (23%); upper limbs/shoulder:
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McGovern 1992 (Continued)
22 (9%); lower limbs/hip: 33 (14%); back = 58 (24%); genitalia = 1 (0.4%)
Index tests VI: ABCD; assessed only ’BCD’; also referred to in paper as 3-point checklist; Glasgow/MacKie
original 7-point checklist (Keefe 1990)
Method of diagnosis: in-person diagnosis
Prior test data: unclear
Diagnostic threshold: described in detail; ABCD excluded asymmetry - one half does not match
the other half )
Diagnosis based on: single observer in clinic diagnoses used (n = NR)
Observer qualifications: NR, likely dermatologists
Experience in practice: not described
Any other details: border irregularity, edges are ragged, notched, or blurred; colour irregularity,
pigmentation is not uniform, shades of tan, brown and black are present with dashes of red, white,
or blue; diameter > 6 mm, the size of a pencil eraser
7-point: increasing size, variegation, inflammation, irregular outline, > 1 cmdiameter, itch, bleeding,
1 point awarded for each feature
Target condition and reference
standard(s)
Reference standard: histological diagnosis alone
Details: shave excision = 109; punch biopsy = 64; excision = 47; snip biopsy = 17
Disease positive: 16 lesions; disease negative: 221
Target condition (final diagnoses)
Melanoma (invasive): 6; lentigo maligna 6; BCC: 4;
Dysplastic naevus 28; SK: 32; benign naevus: 110; lentigo 12; blue naevus 9; AK 6; DF 6; atypical
naevus 4; other 14
Flow and timing Excluded participants: missing data for the different algorithms; approximately 32 lesions unac-
counted for (13 excluded due to lesion size of ≤ 8 mm). ABCD evaluated = 192/224 lesions; 3-
point evaluated = 192/224 lesions; 7-point evaluated = 205/224 lesions
Time interval to reference test: NR
Comparative
Notes -
Methodological quality
Item Authors’ judgement Risk of bias Applicability concerns
DOMAIN 1: Patient Selection
Was a consecutive or random
sample of patients enrolled?
Yes
Was a case-control design
avoided?
Yes
Did the study avoid inappropri-
ate exclusions?
Yes
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McGovern 1992 (Continued)
Are the included patients and
chosen study setting appropri-
ate?
Unclear
Did the study avoid including
participants with multiple le-
sions?
No
Low High
DOMAIN 2: Index Test Visual Inspection - in-person
Were the index test results in-
terpreted without knowledge of
the results of the reference stan-
dard?
Yes
If a threshold was used, was it
pre-specified?
No
For studies reporting the ac-
curacy of multiple diagnostic
thresholds, was each threshold
or algorithm interpreted with-
out knowledge of the results of
the others?
Unclear
Was the test applied and inter-
preted in a clinically applicable
manner?
Yes
Were thresholds or criteria for
diagnosis reported in sufficient
detail to allow replication?
Yes
Was the test interpretation car-
ried out by an experienced ex-
aminer?
Unclear
High Unclear
DOMAIN 3: Reference Standard
Is the reference standards likely
to correctly classify the target
condition?
Yes
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McGovern 1992 (Continued)
Were the reference standard re-
sults
interpreted without knowledge
of the results of the index tests?
Unclear
Expert opinion (with no his-
tological confirmation) was not
used as a reference standard
Yes
Was histology interpretation
carried out by an experienced
histopathologist or by a der-
matopathologist?
Yes
Low Low
DOMAIN 4: Flow and Timing
Was there an appropriate inter-
val between index test and ref-
erence standard?
Unclear
Did all patients receive the same
reference standard?
Yes
Were all patients included in the
analysis?
No
If the reference standard in-
cludes clinical follow-up of
borderline/benign appearing le-
sions, was there a minimum
follow-up following application
of index test(s) of at least: 3
months for melanoma or cSCC
or 6 months for BCC?
If more than one algorithm was
evaluated for the same test, was
the interval between applica-
tion of the different algorithms
1 month or less?
Unclear
High
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Menzies 2009
Study characteristics
Patient sampling Study design: CS
Data collection: prospective
Period of data collection: December 2005-August 2006
Country: Australia
Patient characteristics and set-
ting
Inclusion criteria: pigmented lesions which, after routine naked eye examination by the GP, would
have been biopsied or referred, i.e. a suspicious pigmented lesion. GPs were recruited from practices
with at least 3 clinicians; excluded if they already used dermoscopy or SDDI in their routine practice
Setting: primary
Prior testing: clinical suspicion of malignancy without dermatoscopic suspicion
Setting for prior testing: primary
Exclusion criteria: none reported
Sample size (participants): NR
Sample size (lesions): number included: 374
Participant characteristics: none reported
Lesion characteristics: none reported
Index tests VI: no algorithm
Method of diagnosis: in-person diagnosis
Prior test data: N/A in-person diagnosis
Other test data: clinical diagnosis and placed in a sealed envelope before proceeding to dermoscopy
examination
Diagnostic threshold: NR; initial diagnosis recorded along with confidence of diagnosis (scale 1-
10; 1 not at all confident and 10 extremely confident), certainty of melanoma (scale 0%-100%; 0
definitely not melanoma and 100 definitely melanoma) and management (biopsy, referral)
Diagnosis based on: single observer (n = 63; 102 GPs initially recruited; 74 (72.5%) completed
the educational intervention and online assessment; 63 GPs from 19 practices finally participated)
Observer qualifications: GP
Experience in practice: not fully described; assumed to be low experience with pigmented lesions.
GPs must have each excised or referred ≥ 10 PSL in previous 12-month period; excluded if der-
moscopy or SDDI already used in routine practice. During the pretrial period all GPs underwent a
training programme in the use of dermoscopy
Dermoscopy: evaluated in same study; no algorithm
Target condition and reference
standard(s)
Reference standard: histological diagnosis plus other
Histology (not further described): described as to standard practice and not necessarily blinded to
the GP’s diagnosis; author confirmed that all melanoma had histological diagnosis and > 50% of
benign had histology or follow-up
Total excised or referred: 163. Immediate excision/referral: 110. Excision/referral after SDDI: 48.
Excision/examination after patient self-referral 5
Disease positive: 37; disease negative: total of 126 benign or unknown were ’excised OR referred’
so some would have had specialist diagnosis only
Clinical follow-up plus histology of suspicious lesions: short-term digital monitoring (SDDI) avail-
able as an option for lesions considered not to be melanoma but that were still considered suspicious;
follow-up imaging occurred initially at 3 months with any morphological changes to result in biopsy
or referral; some lesions continued SDDI for a further 3 months; length of follow-up: 3-6 months
Number of participants: initially recommended for SDDI: 192; SDDI continued for further 3
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Menzies 2009 (Continued)
months: 6; Underwent SDDI only (no excision): 146
Disease positive: 15 (SDDI then histologically confirmed); disease negative: 176 benign (including
1 missed in situ melanoma); 4 unknown
Expert opinion: GPs could refer for specialist opinion or lesions could undergo dermoscopy
telemedicine (images reviewed by an expert in dermoscopy and SDDI). Dermoscopy telemedicine
was blinded to the GP’s diagnosis.
Observe for change group, i.e. discharged after dermoscopy: 72, plus a proportion of those in excise/
refer group will have had expert diagnosis alone but details not given
Disease positive: 0; disease negative: 71 benign; 1 unknown
Target condition (final diagnoses)
Melanoma (invasive): 33; melanoma (in situ): 1
BCC: 6
2 Bowen’s disease; 323 benign; 9 unknown
Flow and timing Excluded participants: 9 lesions with unknown diagnoses, plus BCC and Bowen’s excluded from
some analyses
Time interval to reference test: NR; histopathological and specialist examination occurred accord-
ing to standard practice
Comparative
Notes -
Methodological quality
Item Authors’ judgement Risk of bias Applicability concerns
DOMAIN 1: Patient Selection
Was a consecutive or random
sample of patients enrolled?
Yes
Was a case-control design
avoided?
Yes
Did the study avoid inappropri-
ate exclusions?
Yes
Are the included patients and
chosen study setting appropri-
ate?
Yes
Did the study avoid including
participants with multiple le-
sions?
Unclear
Low Unclear
DOMAIN 2: Index Test Visual Inspection - in-person
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Menzies 2009 (Continued)
Were the index test results in-
terpreted without knowledge of
the results of the reference stan-
dard?
Yes
If a threshold was used, was it
pre-specified?
Unclear
For studies reporting the ac-
curacy of multiple diagnostic
thresholds, was each threshold
or algorithm interpreted with-
out knowledge of the results of
the others?
Was the test applied and inter-
preted in a clinically applicable
manner?
Yes
Were thresholds or criteria for
diagnosis reported in sufficient
detail to allow replication?
No
Was the test interpretation car-
ried out by an experienced ex-
aminer?
No
Unclear High
DOMAIN 3: Reference Standard
Is the reference standards likely
to correctly classify the target
condition?
No
Were the reference standard re-
sults
interpreted without knowledge
of the results of the index tests?
No
Expert opinion (with no his-
tological confirmation) was not
used as a reference standard
No
Was histology interpretation
carried out by an experienced
histopathologist or by a der-
matopathologist?
Unclear
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High High
DOMAIN 4: Flow and Timing
Was there an appropriate inter-
val between index test and ref-
erence standard?
Unclear
Did all patients receive the same
reference standard?
No
Were all patients included in the
analysis?
No
If the reference standard in-
cludes clinical follow-up of
borderline/benign appearing le-
sions, was there a minimum
follow-up following application
of index test(s) of at least: 3
months for melanoma or cSCC
or 6 months for BCC?
Yes
If more than one algorithm was
evaluated for the same test, was
the interval between applica-
tion of the different algorithms
1 month or less?
High
Morales Callaghan 2008
Study characteristics
Patient sampling Study design: CS
Data collection: prospective
Period of data collection: 1 January 2005-31 December 2005
Country: Spain
Patient characteristics and set-
ting
Inclusion criteria: randomly selected melanocytic lesions; melanocytic on both clinical and der-
moscopic criteria
Setting: secondary (general dermatology)
Prior testing: dermatoscopic suspicion in all cases
Setting for prior testing: NR
Exclusion criteria: location/site of lesion, palms, soles, mucous membranes of face, under nails;
non-melanocytic appearance
Sample size (participants): number included: 166
161Visual inspection for diagnosing cutaneous melanoma in adults (Review)
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Morales Callaghan 2008 (Continued)
Sample size (lesions): number included: 200
Participant characteristics: mean age 33.7 years (SD 14.5), range 8-84 years; male: 64 (38.6%);
Fitzpatrick phototype II (44%); type III (41.5%)
Lesion characteristics: macular component = 181 (90.5%), papular component = 125 (62.5%),
both = 106 (53%), either one or other = 94 (47%). Asymmetrical 144 (72%). Irregular borders 154
(77%). 4 colours in 40 (20%), 3 colours in 96 (48%), 2 colours in 57 (28.5%), 1 colour in 1 (0.
5%). History of bleeding 7 (3.5%). Changes reported by participant 154 (77%). Lesion site: trunk
155 (77.5%), including the back in 106 (53%). Lesion size: mean long axis diameter 7.9 mm (SD
8.6) mm, mean short axis diameter 5.1 (SD 5)
Index tests VI: no algorithm
Method of diagnosis: in-person diagnosis
Prior test data: clinical examination and/or case notes
Other test data: appears that dermoscopy was undertaken by same clinician(s) subsequent to clini-
cal evaluation; clinical history was constructed following a standardised protocol and a presumptive
clinical diagnosis recorded. Each lesion was then photographed and immediately afterwards exam-
ined using a manual dermatoscope
Diagnostic threshold: NR; presumptive clinical diagnosis
Diagnosis based on: consensus (n = 2)
Observer qualifications: dermatologist
Experience in practice: not clearly described; assumed to be high - “both dermatologists had
experience in dermoscopy.”
Dermoscopy: evaluated in same study; pattern analysis
Target condition and reference
standard(s)
Reference standard: histological diagnosis alone
Details: lesions described using terminology proposed by US National Institutes of Health
Disease positive: 6/6 lesions; disease negative: 194/194 lesions (assuming the 9 ’other’ diagnosis
lesions were not malignant), or 185/185 (removing the 9 ’other’ diagnosis lesions from dataset)
Target condition (final diagnoses)
Melanoma (in situ and invasive, or NR): 6 (3%)
Other: atypical mole = 104, common mole = 70, congenital naevus = 6, blue nevus = 3, Spitz/Reed
naevus = 1, spilus naevus = 1, others (unclear whether benign or malignant) = 9
Flow and timing Exclusions: none reported
Time interval to reference test: “Samples for histologic analysis were taken immediately after
clinical and dermoscopic examination”
Time interval between index test(s): images taken at same time
Comparative
Notes -
Methodological quality
Item Authors’ judgement Risk of bias Applicability concerns
DOMAIN 1: Patient Selection
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Was a consecutive or random
sample of patients enrolled?
Yes
Was a case-control design
avoided?
Yes
Did the study avoid inappropri-
ate exclusions?
No
Are the included patients and
chosen study setting appropri-
ate?
No
Did the study avoid including
participants with multiple le-
sions?
No
High High
DOMAIN 2: Index Test Visual Inspection - in-person
Were the index test results in-
terpreted without knowledge of
the results of the reference stan-
dard?
Yes
If a threshold was used, was it
pre-specified?
Unclear
For studies reporting the ac-
curacy of multiple diagnostic
thresholds, was each threshold
or algorithm interpreted with-
out knowledge of the results of
the others?
Was the test applied and inter-
preted in a clinically applicable
manner?
No
Were thresholds or criteria for
diagnosis reported in sufficient
detail to allow replication?
No
Was the test interpretation car-
ried out by an experienced ex-
aminer?
Yes
Unclear High
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DOMAIN 3: Reference Standard
Is the reference standards likely
to correctly classify the target
condition?
Yes
Were the reference standard re-
sults
interpreted without knowledge
of the results of the index tests?
Unclear
Expert opinion (with no his-
tological confirmation) was not
used as a reference standard
Yes
Was histology interpretation
carried out by an experienced
histopathologist or by a der-
matopathologist?
Unclear
Low Unclear
DOMAIN 4: Flow and Timing
Was there an appropriate inter-
val between index test and ref-
erence standard?
Yes
Did all patients receive the same
reference standard?
Yes
Were all patients included in the
analysis?
Yes
If the reference standard in-
cludes clinical follow-up of
borderline/benign appearing le-
sions, was there a minimum
follow-up following application
of index test(s) of at least: 3
months for melanoma or cSCC
or 6 months for BCC?
If more than one algorithm was
evaluated for the same test, was
the interval between applica-
tion of the different algorithms
1 month or less?
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Low
Morton 1998a
Study characteristics
Patient sampling Study design: CS
Data collection: retrospective
Period of data collection: 1992-1994
Country: Scotland
Patient characteristics and set-
ting
Inclusion criteria: all biopsies generated at PLC during time period
Setting: specialist unit (skin cancer clinic/PLC)
Prior testing: NR
Setting for prior testing: N/A
Exclusion criteria: none reported
Sample size (participants): number eligible: 1999
Sample size (lesions): 763 lesions examined by 1 of 2 consultants
Participant characteristics: none reported
Lesion characteristics: none reported
Index tests VI: no algorithm
Method of diagnosis: in-person diagnosis
Prior test data: N/A, in-person diagnosis referred to as “clinical diagnosis”; no dermoscopy used
Diagnostic threshold: NR; clinical diagnosis
Diagnosis based on: single observer and average data presented; (n = 10 in total)
Observer qualifications: 2 consultant dermatologists
Experience in practice: high (2 consultants each with > 10 years’ experience in dermatology)
Any other detail: data from same study for senior registrar and registrar presented inMorton 1998b
and Morton 1998c
Target condition and reference
standard(s)
Reference standard: histological diagnosis alone
Target condition (final diagnoses; for full sample of 1999 biopsies)
Melanoma (invasive): 102 (82 SSM, 11 nodular melanoma, 4 partially regressed, 2 acral lentiginous,
2 metastatic CM deposits, 1 desmoplastic melanoma); melanoma (in situ): 24; lentigo maligna: 2
Benign: 1871 benign (breakdown by lesion type NR)
Flow and timing Excluded participants: none reported
Time interval to reference test: NR
Time interval between index test(s): N/A
Comparative
Notes -
Methodological quality
Item Authors’ judgement Risk of bias Applicability concerns
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DOMAIN 1: Patient Selection
Was a consecutive or random
sample of patients enrolled?
Yes
Was a case-control design
avoided?
Yes
Did the study avoid inappropri-
ate exclusions?
Unclear
Are the included patients and
chosen study setting appropri-
ate?
No
Did the study avoid including
participants with multiple le-
sions?
Unclear
Unclear High
DOMAIN 2: Index Test Visual Inspection - in-person
Were the index test results in-
terpreted without knowledge of
the results of the reference stan-
dard?
Yes
If a threshold was used, was it
pre-specified?
Unclear
For studies reporting the ac-
curacy of multiple diagnostic
thresholds, was each threshold
or algorithm interpreted with-
out knowledge of the results of
the others?
Was the test applied and inter-
preted in a clinically applicable
manner?
Yes
Were thresholds or criteria for
diagnosis reported in sufficient
detail to allow replication?
No
Was the test interpretation car-
ried out by an experienced ex-
aminer?
Yes
166Visual inspection for diagnosing cutaneous melanoma in adults (Review)
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
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Unclear High
DOMAIN 3: Reference Standard
Is the reference standards likely
to correctly classify the target
condition?
Yes
Were the reference standard re-
sults
interpreted without knowledge
of the results of the index tests?
Unclear
Expert opinion (with no his-
tological confirmation) was not
used as a reference standard
Yes
Was histology interpretation
carried out by an experienced
histopathologist or by a der-
matopathologist?
Yes
Low Low
DOMAIN 4: Flow and Timing
Was there an appropriate inter-
val between index test and ref-
erence standard?
Unclear
Did all patients receive the same
reference standard?
Yes
Were all patients included in the
analysis?
Yes
If the reference standard in-
cludes clinical follow-up of
borderline/benign appearing le-
sions, was there a minimum
follow-up following application
of index test(s) of at least: 3
months for melanoma or cSCC
or 6 months for BCC?
If more than one algorithm was
evaluated for the same test, was
the interval between applica-
tion of the different algorithms
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1 month or less?
Unclear
Morton 1998b
Study characteristics
Patient sampling Study design: CS
Data collection: retrospective
Period of data collection: 1992-1994
Country: Scotland
Patient characteristics and set-
ting
Inclusion criteria: all biopsies generated at PLC during time period
Setting: specialist unit (skin cancer clinic/PLC)
Prior testing: NR
Setting for prior testing: N/A
Exclusion criteria: none reported
Sample size (participants): number eligible: 1999
Sample size (lesions): 567 lesions examined by senior registrar
Participant characteristics: NR
Lesion characteristics: NR
Index tests VI: no algorithm
Method of diagnosis: in-person diagnosis
Prior test data: N/A, in-person diagnosis referred to as ’clinical diagnosis’; no dermoscopy used
Diagnostic threshold: NR; clinical diagnosis
Diagnosis based on: single observer and average data presented; (n = 10 in total)
Observer qualifications: 2 senior registrars
Experience in practice: moderate, 2 senior registrars each with 3-5 years’ experience
Any other detail: data from same study for consultants and for registrar presented inMorton 1998a
and Morton 1998c
Target condition and reference
standard(s)
Reference standard: histological diagnosis alone
Target condition (final diagnoses; for full sample of 1999 biopsies)
Melanoma (invasive): 102 (82 SSM, 11 nodular melanoma, 4 partially regressed, 2 acral lentiginous,
2 metastatic CM deposits, 1 desmoplastic melanoma); melanoma (in situ): 24; lentigo maligna: 2
Benign: 1871 benign (breakdown by lesion type NR)
Flow and timing Excluded participants: none reported
Time interval to reference test: NR
Time interval between index test(s): N/A
Comparative
Notes The study by Morton et al is considered as a single study for quality assessment purposes (as per
Morton 1998a) but as three studies (Morton 1998a;Morton 1998b;Morton 1998c) for the analyses
due to the reporting of three separate cohorts of participants
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Morton 1998b (Continued)
Methodological quality
Item Authors’ judgement Risk of bias Applicability concerns
DOMAIN 1: Patient Selection
Was a consecutive or random
sample of patients enrolled?
Yes
Was a case-control design
avoided?
Yes
Did the study avoid inappropri-
ate exclusions?
Unclear
Are the included patients and
chosen study setting appropri-
ate?
Did the study avoid including
participants with multiple le-
sions?
DOMAIN 2: Index Test Visual Inspection - in-person
Were the index test results in-
terpreted without knowledge of
the results of the reference stan-
dard?
If a threshold was used, was it
pre-specified?
For studies reporting the ac-
curacy of multiple diagnostic
thresholds, was each threshold
or algorithm interpreted with-
out knowledge of the results of
the others?
Was the test applied and inter-
preted in a clinically applicable
manner?
Were thresholds or criteria for
diagnosis reported in sufficient
detail to allow replication?
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Was the test interpretation car-
ried out by an experienced ex-
aminer?
DOMAIN 2: Index Test Visual inspection - image-based
Were the index test results in-
terpreted without knowledge of
the results of the reference stan-
dard?
If a threshold was used, was it
pre-specified?
For studies reporting the ac-
curacy of multiple diagnostic
thresholds, was each threshold
or algorithm interpreted with-
out knowledge of the results of
the others?
Was the test applied and inter-
preted in a clinically applicable
manner?
Were thresholds or criteria for
diagnosis reported in sufficient
detail to allow replication?
Was the test interpretation car-
ried out by an experienced ex-
aminer?
DOMAIN 3: Reference Standard
Is the reference standards likely
to correctly classify the target
condition?
Were the reference standard re-
sults
interpreted without knowledge
of the results of the index tests?
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Expert opinion (with no his-
tological confirmation) was not
used as a reference standard
Was histology interpretation
carried out by an experienced
histopathologist or by a der-
matopathologist?
DOMAIN 4: Flow and Timing
Was there an appropriate inter-
val between index test and ref-
erence standard?
Did all patients receive the same
reference standard?
Were all patients included in the
analysis?
If the reference standard in-
cludes clinical follow-up of
borderline/benign appearing le-
sions, was there a minimum
follow-up following application
of index test(s) of at least: 3
months for melanoma or cSCC
or 6 months for BCC?
If more than one algorithm was
evaluated for the same test, was
the interval between applica-
tion of the different algorithms
1 month or less?
Morton 1998c
Study characteristics
Patient sampling Study design: CS
Data collection: retrospective
Period of data collection: 1992-1994
Country: Scotland
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Patient characteristics and set-
ting
Inclusion criteria: all biopsies generated at PLC during time period
Setting: specialist unit (skin cancer clinic/PLC)
Prior testing: NR
Setting for prior testing: N/A
Exclusion criteria: NR
Sample size (participants): number eligible: 1999
Sample size (lesions): 669 lesions examined by registrar
Participant characteristics: NR
Lesion characteristics: NR
Index tests VI: no algorithm
Method of diagnosis: in-person diagnosis
Prior test data: N/A, in-person diagnosis referred to as ’clinical diagnosis’; no dermoscopy used
Diagnostic threshold: NR; clinical diagnosis
Diagnosis based on: single observer and average data presented; (n = 10 in total)
Observer qualifications: registrars
Experience in practice: low, 6 rotating registrars each with 1-2 years’ experience
Any other detail: data from same study for consultants and for senior registrars presented inMorton
1998a and Morton 1998b
Target condition and reference
standard(s)
Reference standard: histological diagnosis alone
Target condition (final diagnoses; for full sample of 1999 biopsies)
Melanoma (invasive): 102 (82 SSM, 11 nodular melanoma, 4 partially regressed, 2 acral lentiginous,
2 metastatic CM deposits, 1 desmoplastic melanoma); melanoma (in situ): 24; lentigo maligna: 2
Benign: 1871 benign (breakdown by lesion type NR)
Flow and timing Excluded participants: none reported
Time interval to reference test: NR
Time interval between index test(s): N/A
Comparative
Notes The study by Morton et al is considered as a single study for quality assessment purposes (as per
Morton 1998a) but as three studies (Morton 1998a;Morton 1998b;Morton 1998c) for the analyses
due to the reporting of three separate cohorts of participants
Methodological quality
Item Authors’ judgement Risk of bias Applicability concerns
DOMAIN 1: Patient Selection
Was a consecutive or random
sample of patients enrolled?
Yes
Was a case-control design
avoided?
Yes
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Morton 1998c (Continued)
Did the study avoid inappropri-
ate exclusions?
Unclear
Are the included patients and
chosen study setting appropri-
ate?
Did the study avoid including
participants with multiple le-
sions?
DOMAIN 2: Index Test Visual Inspection - in-person
Were the index test results in-
terpreted without knowledge of
the results of the reference stan-
dard?
If a threshold was used, was it
pre-specified?
For studies reporting the ac-
curacy of multiple diagnostic
thresholds, was each threshold
or algorithm interpreted with-
out knowledge of the results of
the others?
Was the test applied and inter-
preted in a clinically applicable
manner?
Were thresholds or criteria for
diagnosis reported in sufficient
detail to allow replication?
Was the test interpretation car-
ried out by an experienced ex-
aminer?
DOMAIN 2: Index Test Visual inspection - image-based
Were the index test results in-
terpreted without knowledge of
the results of the reference stan-
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dard?
If a threshold was used, was it
pre-specified?
For studies reporting the ac-
curacy of multiple diagnostic
thresholds, was each threshold
or algorithm interpreted with-
out knowledge of the results of
the others?
Was the test applied and inter-
preted in a clinically applicable
manner?
Were thresholds or criteria for
diagnosis reported in sufficient
detail to allow replication?
Was the test interpretation car-
ried out by an experienced ex-
aminer?
DOMAIN 3: Reference Standard
Is the reference standards likely
to correctly classify the target
condition?
Were the reference standard re-
sults
interpreted without knowledge
of the results of the index tests?
Expert opinion (with no his-
tological confirmation) was not
used as a reference standard
Was histology interpretation
carried out by an experienced
histopathologist or by a der-
matopathologist?
DOMAIN 4: Flow and Timing
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Was there an appropriate inter-
val between index test and ref-
erence standard?
Did all patients receive the same
reference standard?
Were all patients included in the
analysis?
If the reference standard in-
cludes clinical follow-up of
borderline/benign appearing le-
sions, was there a minimum
follow-up following application
of index test(s) of at least: 3
months for melanoma or cSCC
or 6 months for BCC?
If more than one algorithm was
evaluated for the same test, was
the interval between applica-
tion of the different algorithms
1 month or less?
Pizzichetta 2004
Study characteristics
Patient sampling Study design: CS
Data collection: retrospective image selection/prospective interpretation
Period of data collection: January 1996-December 2001
Country: participants recruited from 5 participating centres (4 in Italy and 1 in USA) study con-
ducted in Italy
Patient characteristics and set-
ting
Inclusion criteria: clinical and/or dermoscopic hypomelanotic (extent of pigmentation ≤ 30%)
and amelanotic skin lesions seen and excised at the 5 participating centres
Setting: secondary (general dermatology)
Prior testing: clinical and/or dermatoscopic suspicion
Setting for prior testing: NR
Exclusion criteria: poor-quality or unavailable index test image (considered under ’Flow and tim-
ing’)
Sample size (participants): number included: 151
Sample size (lesions): number eligible: 174; number included: 151
Participant characteristics: mean age 47 years (± 17.5 SD); male: 73 (48%)
Lesion characteristics: lesion site, head/neck (5.3%); trunk (20.5%); upper limbs/shoulder (11.9%)
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Pizzichetta 2004 (Continued)
; lower limbs/hip (25.2%); back (21.2%); abdomen (11.3%); hand (3.3%); foot (1.3%). Melanoma
thickness: ≤ 1 mm 85.3% (n = 29); > 1 mm 14.7% (n = 15)
Index tests VI: no algorithm
Method of diagnosis: clinical photographs
Prior test data: only the gender, age at diagnosis and the site of the skin lesion were known to the
observer
Other test data: file contained clinical and dermoscopic images; unclear whether both observed at
the same time
Diagnostic threshold: investigated clinical features such as elevation, ulceration, shape, borders,
colour
Diagnosis based on: single observer (n = 1)
Observer qualifications: NR, likely dermatologist
Experience in practice: not described
Experience with index test: not described
Dermoscopy: evaluated in same study; pattern analysis
Target condition and reference
standard(s)
Reference standard: histological diagnosis alone
Target condition (final diagnoses)
Melanoma (invasive): 34 (39 in full sample); melanoma (in situ): 5
Other diagnoses reported only for full sample of 151 (only 108with clinical images for VI evaluation)
:
55 (40 with clinical images) “amelanotic hypomelanotic non melanocytic lesions” (25 BCC, 4
SCC, 10 DF, 8 Bowen’s disease, 8 SK)
52 (29with clinical images) “amelanotic hypomelanotic benignmelanocytic lesions” (24 compound
naevi, 17 dermal naevi, 5 Spitz naevi, 4 congenital naevi and 2 combined naevi)
Flow and timing Excluded participants: 23 lesions excluded due to image quality; further 43 lesions were not
available for evaluation by clinical images (“mainly benign melanocytic lesions”)
Time interval to reference test: NR
Time interval between index test(s): NR
Comparative
Notes -
Methodological quality
Item Authors’ judgement Risk of bias Applicability concerns
DOMAIN 1: Patient Selection
Was a consecutive or random
sample of patients enrolled?
Unclear
Was a case-control design
avoided?
Unclear
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Did the study avoid inappropri-
ate exclusions?
Yes
Are the included patients and
chosen study setting appropri-
ate?
No
Did the study avoid including
participants with multiple le-
sions?
Yes
Unclear High
DOMAIN 2: Index Test Visual inspection - image-based
Were the index test results in-
terpreted without knowledge of
the results of the reference stan-
dard?
Yes
If a threshold was used, was it
pre-specified?
Unclear
For studies reporting the ac-
curacy of multiple diagnostic
thresholds, was each threshold
or algorithm interpreted with-
out knowledge of the results of
the others?
Was the test applied and inter-
preted in a clinically applicable
manner?
No
Were thresholds or criteria for
diagnosis reported in sufficient
detail to allow replication?
No
Was the test interpretation car-
ried out by an experienced ex-
aminer?
Unclear
Unclear High
DOMAIN 3: Reference Standard
Is the reference standards likely
to correctly classify the target
condition?
Yes
177Visual inspection for diagnosing cutaneous melanoma in adults (Review)
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Pizzichetta 2004 (Continued)
Were the reference standard re-
sults
interpreted without knowledge
of the results of the index tests?
Unclear
Expert opinion (with no his-
tological confirmation) was not
used as a reference standard
Yes
Was histology interpretation
carried out by an experienced
histopathologist or by a der-
matopathologist?
Unclear
Low Unclear
DOMAIN 4: Flow and Timing
Was there an appropriate inter-
val between index test and ref-
erence standard?
Unclear
Did all patients receive the same
reference standard?
Yes
Were all patients included in the
analysis?
No
If the reference standard in-
cludes clinical follow-up of
borderline/benign appearing le-
sions, was there a minimum
follow-up following application
of index test(s) of at least: 3
months for melanoma or cSCC
or 6 months for BCC?
If more than one algorithm was
evaluated for the same test, was
the interval between applica-
tion of the different algorithms
1 month or less?
High
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Rao 1997
Study characteristics
Patient sampling Study design: CS
Data collection: retrospective image selection/prospective interpretation
Period of data collection: NR
Country: USA
Patient characteristics and set-
ting
Inclusion criteria: patients with atypical melanocytic lesions or suspected early MM
Setting: private care
Prior testing: selected for excision (no further detail)
Setting for prior testing: private care
Exclusion criteria: lesions > 13 mm in diameter were excluded as they could not fit entirely within
the standardised photographs
Sample size (participants): number included: 63
Sample size (lesions): number included: 72
Participant characteristics: none reported
Lesion characteristics: melanoma thickness ≤ 1 mm: 100% of MM (n = 21)
Index tests VI ABCD
Method of diagnosis: clinical photographs
Prior test data: unclear
Other test data: dermoscopic images also presented to observer but unclear whether both viewed
at the same time or not; ”Each color transparency was independently analyzed“ by observers. The
1) clinical, 2) ”overall” dermoscopic, and 3) ABCD ”scored dermoscopic diagnoses” of either MM
or AMN were recorded for each lesion by the same observers. No indication of blinding between
images
Diagnostic threshold: clinical variables were defined as follows: asymmetry (A): both silhouette
and colour distribution were considered. Border irregularity (B): this was judged by the unevenness
of the perimeter. Colour (C): colour variegation and number of colours were evaluated. Diameter
(D): the largest in situ diameter in mm of each lesion was recorded
Diagnosis based on: single observer (n = 4)
Observer qualifications: 2 experienced dermatologists, and 2 melanoma fellows
Experience in practice: mixed experience (low and high experience combined)
Experience with index test: NR
Dermoscopy: evaluated in same study; ABCD and no algorithm
Target condition and reference
standard(s)
Reference standard: histological diagnosis alone
Details: each of the 72 melanocytic neoplasms was histopathologically diagnosed as with AMN or
an early MM by a dermapathologist with special expertise in melanocytic neoplasms. Each lesion
was completely excised and step-sectioned.
Disease positive: 21 MMs; disease negative: 51 AMN
Target condition (final diagnoses)
Melanoma (invasive): 21
51 AMN
Flow and timing Excluded participants: none reported
Time interval to reference test: NR
Time interval between index test(s): NR
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Comparative
Notes -
Methodological quality
Item Authors’ judgement Risk of bias Applicability concerns
DOMAIN 1: Patient Selection
Was a consecutive or random
sample of patients enrolled?
Unclear
Was a case-control design
avoided?
Yes
Did the study avoid inappropri-
ate exclusions?
Unclear
Are the included patients and
chosen study setting appropri-
ate?
No
Did the study avoid including
participants with multiple le-
sions?
No
Unclear High
DOMAIN 2: Index Test Visual inspection - image-based
Were the index test results in-
terpreted without knowledge of
the results of the reference stan-
dard?
Yes
If a threshold was used, was it
pre-specified?
Unclear
For studies reporting the ac-
curacy of multiple diagnostic
thresholds, was each threshold
or algorithm interpreted with-
out knowledge of the results of
the others?
Was the test applied and inter-
preted in a clinically applicable
manner?
No
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Were thresholds or criteria for
diagnosis reported in sufficient
detail to allow replication?
No
Was the test interpretation car-
ried out by an experienced ex-
aminer?
Yes
Unclear High
DOMAIN 3: Reference Standard
Is the reference standards likely
to correctly classify the target
condition?
Yes
Were the reference standard re-
sults
interpreted without knowledge
of the results of the index tests?
Unclear
Expert opinion (with no his-
tological confirmation) was not
used as a reference standard
Yes
Was histology interpretation
carried out by an experienced
histopathologist or by a der-
matopathologist?
Yes
Low Low
DOMAIN 4: Flow and Timing
Was there an appropriate inter-
val between index test and ref-
erence standard?
Yes
Did all patients receive the same
reference standard?
Yes
Were all patients included in the
analysis?
Yes
If the reference standard in-
cludes clinical follow-up of
borderline/benign appearing le-
sions, was there a minimum
follow-up following application
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of index test(s) of at least: 3
months for melanoma or cSCC
or 6 months for BCC?
If more than one algorithm was
evaluated for the same test, was
the interval between applica-
tion of the different algorithms
1 month or less?
Low
Rosendahl 2011
Study characteristics
Patient sampling Study design: CS
Data collection: retrospective image selection/prospective interpretation
Period of data collection: 30-month period; dates NR
Country: Australia
Patient characteristics and set-
ting
Inclusion criteria: consecutive series of pigmented lesions submitted for histology from the primary
care skin cancer practice of one study author
Setting: primary care skin cancer practice
Prior testing: selected for excision (no further detail)
Setting for prior testing: primary
Exclusion criteria: poor image quality (considered under ’Flow and timing’); no other exclusion
criteria reported
Sample size (participants): number included: 389
Sample size (lesions): number eligible: 466 pigmented lesions out of 1959 lesions excised or
biopsied; number included: 463
Participant characteristics: mean age: 57 years (SD 17); male: 67.4%
Lesion characteristics: (53.1%) melanocytic. Lesion site: 17.7% head or face; trunk: 52.1%; 27.
6% extremities; 2.2% palms or soles. Melanoma thickness: ≤ 1 mm: 1/29 melanoma (3.4%)
Index tests VI: no algorithm
Method of diagnosis: clinical photographs overview and close-up image presented
Prior test data: no further information used
Other test data: dermoscopic images presented to observer subsequent to diagnosis using clinical
images alone
Diagnostic threshold: clinical diagnosis/subjective impression. Observers gave a diagnosis with
level of confidence (from 0 for definitely benign to 100 for definitely malignant) after viewing the
clinical images. (NB used study authors’ threshold for detection of any skin cancer that includes
lesions clinically considered to be MM, BCC pigmented epithelial carcinoma including SCC,
keratoacanthoma, AK and Bowen’s disease as test-positive; review only considered histologically
confirmed MM, BCC or invasive SCC to be disease-positive)
Diagnosis based on: single observer (n = NR)
Observer qualifications: expert dermatologist (based on author communication)
Experience in practice: expert
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Rosendahl 2011 (Continued)
Experience with dermoscopy: expert
Target condition and reference
standard(s)
Reference standard: histological diagnosis alone
Details: excise or biopsy
Disease positive: 138; disease negative: 325
Target condition (final diagnoses)
Melanoma (invasive): 9; melanoma (in situ): 20; BCC: 72; cSCC: 5 (including 2 keratoacanthoma)
’Benign’ diagnoses*: 18 Bowen’s disease and 14 AK, 217 benign melanocytic plus additional 140
benign non melanocytic
*authors considered Bowen’s disease, AK and keratoacanthoma as malignant; all considered benign
for review analysis
Flow and timing Excluded participants: lesions were excluded due to poor image quality (n = 3)
Time interval to reference test: unclear; lesions “routinely photographed” if scheduled for excision
or biopsy but not further described
Time interval between index test(s): consecutive
Comparative
Notes -
Methodological quality
Item Authors’ judgement Risk of bias Applicability concerns
DOMAIN 1: Patient Selection
Was a consecutive or random
sample of patients enrolled?
Yes
Was a case-control design
avoided?
Yes
Did the study avoid inappropri-
ate exclusions?
Yes
Are the included patients and
chosen study setting appropri-
ate?
Yes
Did the study avoid including
participants with multiple le-
sions?
No
Low High
DOMAIN 2: Index Test Visual inspection - image-based
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Were the index test results in-
terpreted without knowledge of
the results of the reference stan-
dard?
Yes
If a threshold was used, was it
pre-specified?
Unclear
For studies reporting the ac-
curacy of multiple diagnostic
thresholds, was each threshold
or algorithm interpreted with-
out knowledge of the results of
the others?
Was the test applied and inter-
preted in a clinically applicable
manner?
No
Were thresholds or criteria for
diagnosis reported in sufficient
detail to allow replication?
No
Was the test interpretation car-
ried out by an experienced ex-
aminer?
Yes
Unclear High
DOMAIN 3: Reference Standard
Is the reference standards likely
to correctly classify the target
condition?
Yes
Were the reference standard re-
sults
interpreted without knowledge
of the results of the index tests?
Unclear
Expert opinion (with no his-
tological confirmation) was not
used as a reference standard
Yes
Was histology interpretation
carried out by an experienced
histopathologist or by a der-
matopathologist?
Unclear
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Low Unclear
DOMAIN 4: Flow and Timing
Was there an appropriate inter-
val between index test and ref-
erence standard?
Unclear
Did all patients receive the same
reference standard?
Yes
Were all patients included in the
analysis?
No
If the reference standard in-
cludes clinical follow-up of
borderline/benign appearing le-
sions, was there a minimum
follow-up following application
of index test(s) of at least: 3
months for melanoma or cSCC
or 6 months for BCC?
If more than one algorithm was
evaluated for the same test, was
the interval between applica-
tion of the different algorithms
1 month or less?
High
Scope 2008
Study characteristics
Patient sampling Study design: CS
Data collection: retrospective image selection/prospective interpretation
Period of data collection: after January 2003
Country: NR
Patient characteristics and set-
ting
Inclusion criteria: images of PSLs selected from a database of standardised patient images provided
by a New Zealand-based teledermatology company (MoleMap). Images were selected on the basis
that (1) at least 8 clinically atypical naevi were apparent on the back; (2) most of the lesions on the
back and all of the atypical naevi had close-up clinical digital images; (3) 1-year follow-up images
(close-up clinical and dermoscopic images) were available to show that lesions considered to be
benign were in fact biologically indolent by revealing no change; and (4) the image quality of both
the overview and the close-up images were acceptable
Setting: New Zealand-based teledermatology company; images were sent electronically to partici-
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pants as a PowerPoint file
Prior testing: NR
Setting for prior testing: unspecified
Exclusion criteria: poor-quality index test image (considered under ’Flow and timing’); naevi on
any body site except the back
Sample size (participants): number eligible: 12; number included: 12
Sample size (lesions): number eligible: 145; number included: 145
Participant characteristics: none reported
Lesion characteristics: none reported
Index tests VI: ugly duckling
Method of diagnosis: clinical photographs
Prior test data: no further information used
Diagnostic threshold: for each lesion that was deemed as different, the participants had to mark
the lesion number on the form, identify it as either completely different or somewhat different from
the other moles, give a short qualitative description of how the lesion differed, and report whether
they would like to have a biopsy performed on the lesion
Diagnosis based on: average (n = 34)
Observer qualifications: 4 subgroups in terms of clinical expertise: group 1, pigmented lesion ex-
perts (n = 8); group 2, dermatologists who were considered non-experts in pigmented lesion evalua-
tion (n = 13); group 3, dermatology nurses (n = 5, including 1 dermatology medical photographer)
; and group 4, non-clinical medical staff (n = 8)
Experience in practice: mixed experience (low and high experience combined)
Other detail: the study was sent electronically to participants as a PowerPoint file (Microsoft Corp,
Redmond, Washington) that contained the clinical image interface and a Word document that
contained questionnaire and response forms. The participants were not shown dermoscopic images.
However, dermoscopic images of lesions (with a 1-year follow-up dermoscopic image) were available
to the investigators to verify that lesions considered benign did not show dermoscopic features
suggestive of malignancy, and the 1-year follow-up images confirmed that the lesions were in fact
biologically indolent by revealing no change
Target condition and reference
standard(s)
Reference standard: histological diagnosis plus follow-up
Details: unclear; all MMs were excised with histological confirmation and all benign had 1-year
follow-up images (close-up clinical and dermoscopic images) to show that lesions considered to be
benign were in fact biologically indolent by revealing no change, not clear whether any of the benign
group were excised
Target condition (final diagnoses)
Melanoma (invasive): 5 “malignant melanoma”
Benign naevus: 140
Flow and timing Excluded participants: excluded if unacceptable image quality of both the overview and the close-
up images
Time interval to reference test: NR
Comparative
Notes -
Methodological quality
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Item Authors’ judgement Risk of bias Applicability concerns
DOMAIN 1: Patient Selection
Was a consecutive or random
sample of patients enrolled?
Unclear
Was a case-control design
avoided?
Yes
Did the study avoid inappropri-
ate exclusions?
Yes
Are the included patients and
chosen study setting appropri-
ate?
Unclear
Did the study avoid including
participants with multiple le-
sions?
No
Unclear High
DOMAIN 2: Index Test Visual inspection - image-based
Were the index test results in-
terpreted without knowledge of
the results of the reference stan-
dard?
Yes
If a threshold was used, was it
pre-specified?
No
For studies reporting the ac-
curacy of multiple diagnostic
thresholds, was each threshold
or algorithm interpreted with-
out knowledge of the results of
the others?
Was the test applied and inter-
preted in a clinically applicable
manner?
No
Were thresholds or criteria for
diagnosis reported in sufficient
detail to allow replication?
Yes
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Was the test interpretation car-
ried out by an experienced ex-
aminer?
Yes
High High
DOMAIN 3: Reference Standard
Is the reference standards likely
to correctly classify the target
condition?
Unclear
Were the reference standard re-
sults
interpreted without knowledge
of the results of the index tests?
Unclear
Expert opinion (with no his-
tological confirmation) was not
used as a reference standard
Unclear
Was histology interpretation
carried out by an experienced
histopathologist or by a der-
matopathologist?
Unclear
Unclear Unclear
DOMAIN 4: Flow and Timing
Was there an appropriate inter-
val between index test and ref-
erence standard?
Unclear
Did all patients receive the same
reference standard?
No
Were all patients included in the
analysis?
No
If the reference standard in-
cludes clinical follow-up of
borderline/benign appearing le-
sions, was there a minimum
follow-up following application
of index test(s) of at least: 3
months for melanoma or cSCC
or 6 months for BCC?
Yes
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If more than one algorithm was
evaluated for the same test, was
the interval between applica-
tion of the different algorithms
1 month or less?
High
Soyer 1995
Study characteristics
Patient sampling Study design: CS
Data collection: unclear
Period of data collection: NR
Country: Austria
Patient characteristics and set-
ting
Inclusion criteria: PSL, difficult to diagnose on clinical grounds alone
Setting: specialist unit (skin cancer clinic/PLC)
Prior testing: clinical suspicion
Setting for prior testing: secondary (general dermatology); referred by dermatologists or general
physicians
Exclusion criteria: none reported
Sample size (participants): NR
Sample size (lesions): number included: 159
Participant characteristics: none reported
Lesion characteristics “23 melanomas with a Breslow index of ≤ 0.75 mm, 13 melanomas with a
Breslow index ≥ 0.76 mm and ≤ 1.5 mm, 12 melanomas with a Breslow index ≥ 1.51 mm and ≤
3.5 mm, 2 melanomas with a Breslow index of ≥ 3.5 mm.”
Index tests VI: no algorithm
Method of diagnosis: in-person diagnosis
Prior test data: N/A in-person diagnosis
Other test data: dermoscopy undertaken by same clinician(s) subsequent to clinical evaluation
Diagnostic threshold: NR
Diagnosis based on: n = 2 (1 or 2 per lesion)
Observer qualifications: dermatologist
Experience in practice: not clearly described; assumed to be high; “Each lesion was examined
clinically by .. one of the authors .. and a clinical diagnosis was recorded.” “After application of a drop
of immersion oil, each lesion was examined dermoscopically …; the examination was performed by
a dermatologist expert in dermoscopy and a dermoscopic diagnosis was recorded”
Experience with index test: not described
Other detail: “Photographic documentation was performed using an incident light stereomicro-
scope (Wild M 650) equipped with a Minolta XG-M camera”
Dermoscopy: evaluated in same study; pattern analysis
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Target condition and reference
standard(s)
Reference standard: histological diagnosis alone
Disease positive: 65 (41%); disease negative: 94 (59%)
Target condition (final diagnoses)
Melanoma (invasive): 50; melanoma (in situ): 15
BCC: pigmented BCC (3)
SK: 18; Clark’s naevus of dysplastic naevus (61 cases); lentigo actinica lentigo (2), pigmented AK
(4), angioma (3), angiokeratoma (2)
Flow and timing Excluded participants: none reported
Time interval to reference test: NR
Comparative
Notes -
Methodological quality
Item Authors’ judgement Risk of bias Applicability concerns
DOMAIN 1: Patient Selection
Was a consecutive or random
sample of patients enrolled?
Unclear
Was a case-control design
avoided?
Yes
Did the study avoid inappropri-
ate exclusions?
Unclear
Are the included patients and
chosen study setting appropri-
ate?
Unclear
Did the study avoid including
participants with multiple le-
sions?
Unclear
Unclear Unclear
DOMAIN 2: Index Test Visual Inspection - in-person
Were the index test results in-
terpreted without knowledge of
the results of the reference stan-
dard?
Yes
If a threshold was used, was it
pre-specified?
Unclear
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For studies reporting the ac-
curacy of multiple diagnostic
thresholds, was each threshold
or algorithm interpreted with-
out knowledge of the results of
the others?
Was the test applied and inter-
preted in a clinically applicable
manner?
Yes
Were thresholds or criteria for
diagnosis reported in sufficient
detail to allow replication?
No
Was the test interpretation car-
ried out by an experienced ex-
aminer?
Yes
Unclear High
DOMAIN 3: Reference Standard
Is the reference standards likely
to correctly classify the target
condition?
Yes
Were the reference standard re-
sults
interpreted without knowledge
of the results of the index tests?
Unclear
Expert opinion (with no his-
tological confirmation) was not
used as a reference standard
Yes
Was histology interpretation
carried out by an experienced
histopathologist or by a der-
matopathologist?
Unclear
Low Unclear
DOMAIN 4: Flow and Timing
Was there an appropriate inter-
val between index test and ref-
erence standard?
Unclear
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Did all patients receive the same
reference standard?
Yes
Were all patients included in the
analysis?
Yes
If the reference standard in-
cludes clinical follow-up of
borderline/benign appearing le-
sions, was there a minimum
follow-up following application
of index test(s) of at least: 3
months for melanoma or cSCC
or 6 months for BCC?
If more than one algorithm was
evaluated for the same test, was
the interval between applica-
tion of the different algorithms
1 month or less?
Unclear
Stanganelli 1998a
Study characteristics
Patient sampling Study design: CCS
Data collection: retrospective image selection/prospective interpretation
Period of data collection: just states 1997
Country: Italy
Patient characteristics and set-
ting
Inclusion criteria: images of PSLs selected from computerised files of the skin cancer clinic
Setting: training study; images selected from skin cancer clinic
Prior testing: NR
Setting for prior testing: unspecified
Exclusion criteria: none reported
Sample size (participants): NR
Sample size (lesions): number included: 30 PSLs
Participant characteristics: none reported
Lesion characteristics: none reported
Index tests VI: no algorithm
Method of diagnosis: clinical photographs
Prior test data: no further information used
Other test data: dermascopic images presented to observer subsequent to diagnosis using clinical
images alone (images were randomised)
Diagnostic threshold: NR
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Stanganelli 1998a (Continued)
Diagnosis based on: average; n = 20
Observer qualifications: dermatologist
Experience in practice: not described; 30 dermatologists with “experience in ELM but [with] no
formal training” attended a seminar on clinical and ELM diagnosis of PSL; 20 then participated in
a test of their diagnostic accuracy. A second session on ELM was then held
Other detail: the observers received 2-h seminar of the principles of clinical diagnosis of NMLs,
BCC, MN and MM. The participants were then invited to undergo an anonymous test of their
diagnostic accuracy
Dermoscopy: evaluated in same study; no algorithm
Target condition and reference
standard(s)
Reference standard: histological diagnosis alone
Target condition (final diagnoses)
Melanoma (in situ and invasive, or NR): 10
BCC: 4
Mild/moderate dysplasia: 3; SK: 3; benign naevus: MN-7
Other: 1 hemangioma, 1 subungunal haemorrhage, 1 plantar intraepidermal haemorrhage
Flow and timing Excluded participants: none reported
Time interval to reference test: NR
Comparative
Notes -
Methodological quality
Item Authors’ judgement Risk of bias Applicability concerns
DOMAIN 1: Patient Selection
Was a consecutive or random
sample of patients enrolled?
Unclear
Was a case-control design
avoided?
No
Did the study avoid inappropri-
ate exclusions?
Unclear
Are the included patients and
chosen study setting appropri-
ate?
No
Did the study avoid including
participants with multiple le-
sions?
Unclear
High High
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DOMAIN 2: Index Test Visual inspection - image-based
Were the index test results in-
terpreted without knowledge of
the results of the reference stan-
dard?
Yes
If a threshold was used, was it
pre-specified?
Unclear
For studies reporting the ac-
curacy of multiple diagnostic
thresholds, was each threshold
or algorithm interpreted with-
out knowledge of the results of
the others?
Was the test applied and inter-
preted in a clinically applicable
manner?
No
Were thresholds or criteria for
diagnosis reported in sufficient
detail to allow replication?
No
Was the test interpretation car-
ried out by an experienced ex-
aminer?
Unclear
Unclear High
DOMAIN 3: Reference Standard
Is the reference standards likely
to correctly classify the target
condition?
Yes
Were the reference standard re-
sults
interpreted without knowledge
of the results of the index tests?
Unclear
Expert opinion (with no his-
tological confirmation) was not
used as a reference standard
Yes
Was histology interpretation
carried out by an experienced
histopathologist or by a der-
Unclear
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matopathologist?
Low Unclear
DOMAIN 4: Flow and Timing
Was there an appropriate inter-
val between index test and ref-
erence standard?
Unclear
Did all patients receive the same
reference standard?
Yes
Were all patients included in the
analysis?
Yes
If the reference standard in-
cludes clinical follow-up of
borderline/benign appearing le-
sions, was there a minimum
follow-up following application
of index test(s) of at least: 3
months for melanoma or cSCC
or 6 months for BCC?
If more than one algorithm was
evaluated for the same test, was
the interval between applica-
tion of the different algorithms
1 month or less?
Unclear
Stanganelli 2000
Study characteristics
Patient sampling Study design: CS
Data collection: retrospective
Period of data collection: 1994-1996
Country: Italy
Patient characteristics and set-
ting
Inclusion criteria: patients with PSLs referred by dermatologists and general practitioners either
for pre-surgical assessment or consultation
Setting: specialist unit (skin cancer clinic/PLC)
Prior testing: patients referred for pre-surgical assessment or consultation indicating they have had
prior tests
Setting for prior testing: primary, some patients referred for consultation only; dermoscopy find-
ings reported back and management decision remains with referring clinician; secondary (general
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dermatology)
Exclusion criteria: none reported
Sample size (participants): number eligible: 1556
Sample size (lesions): number eligible: 3372; number included: 3372
Participant characteristics: median age 30 years, range 10-94; male: 522 (34%)
Lesion characteristics: none reported
Index tests VI: ABCD
Method of diagnosis: in-person diagnosis
Prior test data: N/A, in-person diagnosis
Other test data: dermoscopic and clinical images subsequently presented separately to observer
subsequent to diagnosis using clinical images alone
Diagnostic threshold: NR
Diagnosis based on: single observer; n = 1
Observer qualifications: NR; described as one of the co-authors and study based in skin cancer
clinic; likely dermatologist
Experience in practice: not described
Other detail: a crude clinical image (magn x6 and x10) was recorded in the digital database
Dermoscopy: evaluated in same study (image-based); pattern analysis
Target condition and reference
standard(s)
Reference standard: histological diagnosis plus follow-up; histology report of known surgical exci-
sions (n = 262) plus a cancer registry-based follow-up of benign cases (n = 3110)
Target condition (final diagnoses)
Melanoma (in situ and invasive, or NR): 55; BCC: 43
’Benign’ diagnoses: 3274
Flow and timing Excluded participants: none reported
Time interval to reference test: NR
Time interval between index test(s): not clearly reported just indicated thatD-ELMwas performed
soon after clinical examination
Comparative
Notes -
Methodological quality
Item Authors’ judgement Risk of bias Applicability concerns
DOMAIN 1: Patient Selection
Was a consecutive or random
sample of patients enrolled?
Yes
Was a case-control design
avoided?
Yes
Did the study avoid inappropri-
ate exclusions?
Yes
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Are the included patients and
chosen study setting appropri-
ate?
Yes
Did the study avoid including
participants with multiple le-
sions?
No
Low High
DOMAIN 2: Index Test Visual Inspection - in-person
Were the index test results in-
terpreted without knowledge of
the results of the reference stan-
dard?
Yes
If a threshold was used, was it
pre-specified?
Yes
For studies reporting the ac-
curacy of multiple diagnostic
thresholds, was each threshold
or algorithm interpreted with-
out knowledge of the results of
the others?
Was the test applied and inter-
preted in a clinically applicable
manner?
Yes
Were thresholds or criteria for
diagnosis reported in sufficient
detail to allow replication?
Yes
Was the test interpretation car-
ried out by an experienced ex-
aminer?
Unclear
Low Unclear
DOMAIN 3: Reference Standard
Is the reference standards likely
to correctly classify the target
condition?
No
Were the reference standard re-
sults
Unclear
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interpreted without knowledge
of the results of the index tests?
Expert opinion (with no his-
tological confirmation) was not
used as a reference standard
Yes
Was histology interpretation
carried out by an experienced
histopathologist or by a der-
matopathologist?
Unclear
High Unclear
DOMAIN 4: Flow and Timing
Was there an appropriate inter-
val between index test and ref-
erence standard?
Unclear
Did all patients receive the same
reference standard?
No
Were all patients included in the
analysis?
Yes
If the reference standard in-
cludes clinical follow-up of
borderline/benign appearing le-
sions, was there a minimum
follow-up following application
of index test(s) of at least: 3
months for melanoma or cSCC
or 6 months for BCC?
Yes
If more than one algorithm was
evaluated for the same test, was
the interval between applica-
tion of the different algorithms
1 month or less?
High
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Study characteristics
Patient sampling Study design: unclear (likely CS)
Data collection: retrospective image selection/prospective interpretation
Period of data collection: NR
Country: Italy
Test set derived: a training set of 22 melanomas and 218 MN was randomised from the dataset.
The test set was formed by the complement (the remaining 20 melanomas and 217 naevi). A further
subset of images from the original dataset, consisting of 31 melanomas and 103 naevi, was used for
the comparison between observers and CAD; derivation of the subset NR
Patient characteristics and set-
ting
Inclusion criteria: melanocytic lesions from patients referred to the Skin Cancer Unit and un-
dergoing clinical and dermoscopic evaluation; images were ’selected’ from a larger image database.
Potential overlap with Stanganelli 2000 (not possible to determine).
Setting: specialist unit (skin cancer clinic/PLC)
Prior testing: clinical and/or dermatoscopic suspicion
Setting for prior testing: specialist unit (skin cancer clinic/PLC)
Exclusion criteria: none reported
Sample size (participants): number eligible: 1556. Referred/number included: NR
Sample size (lesions): number eligible: 3274. Number included: 477 melanocytic lesions; 237 in
test set and 134 in comparison between CAD and human operators
Participant characteristics: none reported
Lesion characteristics: melanoma thickness 61.2% < 0.75 mm
Index tests VI: no algorithm
Method of diagnosis: clinical photographs
Prior test data: GPs evaluated only clinical images; unclear for dermatologists
Other test data: dermatologists examined both clinical and dermoscopic images but unclear whether
clinical diagnosis was made prior to presentation of dermoscopic images
Diagnostic threshold: NR
Diagnosis based on: average (n = 6)
Observer qualifications: GP 3; dermatologist 3
Experience in practice: assumed low for GPs; high for dermatologists. Described as “dermatologists
with experience in ELM (2 years)”
Other detail: digital images included melanocytic lesions evaluated in ELM with a fixed x16 mag-
nification
Dermoscopy: evaluated in same study; no algorithm
Target condition and reference
standard(s)
Reference standard: histological diagnosis plus cancer registry
All included lesions underwent histology but some were identified using a cancer registry-based
follow-up of benign diagnoses
Target condition (final diagnoses)
Melanoma (in situ and invasive, or NR): 42 in full sample; 31 in CAD vs human observer interp
and 20 in test set
’Benign’ diagnoses: 435 MN; 103 in CAD-observer comp and 217 in test set
Flow and timing Excluded participants: none reported
Time interval to reference test: NR
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Comparative
Notes -
Methodological quality
Item Authors’ judgement Risk of bias Applicability concerns
DOMAIN 1: Patient Selection
Was a consecutive or random
sample of patients enrolled?
Unclear
Was a case-control design
avoided?
Unclear
Did the study avoid inappropri-
ate exclusions?
Unclear
Are the included patients and
chosen study setting appropri-
ate?
No
Did the study avoid including
participants with multiple le-
sions?
Unclear
Unclear High
DOMAIN 2: Index Test Visual inspection - image-based
Were the index test results in-
terpreted without knowledge of
the results of the reference stan-
dard?
Yes
If a threshold was used, was it
pre-specified?
Unclear
For studies reporting the ac-
curacy of multiple diagnostic
thresholds, was each threshold
or algorithm interpreted with-
out knowledge of the results of
the others?
Was the test applied and inter-
preted in a clinically applicable
manner?
No
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Were thresholds or criteria for
diagnosis reported in sufficient
detail to allow replication?
No
Was the test interpretation car-
ried out by an experienced ex-
aminer?
Yes
Unclear High
DOMAIN 3: Reference Standard
Is the reference standards likely
to correctly classify the target
condition?
Yes
Were the reference standard re-
sults
interpreted without knowledge
of the results of the index tests?
Unclear
Expert opinion (with no his-
tological confirmation) was not
used as a reference standard
Unclear
Was histology interpretation
carried out by an experienced
histopathologist or by a der-
matopathologist?
Unclear
Low Unclear
DOMAIN 4: Flow and Timing
Was there an appropriate inter-
val between index test and ref-
erence standard?
Unclear
Did all patients receive the same
reference standard?
No
Were all patients included in the
analysis?
Yes
If the reference standard in-
cludes clinical follow-up of
borderline/benign appearing le-
sions, was there a minimum
follow-up following application
201Visual inspection for diagnosing cutaneous melanoma in adults (Review)
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Stanganelli 2005 (Continued)
of index test(s) of at least: 3
months for melanoma or cSCC
or 6 months for BCC?
If more than one algorithm was
evaluated for the same test, was
the interval between applica-
tion of the different algorithms
1 month or less?
High
Steiner 1987
Study characteristics
Patient sampling Study design: CS
Data collection: prospective
Period of data collection: not specified
Country: Austria
Patient characteristics and set-
ting
Inclusion criteria: small (< 10 mm) PSLs considered diagnostically equivocal in that there was no
absolute agreement on the clinical diagnosis among investigating clinicians at a PLC
Setting: specialist unit (skin cancer clinic/PLC)
Prior testing: clinical suspicion of malignancy without dermatoscopic suspicion
Setting for prior testing: specialist unit (skin cancer clinic/PLC)
Exclusion criteria: none reported
Sample size (participants): NR
Sample size (lesions): 318
Participant characteristics: none reported
Lesion characteristics: none reported
Index tests VI: no algorithm
Method of diagnosis: in-person diagnosis
Prior test data: N/A
Other test data: dermoscopy undertaken by same clinician(s) subsequent to clinical evaluation
Diagnostic threshold: NR
Diagnosis based on: consensus (3 observers) “All lesions were independently seen and diagnosed
by the three investigators, and the diagnosis that appeared most probable to at least two of the three
investigators was recorded as the clinical”; n = 3
Observer qualifications: dermatologist
Experience in practice: high experience or ‘Expert’ “experienced dermatologists”
Experience with index test: “experienced dermatologists”
Target condition and reference
standard(s)
Reference standard: histological diagnosis alone
Disease positive: 73 melanomas, 20 BCCs; disease negative: 225
Target condition (final diagnoses)
Melanoma (invasive): 49; melanoma (in situ): 15; lentigo maligna 9 (also includes lentigo maligna
melanoma)
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BCC: 20
SK: 20; junctional naevi 39; blue naevus 29; dysplastic naevus 75; LS and nevoid lentigo 19;
angioma/angiokeratoma 15
Flow and timing Excluded participants: none reported
Time interval to reference test: assumed consecutive; following diagnosis, lesions subsequently
excised
Time interval between index test(s): consecutive
Comparative
Notes -
Methodological quality
Item Authors’ judgement Risk of bias Applicability concerns
DOMAIN 1: Patient Selection
Was a consecutive or random
sample of patients enrolled?
Unclear
Was a case-control design
avoided?
Yes
Did the study avoid inappropri-
ate exclusions?
Unclear
Are the included patients and
chosen study setting appropri-
ate?
No
Did the study avoid including
participants with multiple le-
sions?
Unclear
Unclear High
DOMAIN 2: Index Test Visual Inspection - in-person
Were the index test results in-
terpreted without knowledge of
the results of the reference stan-
dard?
Yes
If a threshold was used, was it
pre-specified?
Unclear
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For studies reporting the ac-
curacy of multiple diagnostic
thresholds, was each threshold
or algorithm interpreted with-
out knowledge of the results of
the others?
Was the test applied and inter-
preted in a clinically applicable
manner?
No
Were thresholds or criteria for
diagnosis reported in sufficient
detail to allow replication?
No
Was the test interpretation car-
ried out by an experienced ex-
aminer?
Yes
Unclear High
DOMAIN 3: Reference Standard
Is the reference standards likely
to correctly classify the target
condition?
Yes
Were the reference standard re-
sults
interpreted without knowledge
of the results of the index tests?
Unclear
Expert opinion (with no his-
tological confirmation) was not
used as a reference standard
Yes
Was histology interpretation
carried out by an experienced
histopathologist or by a der-
matopathologist?
Unclear
Low Unclear
DOMAIN 4: Flow and Timing
Was there an appropriate inter-
val between index test and ref-
erence standard?
Yes
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Did all patients receive the same
reference standard?
Yes
Were all patients included in the
analysis?
Yes
If the reference standard in-
cludes clinical follow-up of
borderline/benign appearing le-
sions, was there a minimum
follow-up following application
of index test(s) of at least: 3
months for melanoma or cSCC
or 6 months for BCC?
If more than one algorithm was
evaluated for the same test, was
the interval between applica-
tion of the different algorithms
1 month or less?
Low
Thomas 1998
Study characteristics
Patient sampling Study design: CCS; separate recruitment
Data collection: retrospective
Period of data collection: NR; appears to be post-1992
Country: France
Patient characteristics and set-
ting
Inclusion criteria: retrospective selectionof all 460 cases ofmelanoma and anonselected consecutive
group of 680 nonmelanoma pigmented tumours
Setting: secondary (general dermatology)
Prior testing: selected for excision (no further detail). All excised
Setting for prior testing: NR
Exclusion criteria: NR
Sample size (participants): NR
Sample size (lesions): number included: 1140
Participant characteristics: NR
Lesion characteristics: Other test data: dermoscopy undertaken by same clinician(s) subsequent
to clinical evaluation
Index tests VI: ABCDE
Method of diagnosis: in-person diagnosis; dermatologist making referral for excision made the
diagnosis
Prior test data: N/A in-person diagnosis
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Diagnostic threshold: number of characteristics present (from ≥ 1 to all 5)
Diagnosis based on: single observer; n = NR
Observer qualifications: dermatologist
Experience in practice: assumed to be high; described as ’trained’ dermatologists
Other detail: preliminary meeting held to precisely define each criterion, agree on the significance
of each abnormality and define the appropriate way to fill in the study form. ABCDE: criterion A
was defined as geometrical asymmetry in two axes of the tumour, criterion B as irregular (unsharp
or ill-defined or angular) borders, criterion C as presence of at least 2 different colours within the
lesion (with the exception of the usual symmetrical darkening of the lesion in its centre), criterion
D as diameter ≥ 6 mm. Criterion E, the only anamnestic (based on the patient’s description of the
natural history of the lesion) criterion was defined as enlargement of the surface (and not in height)
of the lesion
Target condition and reference
standard(s)
Reference standard: histological diagnosis alone
Disease positive: 460; disease negative: 680
Target condition (final diagnoses)
Melanoma (in situ and invasive, or NR): 460
BCC: 8
SK: 19; 576 benign pigmented naevus; 55 dysplastic naevi; 4 blue naevi; 2 compound naevi with
Sutton inflammatory infiltrate; 2 Spitz; 1 Reed’s naevi; 3 haemangiomas; 9 DFs; 1 accessory nipple
Flow and timing Excluded participants: none reported
Time interval to reference test: NR
Comparative
Notes -
Methodological quality
Item Authors’ judgement Risk of bias Applicability concerns
DOMAIN 1: Patient Selection
Was a consecutive or random
sample of patients enrolled?
Yes
Was a case-control design
avoided?
No
Did the study avoid inappropri-
ate exclusions?
Unclear
Are the included patients and
chosen study setting appropri-
ate?
No
Did the study avoid including
participants with multiple le-
sions?
Unclear
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High High
DOMAIN 2: Index Test Visual Inspection - in-person
Were the index test results in-
terpreted without knowledge of
the results of the reference stan-
dard?
Yes
If a threshold was used, was it
pre-specified?
No
For studies reporting the ac-
curacy of multiple diagnostic
thresholds, was each threshold
or algorithm interpreted with-
out knowledge of the results of
the others?
Was the test applied and inter-
preted in a clinically applicable
manner?
Yes
Were thresholds or criteria for
diagnosis reported in sufficient
detail to allow replication?
Yes
Was the test interpretation car-
ried out by an experienced ex-
aminer?
Yes
High Low
DOMAIN 3: Reference Standard
Is the reference standards likely
to correctly classify the target
condition?
Yes
Were the reference standard re-
sults
interpreted without knowledge
of the results of the index tests?
No
Expert opinion (with no his-
tological confirmation) was not
used as a reference standard
Yes
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Was histology interpretation
carried out by an experienced
histopathologist or by a der-
matopathologist?
Yes
Low Low
DOMAIN 4: Flow and Timing
Was there an appropriate inter-
val between index test and ref-
erence standard?
Unclear
Did all patients receive the same
reference standard?
Yes
Were all patients included in the
analysis?
Yes
If the reference standard in-
cludes clinical follow-up of
borderline/benign appearing le-
sions, was there a minimum
follow-up following application
of index test(s) of at least: 3
months for melanoma or cSCC
or 6 months for BCC?
If more than one algorithm was
evaluated for the same test, was
the interval between applica-
tion of the different algorithms
1 month or less?
Unclear
Troyanova 2003
Study characteristics
Patient sampling Study design: CCS
Data collection: retrospective image selection/prospective interpretation
Period of data collection: NR
Country: NR
Patient characteristics and set-
ting
Inclusion criteria: Images of PSLs ≤ 13 mm in diameter selected for a dermoscopy training study
Setting: training study
Prior testing: NR
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Setting for prior testing: NR
Exclusion criteria: NR
Sample size (participants): NR
Sample size (lesions): number included: 50 lesions
Participant characteristics: NR
Lesion characteristics: melanoma thickness: ≤ 1 mm: 100%
Index tests VI: no algorithm
Method of diagnosis: clinical photographs and dermoscopic images
Other test data: dermoscopic images presented to observer subsequent to diagnosis using clinical
images alone
Prior test data: no further information used
Diagnostic threshold: NR
Diagnosis based on: average; n = 32
Observer qualifications: dermatologist
Experience in practice: high experience or ‘Expert’
Experience with index test: low experience/novice users; experienced in PSL field but not ELM
Dermoscopy: evaluated in same study; no algorithm
Target condition and reference
standard(s)
Reference standard: histological diagnosis alone
Disease positive: 25; disease negative: 25
Target condition (final diagnoses)
Melanoma (in situ and invasive, or NR): 25
’Benign’ diagnoses: 25 “not melanoma”
Flow and timing Excluded participants: none reported
Time interval to reference test: NR
Time interval between index test(s): NR
Comparative
Notes -
Methodological quality
Item Authors’ judgement Risk of bias Applicability concerns
DOMAIN 1: Patient Selection
Was a consecutive or random
sample of patients enrolled?
Unclear
Was a case-control design
avoided?
No
Did the study avoid inappropri-
ate exclusions?
Unclear
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Are the included patients and
chosen study setting appropri-
ate?
No
Did the study avoid including
participants with multiple le-
sions?
Unclear
High High
DOMAIN 2: Index Test Visual inspection - image-based
Were the index test results in-
terpreted without knowledge of
the results of the reference stan-
dard?
Yes
If a threshold was used, was it
pre-specified?
Unclear
For studies reporting the ac-
curacy of multiple diagnostic
thresholds, was each threshold
or algorithm interpreted with-
out knowledge of the results of
the others?
Was the test applied and inter-
preted in a clinically applicable
manner?
No
Were thresholds or criteria for
diagnosis reported in sufficient
detail to allow replication?
No
Was the test interpretation car-
ried out by an experienced ex-
aminer?
Yes
Unclear High
DOMAIN 3: Reference Standard
Is the reference standards likely
to correctly classify the target
condition?
Yes
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Were the reference standard re-
sults
interpreted without knowledge
of the results of the index tests?
Unclear
Expert opinion (with no his-
tological confirmation) was not
used as a reference standard
Yes
Was histology interpretation
carried out by an experienced
histopathologist or by a der-
matopathologist?
Unclear
Low Unclear
DOMAIN 4: Flow and Timing
Was there an appropriate inter-
val between index test and ref-
erence standard?
Unclear
Did all patients receive the same
reference standard?
Yes
Were all patients included in the
analysis?
Yes
If the reference standard in-
cludes clinical follow-up of
borderline/benign appearing le-
sions, was there a minimum
follow-up following application
of index test(s) of at least: 3
months for melanoma or cSCC
or 6 months for BCC?
If more than one algorithm was
evaluated for the same test, was
the interval between applica-
tion of the different algorithms
1 month or less?
Unclear
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Study characteristics
Patient sampling Study design: CS
Data collection: retrospective image selection/prospective interpretation
Period of data collection: January 2008-January 2010
Country: Turkey
Patient characteristics and set-
ting
Inclusion criteria: melanocytic lesions excised at Ankara University Department of Dermatology
PLC
Setting: specialist unit (skin cancer clinic/PLC) Ankara University Department of Dermatology
PLC
Prior testing: selected for excision (no further detail)
Setting for prior testing: specialist unit (skin cancer/PLC)
Exclusion criteria: location/site of lesion facial, nail and volar acral lesions were excluded; non-
melanocytic appearance
Sample size (participants): number included: 115
Sample size (lesions): number included: 115
Participant characteristics: mean age: 38.72 years (+/- 18.46 years); male: n = 56 (49%)
Lesion characteristics: lesion site: 100% trunk and limbs. Melanoma thickness: 10 (41.7%) < 0.
75 mm; 14 (58.3%) ≥ 0.75 mm
Index tests VI: no algorithm; appears to be original clinical diagnosis at time of lesion presentation
Method of diagnosis: in-person diagnosis. Appears to be diagnosis on presentation
Prior test data: N/A, in-person diagnosis
Other test data: dermoscopic images presented to different observers
Diagnostic threshold: NR
Diagnosis based on: unclear. For VI appears to be single examiner at time of clinic diagnosis (n =
NR); dermoscopic images “scored by three other experienced dermatoscopists” (n = 3)
Observer qualifications: NR; assumed dermatologists. Described as experienced dermatoscopists
Experience in practice: unclear for clinic diagnosis; dermatoscopists described as “experienced”
Experience with index test: described as “experienced”
Dermoscopy: evaluated in same study by 3 experienced dermoscopists; 3-point rule; 7-point check-
list; ABCD; CASH algorithm (image-based)
Target condition and reference
standard(s)
Reference standard: histological diagnosis alone
Disease positive: 24; disease negative: 91
Target condition (final diagnoses)
Melanoma (in situ and invasive, or NR): 24
’Benign’ diagnoses: 91melanocytic benign lesions; 37 (32.2%) dermal naevi; 15 (13%)Clark’s naevi;
14 (12.2%) compound naevi; 13 (11.3%) blue naevi; 6 (5.2%) Spitz naevi; 4 (3.5%) congenital
MN; 2 (1.7%) junctional naevi
Flow and timing Excluded participants: none reported
Time interval to reference test: NR
Time interval between index test(s): appear to be consecutively applied
Comparative
Notes -
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Methodological quality
Item Authors’ judgement Risk of bias Applicability concerns
DOMAIN 1: Patient Selection
Was a consecutive or random
sample of patients enrolled?
Yes
Was a case-control design
avoided?
Yes
Did the study avoid inappropri-
ate exclusions?
No
Are the included patients and
chosen study setting appropri-
ate?
No
Did the study avoid including
participants with multiple le-
sions?
Yes
High High
DOMAIN 2: Index Test Visual Inspection - in-person
Were the index test results in-
terpreted without knowledge of
the results of the reference stan-
dard?
Yes
If a threshold was used, was it
pre-specified?
Unclear
For studies reporting the ac-
curacy of multiple diagnostic
thresholds, was each threshold
or algorithm interpreted with-
out knowledge of the results of
the others?
Was the test applied and inter-
preted in a clinically applicable
manner?
Yes
Were thresholds or criteria for
diagnosis reported in sufficient
detail to allow replication?
No
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Was the test interpretation car-
ried out by an experienced ex-
aminer?
Unclear
Unclear High
DOMAIN 3: Reference Standard
Is the reference standards likely
to correctly classify the target
condition?
Yes
Were the reference standard re-
sults
interpreted without knowledge
of the results of the index tests?
Unclear
Expert opinion (with no his-
tological confirmation) was not
used as a reference standard
Yes
Was histology interpretation
carried out by an experienced
histopathologist or by a der-
matopathologist?
Yes
Low Low
DOMAIN 4: Flow and Timing
Was there an appropriate inter-
val between index test and ref-
erence standard?
Unclear
Did all patients receive the same
reference standard?
Yes
Were all patients included in the
analysis?
Yes
If the reference standard in-
cludes clinical follow-up of
borderline/benign appearing le-
sions, was there a minimum
follow-up following application
of index test(s) of at least: 3
months for melanoma or cSCC
or 6 months for BCC?
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If more than one algorithm was
evaluated for the same test, was
the interval between applica-
tion of the different algorithms
1 month or less?
Unclear
Viglizzo 2004
Study characteristics
Patient sampling Study design: CS
Data collection: NR
Period of data collection: NR
Country: Italy
Patient characteristics and set-
ting
Inclusion criteria: PSLs examined at the Dermoscopy Service and undergoing excision; a modified
version of Kenet’s risk stratification approach for dermoscopy (Ascierto 2000) was used to select
high- and very high-risk lesions for excision; medium- and low-risk lesions were excised based on
cosmetic or functional reasons. (We extracted 2x2 data for melanocytic subgroup only)
Setting: specialist unit (skin cancer clinic/PLC) dermoscopy service at a university department
(Department of Endocrinologic and Metabolic Disease)
Prior testing: clinical suspicion of malignancy without dermatoscopic suspicion
Setting for prior testing: specialist unit (skin cancer clinic/PLC)
Exclusion criteria: none reported
Sample size (participants): number eligible: 349 patients; number included: NR
Sample size (lesions): number eligible: 520 lesions; number included: 79 lesions excised included
in the final analysis
Participant characteristics: none reported
Lesion characteristics: none reported
Index tests VI: no algorithm
Method of diagnosis: in-person diagnosis
Prior test data: unclear
Other test data: dermoscopy undertaken by same clinician(s) subsequent to clinical evaluation
Diagnostic threshold: NR; correct diagnosis of melanoma
Diagnosis based on: single observer (n = NR; “All dermoscopic evaluations were performed by the
same operators”)
Observer qualifications: NR; “each lesion was ... diagnosed clinically and dermoscopically” at the
dermoscopy service
Experience in practice: not described
Experience with dermoscopy: not described; assumed high as diagnosis at ’Dermoscopy service’
Dermoscopy: evaluated in same study; no algorithm
Target condition and reference
standard(s)
Reference standard: histological diagnosis alone
Target condition (final diagnoses)
Melanoma (invasive): 11; melanoma (in situ): 1
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Melanocytic lesion: 67
Flow and timing Excluded participants: none reported
Time interval to reference test: NR
Comparative
Notes -
Methodological quality
Item Authors’ judgement Risk of bias Applicability concerns
DOMAIN 1: Patient Selection
Was a consecutive or random
sample of patients enrolled?
Yes
Was a case-control design
avoided?
Yes
Did the study avoid inappropri-
ate exclusions?
Unclear
Are the included patients and
chosen study setting appropri-
ate?
No
Did the study avoid including
participants with multiple le-
sions?
Unclear
Unclear High
DOMAIN 2: Index Test Visual Inspection - in-person
Were the index test results in-
terpreted without knowledge of
the results of the reference stan-
dard?
Yes
If a threshold was used, was it
pre-specified?
Unclear
For studies reporting the ac-
curacy of multiple diagnostic
thresholds, was each threshold
or algorithm interpreted with-
out knowledge of the results of
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the others?
Was the test applied and inter-
preted in a clinically applicable
manner?
Yes
Were thresholds or criteria for
diagnosis reported in sufficient
detail to allow replication?
No
Was the test interpretation car-
ried out by an experienced ex-
aminer?
Unclear
Unclear High
DOMAIN 3: Reference Standard
Is the reference standards likely
to correctly classify the target
condition?
Yes
Were the reference standard re-
sults
interpreted without knowledge
of the results of the index tests?
Unclear
Expert opinion (with no his-
tological confirmation) was not
used as a reference standard
Yes
Was histology interpretation
carried out by an experienced
histopathologist or by a der-
matopathologist?
Unclear
Low Unclear
DOMAIN 4: Flow and Timing
Was there an appropriate inter-
val between index test and ref-
erence standard?
Unclear
Did all patients receive the same
reference standard?
Yes
Were all patients included in the
analysis?
Yes
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If the reference standard in-
cludes clinical follow-up of
borderline/benign appearing le-
sions, was there a minimum
follow-up following application
of index test(s) of at least: 3
months for melanoma or cSCC
or 6 months for BCC?
If more than one algorithm was
evaluated for the same test, was
the interval between applica-
tion of the different algorithms
1 month or less?
Unclear
Walter 2012
Study characteristics
Patient sampling Study design: RCT (control group only included)
Data collection: prospective
Period of data collection: March 2008-May 2010
Country: UK
Patient characteristics and set-
ting
Inclusion criteria: adults with any suspicious PSL, i.e. any lesion presented by a patient, or oppor-
tunistically seen by a family doctor or practice nurse, that could not immediately be diagnosed as
benign and about which the patient could not be reassured
Setting: primary. 15 general practices in eastern England
Prior testing: clinical suspicion of malignancy without dermatoscopic suspicion
Setting for prior testing: primary
Exclusion criteria: those unable to give informed consent or considered inappropriate to include
by their family doctor
Sample size (participants): number eligible: 1297; number included: 1293
Sample size (lesions): number eligible: 1580; number included: 1583
Participant characteristics: mean age: 44.6 years (SD 16.8). Male: 465 (36%). Ethnicity: white
1214 (93.9%); mixed 45 (3.5%); missing: 34 (2.6%)
Lesion characteristics: lesion thickness ≤ 1 mm: in ’more than half ’ of MM
Index tests VI: Glasgow/MacKie revised 7-point checklist (MacKie 1990)
Method of diagnosis: in-person diagnosis
Prior test data: N/A
Diagnostic threshold: NR
Diagnosis based on: single observer (n = 30)
Observer qualifications: 28 GPs and 2 nurse practitioners recruited as ’lead clinicians’ (2 per
practice); appears as though they conducted all skin examinations. Excluded GPs with known
dermatological expertise, e.g. current hospital practitioners, clinical assistants in dermatology, and
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GPs with a special interest in dermatology
Experience in practice: mixed GP experience, median of 15 years’ experience (range 4-27 years)
; assumed low experience with PSLs. 7 had undergone some training in dermatology: 3 had a
short dermatology training post, 3 were on clinical attachment to an out-patient clinic, and 1 was
unspecified
Target condition and reference
standard(s)
Reference standard: histological diagnosis plus follow-up and expert opinion
Histology (not further described) 215 (histology result missing in further 4)
Disease positive: 35; disease negative: 180
Clinical follow-upplus histology of suspicious lesions: 22 of the 411 referred patients weremonitored
(not further described); 566 of the 1162 not referred underwent expert review and were then re-
assessed at 3-6 months
Disease positive: 1; disease negative: 588
Expert opinion. Reviewed by 2 dermatology experts using the recorded clinical history and exami-
nation, a digital photograph, and MoleMate image where available
Disease positive: 0; disease negative: 725
Target condition (final diagnoses)
Melanoma (invasive): 30; melanoma (in situ): 6; BCC: 10
’Benign’ diagnoses: 1306
Flow and timing Excluded participants: 417 withdrew from control group after randomisation. 10 did not attend
for dermatology assessment; 19 excluded; 1 died; 4 missing histology (in referred group; included
as benign?); plus 12 with unknown outcome (in non-referred group, assumed benign and included)
Time interval to reference test: suspicious lesions referred under 2-week wait system
Comparative
Notes -
Methodological quality
Item Authors’ judgement Risk of bias Applicability concerns
DOMAIN 1: Patient Selection
Was a consecutive or random
sample of patients enrolled?
Yes
Was a case-control design
avoided?
Yes
Did the study avoid inappropri-
ate exclusions?
Yes
Are the included patients and
chosen study setting appropri-
ate?
Yes
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Did the study avoid including
participants with multiple le-
sions?
No
Low High
DOMAIN 2: Index Test Visual Inspection - in-person
Were the index test results in-
terpreted without knowledge of
the results of the reference stan-
dard?
Yes
If a threshold was used, was it
pre-specified?
Yes
For studies reporting the ac-
curacy of multiple diagnostic
thresholds, was each threshold
or algorithm interpreted with-
out knowledge of the results of
the others?
Was the test applied and inter-
preted in a clinically applicable
manner?
Yes
Were thresholds or criteria for
diagnosis reported in sufficient
detail to allow replication?
Yes
Was the test interpretation car-
ried out by an experienced ex-
aminer?
No
Low High
DOMAIN 3: Reference Standard
Is the reference standards likely
to correctly classify the target
condition?
No
Were the reference standard re-
sults
interpreted without knowledge
of the results of the index tests?
No
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Expert opinion (with no his-
tological confirmation) was not
used as a reference standard
No
Was histology interpretation
carried out by an experienced
histopathologist or by a der-
matopathologist?
Unclear
High High
DOMAIN 4: Flow and Timing
Was there an appropriate inter-
val between index test and ref-
erence standard?
Yes
Did all patients receive the same
reference standard?
No
Were all patients included in the
analysis?
No
If the reference standard in-
cludes clinical follow-up of
borderline/benign appearing le-
sions, was there a minimum
follow-up following application
of index test(s) of at least: 3
months for melanoma or cSCC
or 6 months for BCC?
Yes
If more than one algorithm was
evaluated for the same test, was
the interval between applica-
tion of the different algorithms
1 month or less?
High
Westerhoff 2000
Study characteristics
Patient sampling Study design: CCS (for lesion selection; study was an RCT of dermoscopy training for PCPs)
Data collection: retrospective
Period of data collection: NR
Country: Australia
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Patient characteristics and set-
ting
Inclusion criteria: clinically atypical PSLs; 50 invasivemelanomas and 50 nonmelanomas randomly
selected from the Sydney Melanoma Unit PSL image database
Setting: specialist unit (lesion selection)
Prior testing: selected for excision or followed up
Setting for prior testing: specialist unit (skin cancer clinic/PLC)
Exclusion criteria: none reported
Sample size (participants): number included: NR
Sample size (lesions): number included: 100
Participant characteristics: none reported
Lesion characteristics: median Breslow thickness 0.6 mm
Index tests VI: no algorithm
Method of diagnosis: clinical photographs
Prior test data: unclear; all participants “were instructed not to look at the surface microscopic
image until they had scored the clinical image”
Diagnostic threshold: NR
Diagnosis based on: average (n = 37); 74 practising primary care practitioners randomised to
dermoscopy education intervention or not. Diagnoses were recorded for both groups of GPs at
baseline (pre-test) and after the training intervention had been administered to the intervention
group (post-test), resulting in 8 sets of 2x2 data based on interpretation of the same set of 100
lesions; post-test data for the intervention group of GPs was used for the VI analysis
Observer qualifications: GP
Experience in practice: considered to be low; only practitioners who had had no formal training
with surface microscopy and did not use a surface microscope in their clinical practice were included
Experience with dermoscopy: low experience/novice users (non-training arm); ’trained’ for the
intervention arm
Other detail: camera designed for close-up clinical photography (Elicar Macrolens, Japan)
Dermoscopy: evaluated in same study; Menzies criteria (intervention arm underwent training in
Menzies criteria)
Target condition and reference
standard(s)
Reference standard: histological diagnosis plus follow-up
Histology: all the lesions except 2 had been excised after photography and subjected to histopatho-
logical examination
Disease positive: 50; disease negative: 48
Clinical follow-up plus histology of suspicious lesions: the 2 benign PSLs that had not been excised
were monitored over a longer period of time and had shown no morphological change
Length of follow-up: NR; disease positive: 0; disease negative: 2
Target condition (final diagnoses)
Melanoma (invasive): 50; ’benign’ diagnoses: 50
Flow and timing Excluded participants: none reported
Time interval to reference test: “All the lesions except two had been excised after photography”
Comparative
Notes -
Methodological quality
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Item Authors’ judgement Risk of bias Applicability concerns
DOMAIN 1: Patient Selection
Was a consecutive or random
sample of patients enrolled?
Yes
Was a case-control design
avoided?
No
Did the study avoid inappropri-
ate exclusions?
Unclear
Are the included patients and
chosen study setting appropri-
ate?
No
Did the study avoid including
participants with multiple le-
sions?
Unclear
High High
DOMAIN 2: Index Test Visual inspection - image-based
Were the index test results in-
terpreted without knowledge of
the results of the reference stan-
dard?
Yes
If a threshold was used, was it
pre-specified?
Unclear
For studies reporting the ac-
curacy of multiple diagnostic
thresholds, was each threshold
or algorithm interpreted with-
out knowledge of the results of
the others?
Was the test applied and inter-
preted in a clinically applicable
manner?
No
Were thresholds or criteria for
diagnosis reported in sufficient
detail to allow replication?
No
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Was the test interpretation car-
ried out by an experienced ex-
aminer?
Yes
Unclear High
DOMAIN 3: Reference Standard
Is the reference standards likely
to correctly classify the target
condition?
Yes
Were the reference standard re-
sults
interpreted without knowledge
of the results of the index tests?
Unclear
Expert opinion (with no his-
tological confirmation) was not
used as a reference standard
Yes
Was histology interpretation
carried out by an experienced
histopathologist or by a der-
matopathologist?
Unclear
Low Unclear
DOMAIN 4: Flow and Timing
Was there an appropriate inter-
val between index test and ref-
erence standard?
Yes
Did all patients receive the same
reference standard?
No
Were all patients included in the
analysis?
Yes
If the reference standard in-
cludes clinical follow-up of
borderline/benign appearing le-
sions, was there a minimum
follow-up following application
of index test(s) of at least: 3
months for melanoma or cSCC
or 6 months for BCC?
Unclear
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If more than one algorithm was
evaluated for the same test, was
the interval between applica-
tion of the different algorithms
1 month or less?
High
Winkelmann 2016
Study characteristics
Patient sampling Study design: CCS
Data collection: retrospective image selection/prospective interpretation
Period of data collection: NR
Country: NR
Patient characteristics and set-
ting
Inclusion criteria: images of PSLs previously analysed by a digital classifier MSDSLA; method of
selection of the 12 NR
Setting: dermoscopy conference
Prior testing: NR
Setting for prior testing: unspecified
Exclusion criteria: none reported
Sample size (participants): NR
Sample size (lesions): number included: 12
Participant characteristics: none reported
Lesion characteristics: none reported
Index tests VI: no algorithm
Method of diagnosis: clinical photographs
Prior test data: unclear
Other test data: dermoscopic images presented to observer subsequent to diagnosis using clinical
images alone
Diagnostic threshold: NR, biopsy decision
Diagnosis based on: average (n = 70)
Observer qualifications: dermatologist
Experience in practice: not described; recruited “dermatologists at a dermoscopy conference”; no
further details
Other detail: study authors report that practitioners with a particular interest in skin cancer or
technology may have chosen to attend this conference and/or self-selected to take part in the study
Dermoscopy: evaluated in same study; no algorithm
Target condition and reference
standard(s)
Reference standard: histological diagnosis alone
Disease positive: 5; disease negative: 7
Target condition (final diagnoses)
Melanoma (invasive): 3; melanoma (in situ): 2
Mild/moderate dysplasia: 7 low-grade dysplastic naevi
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Flow and timing Excluded participants: none reported
Time interval to reference test: NR
Comparative
Notes -
Methodological quality
Item Authors’ judgement Risk of bias Applicability concerns
DOMAIN 1: Patient Selection
Was a consecutive or random
sample of patients enrolled?
Unclear
Was a case-control design
avoided?
No
Did the study avoid inappropri-
ate exclusions?
Unclear
Are the included patients and
chosen study setting appropri-
ate?
No
Did the study avoid including
participants with multiple le-
sions?
Unclear
High High
DOMAIN 2: Index Test Visual inspection - image-based
Were the index test results in-
terpreted without knowledge of
the results of the reference stan-
dard?
Yes
If a threshold was used, was it
pre-specified?
Unclear
For studies reporting the ac-
curacy of multiple diagnostic
thresholds, was each threshold
or algorithm interpreted with-
out knowledge of the results of
the others?
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Was the test applied and inter-
preted in a clinically applicable
manner?
No
Were thresholds or criteria for
diagnosis reported in sufficient
detail to allow replication?
No
Was the test interpretation car-
ried out by an experienced ex-
aminer?
Unclear
Unclear High
DOMAIN 3: Reference Standard
Is the reference standards likely
to correctly classify the target
condition?
Yes
Were the reference standard re-
sults
interpreted without knowledge
of the results of the index tests?
Unclear
Expert opinion (with no his-
tological confirmation) was not
used as a reference standard
Yes
Was histology interpretation
carried out by an experienced
histopathologist or by a der-
matopathologist?
Unclear
Low Unclear
DOMAIN 4: Flow and Timing
Was there an appropriate inter-
val between index test and ref-
erence standard?
Unclear
Did all patients receive the same
reference standard?
Yes
Were all patients included in the
analysis?
Yes
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If the reference standard in-
cludes clinical follow-up of
borderline/benign appearing le-
sions, was there a minimum
follow-up following application
of index test(s) of at least: 3
months for melanoma or cSCC
or 6 months for BCC?
Yes
If more than one algorithm was
evaluated for the same test, was
the interval between applica-
tion of the different algorithms
1 month or less?
Unclear
Zaumseil 1983
Study characteristics
Patient sampling Study design: CS
Data collection: NR
Period of data collection: 1976-1981
Country: Germany
Patient characteristics and set-
ting
Inclusion criteria: skin lesions undergoing excision
Setting: secondary (not further specified)
Prior testing: selected for excision (no further detail)
Setting for prior testing: specialist unit (skin cancer clinic/PLC) Described as ’skin clinic’
Exclusion criteria: disagreement between evaluators on tumour histological classification. Those in
which the histological diagnosis was ’unclear’ were excluded, melanoma metastases were excluded
Sample size (participants): NR
Sample size (lesions): number included: 7063
Participant characteristics: none reported
Lesion characteristics: none reported
Index tests VI: no algorithm
Method of diagnosis: in-person diagnosis
Prior test data: N/A, in-person diagnosis
Diagnostic threshold: primary diagnosis of melanoma (method of Kopf 1975 was cited)
Diagnosis based on: single observer (n = NR)
Observer qualifications: NR
Experience in practice: not described
Experience with index test: not described
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Target condition and reference
standard(s)
Reference standard: histological diagnosis alone
Disease positive: 337; disease negative: 6726
Target condition (final diagnoses)
Melanoma (invasive or in situ): 337
Other diagnoses only listed for the 89 false-positives: 23 benign naevi; 13 BCC; 12 blue nevus; 11
angiomatosis; 10 SK; 6 histiocytoma; 4 Spitz nevus; 4 lentigo; 3 Bowen’s disease; 1 acrospiroma; 1
keratinizing papilloma
Flow and timing Excluded participants: none reported
Time interval to reference test: NR
Comparative
Notes -
Methodological quality
Item Authors’ judgement Risk of bias Applicability concerns
DOMAIN 1: Patient Selection
Was a consecutive or random
sample of patients enrolled?
Unclear
Was a case-control design
avoided?
Yes
Did the study avoid inappropri-
ate exclusions?
No
Are the included patients and
chosen study setting appropri-
ate?
No
Did the study avoid including
participants with multiple le-
sions?
Unclear
High High
DOMAIN 2: Index Test Visual Inspection - in-person
Were the index test results in-
terpreted without knowledge of
the results of the reference stan-
dard?
Yes
If a threshold was used, was it
pre-specified?
Yes
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For studies reporting the ac-
curacy of multiple diagnostic
thresholds, was each threshold
or algorithm interpreted with-
out knowledge of the results of
the others?
Was the test applied and inter-
preted in a clinically applicable
manner?
Yes
Were thresholds or criteria for
diagnosis reported in sufficient
detail to allow replication?
No
Was the test interpretation car-
ried out by an experienced ex-
aminer?
Unclear
Low High
DOMAIN 3: Reference Standard
Is the reference standards likely
to correctly classify the target
condition?
Yes
Were the reference standard re-
sults
interpreted without knowledge
of the results of the index tests?
Unclear
Expert opinion (with no his-
tological confirmation) was not
used as a reference standard
Yes
Was histology interpretation
carried out by an experienced
histopathologist or by a der-
matopathologist?
Unclear
Low Unclear
DOMAIN 4: Flow and Timing
Was there an appropriate inter-
val between index test and ref-
erence standard?
Unclear
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Did all patients receive the same
reference standard?
Yes
Were all patients included in the
analysis?
Yes
If the reference standard in-
cludes clinical follow-up of
borderline/benign appearing le-
sions, was there a minimum
follow-up following application
of index test(s) of at least: 3
months for melanoma or cSCC
or 6 months for BCC?
If more than one algorithm was
evaluated for the same test, was
the interval between applica-
tion of the different algorithms
1 month or less?
Unclear
ABCD(E): asymmetry, border, colour, differential structures (enlargement); AK: actinic keratosis; AMN: atypical MN; BCC: basal
cell carcinoma; CAD: computer-assisted diagnosis; CCS: case-controlled study; CD: compact disc; CM: cutaneous melanoma;
CMM: cutaneous malignant melanoma; CS: case series; cSCC: cutaneous squamous cell carcinoma; DF: dermatofibroma; ELM:
epiluminescence microscopy; FN: false-negative; FP: false-positive; GP: general practitioner; H&E: haematoxylin and eosin stain;
LPLK: lichen planus-like keratosis; LS: lentigo simplex;MM: malignant (invasive) melanoma;MN: melanocytic naevi;MSDSLA:
multispectral digital skin lesion analysis device; N/A: not applicable; NMLs: non-melanocytic lesions; NR: not reported; PCPs:
primary care providers; PLC: pigmented lesion clinic; PSL: pigmented skin lesion; RCM: reflectance confocal microscopy; RCT:
randomised controlled trial;SCC: squamous cell carcinoma;SD: standard deviation;SDDI: short-term sequential digital dermoscopy
imaging; SK: seborrhoeic keratosis; SSM: superficial spreading melanoma; SVS: support vector system;VI: visual inspection; 7FFM:
seven features for melanoma
Characteristics of excluded studies [ordered by study ID]
Study Reason for exclusion
Abbasi 2004 Not a primary study; systematic review
Aldridge 2011a Ineligible test observer: medical students and lay people
Aldridge 2011b Ineligible test observer
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Aldridge 2013 Unable to construct 2x2 table based on data presented. Not test accuracy study
Alendar 2009 Ineligible reference standard. Only 7 reported verified histologically
Argenziano 1999 Ineligible study population. Only included melanoma
Argenziano 2003 Unable to construct 2x2 table based on data presented. Table V gives se/sp data for 108 lesions but cannot
derive the number of melanoma for this subset of the original 128
Contacted study authors 10 May 2016; 24 June 2016
Argenziano 2012 Ineligible reference standard. No follow-up of test-negatives
Argenziano 2014 Unable to construct 2x2 table based on data presented
Ascierto 2003 Not a primary study
Badertscher 2015 Unable to construct 2x2 table based on data presented
Bafounta 2001 Not a primary study, systematic review
Banky 2005 Ineligible target condition
Ineligible index test
Basarab 1996 Ineligible study population. Not all suspected of skin cancer
Unable to construct 2x2 table based on data presented
Bauer 2000 Ineligible index test. Does not provide 2x2 data for VI alone
Bauer 2005 Ineligible index test, follow-up/monitoring study
Becker 1954 Not a primary study
Benelli 2000 Unable to construct 2x2 table based on data presented. Only inter-rater reliability data given (n = 25);
study authors have published much larger evaluations of 7FFM and ABCD
Blum 2004a Not a primary study, comment paper
Blum 2004b Not a primary study, letter. Only limited data presented. Evaluates ’3-colour’ rule as developed by Mackie
2002 (excluded as assessment of individual lesion features only)
Blum 2004c Ineligible index test, evaluates dermoscopy only
Bolognia 1990 Ineligible reference standard, no reference standard diagnosis for index test-negatives
Bono 2001 Unable to construct 2x2 table based on data presented. Aim of the study was to determine what features
are present in amelanotic cutaneous melanoma
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Borsari 2015 Individual lesion characteristics
Borve 2012 Ineligible study population, included participants without skin lesions
Ineligible sample size, < 5 BCC
Brown 2000 Not a primary study, systematic review
Brown 2009 Ineligible test observer, lay people
Buhl 2012 Ineligible index test, follow-up/monitoring
Duplicate or related publication, same participants as Haenssle 2010
Burki 2015 Not a primary study
Burr 2015 Not a primary study
Burton 1998 Ineligible reference standard
Unable to construct 2x2 table based on data presented, can only get 2x2 data for referral accuracy
Carli 2003b Ineligible reference standard. Only 39/1042 with reference test
Carli 2003c Ineligible sample size
Carli 2004a Ineligible sample size, < 5 MM per arm
Unable to construct 2x2 table based on data presented
Carli 2004b Ineligible index test
Study author passed away; unable to make contact with co-authors
Carli 2004c Ineligible index test, ’clinical diagnosis’. Dataset covers 1997-2001, but dermoscopy routinely introduced
1998; study authors contacted but no response
Carli 2005 Unable to construct 2x2 table based on data presented. Only sensitivity data given (% with correct
diagnosis); % of benign lesions incorrectly diagnosed was not reported
We will try to contact study authors.
Carlos-Ortega 2007 Unable to construct 2x2 table based on data presented. Gives se/sp for VI and dermoscopy in the English
abstract. 68 patients/70 lesions were included but only 36 seem to have had VI results and all underwent
dermoscopy. 2 observers performed each test blinded to each other. Table I gives 22 with BCC and 11
with melanoma overall (number D+ not reported for those with VI results), but using either or both of
these numbers with the se/sp provided does not give the same PPV and NPV as given by the study authors
Data not clearly presented for 2x2; translator suggested alternative but still does not work out to what is
in paper; tried contacting authors twice, no reply
Chen 2001 Not a primary study, systematic review comparing PCP accuracy with dermatologist accuracy
Chen 2006 Unable to construct 2x2 table based on data presented, only given AUC
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Chiaravalloti 2014 Ineligible study population, included melanoma only
Ciudad-Blanco 2014 Ineligible study population, included melanoma only
Cooper 2002 Ineligible target condition, insufficient data for inclusion in melanoma review
Cornell 2015 Ineligible test observer
Cox 2008 Ineligible reference standard. Se and sp estimates for diagnosis of melanoma for both the 7-point checklist
and the revised (10-point) checklist; reference standard not reported for any of the 381 TWR referrals for
melanoma
Study author contacted 10 May 2016; co-author contacted 24 June 2016
De Giorgi 2011 Duplicate publication. Study appears to use same lesions as Carli 2003a (included study). Both studies
have the same numbers of melanomas and benign nevi and have common co-authors (De Giorgi 2011 in
particular). Although not explicit, the De Giorgi 2011 paper appears to have used the same lesions and
study design but with different observers. The original Carli 2003b paper reported using 8 expert observers
while the later paper recruited 8 dermatologists who had undergone a dermoscopy training course but
who reported no experience in assessing pigmented skin lesions
DeCoste 1993 Unable to construct 2x2 table based on data presented. Not given the total number of D+/D- or total
number of lesions included. Just given the se/sp values
Di Carlo 2014 Ineligible index test. Videothermography not relevant for the review and there is no2x2data for dermoscopy
if derivation study. Only included AK and BCC
Di Chiacchio 2010 Ineligible target condition, excluded nail bed melanoma
Unable to construct 2x2 table due to insufficient data to extract
Dreiseitl 2009 Ineligible index test. Did not evaluate VI alone
Duff 2001 Ineligible index test. Did not evaluate VI alone
Edmondson 1999 Ineligible reference standard. It seems that the reference standard here was expert diagnosis. This is not a
teledermatology paper
Emmons 2011 Unable to construct 2x2 table based on data presented. Not test accuracy study; promoted primary
prevention
Engelberg 1999 Ineligible sample size, only 1 confirmed melanoma and 3 BCC
English 2003 Unable to construct 2x2 table based on data presented. No accuracy data given
English 2004 Unable to construct 2x2 table based on data presented. No accuracy data
Fabbrocini 2008 Unable to construct 2x2 table because insufficient data provided for each index test to populate 2x2 table
Contacted study authors to request cross-tabulation of each clinician’s diagnosis (e.g. at threshold of ≥ 3
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on 7-point checklist) against the histological diagnosis or a cross-tabulation of the remote diagnosis against
the face-to-face diagnoses, or both. Study author responded 30 June 2016, cannot access data needed
Federman 1995 Unable to construct 2x2 table based on data presented. Not test accuracy study
Fikrle 2013 Ineligible reference standard. Follow-up study < 50% of study participants had their final diagnosis reached
by histopathology
Freeman 1963 Unable to construct 2x2 table based on data presented. Only gives % correct for each lesion type
Tables 2 and 3 appear to give % correct diagnoses per lesion type, but do not give data on numbers
misclassified as melanoma, or other malignancy, i.e. FPs
Contacted study authors who responded; paper too old, cannot provide data
Friedman 1985 Not a primary study
Funt 1963 Ineligible index test. No 2x2 data to construct 2x2 table
Gerbert 1996 Ineligible target condition. No breakdown of final diagnoses for included lesions
Unable to construct 2x2 table based on data presented
Only gives % correct for each lesion type; not se/sp
Gerbert 1998 Unable to construct 2x2 table based on data presented
Giannotti 2004 Not a primary study, a review
Grana 2003 Ineligible index test. Individual lesion characteristics, only looking at lesion border
Grob 1998 Not a primary study
Guibert 2000 Ineligible reference standard. Not designed as an accuracy study only observational. Cannot get 2x2 data
> 50% of study participants did not receive histology as ref standard
Gunduz 2003 Ineligible sample size, case study
Gutierrez 2013 Ineligible index test, test to improve histopathology diagnosis
Hacioglu 2013 Ineligible target condition. Does not provide sufficient data for detection of melanoma
Haenssle 2010 Ineligible index test. Test used for monitoring and not initial diagnosis; no VI data
Haenssle 2010a Unable to construct 2x2 table based on data presented. Does not report specificity
Duplicate or related publication, same participants as Haenssle 2010
Hallock 1998 Ineligible index test. ’Clinical diagnosis’; dermoscopy used for 3 of the 4 years of study recruitment
Haniffa 2007 Ineligible reference standard, looks like approximately 20% of participants received a final diagnosis by
histology. 179 biopsies were performed. Total sample was 881 lesions
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Har-Shai 2001 Ineligible index test, ’clinical diagnosis’
Heal 2008 Unable to construct 2x2 table based on data presented. Sensitivities and PPVs are given so theoretically a
2x2 could be worked out, but the numbers do not appear to work out
Author response: the 2x2 table the Cochrane researchers want to create is not possible for our results,
because sensitivity and PPV are based on different sample sizes
Healsmith 1994 Ineligible reference standard. Benign lesions described as ’clinically diagnosed’ rather than histology/follow-
up
Higgins 1992 Ineligible study population, included only benign lesions
Ineligible sample size, no melanomas
Unable to construct 2x2 table based on data presented, no malignant cases
Hoorens 2016 Ineligible index test
Ineligible reference standard.No informationonnumbers undergoinghistology; andno follow-up reported
for benign-appearing lesions
Unable to construct 2x2 table based on data presented
Huang 1996 Individual lesion characteristics. Border irregularity not overall diagnosis
Unable to construct 2x2 table based on data presented
Jamora 2003 Ineligible reference standard. No reference standard for index test-negatives
Janda 2014 Ineligible sample size, only 1 case of melanoma, 1 case of BCC and 1 of SCC
Jensen 2015 Not a primary study, comment paper
Jolliffe 2001 Ineligible index test. Provides data for clinical diagnosis (including dermoscopy for some cases)
Jonna 1998 Unable to construct 2x2 table based on data presented, only included index test-positives to get PPV
Kaddu 1997 Ineligible sample size. Sample size < 5; not test accuracy
Keefe 1990 Ineligible reference standard. Only 28% (60/214) of non-melanoma group had excision
Kelly 1986 Ineligible target condition. Cannot disaggregate the severely dysplastic/in situ MM
Ineligible sample size, unclear whether > 5 in situ melanoma
Koh 1990 Ineligible reference standard, screening study; no adequate reference standard
Kroemer 2011 Ineligible index test, provides data for clinical diagnosis (including dermoscopy for some cases)
Krol 1991 Ineligible reference standard. No follow-up reported for those who were test-negative
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Kurvers 2015 Ineligible index test. Collective intelligence - majority rule and quorum rule applied to large number of
test interpreter decisions
Duplicate or related publication, re-analyses data from2 previously published studies to determine whether
collective intelligence (i.e. majority rules or quorum rules across a large number of observers) improves
test accuracy. We have excluded one of these studies as it did not provide the number of melanomas
(Argenziano 2003) and included the other in our dermoscopy review (Zalaudek 2006).
Kvedar 1997 Ineligible study population. Not all suspected of skin cancer
Lechner 2015 Not a primary study, erratum
Lewis 1999 Unable to construct 2x2 table based on data presented. Study appears to meet all eligibility criteria but
disease prevalence not given alongside se/sp
Contacted study authors 10 May 2016; email returned
Lindelöf 1994 Ineligible study population, only malignant melanoma
Unable to construct 2x2 table based on data presented. Not enough information given to derive a 2x2
table. Only given for a sample of 50 participants who had a strong suspicion of melanoma clinically. Do
not know what happened to those with no suspicion clinically
Lorentzen 2000 Ineligible index test. Does not provide data for VI alone
Luttrell 2012 Ineligible test observer. Accuracy data only given for lay-people, not interested in this population of test
observers
Machet 2005 Ineligible study population. (Note: this is a staging study)
MacKenzie-Wood 1998 Ineligible study population, only malignant diagnosis
MacKie 1990 Not a primary study
Mackie 1991 Not a primary study, letter
Mackie 2002 Individual lesion characteristics, presence of ≥ 3 colours on dermoscopy
Mahendran 2005 Ineligible index test. Face to face was ’clinical diagnosis’, i.e. VI +/- use of dermoscopy
Mahon 1997 Not a primary study, a summary of a comparison of 2 screening checklists
Malvehy 2014 Ineligible index test. Does not report data for VI alone
Marghoob 1995 Not a primary study, letter
Marghoob 2007 Not a primary study
Markowitz 2015 Ineligible target condition. Does not report sufficient data for detection of melanoma
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McCarthy 1995 Not a primary study, leaflet
McMullan 1956 Unable to construct 2x2 table based on data presented
Menzies 2008 Ineligible index test, evaluated dermoscopy alone
Menzies 2011 Ineligible index test, surveillance study; data used to id factors predictive of lesion changes
Menzies 2013 Ineligible index test, evaluated dermoscopy only
Moffatt 2006 Ineligible index test, ’clinical diagnosis’
Mohammad 2015 Ineligible study population, only included BCC
Morrison 2001 Unable to construct 2x2 table based on data presented
Study gives % correct diagnosis within each histology group and then gives the % ‘correct’ diagnosis of
skin cancer as 22% for FP and 87% for dermatologist. But these statistics appear to have been reached by
taking the mean of the % correct diagnoses across the malignant groups and do not equate to sensitivity.
i.e. If you take the mean of the FP correct (%) for the 4 malignant groups you get:
(40 + 22 + 25 + 0) / 4 = 21.75%
and then the same for the dermatologist correct (%) column:
(95 + 77 + 75 + 100)/4 = 86.75%
Nachbar 1994 Ineligible index test. Data for VI alone influenced by use of dermoscopy in most cases
Nathansohn 2007 Unable to construct 2x2 table based on data presented. Not test accuracy; follow-up study
Nilles 1994 Ineligible index test. Does not provide data for VI alone
Osborne 1998 Ineligible reference standard. Not clear what the ref standard is
Unable to construct 2x2 table based on data presented
Osborne 1999 Ineligible study population. Only patients with melanoma included
Parslew 1997 Ineligible study population. Not all suspected of skin cancer
Pazzini 1996 Unable to construct 2x2 table based on data presented
Perednia 1992 Unable to construct 2x2 table based on data presented. Not test accuracy
Perrinaud 2007 Ineligible index test. Does not provide data for VI alone
Piccolo 2000 Ineligible index test. No data can be extracted for VI alone
Piccolo 2002 Not a primary study
Not enough data to populate 2x2 table. No breakdown of index test results and ref standard
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Pizzichetta 2001 Unable to construct 2x2 table based on data presented. Observer agreement only
Provost 1998 Unable to construct 2x2 table based on data presented. Not test accuracy; only reports concordance
Quereux 2011 Ineligible index test, self-administered questions to patients attending a GP surgery before their appoint-
ment to determine whether they were at high risk of melanoma, which is meant to highlight to the GP
which patient to examine during their consultation
Rallan 2006 Ineligible index test. No data can be extracted for VI alone
Rampen 1988 Ineligible study population. Only melanoma included
Reeck 1999 Ineligible study population. Only included index test-negatives; i.e. those considered benign by referring
clinician
Ineligible target condition
Riddell 1961 Ineligible study population. All malignant
Rigel 1993 Not a primary study
Robati 2014 Ineligible reference standard. No follow-up of participants not referred to dermatology clinics, who did
not receive histopathology
Robinson 2010 Ineligible index test, self examination
Rosado 2003 Not a primary study, systematic review
Rossi 2000 Ineligible reference standard. Unclear reference standard in disease-negative
Roush 1986 Ineligible target condition, only dysplastic naevus
Salvio 2011 Not a primary study
Ineligible sample size
Schindewolf 1994 Ineligible index test, evaluated CAD not VI
Schmoeckel 1987 Not a primary study
Schwartzberg 2005 Ineligible target condition, does not provide sufficient data for detection of melanoma
Seidenari 2006 Ineligible study population. Assessed best means of follow-in up patients with previous melanoma - total
body exam versus only lesions > 2 cm. No melanoma identified
Seidenari 2006a Individual lesion characteristics. Looks like this study is only looking at asymmetry judgement
Shariff 2010 Ineligible reference standard
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Sondak 2015 Not a primary study, comment paper
Soyer 2004 Ineligible index test. Does not provide data for VI alone
Stanganelli 1998b Unable to construct 2x2 table based on data presented. Cannot derive specificity; only gives exact diagnoses
for MM and 2 benign categories and not number benign misdiagnosed as MM
Stanley 2003 Individual lesion characteristics. Fuzzy histogram based on the lesion’s colour, which is an individual lesion
characteristic
Stathopoulos 2015 Unable to construct 2x2 table based on data presented. Only included index test-positive patients, i.e. no
FN or TN results
Stratigos 2007 Ineligible reference standard
Unable to construct 2x2 table based on data presented
Tandjung 2015 Ineligible target condition. ’Malignant’ included: AK, Bowen’s, dysplastic nevus, lentigo maligna, SCC,
BCC, MM, keratoacanthoma
Ineligible index test. GPs sent images for telederm opinion; then free to send for biopsy or not; results
shown are only for those that were biopsied, according to TD advice
Terrill 2009 Ineligible index test. Whole body skin examination after participants referred on for further assessment by
a specialist
Unable to construct 2x2 table based on data presented
Terushkin 2010a Unable to construct 2x2 table based on data presented. Not test accuracy, reports final diagnoses of those
excised over a number of time periods and benign-malignant ratio
Terushkin 2010b Unable to construct 2x2 table based on data presented. Not test accuracy - reports final diagnoses of those
excised over a number of time periods and benign-malignant ratio
Thomson 2005 Not a primary study, letter
Torrey 1941 Ineligible target condition, included non-cutaneous lesions
Ulrich 2015 Ineligible target condition. Does not provide sufficient data for evaluation of melanoma
Van der Rhee 2010 Ineligible reference standard.< 50% of disease-negative have an adequate reference standard
Van der Rhee 2011 Ineligible sample size, < 5 cases
Vasili 2010 Conference abstract
Wagner 1985 Unable to construct 2x2 table based on data presented
Walter 2010 Not a primary study, clinical trial protocol
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Walter 2013 Ineligible reference standard. Final diagnosis reached by histology or expert opinion; no follow-up of non-
excised lesions reported in this paper. The Walter 2012 trial report does report follow-up for enough
benign lesions for control arm (weighted 7-point checklist) data to be included. Study authors contacted
and confirmed calculations (2 March 2016)
Warshaw 2009a Unable to construct 2x2 table based on data presented. Study presents diagnostic accuracy of teleder-
matology and clinic diagnosis in comparison to histopathology; in order to include in our review, data
would need to be presented as a 2x2 contingency table, either per type of malignancy e.g. tele-diagnosis
classification of melanoma vs not melanoma against histological diagnosis of melanoma/not melanoma,
or with malignant diagnoses grouped together, ie tele-diagnosis of malignancy vs not malignant against
same histological breakdown
Study authors contacted: ”the 2x2 table the Cochrane researchers want to create is not possible for our
results, because sensitivity and PPV are based on different sample sizes. This can be seen in Table 2 of the
paper which actually adds up to 11870 skin lesions across, as for each histological diagnosis of interest the
first lesion with such a histological diagnosis was considered per patient. Hence, a patient might appear
several times across the columns. Table 1 adds up to 8585 skin lesions - the first skin lesion in the data set
per patient with a clinical diagnosis.“
Warshaw 2009b Unable to construct 2x2 table based on data presented, as per Warshaw 2009a
Warshaw 2010 Unable to construct 2x2 table based on data presented, as per Warshaw 2009a; this 2010 paper presents
combined data for pigmented and nonpigmented lesions
Westbrook 2006 Unable to construct 2x2 table based on data presented
Whitaker-Worth 1998 Ineligible study population
Ineligible test observer, mixed medical student/clinicians
Unable to construct 2x2 table based on data presented, not test accuracy study
Whited 1998 Ineligible sample size
Williams 1991 Unable to construct 2x2 table based on data presented
Winkelmann 2015a Duplicate or related publication
Winkelmann 2015b Duplicate or related publication
Wolf 1998 Ineligible index test, clinical diagnosis study. Test clearly described, ”concerning the clinical diagnosis, we
were not able to ascertain from the clinical data sheet whether the referring physicians used additional
diagnostics techniques such as dermoscopy“
Yoo 2015 Conference abstract
Youl 2007a Ineligible index test, ’clinical diagnosis’ - dermoscopy used in some but not all cases
Response from study author, ”One of the main issues is that we just don’t know to what extent dermoscopy
was used in that study. We just asked where they used it in a general sense and not for each case. However
for each case GPs and skin clinic doctors did indicate whether they conducted a whole- or part-body skin
examination (or just lesion specific)
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Youl 2007b Ineligible index test. Evaluates clinical diagnosis (some lesions had dermoscopy)
Zaballos 2013 Ineligible study population. They do not have enough benign cases to include as full report
Zou 2001 Not a primary study. Study uses results from Stolz 1994
Unable to construct 2x2 table based on data presented. Just showing ROC curves
AK: actinic keratosis; AUC: area under the curve; BCC - basal cell carcinoma; CAD: computer assisted diagnosis; D+/D-: disease-
positive/disease-negative; 7FFM: seven features for melanoma; FPs: false-positives; FN: false-negative; GP: general practitioner;
PCP - primary care provider; PPV: positive predictive value;MM: malignant (invasive) melanoma; NPV: negative predictive value;
ref: reference; SCC: squamous cell carcinoma; se/sp: sensitivity/specificity; TD: teledermatology; TN: true negative; TWR: two
week rule; VI: visual inspection
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D A T A
Presented below are all the data for all of the tests entered into the review.
Tests. Data tables by test
Test
No. of
studies
No. of
participants
1 Visual inspection - in-person
(MM)
7 6857
2 Visual inspection - image-based
(MM)
5 599
3 Visual inspection - in-person
(MEL)
28 25604
4 Visual inspection - image-based
(MEL)
11 1243
5 Visual inspection - in-person
(Any)
7 8091
6 Visual inspection - image-based
(Any)
3 547
7 MEL- VI - in-person - no
algorithm
21 19330
8 MEL- VI - in-person -
no algorithm (alternative
thresholds)
2 475
9 MEL- VI - in-person -
(A)BCD(E) at NR or standard
threshold
6 5501
10 MEL-VI - in-person - ABCD
at NR
2 3548
11 MEL-VI - in-person - ABCDE
at ≥ 1
2 1541
12 MEL-VI - in-person - ABCDE
at ≥ 2
3 1761
13 MEL-VI - in-person - ABCDE
at ≥ 3
2 1541
14 MEL-VI - in-person - ABCDE
at ≥ 4
2 1541
15 MEL-VI - in-person - ABCDE
at ≥ 5
2 1541
16 MEL-VI - in-person - BCD at
≥ 1
1 192
17 MEL-VI - in-person - BCD at
≥ 2
1 192
18 MEL-VI - in-person - BCD at
≥ 3
1 192
19 MEL-VI - in-person - 7point at
≥ 2
1 205
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20 MEL-VI - in-person - 7point at
≥ 3
1 205
21 MEL-VI - in-person - 7point at
≥ 4
1 205
22 MEL-VI - in-person -
7point(rev) at ≥ 3
1 773
23 MEL-VI - in-person - Collas at
≥ 1
1 353
24 MEL- VI - image-based - no
algorithm
9 1090
26 MEL-VI - image-based -
ABCD(E) at standard
2 153
27 MEL-VI - image-based -
ABCD at ≥ 2
1 103
28 MEL-VI - image-based -
ABCD at ≥ 3
1 103
29 MEL-VI - image-based -
ABCDE at ≥ 2
1 50
30 MEL-VI - image-based -
ABCDE at ≥ 3
1 50
31 MEL- VI - in-person -
experience NR
12 16778
32 MEL- VI - in-person -
experience high
9 3547
33 MEL- VI - in-person -
experience moderate
1 567
34 MEL- VI - in-person -
experience low
4 2008
35 MEL- VI - in-person -
experience mixed
2 2704
36 MEL- VI - image-based -
experience NR
5 663
37 MEL- VI - image-based -
experience high
5 540
38 MEL- VI - image-based -
experience low
1 134
39 MEL- VI - image-based -
experience mixed
2 90
40 VI - in-person - expert
consultant (MEL)
9 3547
41 VI - in-person - consultant
(MEL)
12 16778
42 VI - in-person -
resident/registrar (MEL)
2 1236
43 VI - in-person - mixed
qualifications (secondary care)
(MEL)
2 2704
44 VI - in-person - GP (MEL) 3 1339
45 MEL- VI - image-based -
expert consultant
4 700
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46 MEL- VI - image-based -
consultant
4 200
47 MEL- VI - image-based - mixed
qualifications (secondary care)
1 200
48 MEL- VI - image-based
- mixed qualifications
(secondary/primary care)
1 40
49 MEL- VI - image-based - mixed
qualifications (primary care)
2 184
51 MEL - Selected on quality -
pathway 2 or 3
5 5728
52 MEL - Selected on quality -
pathway 5
9 3556
Test 1. Visual inspection - in-person (MM).
Review: Visual inspection for diagnosing cutaneous melanoma in adults
Test: 1 Visual inspection - in-person (MM)
Study TP FP FN TN Sensitivity Specificity Sensitivity Specificity
Bono 1996 16 6 2 19 0.89 [ 0.65, 0.99 ] 0.76 [ 0.55, 0.91 ]
Green 1994 15 23 3 123 0.83 [ 0.59, 0.96 ] 0.84 [ 0.77, 0.90 ]
Kopf 1975 76 19 23 5420 0.77 [ 0.67, 0.85 ] 1.00 [ 0.99, 1.00 ]
Krahn 1998 31 9 8 32 0.79 [ 0.64, 0.91 ] 0.78 [ 0.62, 0.89 ]
McGovern 1992 6 21 0 165 1.00 [ 0.54, 1.00 ] 0.89 [ 0.83, 0.93 ]
Viglizzo 2004 8 3 4 52 0.67 [ 0.35, 0.90 ] 0.95 [ 0.85, 0.99 ]
Walter 2012 15 152 1 605 0.94 [ 0.70, 1.00 ] 0.80 [ 0.77, 0.83 ]
0 0.2 0.4 0.6 0.8 1 0 0.2 0.4 0.6 0.8 1
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Test 2. Visual inspection - image-based (MM).
Review: Visual inspection for diagnosing cutaneous melanoma in adults
Test: 2 Visual inspection - image-based (MM)
Study TP FP FN TN Sensitivity Specificity Sensitivity Specificity
Lorentzen 1999 38 20 11 163 0.78 [ 0.63, 0.88 ] 0.89 [ 0.84, 0.93 ]
Rao 1997 18 13 3 38 0.86 [ 0.64, 0.97 ] 0.75 [ 0.60, 0.86 ]
Scope 2008 4 7 1 133 0.80 [ 0.28, 0.99 ] 0.95 [ 0.90, 0.98 ]
Troyanova 2003 18 5 7 20 0.72 [ 0.51, 0.88 ] 0.80 [ 0.59, 0.93 ]
Westerhoff 2000 31 23 19 27 0.62 [ 0.47, 0.75 ] 0.54 [ 0.39, 0.68 ]
0 0.2 0.4 0.6 0.8 1 0 0.2 0.4 0.6 0.8 1
Test 3. Visual inspection - in-person (MEL).
Review: Visual inspection for diagnosing cutaneous melanoma in adults
Test: 3 Visual inspection - in-person (MEL)
Study TP FP FN TN Sensitivity Specificity Sensitivity Specificity
Barzegari 2005 5 5 1 111 0.83 [ 0.36, 1.00 ] 0.96 [ 0.90, 0.99 ]
Benelli 1999 51 189 9 152 0.85 [ 0.73, 0.93 ] 0.45 [ 0.39, 0.50 ]
Bono 2002a 57 56 9 191 0.86 [ 0.76, 0.94 ] 0.77 [ 0.72, 0.82 ]
Bono 2002b 10 39 3 109 0.77 [ 0.46, 0.95 ] 0.74 [ 0.66, 0.81 ]
Bono 2006 10 16 13 167 0.43 [ 0.23, 0.66 ] 0.91 [ 0.86, 0.95 ]
Carli 2002a 35 46 19 156 0.65 [ 0.51, 0.77 ] 0.77 [ 0.71, 0.83 ]
Collas 1999 30 19 8 296 0.79 [ 0.63, 0.90 ] 0.94 [ 0.91, 0.96 ]
Cristofolini 1994 28 46 5 141 0.85 [ 0.68, 0.95 ] 0.75 [ 0.69, 0.81 ]
Cristofolini 1997 29 4 6 137 0.83 [ 0.66, 0.93 ] 0.97 [ 0.93, 0.99 ]
Dummer 1993 15 49 8 699 0.65 [ 0.43, 0.84 ] 0.93 [ 0.91, 0.95 ]
Ek 2005 11 23 12 2536 0.48 [ 0.27, 0.69 ] 0.99 [ 0.99, 0.99 ]
Gachon 2005 141 1058 8 2829 0.95 [ 0.90, 0.98 ] 0.73 [ 0.71, 0.74 ]
0 0.2 0.4 0.6 0.8 1 0 0.2 0.4 0.6 0.8 1
(Continued . . . )
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(. . . Continued)
Study TP FP FN TN Sensitivity Specificity Sensitivity Specificity
Green 1991 3 2 2 63 0.60 [ 0.15, 0.95 ] 0.97 [ 0.89, 1.00 ]
Grimaldi 2009 5 63 0 167 1.00 [ 0.48, 1.00 ] 0.73 [ 0.66, 0.78 ]
Langley 2001 4 0 2 34 0.67 [ 0.22, 0.96 ] 1.00 [ 0.90, 1.00 ]
McGovern 1992 8 21 3 160 0.73 [ 0.39, 0.94 ] 0.88 [ 0.83, 0.93 ]
Menzies 2009 12 46 20 253 0.38 [ 0.21, 0.56 ] 0.85 [ 0.80, 0.89 ]
Morales Callaghan 2008 3 5 3 189 0.50 [ 0.12, 0.88 ] 0.97 [ 0.94, 0.99 ]
Morton 1998a 63 10 6 684 0.91 [ 0.82, 0.97 ] 0.99 [ 0.97, 0.99 ]
Morton 1998b 28 14 3 522 0.90 [ 0.74, 0.98 ] 0.97 [ 0.96, 0.99 ]
Morton 1998c 22 11 6 630 0.79 [ 0.59, 0.92 ] 0.98 [ 0.97, 0.99 ]
Soyer 1995 61 17 4 77 0.94 [ 0.85, 0.98 ] 0.82 [ 0.73, 0.89 ]
Stanganelli 2000 37 21 18 3296 0.67 [ 0.53, 0.79 ] 0.99 [ 0.99, 1.00 ]
Steiner 1987 43 31 30 214 0.59 [ 0.47, 0.70 ] 0.87 [ 0.83, 0.91 ]
Thomas 1998 411 236 49 444 0.89 [ 0.86, 0.92 ] 0.65 [ 0.62, 0.69 ]
Unlu 2014 18 39 6 52 0.75 [ 0.53, 0.90 ] 0.57 [ 0.46, 0.67 ]
Walter 2012 17 152 1 603 0.94 [ 0.73, 1.00 ] 0.80 [ 0.77, 0.83 ]
Zaumseil 1983 312 76 25 6650 0.93 [ 0.89, 0.95 ] 0.99 [ 0.99, 0.99 ]
0 0.2 0.4 0.6 0.8 1 0 0.2 0.4 0.6 0.8 1
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Test 4. Visual inspection - image-based (MEL).
Review: Visual inspection for diagnosing cutaneous melanoma in adults
Test: 4 Visual inspection - image-based (MEL)
Study TP FP FN TN Sensitivity Specificity Sensitivity Specificity
Benelli 2001 7 18 5 20 0.58 [ 0.28, 0.85 ] 0.53 [ 0.36, 0.69 ]
Bourne 2012 2 12 7 29 0.22 [ 0.03, 0.60 ] 0.71 [ 0.54, 0.84 ]
Carli 2002b 8 7 2 36 0.80 [ 0.44, 0.97 ] 0.84 [ 0.69, 0.93 ]
Carli 2003a 45 27 19 109 0.70 [ 0.58, 0.81 ] 0.80 [ 0.72, 0.86 ]
de Giorgi 2012 17 11 17 58 0.50 [ 0.32, 0.68 ] 0.84 [ 0.73, 0.92 ]
Dolianitis 2005 12 3 8 17 0.60 [ 0.36, 0.81 ] 0.85 [ 0.62, 0.97 ]
Pizzichetta 2004 25 8 14 61 0.64 [ 0.47, 0.79 ] 0.88 [ 0.78, 0.95 ]
Rosendahl 2011 6 14 23 420 0.21 [ 0.08, 0.40 ] 0.97 [ 0.95, 0.98 ]
Stanganelli 1998a 4 5 6 15 0.40 [ 0.12, 0.74 ] 0.75 [ 0.51, 0.91 ]
Stanganelli 2005 23 18 8 85 0.74 [ 0.55, 0.88 ] 0.83 [ 0.74, 0.89 ]
Winkelmann 2016 3 3 2 4 0.60 [ 0.15, 0.95 ] 0.57 [ 0.18, 0.90 ]
0 0.2 0.4 0.6 0.8 1 0 0.2 0.4 0.6 0.8 1
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Test 5. Visual inspection - in-person (Any).
Review: Visual inspection for diagnosing cutaneous melanoma in adults
Test: 5 Visual inspection - in-person (Any)
Study TP FP FN TN Sensitivity Specificity Sensitivity Specificity
Argenziano 2006 30 16 23 16 0.57 [ 0.42, 0.70 ] 0.50 [ 0.32, 0.68 ]
Chang 2013 131 84 21 533 0.86 [ 0.80, 0.91 ] 0.86 [ 0.83, 0.89 ]
Ek 2005 1711 722 43 106 0.98 [ 0.97, 0.98 ] 0.13 [ 0.11, 0.15 ]
McGovern 1992 11 21 4 156 0.73 [ 0.45, 0.92 ] 0.88 [ 0.82, 0.93 ]
Stanganelli 2000 70 29 28 3245 0.71 [ 0.61, 0.80 ] 0.99 [ 0.99, 0.99 ]
Steiner 1987 62 31 31 194 0.67 [ 0.56, 0.76 ] 0.86 [ 0.81, 0.90 ]
Walter 2012 18 152 4 599 0.82 [ 0.60, 0.95 ] 0.80 [ 0.77, 0.83 ]
0 0.2 0.4 0.6 0.8 1 0 0.2 0.4 0.6 0.8 1
Test 6. Visual inspection - image-based (Any).
Review: Visual inspection for diagnosing cutaneous melanoma in adults
Test: 6 Visual inspection - image-based (Any)
Study TP FP FN TN Sensitivity Specificity Sensitivity Specificity
Carli 2002b 16 9 4 25 0.80 [ 0.56, 0.94 ] 0.74 [ 0.56, 0.87 ]
Rosendahl 2011 79 54 25 305 0.76 [ 0.67, 0.84 ] 0.85 [ 0.81, 0.88 ]
Stanganelli 1998a 9 4 5 12 0.64 [ 0.35, 0.87 ] 0.75 [ 0.48, 0.93 ]
0 0.2 0.4 0.6 0.8 1 0 0.2 0.4 0.6 0.8 1
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Test 7. MEL- VI - in-person - no algorithm.
Review: Visual inspection for diagnosing cutaneous melanoma in adults
Test: 7 MEL- VI - in-person - no algorithm
Study TP FP FN TN Sensitivity Specificity Sensitivity Specificity
Barzegari 2005 5 5 1 111 0.83 [ 0.36, 1.00 ] 0.96 [ 0.90, 0.99 ]
Bono 2002a 57 56 9 191 0.86 [ 0.76, 0.94 ] 0.77 [ 0.72, 0.82 ]
Bono 2002b 10 39 3 109 0.77 [ 0.46, 0.95 ] 0.74 [ 0.66, 0.81 ]
Bono 2006 10 16 13 167 0.43 [ 0.23, 0.66 ] 0.91 [ 0.86, 0.95 ]
Carli 2002a 35 46 19 156 0.65 [ 0.51, 0.77 ] 0.77 [ 0.71, 0.83 ]
Collas 1999 30 19 8 296 0.79 [ 0.63, 0.90 ] 0.94 [ 0.91, 0.96 ]
Dummer 1993 15 49 8 699 0.65 [ 0.43, 0.84 ] 0.93 [ 0.91, 0.95 ]
Ek 2005 11 23 12 2536 0.48 [ 0.27, 0.69 ] 0.99 [ 0.99, 0.99 ]
Gachon 2005 141 1058 8 2829 0.95 [ 0.90, 0.98 ] 0.73 [ 0.71, 0.74 ]
Green 1991 3 2 2 63 0.60 [ 0.15, 0.95 ] 0.97 [ 0.89, 1.00 ]
Grimaldi 2009 5 63 0 167 1.00 [ 0.48, 1.00 ] 0.73 [ 0.66, 0.78 ]
Langley 2001 4 0 2 34 0.67 [ 0.22, 0.96 ] 1.00 [ 0.90, 1.00 ]
Menzies 2009 12 46 20 253 0.38 [ 0.21, 0.56 ] 0.85 [ 0.80, 0.89 ]
Morales Callaghan 2008 3 5 3 189 0.50 [ 0.12, 0.88 ] 0.97 [ 0.94, 0.99 ]
Morton 1998a 63 10 6 684 0.91 [ 0.82, 0.97 ] 0.99 [ 0.97, 0.99 ]
Morton 1998b 28 14 3 522 0.90 [ 0.74, 0.98 ] 0.97 [ 0.96, 0.99 ]
Morton 1998c 22 11 6 630 0.79 [ 0.59, 0.92 ] 0.98 [ 0.97, 0.99 ]
Soyer 1995 61 17 4 77 0.94 [ 0.85, 0.98 ] 0.82 [ 0.73, 0.89 ]
Steiner 1987 43 31 30 214 0.59 [ 0.47, 0.70 ] 0.87 [ 0.83, 0.91 ]
Unlu 2014 18 39 6 52 0.75 [ 0.53, 0.90 ] 0.57 [ 0.46, 0.67 ]
Zaumseil 1983 312 76 25 6650 0.93 [ 0.89, 0.95 ] 0.99 [ 0.99, 0.99 ]
0 0.2 0.4 0.6 0.8 1 0 0.2 0.4 0.6 0.8 1
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Test 8. MEL- VI - in-person - no algorithm (alternative thresholds).
Review: Visual inspection for diagnosing cutaneous melanoma in adults
Test: 8 MEL- VI - in-person - no algorithm (alternative thresholds)
Study TP FP FN TN Sensitivity Specificity Sensitivity Specificity
Barzegari 2005 6 13 0 103 1.00 [ 0.54, 1.00 ] 0.89 [ 0.82, 0.94 ]
Collas 1999 37 114 1 201 0.97 [ 0.86, 1.00 ] 0.64 [ 0.58, 0.69 ]
0 0.2 0.4 0.6 0.8 1 0 0.2 0.4 0.6 0.8 1
Test 9. MEL- VI - in-person - (A)BCD(E) at NR or standard threshold.
Review: Visual inspection for diagnosing cutaneous melanoma in adults
Test: 9 MEL- VI - in-person - (A)BCD(E) at NR or standard threshold
Study TP FP FN TN Sensitivity Specificity Sensitivity Specificity
Benelli 1999 51 189 9 152 0.85 [ 0.73, 0.93 ] 0.45 [ 0.39, 0.50 ]
Cristofolini 1994 28 46 5 141 0.85 [ 0.68, 0.95 ] 0.75 [ 0.69, 0.81 ]
Cristofolini 1997 29 4 6 137 0.83 [ 0.66, 0.93 ] 0.97 [ 0.93, 0.99 ]
McGovern 1992 8 21 3 160 0.73 [ 0.39, 0.94 ] 0.88 [ 0.83, 0.93 ]
Stanganelli 2000 37 21 18 3296 0.67 [ 0.53, 0.79 ] 0.99 [ 0.99, 1.00 ]
Thomas 1998 411 236 49 444 0.89 [ 0.86, 0.92 ] 0.65 [ 0.62, 0.69 ]
0 0.2 0.4 0.6 0.8 1 0 0.2 0.4 0.6 0.8 1
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Test 10. MEL-VI - in-person - ABCD at NR.
Review: Visual inspection for diagnosing cutaneous melanoma in adults
Test: 10 MEL-VI - in-person - ABCD at NR
Study TP FP FN TN Sensitivity Specificity Sensitivity Specificity
Cristofolini 1997 29 4 6 137 0.83 [ 0.66, 0.93 ] 0.97 [ 0.93, 0.99 ]
Stanganelli 2000 37 21 18 3296 0.67 [ 0.53, 0.79 ] 0.99 [ 0.99, 1.00 ]
0 0.2 0.4 0.6 0.8 1 0 0.2 0.4 0.6 0.8 1
Test 11. MEL-VI - in-person - ABCDE at ≥ 1.
Review: Visual inspection for diagnosing cutaneous melanoma in adults
Test: 11 MEL-VI - in-person - ABCDE at≥ 1
Study TP FP FN TN Sensitivity Specificity Sensitivity Specificity
Benelli 1999 55 297 5 44 0.92 [ 0.82, 0.97 ] 0.13 [ 0.10, 0.17 ]
Thomas 1998 448 435 12 245 0.97 [ 0.95, 0.99 ] 0.36 [ 0.32, 0.40 ]
0 0.2 0.4 0.6 0.8 1 0 0.2 0.4 0.6 0.8 1
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Test 12. MEL-VI - in-person - ABCDE at ≥ 2.
Review: Visual inspection for diagnosing cutaneous melanoma in adults
Test: 12 MEL-VI - in-person - ABCDE at≥ 2
Study TP FP FN TN Sensitivity Specificity Sensitivity Specificity
Benelli 1999 51 189 9 152 0.85 [ 0.73, 0.93 ] 0.45 [ 0.39, 0.50 ]
Cristofolini 1994 28 46 5 141 0.85 [ 0.68, 0.95 ] 0.75 [ 0.69, 0.81 ]
Thomas 1998 411 236 49 444 0.89 [ 0.86, 0.92 ] 0.65 [ 0.62, 0.69 ]
0 0.2 0.4 0.6 0.8 1 0 0.2 0.4 0.6 0.8 1
Test 13. MEL-VI - in-person - ABCDE at ≥ 3.
Review: Visual inspection for diagnosing cutaneous melanoma in adults
Test: 13 MEL-VI - in-person - ABCDE at≥ 3
Study TP FP FN TN Sensitivity Specificity Sensitivity Specificity
Benelli 1999 40 70 20 271 0.67 [ 0.53, 0.78 ] 0.79 [ 0.75, 0.84 ]
Thomas 1998 301 136 159 544 0.65 [ 0.61, 0.70 ] 0.80 [ 0.77, 0.83 ]
0 0.2 0.4 0.6 0.8 1 0 0.2 0.4 0.6 0.8 1
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Test 14. MEL-VI - in-person - ABCDE at ≥ 4.
Review: Visual inspection for diagnosing cutaneous melanoma in adults
Test: 14 MEL-VI - in-person - ABCDE at≥ 4
Study TP FP FN TN Sensitivity Specificity Sensitivity Specificity
Benelli 1999 23 15 37 326 0.38 [ 0.26, 0.52 ] 0.96 [ 0.93, 0.98 ]
Thomas 1998 248 44 212 636 0.54 [ 0.49, 0.59 ] 0.94 [ 0.91, 0.95 ]
0 0.2 0.4 0.6 0.8 1 0 0.2 0.4 0.6 0.8 1
Test 15. MEL-VI - in-person - ABCDE at ≥ 5.
Review: Visual inspection for diagnosing cutaneous melanoma in adults
Test: 15 MEL-VI - in-person - ABCDE at≥ 5
Study TP FP FN TN Sensitivity Specificity Sensitivity Specificity
Benelli 1999 4 2 56 339 0.07 [ 0.02, 0.16 ] 0.99 [ 0.98, 1.00 ]
Thomas 1998 198 3 262 677 0.43 [ 0.38, 0.48 ] 1.00 [ 0.99, 1.00 ]
0 0.2 0.4 0.6 0.8 1 0 0.2 0.4 0.6 0.8 1
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Test 16. MEL-VI - in-person - BCD at ≥ 1.
Review: Visual inspection for diagnosing cutaneous melanoma in adults
Test: 16 MEL-VI - in-person - BCD at≥ 1
Study TP FP FN TN Sensitivity Specificity Sensitivity Specificity
McGovern 1992 11 65 0 116 1.00 [ 0.72, 1.00 ] 0.64 [ 0.57, 0.71 ]
0 0.2 0.4 0.6 0.8 1 0 0.2 0.4 0.6 0.8 1
Test 17. MEL-VI - in-person - BCD at ≥ 2.
Review: Visual inspection for diagnosing cutaneous melanoma in adults
Test: 17 MEL-VI - in-person - BCD at≥ 2
Study TP FP FN TN Sensitivity Specificity Sensitivity Specificity
McGovern 1992 8 21 3 160 0.73 [ 0.39, 0.94 ] 0.88 [ 0.83, 0.93 ]
0 0.2 0.4 0.6 0.8 1 0 0.2 0.4 0.6 0.8 1
Test 18. MEL-VI - in-person - BCD at ≥ 3.
Review: Visual inspection for diagnosing cutaneous melanoma in adults
Test: 18 MEL-VI - in-person - BCD at≥ 3
Study TP FP FN TN Sensitivity Specificity Sensitivity Specificity
McGovern 1992 6 3 5 178 0.55 [ 0.23, 0.83 ] 0.98 [ 0.95, 1.00 ]
0 0.2 0.4 0.6 0.8 1 0 0.2 0.4 0.6 0.8 1
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Test 19. MEL-VI - in-person - 7point at ≥ 2.
Review: Visual inspection for diagnosing cutaneous melanoma in adults
Test: 19 MEL-VI - in-person - 7point at≥ 2
Study TP FP FN TN Sensitivity Specificity Sensitivity Specificity
McGovern 1992 11 64 1 129 0.92 [ 0.62, 1.00 ] 0.67 [ 0.60, 0.73 ]
0 0.2 0.4 0.6 0.8 1 0 0.2 0.4 0.6 0.8 1
Test 20. MEL-VI - in-person - 7point at ≥ 3.
Review: Visual inspection for diagnosing cutaneous melanoma in adults
Test: 20 MEL-VI - in-person - 7point at≥ 3
Study TP FP FN TN Sensitivity Specificity Sensitivity Specificity
McGovern 1992 5 11 7 182 0.42 [ 0.15, 0.72 ] 0.94 [ 0.90, 0.97 ]
0 0.2 0.4 0.6 0.8 1 0 0.2 0.4 0.6 0.8 1
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Test 21. MEL-VI - in-person - 7point at ≥ 4.
Review: Visual inspection for diagnosing cutaneous melanoma in adults
Test: 21 MEL-VI - in-person - 7point at≥ 4
Study TP FP FN TN Sensitivity Specificity Sensitivity Specificity
McGovern 1992 3 2 9 191 0.25 [ 0.05, 0.57 ] 0.99 [ 0.96, 1.00 ]
0 0.2 0.4 0.6 0.8 1 0 0.2 0.4 0.6 0.8 1
Test 22. MEL-VI - in-person - 7point(rev) at ≥ 3.
Review: Visual inspection for diagnosing cutaneous melanoma in adults
Test: 22 MEL-VI - in-person - 7point(rev) at≥ 3
Study TP FP FN TN Sensitivity Specificity Sensitivity Specificity
Walter 2012 17 152 1 603 0.94 [ 0.73, 1.00 ] 0.80 [ 0.77, 0.83 ]
0 0.2 0.4 0.6 0.8 1 0 0.2 0.4 0.6 0.8 1
Test 23. MEL-VI - in-person - Collas at ≥ 1.
Review: Visual inspection for diagnosing cutaneous melanoma in adults
Test: 23 MEL-VI - in-person - Collas at≥ 1
Study TP FP FN TN Sensitivity Specificity Sensitivity Specificity
Collas 1999 29 157 9 158 0.76 [ 0.60, 0.89 ] 0.50 [ 0.44, 0.56 ]
0 0.2 0.4 0.6 0.8 1 0 0.2 0.4 0.6 0.8 1
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Test 24. MEL- VI - image-based - no algorithm.
Review: Visual inspection for diagnosing cutaneous melanoma in adults
Test: 24 MEL- VI - image-based - no algorithm
Study TP FP FN TN Sensitivity Specificity Sensitivity Specificity
Bourne 2012 2 12 7 29 0.22 [ 0.03, 0.60 ] 0.71 [ 0.54, 0.84 ]
Carli 2002b 8 7 2 36 0.80 [ 0.44, 0.97 ] 0.84 [ 0.69, 0.93 ]
Carli 2003a 45 27 19 109 0.70 [ 0.58, 0.81 ] 0.80 [ 0.72, 0.86 ]
Dolianitis 2005 12 3 8 17 0.60 [ 0.36, 0.81 ] 0.85 [ 0.62, 0.97 ]
Pizzichetta 2004 25 8 14 61 0.64 [ 0.47, 0.79 ] 0.88 [ 0.78, 0.95 ]
Rosendahl 2011 6 14 23 420 0.21 [ 0.08, 0.40 ] 0.97 [ 0.95, 0.98 ]
Stanganelli 1998a 4 5 6 15 0.40 [ 0.12, 0.74 ] 0.75 [ 0.51, 0.91 ]
Stanganelli 2005 23 18 8 85 0.74 [ 0.55, 0.88 ] 0.83 [ 0.74, 0.89 ]
Winkelmann 2016 3 3 2 4 0.60 [ 0.15, 0.95 ] 0.57 [ 0.18, 0.90 ]
0 0.2 0.4 0.6 0.8 1 0 0.2 0.4 0.6 0.8 1
Test 26. MEL-VI - image-based - ABCD(E) at standard.
Review: Visual inspection for diagnosing cutaneous melanoma in adults
Test: 26 MEL-VI - image-based - ABCD(E) at standard
Study TP FP FN TN Sensitivity Specificity Sensitivity Specificity
Benelli 2001 7 18 5 20 0.58 [ 0.28, 0.85 ] 0.53 [ 0.36, 0.69 ]
de Giorgi 2012 17 11 17 58 0.50 [ 0.32, 0.68 ] 0.84 [ 0.73, 0.92 ]
0 0.2 0.4 0.6 0.8 1 0 0.2 0.4 0.6 0.8 1
258Visual inspection for diagnosing cutaneous melanoma in adults (Review)
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Test 27. MEL-VI - image-based - ABCD at ≥ 2.
Review: Visual inspection for diagnosing cutaneous melanoma in adults
Test: 27 MEL-VI - image-based - ABCD at≥ 2
Study TP FP FN TN Sensitivity Specificity Sensitivity Specificity
de Giorgi 2012 17 11 17 58 0.50 [ 0.32, 0.68 ] 0.84 [ 0.73, 0.92 ]
0 0.2 0.4 0.6 0.8 1 0 0.2 0.4 0.6 0.8 1
Test 28. MEL-VI - image-based - ABCD at ≥ 3.
Review: Visual inspection for diagnosing cutaneous melanoma in adults
Test: 28 MEL-VI - image-based - ABCD at≥ 3
Study TP FP FN TN Sensitivity Specificity Sensitivity Specificity
de Giorgi 2012 5 6 29 63 0.15 [ 0.05, 0.31 ] 0.91 [ 0.82, 0.97 ]
0 0.2 0.4 0.6 0.8 1 0 0.2 0.4 0.6 0.8 1
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Test 29. MEL-VI - image-based - ABCDE at ≥ 2.
Review: Visual inspection for diagnosing cutaneous melanoma in adults
Test: 29 MEL-VI - image-based - ABCDE at≥ 2
Study TP FP FN TN Sensitivity Specificity Sensitivity Specificity
Benelli 2001 7 18 5 20 0.58 [ 0.28, 0.85 ] 0.53 [ 0.36, 0.69 ]
0 0.2 0.4 0.6 0.8 1 0 0.2 0.4 0.6 0.8 1
Test 30. MEL-VI - image-based - ABCDE at ≥ 3.
Review: Visual inspection for diagnosing cutaneous melanoma in adults
Test: 30 MEL-VI - image-based - ABCDE at≥ 3
Study TP FP FN TN Sensitivity Specificity Sensitivity Specificity
Benelli 2001 4 11 8 27 0.33 [ 0.10, 0.65 ] 0.71 [ 0.54, 0.85 ]
0 0.2 0.4 0.6 0.8 1 0 0.2 0.4 0.6 0.8 1
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Test 31. MEL- VI - in-person - experience NR.
Review: Visual inspection for diagnosing cutaneous melanoma in adults
Test: 31 MEL- VI - in-person - experience NR
Study TP FP FN TN Sensitivity Specificity Sensitivity Specificity
Benelli 1999 51 189 9 152 0.85 [ 0.73, 0.93 ] 0.45 [ 0.39, 0.50 ]
Bono 2006 10 16 13 167 0.43 [ 0.23, 0.66 ] 0.91 [ 0.86, 0.95 ]
Collas 1999 30 19 8 296 0.79 [ 0.63, 0.90 ] 0.94 [ 0.91, 0.96 ]
Dummer 1993 15 49 8 699 0.65 [ 0.43, 0.84 ] 0.93 [ 0.91, 0.95 ]
Gachon 2005 141 1058 8 2829 0.95 [ 0.90, 0.98 ] 0.73 [ 0.71, 0.74 ]
Green 1991 3 2 2 63 0.60 [ 0.15, 0.95 ] 0.97 [ 0.89, 1.00 ]
Langley 2001 4 0 2 34 0.67 [ 0.22, 0.96 ] 1.00 [ 0.90, 1.00 ]
McGovern 1992 8 21 3 160 0.73 [ 0.39, 0.94 ] 0.88 [ 0.83, 0.93 ]
Soyer 1995 61 17 4 77 0.94 [ 0.85, 0.98 ] 0.82 [ 0.73, 0.89 ]
Stanganelli 2000 37 21 18 3296 0.67 [ 0.53, 0.79 ] 0.99 [ 0.99, 1.00 ]
Unlu 2014 18 39 6 52 0.75 [ 0.53, 0.90 ] 0.57 [ 0.46, 0.67 ]
Zaumseil 1983 312 76 25 6650 0.93 [ 0.89, 0.95 ] 0.99 [ 0.99, 0.99 ]
0 0.2 0.4 0.6 0.8 1 0 0.2 0.4 0.6 0.8 1
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Test 32. MEL- VI - in-person - experience high.
Review: Visual inspection for diagnosing cutaneous melanoma in adults
Test: 32 MEL- VI - in-person - experience high
Study TP FP FN TN Sensitivity Specificity Sensitivity Specificity
Bono 2002a 57 56 9 191 0.86 [ 0.76, 0.94 ] 0.77 [ 0.72, 0.82 ]
Bono 2002b 10 39 3 109 0.77 [ 0.46, 0.95 ] 0.74 [ 0.66, 0.81 ]
Carli 2002a 35 46 19 156 0.65 [ 0.51, 0.77 ] 0.77 [ 0.71, 0.83 ]
Cristofolini 1994 28 46 5 141 0.85 [ 0.68, 0.95 ] 0.75 [ 0.69, 0.81 ]
Cristofolini 1997 29 4 6 137 0.83 [ 0.66, 0.93 ] 0.97 [ 0.93, 0.99 ]
Morales Callaghan 2008 3 5 3 189 0.50 [ 0.12, 0.88 ] 0.97 [ 0.94, 0.99 ]
Morton 1998a 63 10 6 684 0.91 [ 0.82, 0.97 ] 0.99 [ 0.97, 0.99 ]
Steiner 1987 43 31 30 214 0.59 [ 0.47, 0.70 ] 0.87 [ 0.83, 0.91 ]
Thomas 1998 411 236 49 444 0.89 [ 0.86, 0.92 ] 0.65 [ 0.62, 0.69 ]
0 0.2 0.4 0.6 0.8 1 0 0.2 0.4 0.6 0.8 1
Test 33. MEL- VI - in-person - experience moderate.
Review: Visual inspection for diagnosing cutaneous melanoma in adults
Test: 33 MEL- VI - in-person - experience moderate
Study TP FP FN TN Sensitivity Specificity Sensitivity Specificity
Morton 1998b 28 14 3 522 0.90 [ 0.74, 0.98 ] 0.97 [ 0.96, 0.99 ]
0 0.2 0.4 0.6 0.8 1 0 0.2 0.4 0.6 0.8 1
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Test 34. MEL- VI - in-person - experience low.
Review: Visual inspection for diagnosing cutaneous melanoma in adults
Test: 34 MEL- VI - in-person - experience low
Study TP FP FN TN Sensitivity Specificity Sensitivity Specificity
Grimaldi 2009 5 63 0 167 1.00 [ 0.48, 1.00 ] 0.73 [ 0.66, 0.78 ]
Menzies 2009 12 46 20 253 0.38 [ 0.21, 0.56 ] 0.85 [ 0.80, 0.89 ]
Morton 1998c 22 11 6 630 0.79 [ 0.59, 0.92 ] 0.98 [ 0.97, 0.99 ]
Walter 2012 17 152 1 603 0.94 [ 0.73, 1.00 ] 0.80 [ 0.77, 0.83 ]
0 0.2 0.4 0.6 0.8 1 0 0.2 0.4 0.6 0.8 1
Test 35. MEL- VI - in-person - experience mixed.
Review: Visual inspection for diagnosing cutaneous melanoma in adults
Test: 35 MEL- VI - in-person - experience mixed
Study TP FP FN TN Sensitivity Specificity Sensitivity Specificity
Barzegari 2005 5 5 1 111 0.83 [ 0.36, 1.00 ] 0.96 [ 0.90, 0.99 ]
Ek 2005 11 23 12 2536 0.48 [ 0.27, 0.69 ] 0.99 [ 0.99, 0.99 ]
0 0.2 0.4 0.6 0.8 1 0 0.2 0.4 0.6 0.8 1
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Test 36. MEL- VI - image-based - experience NR.
Review: Visual inspection for diagnosing cutaneous melanoma in adults
Test: 36 MEL- VI - image-based - experience NR
Study TP FP FN TN Sensitivity Specificity Sensitivity Specificity
Benelli 2001 6 19 6 19 0.50 [ 0.21, 0.79 ] 0.50 [ 0.33, 0.67 ]
Pizzichetta 2004 25 8 14 61 0.64 [ 0.47, 0.79 ] 0.88 [ 0.78, 0.95 ]
Rosendahl 2011 6 14 23 420 0.21 [ 0.08, 0.40 ] 0.97 [ 0.95, 0.98 ]
Stanganelli 1998a 4 5 6 15 0.40 [ 0.12, 0.74 ] 0.75 [ 0.51, 0.91 ]
Winkelmann 2016 3 3 2 4 0.60 [ 0.15, 0.95 ] 0.57 [ 0.18, 0.90 ]
0 0.2 0.4 0.6 0.8 1 0 0.2 0.4 0.6 0.8 1
Test 37. MEL- VI - image-based - experience high.
Review: Visual inspection for diagnosing cutaneous melanoma in adults
Test: 37 MEL- VI - image-based - experience high
Study TP FP FN TN Sensitivity Specificity Sensitivity Specificity
Benelli 2001 7 18 5 20 0.58 [ 0.28, 0.85 ] 0.53 [ 0.36, 0.69 ]
Carli 2002b 8 7 2 36 0.80 [ 0.44, 0.97 ] 0.84 [ 0.69, 0.93 ]
Carli 2003a 45 27 19 109 0.70 [ 0.58, 0.81 ] 0.80 [ 0.72, 0.86 ]
de Giorgi 2012 17 11 17 58 0.50 [ 0.32, 0.68 ] 0.84 [ 0.73, 0.92 ]
Stanganelli 2005 23 18 8 85 0.74 [ 0.55, 0.88 ] 0.83 [ 0.74, 0.89 ]
0 0.2 0.4 0.6 0.8 1 0 0.2 0.4 0.6 0.8 1
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Test 38. MEL- VI - image-based - experience low.
Review: Visual inspection for diagnosing cutaneous melanoma in adults
Test: 38 MEL- VI - image-based - experience low
Study TP FP FN TN Sensitivity Specificity Sensitivity Specificity
Stanganelli 2005 25 28 6 75 0.81 [ 0.63, 0.93 ] 0.73 [ 0.63, 0.81 ]
0 0.2 0.4 0.6 0.8 1 0 0.2 0.4 0.6 0.8 1
Test 39. MEL- VI - image-based - experience mixed.
Review: Visual inspection for diagnosing cutaneous melanoma in adults
Test: 39 MEL- VI - image-based - experience mixed
Study TP FP FN TN Sensitivity Specificity Sensitivity Specificity
Bourne 2012 2 12 7 29 0.22 [ 0.03, 0.60 ] 0.71 [ 0.54, 0.84 ]
Dolianitis 2005 12 3 8 17 0.60 [ 0.36, 0.81 ] 0.85 [ 0.62, 0.97 ]
0 0.2 0.4 0.6 0.8 1 0 0.2 0.4 0.6 0.8 1
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Test 40. VI - in-person - expert consultant (MEL).
Review: Visual inspection for diagnosing cutaneous melanoma in adults
Test: 40 VI - in-person - expert consultant (MEL)
Study TP FP FN TN Sensitivity Specificity Sensitivity Specificity
Bono 2002a 57 56 9 191 0.86 [ 0.76, 0.94 ] 0.77 [ 0.72, 0.82 ]
Bono 2002b 10 39 3 109 0.77 [ 0.46, 0.95 ] 0.74 [ 0.66, 0.81 ]
Carli 2002a 35 46 19 156 0.65 [ 0.51, 0.77 ] 0.77 [ 0.71, 0.83 ]
Cristofolini 1994 28 46 5 141 0.85 [ 0.68, 0.95 ] 0.75 [ 0.69, 0.81 ]
Cristofolini 1997 29 4 6 137 0.83 [ 0.66, 0.93 ] 0.97 [ 0.93, 0.99 ]
Morales Callaghan 2008 3 5 3 189 0.50 [ 0.12, 0.88 ] 0.97 [ 0.94, 0.99 ]
Morton 1998a 63 10 6 684 0.91 [ 0.82, 0.97 ] 0.99 [ 0.97, 0.99 ]
Steiner 1987 43 31 30 214 0.59 [ 0.47, 0.70 ] 0.87 [ 0.83, 0.91 ]
Thomas 1998 411 236 49 444 0.89 [ 0.86, 0.92 ] 0.65 [ 0.62, 0.69 ]
0 0.2 0.4 0.6 0.8 1 0 0.2 0.4 0.6 0.8 1
Test 41. VI - in-person - consultant (MEL).
Review: Visual inspection for diagnosing cutaneous melanoma in adults
Test: 41 VI - in-person - consultant (MEL)
Study TP FP FN TN Sensitivity Specificity Sensitivity Specificity
Benelli 1999 51 189 9 152 0.85 [ 0.73, 0.93 ] 0.45 [ 0.39, 0.50 ]
Bono 2006 10 16 13 167 0.43 [ 0.23, 0.66 ] 0.91 [ 0.86, 0.95 ]
Collas 1999 30 19 8 296 0.79 [ 0.63, 0.90 ] 0.94 [ 0.91, 0.96 ]
Dummer 1993 15 49 8 699 0.65 [ 0.43, 0.84 ] 0.93 [ 0.91, 0.95 ]
Gachon 2005 141 1058 8 2829 0.95 [ 0.90, 0.98 ] 0.73 [ 0.71, 0.74 ]
Green 1991 3 2 2 63 0.60 [ 0.15, 0.95 ] 0.97 [ 0.89, 1.00 ]
Langley 2001 4 0 2 34 0.67 [ 0.22, 0.96 ] 1.00 [ 0.90, 1.00 ]
McGovern 1992 8 21 3 160 0.73 [ 0.39, 0.94 ] 0.88 [ 0.83, 0.93 ]
0 0.2 0.4 0.6 0.8 1 0 0.2 0.4 0.6 0.8 1
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(. . . Continued)
Study TP FP FN TN Sensitivity Specificity Sensitivity Specificity
Soyer 1995 61 17 4 77 0.94 [ 0.85, 0.98 ] 0.82 [ 0.73, 0.89 ]
Stanganelli 2000 37 21 18 3296 0.67 [ 0.53, 0.79 ] 0.99 [ 0.99, 1.00 ]
Unlu 2014 18 39 6 52 0.75 [ 0.53, 0.90 ] 0.57 [ 0.46, 0.67 ]
Zaumseil 1983 312 76 25 6650 0.93 [ 0.89, 0.95 ] 0.99 [ 0.99, 0.99 ]
0 0.2 0.4 0.6 0.8 1 0 0.2 0.4 0.6 0.8 1
Test 42. VI - in-person - resident/registrar (MEL).
Review: Visual inspection for diagnosing cutaneous melanoma in adults
Test: 42 VI - in-person - resident/registrar (MEL)
Study TP FP FN TN Sensitivity Specificity Sensitivity Specificity
Morton 1998b 28 14 3 522 0.90 [ 0.74, 0.98 ] 0.97 [ 0.96, 0.99 ]
Morton 1998c 22 11 6 630 0.79 [ 0.59, 0.92 ] 0.98 [ 0.97, 0.99 ]
0 0.2 0.4 0.6 0.8 1 0 0.2 0.4 0.6 0.8 1
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Test 43. VI - in-person - mixed qualifications (secondary care) (MEL).
Review: Visual inspection for diagnosing cutaneous melanoma in adults
Test: 43 VI - in-person - mixed qualifications (secondary care) (MEL)
Study TP FP FN TN Sensitivity Specificity Sensitivity Specificity
Barzegari 2005 5 5 1 111 0.83 [ 0.36, 1.00 ] 0.96 [ 0.90, 0.99 ]
Ek 2005 11 23 12 2536 0.48 [ 0.27, 0.69 ] 0.99 [ 0.99, 0.99 ]
0 0.2 0.4 0.6 0.8 1 0 0.2 0.4 0.6 0.8 1
Test 44. VI - in-person - GP (MEL).
Review: Visual inspection for diagnosing cutaneous melanoma in adults
Test: 44 VI - in-person - GP (MEL)
Study TP FP FN TN Sensitivity Specificity Sensitivity Specificity
Grimaldi 2009 5 63 0 167 1.00 [ 0.48, 1.00 ] 0.73 [ 0.66, 0.78 ]
Menzies 2009 12 46 20 253 0.38 [ 0.21, 0.56 ] 0.85 [ 0.80, 0.89 ]
Walter 2012 17 152 1 603 0.94 [ 0.73, 1.00 ] 0.80 [ 0.77, 0.83 ]
0 0.2 0.4 0.6 0.8 1 0 0.2 0.4 0.6 0.8 1
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Test 45. MEL- VI - image-based - expert consultant.
Review: Visual inspection for diagnosing cutaneous melanoma in adults
Test: 45 MEL- VI - image-based - expert consultant
Study TP FP FN TN Sensitivity Specificity Sensitivity Specificity
Benelli 2001 7 18 5 20 0.58 [ 0.28, 0.85 ] 0.53 [ 0.36, 0.69 ]
Carli 2002b 8 7 2 36 0.80 [ 0.44, 0.97 ] 0.84 [ 0.69, 0.93 ]
Rosendahl 2011 6 14 23 420 0.21 [ 0.08, 0.40 ] 0.97 [ 0.95, 0.98 ]
Stanganelli 2005 23 18 8 85 0.74 [ 0.55, 0.88 ] 0.83 [ 0.74, 0.89 ]
0 0.2 0.4 0.6 0.8 1 0 0.2 0.4 0.6 0.8 1
Test 46. MEL- VI - image-based - consultant.
Review: Visual inspection for diagnosing cutaneous melanoma in adults
Test: 46 MEL- VI - image-based - consultant
Study TP FP FN TN Sensitivity Specificity Sensitivity Specificity
Benelli 2001 6 19 6 19 0.50 [ 0.21, 0.79 ] 0.50 [ 0.33, 0.67 ]
Pizzichetta 2004 25 8 14 61 0.64 [ 0.47, 0.79 ] 0.88 [ 0.78, 0.95 ]
Stanganelli 1998a 4 5 6 15 0.40 [ 0.12, 0.74 ] 0.75 [ 0.51, 0.91 ]
Winkelmann 2016 3 3 2 4 0.60 [ 0.15, 0.95 ] 0.57 [ 0.18, 0.90 ]
0 0.2 0.4 0.6 0.8 1 0 0.2 0.4 0.6 0.8 1
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Test 47. MEL- VI - image-based - mixed qualifications (secondary care).
Review: Visual inspection for diagnosing cutaneous melanoma in adults
Test: 47 MEL- VI - image-based - mixed qualifications (secondary care)
Study TP FP FN TN Sensitivity Specificity Sensitivity Specificity
Carli 2003a 45 27 19 109 0.70 [ 0.58, 0.81 ] 0.80 [ 0.72, 0.86 ]
0 0.2 0.4 0.6 0.8 1 0 0.2 0.4 0.6 0.8 1
Test 48. MEL- VI - image-based - mixed qualifications (secondary/primary care).
Review: Visual inspection for diagnosing cutaneous melanoma in adults
Test: 48 MEL- VI - image-based - mixed qualifications (secondary/primary care)
Study TP FP FN TN Sensitivity Specificity Sensitivity Specificity
Dolianitis 2005 12 3 8 17 0.60 [ 0.36, 0.81 ] 0.85 [ 0.62, 0.97 ]
0 0.2 0.4 0.6 0.8 1 0 0.2 0.4 0.6 0.8 1
Test 49. MEL- VI - image-based - mixed qualifications (primary care).
Review: Visual inspection for diagnosing cutaneous melanoma in adults
Test: 49 MEL- VI - image-based - mixed qualifications (primary care)
Study TP FP FN TN Sensitivity Specificity Sensitivity Specificity
Bourne 2012 2 12 7 29 0.22 [ 0.03, 0.60 ] 0.71 [ 0.54, 0.84 ]
Stanganelli 2005 25 28 6 75 0.81 [ 0.63, 0.93 ] 0.73 [ 0.63, 0.81 ]
0 0.2 0.4 0.6 0.8 1 0 0.2 0.4 0.6 0.8 1
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Test 51. MEL - Selected on quality - pathway 2 or 3.
Review: Visual inspection for diagnosing cutaneous melanoma in adults
Test: 51 MEL - Selected on quality - pathway 2 or 3
Study TP FP FN TN Sensitivity Specificity Sensitivity Specificity
Collas 1999 30 19 8 296 0.79 [ 0.63, 0.90 ] 0.94 [ 0.91, 0.96 ]
Gachon 2005 141 1058 8 2829 0.95 [ 0.90, 0.98 ] 0.73 [ 0.71, 0.74 ]
Grimaldi 2009 5 63 0 167 1.00 [ 0.48, 1.00 ] 0.73 [ 0.66, 0.78 ]
Menzies 2009 12 46 20 253 0.38 [ 0.21, 0.56 ] 0.85 [ 0.80, 0.89 ]
Walter 2012 17 152 1 603 0.94 [ 0.73, 1.00 ] 0.80 [ 0.77, 0.83 ]
0 0.2 0.4 0.6 0.8 1 0 0.2 0.4 0.6 0.8 1
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Test 52. MEL - Selected on quality - pathway 5.
Review: Visual inspection for diagnosing cutaneous melanoma in adults
Test: 52 MEL - Selected on quality - pathway 5
Study TP FP FN TN Sensitivity Specificity Sensitivity Specificity
Bono 2002b 10 39 3 109 0.77 [ 0.46, 0.95 ] 0.74 [ 0.66, 0.81 ]
Bono 2006 10 16 13 167 0.43 [ 0.23, 0.66 ] 0.91 [ 0.86, 0.95 ]
Cristofolini 1994 28 46 5 141 0.85 [ 0.68, 0.95 ] 0.75 [ 0.69, 0.81 ]
Dummer 1993 15 49 8 699 0.65 [ 0.43, 0.84 ] 0.93 [ 0.91, 0.95 ]
Langley 2001 4 0 2 34 0.67 [ 0.22, 0.96 ] 1.00 [ 0.90, 1.00 ]
Morton 1998a 63 10 6 684 0.91 [ 0.82, 0.97 ] 0.99 [ 0.97, 0.99 ]
Morton 1998b 28 14 3 522 0.90 [ 0.74, 0.98 ] 0.97 [ 0.96, 0.99 ]
Morton 1998c 22 11 6 630 0.79 [ 0.59, 0.92 ] 0.98 [ 0.97, 0.99 ]
Soyer 1995 61 17 4 77 0.94 [ 0.85, 0.98 ] 0.82 [ 0.73, 0.89 ]
0 0.2 0.4 0.6 0.8 1 0 0.2 0.4 0.6 0.8 1
A D D I T I O N A L T A B L E S
Table 1. Primary analyses for detection of invasive melanoma or atypical intraepidermal melanocytic variants by position on
the clinical pathway
In-person evaluations (n = 28)
Position on
pathway
Datasets Lesions
(melanomas)
Sensitivity %
(95% CI %)
Variance Specificity %
(95% CI %)
Variance
Participants with limited prior testing (unselected on reference standard)
Clear 3 1339 (55) 92.4
(26.2 to 99.8)
6.26 79.7
(73.7 to 84.7)
0.07
Participants with limited prior testing (selected for excision)
Clear 2a 4228 (160) 90.1
(70.0 to 97.3)
0.53 81.3
(67.5 to 90.0)
0.25
Unclear 1 353 (38) 78.9
(62.7 to 90.4)
- 94.0
(90.7 to 96.3)
-
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Table 1. Primary analyses for detection of invasive melanoma or atypical intraepidermal melanocytic variants by position on
the clinical pathway (Continued)
Combined 3 4581 (198) 87.2
(73.2 to 94.4)
0.45 87.1
(74.6 to 94.0)
0.51
Referred participants (unselected on reference standard)
Clear 2 3494 (61) 74.6
(48.9 to 90.0)
0.14 98.6
(94.7 to 99.6)
0.77
Referred participants (selected for excision)
Clear 8 5331 (258) 76.7
(61.7 to 87.1)
0.78 95.7
(89.7 to 98.3)
1.73
Unclear 9 9611 (1015) 82.8
(74.4 to 88.9)
0.34 89.2
(71.1 to 96.5)
3.21
Combined 17 14942
(1273)
79.7
(71.7 to 85.8)
0.59 93.0
(85.4 to 96.8)
2.59
Referred participants with equivocal lesions (selected for excision)
Clear 2a 930 (88) 84.7
(55.5 to 96.1)
0.93 89.5
(79.5 to 95.0)
0.27
Unclear 1 318 (73) 61.4
(49.0 to 72.9)
- 87.3
(82.5 to 91.2)
-
Combined 3 1248 (161) 76.4
(48.4 to 91.8)
1.03 88.8
(81.8 to 93.3)
0.21
b. Image-based evaluations (n = 11)
Position on
pathway
Datasets Lesions
(melanomas)
Sensitivity
(95% CI %)
Variance Specificity
(95% CI %)
Variance
Participants with limited prior testing (selected for excision)
Clear 1 50 (9) 22.2
(2.8 to 60.0)
- 70.7
(54.4 to 83.9)
-
Unclear 1 463 (29) 20.7
(8.0 to 39.7)
- 96.8
(94.6 to 98.2)
-
Combined 2 513 (38) 21.4
(10.0 to 40.1)
0 90.9
(60.7 to 98.1)
1.50
Referred participants (unselected on reference standard)
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Table 1. Primary analyses for detection of invasive melanoma or atypical intraepidermal melanocytic variants by position on
the clinical pathway (Continued)
Clear 1 134 (31) 74.2
(55.4 to 88.1)
- 82.5
(73.8 to 89.3)
1
Referred participants (selected for excision)
Unclear 6 293 (96) 60.3
(49.2 to 70.5)
0.02 77.0
(63.9 to 86.4)
0.40
Referred participants with equivocal lesions (selected for excision)
Unclear 2 303 (98) 61.9
(46.7 to 75.0)
0.10 81.8
(75.2 to 87.0)
0.01
CI: confidence interval
aSensitivity and specificity estimated independently in separate models due to sparse data.
Table 2. Secondary analyses for primary target condition by covariate
Subgroup Datasets Lesions
(melanomas)
Diagnostic odds
ratio (DOR)
(95% CI)
Relative DOR
(95% CI)
P value (DOR) P valuea (hierar-
chical
summary receiver-
operator curves
(HSROC) models)
Differences: in-person and image based evaluations
In-person 28 25,604 (1748) 37.5 (21.7 to 64.
7)
8.54 (2.89 to 25.
3)
< 0.001 0.001
Image-based 11 1243 (263) 4.38 (1.79 to 10.
8)
- - -
Analyses based on in-person evaluations only (n = 28)
Study setting
Primary/com-
munity/private
6 5920 (253) 27.6 (6.95 to 109) - - -
Secondary 10 10,419 (1019) 39.0 (13.8 to 110) - - -
Specialist clinic 12 9265 (476) 44.4 (17.2 to 115) Secondary/spe-
cialist vs primary
b: 1.51 (0.32 to 7.
09)
0.59 0.62
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Table 2. Secondary analyses for primary target condition by covariate (Continued)
Use of a diagnostic algorithm
No algorithm
used
21 19,330 (1076) 37.3 (18.0 to 77.
3)
- - -
Any algorithm
used
7 6274 (672) 38.5 (11.3 to 132) 1.03 (0.25 to 4.
34)
0.96 0.55
Type of reference standard used
Histology alone 22 20,783 (1627) 39.1 (19.7 to 77.
8)
- - -
Histology plus
any other
6 4821 (121) 29.7 (6.60 to 134) 0.76 (0.14 to 4.
02)
0.74 0.68
Prevalence
Prevalence≤ 0.1 16 21,907 (811) 63.7 (28.6 to 142) - - -
Prevalence > 0.1 12 3697 (937) 19.6 (8.39 to 45.
8)
0.31 (0.09 to 1.
00)
0.05 0.06
CI: confidence interval; DOR: diagnostic odds ratio; RDOR: relative diagnostic odds ratio
aLikelihood ratio test assessing differences in both accuracy and threshold.
bSecondary vs primary 1.41 (0.25 to 7.93), P = 0.68; specialist vs primary 1.61 (0.30 to 8.63), P = 0.56; specialist vs secondary 1.14
(0.28 to 4.68), P = 0.85.
Table 3. Visual inspection for detection of melanoma and atypical intraepidermal melanocytic variants - by algorithm
Test (threshold) Datasets Lesions
(melanomas)
Pooled sensitivity
(95% CI %)
Pooled specificity
(95% CI %)
Diagnostic odds ratio
(DOR)
(95% CI)
In-person evaluations
No algorithm 21 19,330 (1076) 78% (68 to 85) 93% (88 to 96) 46.2 (21.9 to 97.5)
(A)BCD(E)a 6b 5501 (654) 83% (75 to 88) 88% (64 to 97) 36.6 (7.94 to 168)
7-point checklist at
≥ 2
1 205 (12) 92% (62 to 1.00) 65% (58 to 72) 22.8 (2.08 to 176)
7-point checklist at
≥ 3
1 205 (12) 42% (15 to 72) 93% (89 to 96) 11.8 (3.22 to 43.3)
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Table 3. Visual inspection for detection of melanoma and atypical intraepidermal melanocytic variants - by algorithm (Con-
tinued)
7-point checklist at
≥ 4
1 205 (12) 25% (07 to 57) 98% (96 to 100) 31.8 (4.71 to 215)
7-point checklist
(revised) at ≥ 3
1 773 (18) 94% (73 to 100) 80% (77 to 83) -
Collas algorithm at
≥ 1
1 353 (38) 76% (60 to 89) 50% (44 to 56) 3.24 (1.49 to 7.07)
Image-based evaluations
No algorithm 9 1090 (217) 58% (43 to 71) 84% (76 to 90) 7.47 (4.12 to 13.5)
ABCD(E)d 2 153 (46) 53% (37 to 70) 71% (45 to 88) 2.87 (0.93 to 8.79)
CI: confidence interval
aCombines data from studies using ABCD with threshold not reported (n = 2), ABCDE with at least 2 characteristics present (n = 3)
and BCD with at least 2 characteristics present (n = 1).
bDue to non-convergence, the bivariate models were fitted assuming zero correlation between the logit sensitivity and logit specificity
and removing the random-effects term for specificity when estimating sensitivity and the random-effects term for sensitivity when
estimating specificity.
cStudy authors developed and used own algorithm.
dCombines data from studies using ABCD with at least 2 characteristics present (n = 1) and ABCDE with at least 2 characteristics
present (n = 1).
Table 4. Secondary analyses for detection of melanoma and atypical intraepidermal melanocytic variants by observer
Subgroup Datasets Lesions
(melanomas)
Diagnostic odds
ratio (DOR)
(95% CI)
Relative DOR
(RDOR)
(95% CI)
P value (for
RDOR)
P valuea (hierar-
chical summary
receiver-operator
curves (HSROC)
models)
In-person evaluations
Expert
consultant
9 3547 29.0 (11.0 to 76.
2)
1 - 0.36
Consultant 13 16,858 38.4 (16.9 to 87.
6)
1.32 (0.37 to 4.
71)
0.65 -
Resident/
registrar
2 1339 12.9 (1.99 to 84.
0)
0.45 (0.05 to 3.
67)
0.44 -
Mixed
(secondary care)
2 2704 48.0 (4.54 to 507) 1.65 (0.13 to 21.
4)
0.69 -
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Table 4. Secondary analyses for detection of melanoma and atypical intraepidermal melanocytic variants by observer (Con-
tinued)
GP 3 1236 211 (24.9 to
1788)
7.28 (0.69 to 76.
3)
0.09 -
Image-based evaluations
Expert
consultant
6 974 20.5 (4.82 to 86.
9)
1 - 0.22
Consultant 4 200 3.76 (1.15 to 12.
3)
0.18 (0.04 to 0.
90)
0.04 -
Mixed
(secondary care)
1 200 10.9 (2.02 to 59.
2)
0.53 (0.07 to 3.
97)
0.50 -
Mixed
(secondary/
primary care)
1 40 11.5 (0.94 to 142) 0.56 (0.04 to 7.
51)
0.63 -
Mixed (primary
care)
2 184 6.60 (1.73 to 25.
2)
0.32 (0.07 to 1.
40)
0.11 -
CI: confidence interval; DOR: diagnostic odds ratio; RDOR: relative diagnostic odds ratio
aLikelihood ratio test assessing differences in both accuracy and threshold.
Table 5. Results for studies reporting data for more than one observer
Study
Algo-
rithm (di-
agnostic
approach)
Dis/non-
dis; preva-
lence
Observer
qualifica-
tion
Sensitiv-
ity (95%
CI %)
Specificity
(95% CI
%)
Observer
qualifica-
tion
Sensitiv-
ity (95%
CI %)
Specificity
(95% CI
%)
Observer
qualifica-
tion
Sensitiv-
ity (95%
CI %)
Specificity
(95% CI
%)
Target condition: invasive melanoma and/or atypical intraepidermalmelanocytic variants
Benelli
2001
ABCDE
(i-b)
12/38;
24%
- - - Dermatol-
ogist (n =
65)
50%
(21 to 79)
50%
(33 to 67)
Expert der-
ma-
tologists (n
= 1)
58%
(28 to 85)
53%
(36 to 69)
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Table 5. Results for studies reporting data for more than one observer (Continued)
Morton
1998a;
Morton
1998b;
Morton
1998c
No algo-
rithm (in-
p)
Different
lesions per
obs
Registrar
(n = 6)
69/694;
9%
79%
(59 to 92)
98%
(97 to 99)
Senior reg-
istrar (n =
2)
31/536;
5%
90%
(74 to 98)
97%
(96 to 99)
Expert der-
ma-
tologists (n
= 2)
28/641;
4%
91%
(82 to 97)
99%
(97 to 99)
Stanganelli
2005
No algo-
rithm (i-b)
31/103;
23%
GP (n = 3) 81%
(63 to 93)
73%
(63 to 81)
- - - Experi-
enced der-
ma-
tologists (n
= 3)
74%
(55 to 88)
83%
(74 to 89)
Target condition: invasive melanoma alone
Lorentzen
1999
No algo-
rithm (i-b)
49/183;
21%
- - - Non-
expert der-
ma-
tology resi-
dents (n =
5)
61%
(46 to 75)
88%
(82 to 92)
Experi-
enced der-
ma-
tologists (n
= 4)
78%
(63 to 88)
89%
(84 to 93)
Rao 1997
ABCD (i-
b)
21/51;
29%
- - - Melanoma
Fellow 1 (n
= 1)
90%
(70 to 99)
80%
(67 to 90)
Dermatol-
ogist 1 (n =
1)
76%
(53 to 92)
82%
(69 to 92)
Melanoma
Fellow 2 (n
= 1)
86%
(64 to 97)
75%
(60 to 86)
Dermatol-
ogist 2 (n =
1)
86%
(64 to 97)
75%
(60 to 86)
Scope
2008
Ugly duck-
ling (i-b)
5/140; 3%
Dermatol-
ogy nurse +
medi-
cal photog-
rapher (n =
5)
60%
(15 to 95)
96%
(91 to 98)
Gen-
eral derma-
tologists (n
= 13)
80%
(28 to 99)
86%
(79 to 91)
Expert der-
ma-
tologists (n
= 8)
80%
(28 to 99)
95%
(90 to 98)
Westerhoff
2000
No algo-
rithm (i-b)
50/50;
GP pre-
der-
moscopy
training (n
= 37)
54%
(39 to 68)
53%
(38 to 67)
GP
post- der-
moscopy
training
(n = 37)
62%
(47 to 75)
54%
(39 to 68)
- - -
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Table 5. Results for studies reporting data for more than one observer (Continued)
50%
CI: confidence interval; GP: general practitioner; in-p: in-person; i-b: image-based; obs: observer
aNumber of diseased/number of non-diseased (prevalence of disease), for each definition of the target condition
Table 6. Secondary analyses for alternative definitions of the target condition
Subgroup Datasets Participants
(cases)
Diagnos-
tic odds ra-
tio (DOR)
(95% CI)
Sensitivity
(95% CI %)
Specificity
(95% CI %)
Rel-
ative DOR
(RDOR)
(95% CI)
P value
(RDOR)
P valuea (hi-
erar-
chical sum-
mary re-
ceiver-oper-
ator curves
(HSROC)
models)
Differences between in-person and image-based evaluations
Detection of invasive melanoma alone
In-person 7 6857 (208) 62.4 (17.6 to
222)
86%
(68 to 94)
91%
(81 to 96)
4.21 (0.62 to
28.6)
0.13 0.27
Image-based 5 599 (150) 14.8 (3.56 to
61.9)
76%
(50 to 91)
83%
(62 to 93)
- - -
Detection of any skin lesion requiring excision
In-person 7 8091 (2187) 20.5 (7.11 to
59.3)
81%
(68 to 90)
81%
(56 to 93)
1.70 (0.24 to
12.3)
0.55 0.87
Image-based 3 547 (138) 11.9 (2.22 to
65.3)
75%
(49 to 90)
79%
(38 to 96)
- - -
aLikelihood ratio test assessing differences in both accuracy and threshold.
Table 7. Results for studies reporting data for more than one definition of the target condition
Detection of invasive melanoma Detection of invasive melanoma or
atypical intraepidermalmelanocytic
variants
Detection of any lesion requiring ex-
cision
Study au-
thor
Dis/non-
dis; preva
Sensitivity
(95% CIs)
Specificity
(95% CIs)
Dis/non-
dis; preva
Sensitivity
(95% CIs)
Specificity
(95% CIs)
Dis/non-
dis; preva
Sensitivity
(95% CIs)
Specificity
(95% CIs)
279Visual inspection for diagnosing cutaneous melanoma in adults (Review)
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Table 7. Results for studies reporting data for more than one definition of the target condition (Continued)
In-person
Ek 2005 - - - 23/2559;
1%
48% (27 to
69)
99% (99 to
99)
1754 /828;
68%
98% (97 to
98)
13% (11 to
15)
McGovern
1992
6/186; 3% 100% (54
to 100)
89% (83 to
93)
11/181;
6%
73% (39 to
94)
88% (83 to
93)
15/177;
8%
73% (45 to
92)
88% (82 to
93)
Stanganelli
2000
- - - 55/3317;
2%
67% (53 to
79)
99% (99 to
100)
98/3274;
3%
71% (61 to
80)
99% (99 to
99)
Steiner
1987
- - - 73/245;
23%
59% (47 to
70)
87% (83 to
91)
93/225;
29%
67% (56 to
76)
86% (81 to
90)
Walter
2012
16/757;
2%
94% (70 to
100)
80% (77 to
83)
18/755;
2%
94% (73 to
100)
80% (77 to
83)
22/751;
3%
82% (60 to
95)
80% (77 to
83)
Image-based
Carli
2002b
- - - 10/43;
19%
80% (44 to
97)
84% (69 to
93)
20/34;
37%
80% (56 to
94)
74% (56 to
87)
Rosendahl
2011
- - - 29/434;
6%
21% (08 to
40)
97% (95 to
98)
104/359;
22%
76% (67 to
84)
85% (81 to
88)
Stanganelli
1998a
- - - 10/20;
33%
40% (12 to
74)
75% (51 to
91)
14/16;
47%
64% (35 to
87)
75% (48 to
93)
aNumber of diseased/number of non-diseased; prevalence of disease, for each definition of the target condition.
A P P E N D I C E S
Appendix 1. Current content and structure of the Programme Grant
LIST OF REVIEWS Number of studies
Diagnosis of melanoma
1 Visual inspection 49
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(Continued)
2 Dermoscopy +/- visual inspection 104
3 Teledermatology 22
4 Smartphone applications 2
5a Computer-assisted diagnosis - dermoscopy-based techniques 42
5b Computer-assisted diagnosis - spectroscopy-based techniques Review amalgamated into 5a
6 Reflectance confocal microscopy 18
7 High-frequency ultrasound 5
Diagnosis of keratinocyte skin cancer (BCC and cSCC)
8 Visual inspection +/- Dermoscopy 24
5c Computer-assisted diagnosis - dermoscopy-based techniques Review amalgamated into 5a
5d Computer-assisted diagnosis - spectroscopy-based techniques Review amalgamated into 5a
9 Optical coherence tomography 5
10 Reflectance confocal microscopy 10
11 Exfoliative cytology 9
Staging of melanoma
12 Imaging tests (ultrasound, CT, MRI, PET-CT) 38
13 Sentinel lymph node biopsy 160
Staging of cSCC
Imaging tests review Review dropped; only one study identified
13 Sentinel lymph node biopsy Review amalgamated into 13 above (n = 15 studies)
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Appendix 2. Glossary of terms
Term Definition
Atypical intraepidermal melanocytic variant Unusual area of darker pigmentation contained within the epidermis that may
progress to an invasive melanoma; includes melanoma in situ and lentigo maligna
Atypical naevi Unusual looking but noncancerous mole or area of darker pigmentation of the
skin
BRAF V600 mutation BRAF is a human gene that makes a protein called B-Raf which is involved in the
control of cell growth. BRAF mutations (damaged DNA) occur in around 40%
of melanomas, which can then be treated with particular drugs
BRAF inhibitors Therapeutic agents that inhibit the serine-threonine protein kinase BRAFmutated
metastatic melanoma
Breslow thickness A scale for measuring the thickness of melanomas by the pathologist using a
microscope, measured in mm from the top layer of skin to the bottom of the
tumour
Congenital naevi A type of mole found on infants at birth
Dermoscopy Whereby a handheld microscope is used to allow more detailed, magnified, ex-
amination of the skin compared to examination by the naked eye alone
False-negative An individual who is truly positive for a disease, but whom a diagnostic test
classifies as disease-free
False-positive An individual who is truly disease-free, but whom a diagnostic test classifies as
having the disease
Histopathology/histology The study of tissue, usually obtained by biopsy or excision, for example under a
microscope
Incidence The number of new cases of a disease in a given time period
Index test A diagnostic test under evaluation in a primary study
Lentigo maligna Unusual area of darker pigmentation contained within the epidermis that includes
malignant cells butwith no invasive growth.May progress to an invasivemelanoma
Lymph node Lymph nodes filter the lymphatic fluid (clear fluid containing white blood cells)
that travels around the body to help fight disease; they are located throughout the
body often in clusters (nodal basins)
Melanocytic naevus An area of skin with darker pigmentation (or melanocytes) also referred to as
‘moles’
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(Continued)
Meta-analysis A form of statistical analysis used to synthesise results from a collection of indi-
vidual studies
Metastases/metastatic disease Spread of cancer away from the primary site to somewhere else through the blood-
stream or the lymphatic system
Micrometastases Micrometastases are metastases so small that they can only be seen under a mi-
croscope
Mitotic rate Microscopic evaluation of number of cells actively dividing in a tumour
Morbidity Detrimental effects on health
Mortality Either (1) the condition of being subject to death; or (2) the death rate, which
reflects the number of deaths per unit of population in relation to any specific
region, age group, disease, treatment or other classification, usually expressed as
deaths per 100, 1000, 10,000 or 100,000 people
Multidisciplinary team A team with members from different healthcare professions and specialties (e.g.
urology, oncology, pathology, radiology, and nursing). Cancer care in theNational
Health Service (NHS) uses this system to ensure that all relevant health profes-
sionals are engaged to discuss the best possible care for a patient
Prevalence The proportion of a population found to have a condition
Prognostic factors/indicators Specific characteristics of a cancer or the person who has it, which might affect
the patient’s prognosis
Receiver operating characteristic (ROC) plot A plot of the sensitivity against the inverse of the specificity of a test at different
thresholds for test positivity; represents the diagnostic capability of a test with a
range of binary test results
Receiver operating characteristic (ROC) analysis The analysis of a ROCplot of a test to select an optimal threshold for test positivity
Recurrence Recurrence is when new cancer cells are detected following treatment. This can
occur either at the site of the original tumour or at other sites in the body
Reference standard A test or combination of tests used to establish the final or ‘true’ diagnosis of a
patient in an evaluation of a diagnostic test
Reflectance confocal microscopy (RCM) A microscopic technique using infrared light (either in a handheld device or a
static unit) that can create images of the deeper layers of the skin
Sensitivity In this context the term is used to mean the proportion of individuals with a
disease who have that disease correctly identified by the study test
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Specificity The proportion of individuals without the disease of interest (in this case with
benign skin lesions) who have that absence of disease correctly identified by the
study test
Staging Clinical description of the size and spread of a patient’s tumour, fitting into inter-
nationally agreed categories
Subclinical (disease) Disease that is usually asymptomatic and not easily observable, e.g. by clinical or
physical examination
Systemic treatment Treatment, usually given by mouth or by injection, that reaches and affects cancer
cells throughout the body rather than targeting one specific area
Appendix 3. Table of acronyms and abbreviations used
Acronym Definition
3PCL three-point checklist
7FFM seven features for melanoma
7PCL seven-point checklist
ABCD(E) asymmetry, border, colour, differential structures (enlargement)
AHM amelanotic or hypomelanotic melanoma
AK actinic keratosis
AMN atypical melanocytic naevi
AUC area under the curve
BCC basal cell carcinoma
BD Bowen’s disease
BN benign naevi
BNM benign non-melanocytic
BPC between-person comparison (of tests)
CAD computer-assisted diagnosis
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(Continued)
CCS case-control study
CD compact disc
CM cutaneous melanoma
CMM cutaneous malignant melanoma
CS case series
CSCC cutaneous squamous cell carcinoma
D- disease-negative
D+ disease-positive
DF dermatofibroma
Dx diagnosis
ELM epiluminescence microscopy
FN false-negative
FP false-positive
FU follow-up
GP general practitioner
H&E haematoxylin and eosin stain
LPLK lichen planus-like keratosis
LS lentigo simplex
MiS melanoma in situ (or lentigo maligna)
MM malignant (invasive) melanoma
MN melanocytic naevi
MSDSLA multispectral digital skin lesion analysis device
N/A not applicable
NC non comparative
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(Continued)
NMLs non melanocytic lesions
NPV negative predictive value
NR not reported
P prospective
PCPs primary care providers
PLC pigmented lesion clinic
PPV positive predictive value
PSL pigmented skin lesion
R retrospective
RCM reflectance confocal microscopy
RCT randomised controlled trial
SCC squamous cell carcinoma
SD standard deviation
SDDI Short term sequential digital dermoscopy imaging
se sensitivity
sp specificity
SK seborrhoeic keratosis
SN Spitz naevi
SSM superficial spreading melanoma
SVS support vector system
TD teledermatology
TN true negative
TWR two-week rule
VI visual inspection
286Visual inspection for diagnosing cutaneous melanoma in adults (Review)
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
(Continued)
WPC within-person comparison (of tests)
WPC-algs within-person comparison (of algorithms)
Appendix 4. Content of algorithms used to assist melanoma diagnosis by visual inspection alone
ABCD (Friedman 1985; Rigel 1993;
Pehamberger 1993)
ABCDE (Abbasi 2004; Benelli 1999;
Benelli 2001; Carli 1994; Cristofolini
1994; Thomas 1998)
BCD (McGovern 1992)
Seven-point checklist (Keefe 1990;
MacKie 1985; MacKie 1990)
Seven-point checklist (revised)
(Healsmith 1994; MacKie 1990)
A - asymmetry
• variable centripetal growth of
melanocytes (Friedman 1985)
• “geometrical asymmetry in two axes
of the tumour” (Benelli 1999; Benelli
2001; Thomas 1998)
• “one half does not match the other
half ” (McGovern 1992); not separately
scored in study “because we believed that
asymmetry and border irregularity were
linked”
B - irregular borders
• irregular shape with notching or
scalloping of border (Friedman 1985)
• “edges are ragged, notched, or
blurred” (McGovern 1992)
• “irregular and notched” (Cristofolini
1994)
• “unsharp or ill-defined or angular”
(Thomas 1998)
• “ragged or indented” (Benelli 1999;
Benelli 2001)
C - colour
• variable pigmentation, multiple
colours; various of hues of brown, also
black, blue, red and white (Friedman
1985 )
• “pigmentation is not uniform; shades
of tan, brown and black are present with
dashes of red, white, or blue” (McGovern
1992)
• “mottled-haphazard display”
• sensory change (greater awareness of
the lesion or mild itch);
• diameter of ≥ 1 cm;
• growth of the lesion;
• an irregular edge;
• irregular pigment with different
shades of brown and black in the lesion;
• inflammation
• crusting, oozing, or bleeding.
Presence of 3 or more suggestive of
melanoma
Healsmith 1994 , MacKie 1990 and
Mackie 1991 describe the revised criteria
as:
major signs
• change in size
• change in shape
• change in colour
minor signs
• inflammation
• crusting or bleeding
• sensory change
• diameter ≥ 7 mm
“a patient with a pigmented lesion with any
one of themajor signs should be considered
for referral and that the presence of any of
the minor signs should be a further stimu-
lus to referral.” (MacKie 1990)
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(Cristofolini 1994)
• “presence of at least two different
colours within the lesion (with the
exception of the usual symmetrical
darkening of the lesion in its center)”
(Benelli 2001; Thomas 1998)
• “multiple colours” (Abbasi 2004)
D - diameter equal or superior to 6 mm
• all studies agree
E - evolution
• “changes in pigmentation”
(Cristofolini 1994)
• “enlargement of the surface (and not
in height) of the lesion; anamnestic
criterion based on the patient’s description
of the natural history of the lesion”
(Thomas 1998)
• “elevation, enlargement or change in
the color of the lesion” (Benelli 1999;
Benelli 2001)
• “evolving (with respect to size, shape,
shades of colour, surface features, or
symptoms)” (Abbasi 2004)
McGovern 1992 describes 7 characteristics
as: “increasing size, variegation, inflamma-
tion, irregular outline, greater than 1cm di-
ameter, itch, bleeding”
These are expanded on in MacKie 1990,
who describes the original (1985) criteria
as:
• sensory change, often described as a
greater awareness of the lesion but also as
a mild itch;
• diameter of 1 cm or greater;
• growth of the lesion;
• an irregular edge;
• irregular pigment with different
shades of brown and black in the lesion;
• inflammation (a reddish tinge within
the lesion); and
• crusting, oozing, or bleeding.
• ≥ 3 criteria should prompt referral
(MacKie 1990)
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Appendix 5. Proposed sources of heterogeneity
i. Population characteristics
• general versus higher risk populations
• patient population: primary/secondary/specialist unit
• lesion suspicion: general suspicion/atypical/equivocal/NR
• lesion type: any pigmented; melanocytic
• inclusion of multiple lesions per participant
• ethnicity
ii. Index test characteristics
• the nature of and definition of criteria for test positivity
• observer experience with the index test
• approaches to lesion preparation (e.g. the use of oil or antiseptic gel for dermoscopy)
iii. Reference standard characteristics
• reference standard used
• whether histology-reporting meets pathology-reporting guidelines
• use of excisional versus diagnostic biopsy
• whether two independent dermatopathologists reviewed histological diagnosis
iv. Study quality
• consecutive or random sample of participants recruited
• index test interpreted blinded to the reference standard result
• index test interpreted blinded to the result of any other index test
• presence of partial or differential verification bias (whereby only a sample of those subject to the index test are verified by the
reference test or by the same reference test with selection dependent on the index test result)
• use of an adequate reference standard
• overall risk of bias
Appendix 6. Final search strategies
Database: Ovid MEDLINE(R) 1946 to August week 3 2016
Search strategy:
1 exp melanoma/
2 exp skin cancer/
3 exp basal cell carcinoma/
4 basalioma$1.ti,ab.
5 ((basal cell or skin) adj2 (cancer$1 or carcinoma$1 or mass or masses or tumour$1 or tumor$1 or neoplasm$1 or adenoma$1 or
epithelioma$1 or lesion$1 or malignan$ or nodule$1)).ti,ab.
6 (pigmented adj2 (lesion$1 or mole$ or nevus or naevi or naevus or naevi or skin)).ti,ab.
7 (melanom$1 or nonmelanoma$1 or non-melanoma$1 or melanocyt$ or non-melanocyt$ or nonmelanocyt$ or keratinocyt$).ti,ab.
8 nmsc.ti,ab.
9 (squamous cell adj2 (cancer$1 or carcinoma$1 or mass or masses or tumor$1 or tumour$1 or neoplasm$1 or adenoma$1 or
epithelioma$1 or epithelial or lesion$1 or malignan$ or nodule$1) adj2 (skin or epiderm$ or cutaneous)).ti,ab.
10 (BCC or CSCC or NMSC).ti,ab.
11 keratinocy$.ti,ab.
12 Keratinocytes/
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13 or/1-12
14 dermoscop$.ti,ab.
15 dermatoscop$.ti,ab.
16 photomicrograph$.ti,ab.
17 exp epiluminescence microscopy/
18 (epiluminescence adj2 microscop$).ti,ab.
19 (confocal adj2 microscop$).ti,ab.
20 (incident light adj2 microscop$).ti,ab.
21 (surface adj2 microscop$).ti,ab.
22 (visual adj (inspect$ or examin$)).ti,ab.
23 ((clinical or physical) adj examin$).ti,ab.
24 3 point.ti,ab.
25 three point.ti,ab.
26 pattern analys$.ti,ab.
27 ABCD$.ti,ab.
28 menzies.ti,ab.
29 7 point.ti,ab.
30 seven point.ti,ab.
31 (digital adj2 (dermoscop$ or dermatoscop$)).ti,ab.
32 artificial intelligence.ti,ab.
33 AI.ti,ab.
34 computer assisted.ti,ab.
35 computer aided.ti,ab.
36 neural network$.ti,ab.
37 exp diagnosis, computer-assisted/
38 MoleMax.ti,ab.
39 image process$.ti,ab.
40 automatic classif$.ti,ab.
41 image analysis.ti,ab.
42 SIAscop$.ti,ab.
43 Aura.ti,ab.
44 (optical adj2 scan$).ti,ab.
45 MelaFind.ti,ab.
46 SIMSYS.ti,ab.
47 MoleMate.ti,ab.
48 SolarScan.ti,ab.
49 VivaScope.ti,ab.
50 (high adj3 ultraso$).ti,ab.
51 (canine adj2 detect$).ti,ab.
52 ((mobile or cell or cellular or smart) adj ((phone$1 adj2 app$1) or application$1)).ti,ab.
53 smartphone$.ti,ab.
54 (DermoScan or SkinVision or DermLink or SpotCheck).ti,ab.
55 Mole Detective.ti,ab.
56 Spot Check.ti,ab.
57 (mole$1 adj2 map$).ti,ab.
58 (total adj2 body).ti,ab.
59 exfoliative cytolog$.ti,ab.
60 digital analys$.ti,ab.
61 (image$1 adj3 software).ti,ab.
62 (teledermatolog$ or tele-dermatolog$ or telederm or tele-derm or teledermoscop$ or tele-dermoscop$ or teledermatoscop$ or tele-
dermatoscop$).ti,ab.
63 (optical coherence adj (technolog$ or tomog$)).ti,ab.
64 (computer adj2 diagnos$).ti,ab.
290Visual inspection for diagnosing cutaneous melanoma in adults (Review)
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
65 exp sentinel lymph node biopsy/
66 (sentinel adj2 node).ti,ab.
67 naevisense.mp. or HFUS.ti,ab.
68 electrical impedance spectroscopy.ti,ab.
69 history taking.ti,ab.
70 patient history.ti,ab.
71 (naked eye adj (exam$ or assess$)).ti,ab.
72 (skin adj exam$).ti,ab.
73 physical examination/
74 ugly duckling.mp. or UD.ti,ab.
75 ((physician$ or clinical or physical) adj (exam$ or triage or recog$)).ti,ab.
76 ABCDE.mp. or VOC.ti,ab.
77 clinical accuracy.ti,ab.
78 Family Practice/ or Physicians, Family/ or clinical competence/
79 (confocal adj2 microscop$).ti,ab.
80 diagnostic algorithm$1.ti,ab.
81 checklist$.ti,ab.
82 virtual imag$1.ti,ab.
83 volatile organic compound$1.ti,ab.
84 dog$1.ti,ab.
85 gene expression analy$.ti,ab.
86 reflex transmission imag$.ti,ab.
87 thermal imaging.ti,ab.
88 elastography.ti,ab.
89 or/14-88
90 (CT or PET).ti,ab.
91 PET-CT.ti,ab.
92 (FDG or F18 or Fluorodeoxyglucose or radiopharmaceutical$).ti,ab.
93 exp Deoxyglucose/
94 deoxy-glucose.ti,ab.
95 deoxyglucose.ti,ab.
96 CATSCAN.ti,ab.
97 exp Tomography, Emission-Computed/
98 exp Tomography, X-ray computed/
99 positron emission tomograph$.ti,ab.
100 exp magnetic resonance imaging/
101 (MRI or fMRI or NMRI or scintigraph$).ti,ab.
102 exp echography/
103 Doppler echography.ti,ab.
104 sonograph$.ti,ab.
105 ultraso$.ti,ab.
106 doppler.ti,ab.
107 magnetic resonance imag$.ti,ab.
108 or/90-107
109 (stage$ or staging or metasta$ or recurrence or sensitivity or specificity or false negative$ or thickness$).ti,ab.
110 “Sensitivity and Specificity”/
111 exp cancer staging/
112 or/109-111
113 108 and 112
114 89 or 113
115 13 and 114
Database: Ovid MEDLINE(R) In-Process & Other Non-Indexed Citations 29 August, 2016
Search strategy:
291Visual inspection for diagnosing cutaneous melanoma in adults (Review)
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
1 basalioma$1.ti,ab.
2 ((basal cell or skin) adj2 (cancer$1 or carcinoma$1 or mass or masses or tumour$1 or tumor$1 or neoplasm$1 or adenoma$1 or
epithelioma$1 or lesion$1 or malignan$ or nodule$1)).ti,ab.
3 (pigmented adj2 (lesion$1 or mole$ or nevus or naevi or naevus or naevi or skin)).ti,ab.
4 (melanom$1 or nonmelanoma$1 or non-melanoma$1 or melanocyt$ or non-melanocyt$ or nonmelanocyt$ or keratinocyt$).ti,ab.
5 nmsc.ti,ab.
6 (squamous cell adj2 (cancer$1 or carcinoma$1 or mass or masses or tumor$1 or tumour$1 or neoplasm$1 or adenoma$1 or
epithelioma$1 or epithelial or lesion$1 or malignan$ or nodule$1) adj2 (skin or epiderm$ or cutaneous)).ti,ab.
7 (BCC or CSCC or NMSC).ti,ab.
8 keratinocy$.ti,ab.
9 or/1-8
10 dermoscop$.ti,ab.
11 dermatoscop$.ti,ab.
12 photomicrograph$.ti,ab.
13 (epiluminescence adj2 microscop$).ti,ab.
14 (confocal adj2 microscop$).ti,ab.
15 (incident light adj2 microscop$).ti,ab.
16 (surface adj2 microscop$).ti,ab.
17 (visual adj (inspect$ or examin$)).ti,ab.
18 ((clinical or physical) adj examin$).ti,ab.
19 3 point.ti,ab.
20 three point.ti,ab.
21 pattern analys$.ti,ab.
22 ABCD$.ti,ab.
23 menzies.ti,ab.
24 7 point.ti,ab.
25 seven point.ti,ab.
26 (digital adj2 (dermoscop$ or dermatoscop$)).ti,ab.
27 artificial intelligence.ti,ab.
28 AI.ti,ab.
29 computer assisted.ti,ab.
30 computer aided.ti,ab.
31 neural network$.ti,ab.
32 MoleMax.ti,ab.
33 image process$.ti,ab.
34 automatic classif$.ti,ab.
35 image analysis.ti,ab.
36 SIAscop$.ti,ab.
37 Aura.ti,ab.
38 (optical adj2 scan$).ti,ab.
39 MelaFind.ti,ab.
40 SIMSYS.ti,ab.
41 MoleMate.ti,ab.
42 SolarScan.ti,ab.
43 VivaScope.ti,ab.
44 (high adj3 ultraso$).ti,ab.
45 (canine adj2 detect$).ti,ab.
46 ((mobile or cell or cellular or smart) adj ((phone$1 adj2 app$1) or application$1)).ti,ab.
47 smartphone$.ti,ab.
48 (DermoScan or SkinVision or DermLink or SpotCheck).ti,ab.
49 Mole Detective.ti,ab.
50 Spot Check.ti,ab.
51 (mole$1 adj2 map$).ti,ab.
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52 (total adj2 body).ti,ab.
53 exfoliative cytolog$.ti,ab.
54 digital analys$.ti,ab.
55 (image$1 adj3 software).ti,ab.
56 (teledermatolog$ or tele-dermatolog$ or telederm or tele-derm or teledermoscop$ or tele-dermoscop$ or teledermatoscop$ or tele-
dermatoscop$).ti,ab.
57 (optical coherence adj (technolog$ or tomog$)).ti,ab.
58 (computer adj2 diagnos$).ti,ab.
59 (sentinel adj2 node).ti,ab.
60 naevisense.mp. or HFUS.ti,ab.
61 electrical impedance spectroscopy.ti,ab.
62 history taking.ti,ab.
63 patient history.ti,ab.
64 (naked eye adj (exam$ or assess$)).ti,ab.
65 (skin adj exam$).ti,ab.
66 ugly duckling.mp. or UD.ti,ab.
67 ((physician$ or clinical or physical) adj (exam$ or triage or recog$)).ti,ab.
68 ABCDE.mp. or VOC.ti,ab.
69 clinical accuracy.ti,ab.
70 (Family adj (Practice or Physicians)).ti,ab.
71 (confocal adj2 microscop$).ti,ab.
72 clinical competence.ti,ab.
73 diagnostic algorithm$1.ti,ab.
74 checklist$.ti,ab.
75 virtual imag$1.ti,ab.
76 volatile organic compound$1.ti,ab.
77 dog$1.ti,ab.
78 gene expression analy$.ti,ab.
79 reflex transmission imag$.ti,ab.
80 thermal imaging.ti,ab.
81 elastography.ti,ab.
82 or/10-81
83 (CT or PET).ti,ab.
84 PET-CT.ti,ab.
85 (FDG or F18 or Fluorodeoxyglucose or radiopharmaceutical$).ti,ab.
86 deoxy-glucose.ti,ab.
87 deoxyglucose.ti,ab.
88 CATSCAN.ti,ab.
89 positron emission tomograph$.ti,ab.
90 (MRI or fMRI or NMRI or scintigraph$).ti,ab.
91 Doppler echography.ti,ab.
92 sonograph$.ti,ab.
93 ultraso$.ti,ab.
94 doppler.ti,ab.
95 magnetic resonance imag$.ti,ab.
96 or/83-95
97 (stage$ or staging or metasta$ or recurrence or sensitivity or specificity or false negative$ or thickness$).ti,ab.
98 96 and 97
99 82 or 98
100 9 and 99
Database: Embase 1974 to 29 August 2016
Search strategy:
1 *melanoma/
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2 *skin cancer/
3 *basal cell carcinoma/
4 basalioma$.ti,ab.
5 ((basal cell or skin) adj2 (cancer$1 or carcinoma$1 or mass or masses or tumour$1 or tumor$1 or neoplasm$ or adenoma$ or
epithelioma$ or lesion$ or malignan$ or nodule$)).ti,ab.
6 (pigmented adj2 (lesion$1 or mole$ or nevus or naevi or naevus or naevi or skin)).ti,ab.
7 (melanom$1 or nonmelanoma$1 or non-melanoma$1 or melanocyt$ or non-melanocyt$ or nonmelanocyt$ or keratinocyt$).ti,ab.
8 nmsc.ti,ab.
9 (squamous cell adj2 (cancer$1 or carcinoma$1 or mass or tumor$1 or tumour$1 or neoplasm$1 or adenoma$1 or epithelioma$1 or
epithelial or lesion$1 or malignan$ or nodule$1) adj2 (skin or epiderm$ or cutaneous)).ti,ab.
10 (BCC or cscc).mp. or NMSC.ti,ab.
11 keratinocyte.ti,ab.
12 keratinocy$.ti,ab.
13 or/1-12
14 dermoscop$.ti,ab.
15 dermatoscop$.ti,ab.
16 photomicrograph$.ti,ab.
17 *epiluminescence microscopy/
18 (epiluminescence adj2 microscop$).ti,ab.
19 (confocal adj2 microscop$).ti,ab.
20 (incident light adj2 microscop$).ti,ab.
21 (surface adj2 microscop$).ti,ab.
22 (visual adj (inspect$ or examin$)).ti,ab.
23 ((clinical or physical) adj examin$).ti,ab.
24 3 point.ti,ab.
25 three point.ti,ab.
26 pattern analys$.ti,ab.
27 ABCD$.ti,ab.
28 menzies.ti,ab.
29 7 point.ti,ab.
30 seven point.ti,ab.
31 (digital adj2 (dermoscop$ or dermatoscop$)).ti,ab.
32 artificial intelligence.ti,ab.
33 AI.ti,ab.
34 computer assisted.ti,ab.
35 computer aided.ti,ab.
36 neural network$.ti,ab.
37 MoleMax.ti,ab.
38 exp diagnosis, computer-assisted/
39 image process$.ti,ab.
40 automatic classif$.ti,ab.
41 image analysis.ti,ab.
42 SIAscop$.ti,ab.
43 (optical adj2 scan$).ti,ab.
44 Aura.ti,ab.
45 MelaFind.ti,ab.
46 SIMSYS.ti,ab.
47 MoleMate.ti,ab.
48 SolarScan.ti,ab.
49 VivaScope.ti,ab.
50 confocal microscop$.ti,ab.
51 (high adj3 ultraso$).ti,ab.
52 (canine adj2 detect$).ti,ab.
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53 ((mobile or cell$ or cellular or smart) adj ((phone$1 adj2 app$1) or application$1)).ti,ab.
54 smartphone$.ti,ab.
55 (DermoScan or SkinVision or DermLink or SpotCheck).ti,ab.
56 Spot Check.ti,ab.
57 Mole Detective.ti,ab.
58 (mole$1 adj2 map$).ti,ab.
59 (total adj2 body).ti,ab.
60 exfoliative cytolog$.ti,ab.
61 digital analys$.ti,ab.
62 (image$1 adj3 software).ti,ab.
63 (optical coherence adj (technolog$ or tomog$)).ti,ab.
64 (teledermatolog$ or tele-dermatolog$ or telederm or tele-derm or teledermoscop$ or tele-dermoscop$ or teledermatoscop$).mp. or
tele-dermatoscop$.ti,ab.
65 (computer adj2 diagnos$).ti,ab.
66 *sentinel lymph node biopsy/
67 (sentinel adj2 node).ti,ab.
68 naevisense.ti,ab.
69 HFUS.ti,ab.
70 electrical impedance spectroscopy.ti,ab.
71 history taking.ti,ab.
72 patient history.ti,ab.
73 (naked eye adj (exam$ or assess$)).ti,ab.
74 (skin adj exam$).ti,ab.
75 *physical examination/
76 ugly duckling.ti,ab.
77 UD sign$.ti,ab.
78 ((physician$ or clinical or physical) adj (exam$ or recog$ or triage)).ti,ab.
79 ABCDE.ti,ab.
80 clinical accuracy.ti,ab.
81 *general practice/
82 (confocal adj2 microscop$).ti,ab.
83 clinical competence/
84 diagnostic algorithm$.ti,ab.
85 checklist$1.ti,ab.
86 virtual image$1.ti,ab.
87 volatile organic compound$1.ti,ab.
88 VOC.ti,ab.
89 dog$1.ti,ab.
90 gene expression analys$.ti,ab.
91 reflex transmission imaging.ti,ab.
92 thermal imaging.ti,ab.
93 elastography.ti,ab.
94 dog$1.ti,ab.
95 gene expression analys$.ti,ab.
96 reflex transmission imaging.ti,ab.
97 thermal imaging.ti,ab.
98 elastography.ti,ab.
99 or/14-93
100 PET-CT.ti,ab.
101 (CT or PET).ti,ab.
102 (FDG or F18 or Fluorodeoxyglucose or radiopharmaceutical$).ti,ab.
103 exp Deoxyglucose/
104 CATSCAN.ti,ab.
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105 deoxyglucose.ti,ab.
106 deoxy-glucose.ti,ab.
107 *positron emission tomography/
108 *computer assisted tomography/
109 positron emission tomograph$.ti,ab.
110 *nuclear magnetic resonance imaging/
111 (MRI or fMRI or NMRI or scintigraph$).ti,ab.
112 *echography/
113 Doppler.ti,ab.
114 sonograph$.ti,ab.
115 ultraso$.ti,ab.
116 magnetic resonance imag$.ti,ab.
117 or/100-116
118 (stage$ or staging or metasta$ or recurrence or sensitivity or specificity or false negative$ or thickness$).ti,ab.
119 “Sensitivity and Specificity”/
120 *cancer staging/
121 or/118-120
122 117 and 121
123 99 or 122
124 13 and 123
Database: Cochrane Library (Wiley) 2016 searched 30 August 2016 CDSR Issue 8 of 12 2016 CENTRAL Issue 7 of 12 2016
HTA Issue 3 of 4 July 2016 DARE Issue 3 of 4 2015
Search strategy:
#1 melanoma* or nonmelanoma* or non-melanoma* or melanocyt* or non-melanocyt* or nonmelanocyt* or keratinocyte*
#2 MeSH descriptor: [Melanoma] explode all trees
#3 “skin cancer*”
#4 MeSH descriptor: [Skin Neoplasms] explode all trees
#5 skin near/2 (cancer* or carcinoma* or mass or masses or tumour* or tumor* or neoplasm* or adenoma* or epithelioma* or lesion*
or malignan* or nodule*)
#6 nmsc
#7 “squamous cell” near/2 (cancer* or carcinoma* or mass or masses or tumour* or tumor* or neoplasm* or adenoma* or epithelioma*
or lesion* or malignan* or nodule*) near/2 (skin or epiderm* or cutaneous)
#8 “basal cell” near/2 (cancer* or carcinoma* or mass or masses or tumour* or tumor* or neoplasm* or adenoma* or epithelioma* or
lesion* or malignan* or nodule*)
#9 pigmented near/2 (lesion* or nevus or mole* or naevi or naevus or naevi or skin)
#10 #1 or #2 or #3 or #4 or #5 or #6 or #7 or #8 or #9
#11 dermoscop*
#12 dermatoscop*
#13 Photomicrograph*
#14 MeSH descriptor: [Dermoscopy] explode all trees
#15 confocal near/2 microscop*
#16 epiluminescence near/2 microscop*
#17 incident next light near/2 microscop*
#18 surface near/2 microscop*
#19 “visual inspect*”
#20 “visual exam*”
#21 (clinical or physical) next (exam*)
#22 “3 point”
#23 “three point”
#24 “pattern analys*”
#25 ABDC
#26 menzies
#27 “7 point”
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#28 “seven point”
#29 digital near/2 (dermoscop* or dermatoscop*)
#30 “artificial intelligence”
#31 “AI”
#32 “computer assisted”
#33 “computer aided”
#34 AI
#35 “neural network*”
#36 MoleMax
#37 “computer diagnosis”
#38 “image process*”
#39 “automatic classif*”
#40 SIAscope
#41 “image analysis”
#42 “optical near/2 scan*”
#43 Aura
#44 MelaFind
#45 SIMSYS
#46 MoleMate
#47 SolarScan
#48 Vivascope
#49 “confocal microscopy”
#50 high near/3 ultraso*
#51 canine near/2 detect*
#52 Mole* near/2 map*
#53 total near/2 body
#54 mobile* or smart near/2 phone*
#55 cell next phone*
#56 smartphone*
#57 “mitotic index”
#58 DermoScan or SkinVision or DermLink or SpotCheck
#59 “Mole Detective”
#60 “Spot Check”
#61 mole* near/2 map*
#62 total near/2 body
#63 “exfoliative cytolog*”
#64 “digital analys*”
#65 image near/3 software
#66 teledermatolog* or tele-dermatolog* or telederm or tele-derm or teledermoscop* or tele-dermoscop* or teledermatoscop* or tele-
dermatolog*
#67 “optical coherence” next (technolog* or tomog*)
#68 computer near/2 diagnos*
#69 sentinel near/2 node*
#70 #11 or #12 or #13 or #14 or #15 or #16 or #17 or #18 or #19 or #20 or #21 or #22 or #23 or #24 or #25 or #26 or #27 or #28
or #29 or #30 or #31 or #32 or #33 or #34 or #35 or #36 or #37 or #38 or #39 or #40 or #41 or #42 or #43 or #44 or #45 or #46 or
#47 or #48 or #49 or #50 or #51 or #52 or #53 or #54 or #55 or #56 or #57 or #58 or #59 or #60 or #61 or #62 or #63 or #64 or #
65 or #66 or #67 or #68 or #69
#71 ultraso*
#72 sonograph*
#73 MeSH descriptor: [Ultrasonography] explode all trees
#74 Doppler
#75 CT or PET or PET-CT
#76 “CAT SCAN” or “CATSCAN”
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#77 MeSH descriptor: [Positron-Emission Tomography] explode all trees
#78 MeSH descriptor: [Tomography, X-Ray Computed] explode all trees
#79 MRI
#80 MeSH descriptor: [Magnetic Resonance Imaging] explode all trees
#81 MRI or fMRI or NMRI or scintigraph*
#82 “magnetic resonance imag*”
#83 MeSH descriptor: [Deoxyglucose] explode all trees
#84 deoxyglucose or deoxy-glucose
#85 “positron emission tomograph*”
#86 #71 or #72 or #73 or #74 or #75 or #76 or #77 or #78 or #79 or #80 or #81 or #82 or #83 or #84 or #85
#87 stage* or staging or metasta* or recurrence or sensitivity or specificity or “false negative*” or thickness*
#88 MeSH descriptor: [Neoplasm Staging] explode all trees
#89 #87 or #88
#90 #89 and #86
#91 #70 or #90
#92 #10 and #91
#93 BCC or CSCC or NMCS
#94 keratinocy*
#95 #93 or #94
#96 #10 or #95
#97 naevisense
#98 HFUS
#99 “electrical impedance spectroscopy”
#100 “history taking”
#101 “patient history”
#102 naked next eye near/1 (exam* or assess*)
#103 skin next exam*
#104 “ugly duckling” or (UD sign*)
#105 MeSH descriptor: [Physical Examination] explode all trees
#106 (physician* or clinical or physical) near/1 (exam* or recog* or triage*)
#107 ABCDE
#108 “clinical accuracy”
#109 MeSH descriptor: [General Practice] explode all trees
#110 confocal near microscop*
#111 “diagnostic algorithm*”
#112 MeSH descriptor: [Clinical Competence] explode all trees
#113 checklist*
#114 “virtual image*”
#115 “volatile organic compound*”
#116 dog or dogs
#117 VOC
#118 “gene expression analys*”
#119 “reflex transmission imaging”
#120 “thermal imaging”
#121 elastography
#122 #97 or #98 or #99 or #100 or #101 or #102 or #103 or #104 or #105 or #106 or #107 or #108 or #109 or #110 or #111 or #
112 or #113 or #114 or #115 or #116 or #117 or #118 or #119 or #120 or #121
#123 #70 or #122
#124 #96 and #123
#125 #96 and #90
#126 #125 or #124
#127 #10 and #126
Database : CINAHL Plus (EBSCO) 1937 to 30 August 2016
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Search strategy:
S1 (MH “Melanoma”) OR (MH “naevi and Melanomas+”)
S2 (MH “Skin Neoplasms+”)
S3 (MH “Carcinoma, Basal Cell+”)
S4 basalioma*
S5 (basal cell) N2 (cancer* or carcinoma* or mass or masses or tumor* or tumour* or neoplasm* or adenoma* or epithelioma* or
lesion* or malignan* or nodule*)
S6 (pigmented) N2 (lesion* or mole* or nevus or naevi or naevus or naevi or skin)
S7 melanom* or nonmelanoma* or non-melanoma* or melanocyt* or non-melanocyt* or nonmelanocyt*
S8 nmsc
S9 TX BCC or cscc or NMSC
S10 (MH “Keratinocytes”)
S11 keratinocyt*
S12 S1 OR S2 OR S3 OR S4 OR S5 OR S6 OR S7 OR S8 OR S9 OR S10 OR S11
S13 dermoscop* or dermatoscop* or photomicrograph* or (3 point) or (three point) or ABCD* or menzies or (7 point) or (seven
point) or AI or Molemax or SIASCOP* or Aura or MelaFind or SIMSYS or MoleMate or SolarScan or smartphone* or DermoScan
or SkinVision or DermLink or SpotCheck
S14 (epiluminescence or confocal or incident or surface) N2 (microscop*)
S15 visual N1 (inspect* or examin*)
S16 (clinical or physical) N1 (examin*)
S17 pattern analys*
S18 (digital) N2 (dermoscop* or dermatoscop*)
S19 (artificial intelligence)
S20 (computer) N2 (assisted or aided)
S21 (neural network*)
S22 (MH “Diagnosis, Computer Assisted+”)
S23 (image process*)
S24 (automatic classif*)
S25 (image analysis)
S26 SIAScop*
S27 (optical) N2 (scan*)
S28 (high) N3 (ultraso*)
S29 elastography
S30 (mobile or cell or cellular or smart) N2 (phone*) N2 (app or application*)
S31 (mole*) N2 (map*)
S32 total N2 body
S33 exfoliative cytolog*
S34 digital analys*
S35 image N3 software
S36 teledermatolog* or tele-dermatolog* or telederm or tele-derm or teledermoscop* or tele-dermoscop* or teledermatoscop* or tele-
dermatoscop* teledermatolog* or tele-dermatolog* or telederm or tele-derm or teledermoscop*
S37 (optical coherence) N1 (technolog* or tomog*)
S38 computer N2 diagnos*
S39 sentinel N2 node
S40 (MH “Sentinel Lymph Node Biopsy”)
S41 naevisense or HFUS or checklist* or VOC or dog*
S42 electrical impedance spectroscopy
S43 history taking
S44 “Patient history”
S45 naked eye
S46 skin exam*
S47 physical exam*
S48 ugly duckling
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S49 UD sign*
S50 (physician* or clinical or physical) N1 (exam*)
S51 clinical accuracy
S52 general practice
S53 (physician* or clinical or physical) N1 (recog* or triage)
S54 confocal microscop*
S55 clinical competence
S56 diagnostic algorithm*
S57 checklist*
S58 virtual image*
S59 volatile organic compound*
S60 gene expression analys*
S61 reflex transmission imag*
S62 thermal imaging
S63 S13 or S14 or S15 OR S16 OR S17 OR S18 OR S19 OR S20 OR S21 OR S22 OR S23 OR S24 OR S25 OR S26 OR S27 OR
S28 OR S29 OR S30 OR S31 OR S32 OR S33 OR S34 OR S35 OR S36 OR S37 OR S38 OR S39 OR S40 OR S41 OR S42 OR
S43 OR S44 OR S45 OR S46 OR S47 OR S48 OR S49 OR S50 OR S51 OR S52 OR S53 OR S54 OR S55 OR S56 OR S57 OR
S58 OR S59 OR S60 OR S61 OR S62
S64 CT or PET
S65 PET-CT
S66 FDG or F18 or Fluorodeoxyglucose or radiopharmaceutical*
S67 (MH “Deoxyglucose+”)
S68 deoxy-glucose or deoxyglucose
S69 CATSCAN
S70 CAT-SCAN
S71 (MH “Deoxyglucose+”)
S72 (MH “Tomography, Emission-Computed+”)
S73 (MH “Tomography, X-Ray Computed”)
S74 positron emission tomograph*
S75 (MH “Magnetic Resonance Imaging+”)
S76 MRI or fMRI or NMRI or scintigraph*
S77 echography
S78 doppler
S79 sonograph*
S80 ultraso*
S81 magnetic resonance imag*
S82 S64 OR S65 OR S66 OR S67 OR S68 OR S69 OR S70 OR S71 OR S72 OR S73 OR S74 OR S75 OR S76 OR S77 OR S78
OR S79 OR S80 OR S81
S83 stage* or staging or metasta* or recurrence or sensitivity or specificity or (false negative*) or thickness
S84 (MH “Neoplasm Staging”)
S85 S83 OR S84
S86 S82 AND S85
S87 S63 OR S86
S88 S12 AND S87
Database: Science Citation Index SCI Expanded (Web of Science) 1900 to 30 August 2016
Conference Proceedings Citation Index (Web of Science) 1900 to 1 September 2016
Search strategy:
#1 (melanom* or nonmelanom* or non-melanoma* or melanocyt* or non-melanocyt* or nonmelanocyt* or keratinocyt*)
#2 (basalioma*)
#3 ((skin) near/2 (cancer* or carcinoma or mass or masses or tumour* or tumor* or neoplasm* or adenoma* or epithelioma* or lesion*
or malignan* or nodule*))
#4 ((basal) near/2 (cancer* or carcinoma* or mass or masses or tumour* or tumor* or neoplasm* or adenoma* or epithelioma* or
lesion* or malignan* or nodule*))
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#5 ((pigmented) near/2 (lesion* or mole* or nevus or naevi or naevus or naevi or skin))
#6 (nmsc or BCC or NMSC or keratinocy*)
#7 ((squamous cell (cancer* or carcinoma* or mass or masses or tumour* or tumor* or neoplasm* or adenoma* or epithelioma* or
lesion* or malignan* or nodule*))
#8 (skin or epiderm* or cutaneous)
#9 #8 AND #7
#10 #9 OR #6 OR #5 OR #4 OR #3 OR #2 OR #1
#11 ((dermoscop* or dermatoscop* or photomicrograph* or epiluminescence or confocal or “incident light” or “surface microscop*”
or “visual inspect*” or “physical exam*” or 3 point or three point or pattern analy* or ABCDE or menzies or 7 point or seven point
or dermoscop* or dermatoscop* or AI or artificial or computer aided or computer assisted or neural network* or Molemax or image
process* or automatic classif* or image analysis or siascope or optical scan* or Aura or melafind or simsys or molemate or solarscan or
vivascope or confocal microscop* or high ultraso* or canine detect* or cellphone* or mobile* or phone* or smartphone or dermoscan
or skinvision or dermlink or spotcheck or spot check or mole detective or mole map* or total body or exfoliative psychology or digital
or image software or optical coherence or teledermatology or telederm* or teledermoscop* or teledermatoscop* or computer diagnos*
or sentinel))
#12 ((naevisense or HFUS or impedance spectroscopy or history taking or patient history or naked eye or skin exam* or physical exam*
or ugly duckling or UD sign* or physician* exam* or physical exam* or ABCDE or clinical accuracy or general practice or confocal
microscop* or clinical competence or diagnostic algorithm* or checklist* or virtual image* or volatile organic or VOC or dog* or gene
expression or reflex transmission or thermal imag* or elastography))
#13 #11 or #12
#14 ((PET or CT or FDG or deoxyglucose or deoxy-glucose or fluorodeoxy* or radiopharma* or CATSCAN or positron emission or
computer assisted or nuclear magnetic or MRI or FMRI or NMRI or scintigraph* or echograph* or Doppler or sonograph* or ultraso*
or magnetic reson*))
#15 ((stage* or staging or metast* or recurrence or sensitivity or specificity or false negative* or thickness*))
#16 #14 AND #15
#17 #16 OR #13
#18 #10 AND #17
Refined by: DOCUMENT TYPES: (MEETING ABSTRACT OR PROCEEDINGS PAPER)
Appendix 7. Full text inclusion criteria
Criterion Inclusion Exclusion
Study design For diagnostic and staging reviews
• Any study for which a 2×2 contingency table
can be extracted, e.g.
◦ diagnostic case control studies
◦ ’cross-sectional’ test accuracy study with
retrospective or prospective data collection
◦ studies where estimation of test accuracy
was not the primary objective but test results for
both index and reference standard were available
◦ RCTs of tests or testing strategies where
participants were randomised between index tests
and all undergo a reference standard (i.e. accuracy
RCTs)
• < 5 melanoma cases (diagnosis reviews)
• < 10 participants (staging reviews)
• Studies developing new criteria for diagnosis
unless a separate ’test set’ of images were used to
evaluate the criteria (mainly digital dermoscopy)
• Studies using ’normal’ skin as controls
• Letters, editorials, comment papers, narrative
reviews
• Insufficient data to construct a 2×2 table
301Visual inspection for diagnosing cutaneous melanoma in adults (Review)
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
(Continued)
Target condition • Melanoma
• Keratinocyte skin cancer (or non-melanoma
skin cancer)
◦ BCC or epithelioma
◦ cSCC
• Studies exclusively conducted in children
• Studies of non-cutaneous melanoma or SCC
Population For diagnostic reviews
• Adults with a skin lesion suspicious for
melanoma, BCC, or cSCC (other terms include
pigmented skin lesion/naevi, melanocytic,
keratinocyte, etc.)
• Adults at high risk of developing melanoma
skin cancer, BCC, or cSCC
For staging reviews
• Adults with a diagnosis of melanoma or cSCC
undergoing tests for staging of lymph nodes or
distant metastases or both
• People suspected of other forms of skin cancer
• Studies conducted exclusively in children
Index tests For diagnosis
• Visual inspection/clinical examination
• Dermoscopy/dermatoscopy
• Teledermoscpoy
• Smartphone/mobile phone applications
• Digital dermoscopy/artificial intelligence
• Confocal microscopy
• Ocular coherence tomography
• Exfoliative cytology
• High-frequency ultrasound
• Canine odour detection
• DNA expression analysis/gene chip analysis
• Other
For staging
• CT
• PET
• PET-CT
• MRI
• Ultrasound +/fine needle aspiration cytology
FNAC
• SLNB +/high-frequency ultrasound
• Other
Any test combination and in any order
Any test positivity threshold
Any variation in testing procedure (e.g. radioisotope
used)
• Sentinel lymph biopsy for therapeutic rather
than staging purposes
• Tests to determine melanoma thickness
• Tests to determine surgical margins/lesion
borders
• Tests to improve histopathology diagnose
• LND
Reference standard For diagnostic studies
• Histopathology of the excised lesion
• Clinical follow-up of non-excised/benign
appearing lesions with later histopathology if
For diagnostic studies
• Exclude if any disease-positive participants have
diagnosis unconfirmed by histology
• Exclude if > 50% of disease-negative
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(Continued)
suspicious
• Expert diagnosis (studies should not be
included if expert diagnosis is the sole reference
standard)
For studies of imaging tests for staging
• Histopathology (via LND or SLMB)
• Clinical/radiological follow-up
• A combination of the above
For studies of SLNB accuracy for staging
• LND of both SLN+ and SLn participants to
identify all diseased nodes
• LND of SLN+ participants and follow-up of
SLN participants to identify a subsequent nodal
recurrence in a previously investigated nodal basin
participants have diagnosis confirmed by expert
opinion with no histology or follow-up
• Exclude studies of referral accuracy, i.e.
comparing referral decision with expert diagnosis,
unless evaluations of teledermatology or mobile
phone applications
BCC: basal cell carcinoma; cSCC: cutaneous squamous cell carcinoma; CT: computed tomography; FNAC: fine needle aspiration
cytology; LND: lymph node dissection;MRI: magnetic resonance imaging; PET: positron emission tomography; PET-CT: positron
emission tomography computed tomography; RCT: randomised controlled trial; SCC: squamous cell carcinoma; SLN+: positive
sentinel lymph node; SLn: negative sentinel lymph node; SLNB: sentinel lymph node biopsy
Appendix 8. Quality assessment (based on QUADAS-2)
We tailored the QUADAS-2 checklist (Whiting 2011) to the review topic as follows below.
Patient selection domain (1)
Selective recruitment of study participants can be a key influence on test accuracy. In general terms, all participants eligible to undergo
a test should be included in a study, allowing for the intended use of that test within the context of the study. We considered studies that
separately sampled malignant and benign lesions to have used a case-control design; and those that supplemented a series of suspicious
lesions with additional malignant or benign lesions to be at unclear risk of bias
In terms of exclusions, we considered studies that excluded particular lesion types (e.g. lentigo maligna), particular lesion sites, or that
excluded lesions on the basis of image quality or lack of observer agreement (e.g. on histopathology) to be at high risk of bias.
In judging the applicability of patient populations to the review question, we considered restriction to particular lesion populations,
such as melanocytic, nodular, high risk or restrictions by size to be of high concern for applicability.
Given that diagnosis of skin cancer is primarily lesion-based, there is the potential for study participants with multiple lesions to
contribute disproportionately to estimates of test accuracy, especially if they are at particular risk of having skin cancer. We considered
studies that included a high number of lesions in relation to the number of study to be less representative than studies conducted in a
more general population participants (i.e. if the difference between the number of included lesions and number of included participants
is greater than 5%).
Index test domain (2)
Given the potential for subjective differences in test interpretation for melanoma, the interpretation of the index test blinded to the
result of the reference standard is a key means of reducing bias. For prospective studies and retrospective studies that used the original
index test interpretation, the diagnosis will by nature be interpreted and recorded before the result of the reference standard is known;
however, studies using previously acquired images could be particularly susceptible to information bias. For these studies to be at low
risk of bias, we required a clear indication that observers were unaware of the reference standard diagnosis at time of test interpretation.
We also added an item to assess the presence of blinding between interpretations of different algorithms, however we did not include
this item in the overall assessment of risk of bias.
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We considered pre-specification of the index test threshold to be present if the study clearly reported that the threshold used was not
data driven, that is, was not based on study results. Studies that did not clearly describe the threshold used but that required clinicians
to record a diagnosis or management decision for a lesion, we considered to be unclear on this criterion. Studies reporting accuracy
for multiple numeric thresholds, where ROC analysis was used to select the threshold, or that reported accuracy for the presence of
independently significant lesion characteristics with no separate test set of lesions, we considered at high risk of bias.
In terms of applicability of the index test to the review question, we required the test to be applied and interpreted as it would be in a
clinical practice setting, that is, in-person or face-to-face with the patient, and by a single observer as opposed to a consensus decision
or average across multiple observers. We considered image-based studies to be high concern, although reflectance confocal microscopy
(RCM) image interpretations where the observer was also supplied with a clinical or dermoscopic image of the lesion along with some
patient characteristics were considered ‘unclear’.
Despite the often subjective nature of test interpretation, it is also important for study authors to outline the particular lesion char-
acteristics that were considered to be indicative for melanoma, particularly where established algorithms or checklists were not used.
We considered studies to be of low concern if the threshold used was established in a prior study or sufficient threshold details were
presented to allow replication.
The experience of the examiner will also impact on the applicability of study results. We required studies to describe the test interpreter
as ‘experienced’ or ‘expert’ in RCM to have low concern about applicability.
Reference standard domain (3)
In an ideal study, consecutively recruited participants should all undergo incisional or excisional biopsy of the skin lesion regardless of
level of clinical suspicion of melanoma. In reality, both partial and differential verification bias are likely. Partial verification bias may
occur where histology is the only reference standard used, and only those participants with a certain degree of suspicion of malignancy
based on the result of the index test undergo verification, the others either being excluded from the study or defined as being disease-
negative without further assessment or follow-up, as discussed above.
Differential verification bias will be present where other reference standards are used in addition to histological verification of suspicious
lesions. A typical example of verification bias in skin cancer occurs when investigators do not biopsy people with benign-appearing
lesions but instead follow them up for a period of time to determine whether any malignancy subsequently develops (these would be
false-negatives on the index test). We defined an ’adequate’ reference standard as: all disease-positive individuals having a histological
reference standard either at the time of application of the index test or after a period of clinical follow-up; and at least 80% of disease-
negative participants have received a histological diagnosis, with up to 20% undergoing at least three months’ follow-up of benign-
appearing lesions.
A further challenge is the potential for incorporation bias, that is, where the result of the index test is used to help determine the reference
standard diagnosis. It is normal practice for the clinical diagnosis (usually by visual inspection or dermoscopy) to be included on
pathology request forms and for the histopathologist to use this diagnosis to help with the pathology interpretation. Although inclusion
of such clinical information on the histopathology request form is theoretically a form of incorporation bias, blinded interpretation
of the histopathology reference standard is not normal practice, and enforcement of such conditions would significantly limit the
generalisability of the study results. For studies evaluating RCM, we divided this item into two questions, firstly whether the reference
standard was blinded to the index test result (RCM), and secondly whether it was blinded to the clinical diagnosis. We included only
the response to the first part (i.e. blinding to RCM) in our overall assessment of risk of bias for the reference standard domain.
In judging the applicability of the reference standard to our review question, we scored studies as high concern around applicability if
they used expert diagnosis (with no follow-up) as a reference standard in any participant, or did not report histology interpretation by
a dermatopathologist.
Flow and timing domain (4)
In the ideal study, the diagnosis based on the index test and reference standard should be made consecutively or as near to each other in
time as possible to avoid changes in lesion over time. For lesions with a histological reference standard, we have defined a one-month
period as an appropriate interval between application of the index test and the reference standard. For studies using clinical follow-up,
we defined a minimum three-month follow-up period as at low risk of bias for detecting false-negatives. We chose this interval based on
a study showing that most false-negative melanomas will be diagnosed within three months of the initial negative index test although
a small number will be diagnosed up to 12 months subsequently (Altamura 2008).
In assessing whether all participants were included in the analysis, we considered studies at high risk of bias if they excluded participants
following recruitment.
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Comparative domain
We added a comparative domain to the QUADAS-2 checklist for studies comparing the accuracy of RCM and dermoscopy. We
included items to assess the presence of blinding of interpretation between tests, and to specify a maximum one-month interval between
application of index tests, as intervals greater than these may be accompanied by changes in tumour characteristics. As it would not be
normal practice for RCM to be interpreted blinded to the clinical or dermoscopic diagnosis, the scoring of this item did not contribute
to our overall assessment of risk of bias. We also considered whether both tests were applied and interpreted in a clinically applicable
manner.
The following tables use text that was originally published in the QUADAS-2 tool by Whiting and colleagues (Whiting 2011).
Item Response (delete as required)
Participant selection 1. Risk of bias
1. Was a consecutive or random sample of participants or images
enrolled?
Yes - if paper states consecutive or random
No - if paper describes other method of sampling
Unclear - if participant sampling not described
2. Was a case-control design avoided? Yes - if consecutive or random or case-control design clearly not
used
No - if study described as case-control or describes sampling spe-
cific numbers of participants with particular diagnoses
Unclear - if not described
3. Did the study avoid inappropriate exclusions, e.g.
• ’difficult-to-diagnose’ lesions not excluded
• lesions not excluded on basis of disagreement between
evaluators
Yes if inappropriate exclusions were avoided
No - if lesions were excluded that might affect test accuracy, e.
g. ’difficult-to-diagnose’ lesions, or where disagreement between
evaluators was observed
Unclear - if not clearly reported but there is suspicion that diffi-
cult-to-diagnose lesions may have been excluded
4. For between-person comparative studies only (i.e. allocating
different tests to different study participants):
• A. were the same participant selection criteria used for
those allocated to each test?
• B. was the potential for biased allocation between tests
avoided through adequate generation of a randomised sequence?
• C. was the potential for biased allocation between tests
avoided through concealment of allocation prior to assignment?
For A
• Yes - if same selection criteria were used for each index test,
• No - if different selection criteria were used for each index
test,
• Unclear - if selection criteria per test were not described,
• N/A - if only 1 index test was evaluated or all participants
received all tests
For B
• Yes - if adequate randomisation procedures are described,
• No - if inadequate randomisation procedures are described,
• Unclear - if the method of allocation to groups is not
described (a description of ’random’ or ’randomised’ is
insufficient),
• N/A - if only 1 index test was evaluated or all participants
received all tests
For C
• Yes - if appropriate methods of allocation concealment are
described,
• No - if appropriate methods of allocation concealment are
not described,
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(Continued)
• Unclear - if the method of allocation concealment is not
described (sufficient detail to allow a definite judgement is
required),
• N/A - if only 1 index test was evaluated
Could the selection of participants have introduced bias?
For non-comparative and within-person-comparative studies
1. If answers to all of questions 1, 2, and 3 ’Yes’
2. If answers to any 1 of questions 1, 2, or 3 ’No’
3. If answers to any 1 of questions 1, 2, or 3 ’Unclear’
For between-person comparative studies
1. If answers to all of questions 1, 2, 3, and 4 ’Yes’
2. If answers to any 1 of questions 1, 2, 3, or 4 ’No’
3. If answers to any 1 of questions 1, 2, 3, or 4 ’Unclear’
For non-comparative and within-person-comparative studies
1. Risk is low
2. Risk is high
3. Risk unclear
For between-person comparative studies
1. Risk is low
2. Risk is high
3. Risk unclear
Participant selection 1. Concerns regarding applicability
1. Are the included participants and chosen study setting appro-
priate to answer the review question, i.e. are the study results gen-
eralisable?
• This item is not asking whether exclusion of certain
participant groups might bias the study’s results (as in Risk of
bias above), but is asking whether the chosen study participants
and setting are appropriate to answer our review question.
Because we are looking to establish test accuracy in both primary
presentation and referred participants, a study could be
appropriate for 1 setting and not for the other, or it could be
unclear as to whether the study can appropriately answer either
question
• For each study assessed, please consider whether it is more
relevant for A, participants with a primary presentation of a skin
lesion or B, referred participants, and respond to the questions
in either A or B accordingly. If the study gives insufficient
details, please respond Unclear to both parts of the question
A. For studies that will contribute to the analysis of partic-
ipants with a primary presentation of a skin lesion (i.e. test
naive)
• Yes - if participants included in the study appear to be
generally representative of those who might present in a usual
practice setting
• No - if study participants appear to be unrepresentative of
usual practice, e.g. in terms of severity of disease, demographic
features, presence of differential diagnosis or comorbidity, setting
of the study, and previous testing protocols
• Unclear - if insufficient details are provided to determine
the generalisability of study participants
B. For studies that will contribute to the analysis of referred
participants (i.e. who have already undergone some form of
testing)
• Yes - if study participants appear to be representative of
those who might be referred for further investigation. If the
study focuses only on those with equivocal lesions, for example,
we would suggest that this is not representative of the wider
referred population
• No - if study participants appear to be unrepresentative of
usual practice, e.g. if a particularly high proportion of
participants have been self-referred or referred for cosmetic
reasons. Other factors to consider include severity of disease,
demographic features, presence of differential diagnosis or
comorbidity, setting of the study, and previous testing protocols
• Unclear - if insufficient details are provided to determine
the generalisability of study participants
2. Did the study avoid including participants with multiple le-
sions?
• Yes - if the difference between the number of included
lesions and number of included participants is less than 5%
• No - if the difference between the number of included
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lesions and number of included participants is greater than 5%
• Unclear - if it is not possible to assess
Is there concern that the included participants do not match the
review question?
1. If the answer to question 1 or 2 ’Yes’
2. If the answer to question 1 or 2 ’No’
3. If the answer to question 1 or 2 ’Unclear’
1. Concern is low
2. Concern is high
3. Concern is unclear
Index test 2. Risk of bias (to be completed per test evaluated)
1. Was the index test or testing strategy result interpreted without
knowledge of the results of the reference standard?
• Yes - if index test described as interpreted without
knowledge of reference standard result or, for prospective
studies, if index test is always conducted and interpreted prior to
the reference standard
• No - if index test described as interpreted in knowledge of
reference standard result
• Unclear - if index test blinding is not described
2. Was the diagnostic threshold at which the test was considered
positive (i.e. melanoma present) prespecified?
• Yes - if threshold was prespecified (i.e. prior to analysing
study results)
• No - if threshold was not prespecified
• Unclear - if not possible to tell whether or not diagnostic
threshold was prespecified
3. For within-person comparisons of index tests or testing strate-
gies (i.e. > 1 index test applied per participant), was each index
test result interpreted without knowledge of the results of other
index tests or testing strategies?
• Yes - if all index tests were described as interpreted without
knowledge of the results of the others
• No - if the index tests were described as interpreted in the
knowledge of the results of the others
• Unclear - if it is not possible to tell whether knowledge of
other index tests could have influenced test interpretation
• N/A - if only 1 index test was evaluated
Could the conduct or interpretation of the index test have intro-
duced bias?
For non-comparative and between-person comparison studies
1. If answers to questions 1 and 2 ’Yes’
2. If answers to either questions 1 or 2 ’No’
3. If answers to either questions 1 or 2 ’Unclear’
For within-person comparative studies
1. If answers to all questions 1, 2, for any index test and 3 ’Yes’
2. If answers to any 1 of questions 1 or 2 for any index test or
3 ’No’
3. If answers to any 1 of questions 1 or 2 for any index test or
3 ’Unclear’
For non-comparative and between-person comparison studies
1. Risk is low
2. Risk is high
3. Risk is unclear
For within-person comparative studies
1. Risk is low
2. Risk is high
3. Risk is unclear
Index test 2. Concern about applicability
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1. Was the diagnostic threshold to determine presence or absence
of disease established in a previously published study?
E.g. previously evaluated/established
• algorithm/checklist used
• lesion characteristics indicative of melanoma used
• objective (usually numerical) threshold used
• Yes - if a previously evaluated/established tool to aid
diagnosis of melanoma was used or if the diagnostic threshold
used was established in a previously published study
• No - if an unfamiliar/new tool to aid diagnosis of
melanoma was used, if no particular algorithm was used, or if
the objective threshold reported was chosen based on results in
the current study
• Unclear - if insufficient information was reported
2. Were thresholds or criteria for diagnosis reported in sufficient
detail to allow replication?
Study results can only be reproduced if the diagnostic threshold is
described in sufficient detail. This item applies equally to studies
using pattern recognition and those using checklists or algorithms
to aid test interpretation
• Yes - If the criteria for diagnosis of melanoma were
reported in sufficient detail to allow replication
• No - if the criteria for diagnosis of melanoma were not
reported in sufficient detail to allow replication
• Unclear - If some but not sufficient information on criteria
for diagnosis to allow replication were provided
3. Was the test interpretation carried out by an experienced ex-
aminer?
• Yes - if the test was interpreted by 1 or more speciality-
accredited dermatologists, or by examiners of any clinical
background with special interest in dermatology and with any
formal training in the use of the test
• No - if the test was not interpreted by an experienced
examiner (see above)
• Unclear - if the experience of the examiner(s) was not
reported in sufficient detail to judge or if examiners were
described as ’Expert’ with no further detail given
• N/A - if system-based diagnosis, i.e. no observer
interpretation
Is there concern that the index test, its conduct, or interpretation
differ from the review question?
1. If answers to questions 1, 2, and 3 ’Yes’
2. If answers to questions 1, 2, or 3 ’No’
3. If answers to questions 1, 2, or 3 ’Unclear’
1. Concern is low
2. Concern is high
3. Concern is unclear
Reference standard 3. Risk of bias
1. Is the reference standard likely to correctly classify the target
condition?
A. Disease-positive - 1 or more of the following:
• histological confirmation of melanoma following biopsy or
lesion excision
• clinical follow-up of benign-appearing lesions for at least 3
months following the application of the index test, leading to a
histological diagnosis of melanoma
B) Disease-negative - 1 or more of the following:
• histological confirmation of absence of melanoma
following biopsy or lesion excision in at least 80% of disease-
negative participants
• clinical follow-up of benign-appearing lesions for a
A. Disease-positive
• Yes - if all participants with a final diagnosis of melanoma
underwent 1 of the listed reference standards
• No - If a final diagnosis of melanoma for any participant
was reached without histopathology
• Unclear - if the method of final diagnosis was not reported
for any participant with a final diagnosis of melanoma or if the
length of clinical follow-up used was not clear or if a clinical
follow-up reference standard was reported in combination with a
participant-based analysis and it was not possible to determine
whether the detection of a malignant lesion during follow-up is
the same lesion that originally tested negative on the index test
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minimum of 3 months following the index test in up to 20% of
disease-negative participants
B. Disease-negative
• Yes - if at least 80% of benign diagnoses were reached by
histology and up to 20% were reached by clinical follow-up for a
minimum of 3 months following the index test
• No - if more than 20% of benign diagnoses were reached
by clinical follow-up for a minimum of 3 months following the
index test or if clinical follow-up period was less than 3 months
• Unclear - if the method of final diagnosis was not reported
for any participant with benign or non-melanoma diagnosis
2. Were the reference standard results interpreted without knowl-
edge of the results of the index test?
Please score this item for all studies even though histopathology
interpretation is usually conducted with knowledge of the clinical
diagnosis (from visual inspection or dermoscopy or both).We will
deal with this by not including the response to this item in the
’Risk of bias’ assessment for these tests. For reviews of all other
tests, this item will be retained
• Yes - if the reference standard diagnosis was reached
blinded to the index test result
• No - if the reference standard diagnosis was reached with
knowledge of the index test result
• Unclear - if blinded reference test interpretation was not
clearly reported
Could the reference standard, its conduct, or its interpretation
have introduced bias?
For visual inspection/dermoscopy evaluations
1. If answer to question 1 ’Yes’
2. If answer to question 1 ’No’
3. If answer to question 1 ’Unclear’
For all other tests
1. If answers to questions 1 and 2 ’Yes’
2. If answers to questions 1 or 2 ’No’
3. If answers to questions 1 or 2 ’Unclear’
For visual inspection/dermoscopy evaluations
1. Risk is low
2. Risk is high
3. Risk is unclear
For all other tests
1. Risk is low
2. Risk is high
3. Risk is unclear
Reference standard 3. Concern about applicability
1. Are index test results presented separately for each component
of the target condition (i.e. separate results presented for those
with invasivemelanoma,melanoma in situ, lentigomaligna, severe
dysplasia, BCC, and cSCC)?
• Yes - if index test results for each component of the target
condition can be disaggregated
• No - if index test results for the different components of the
target condition cannot be disaggregated
• Unclear - if not clearly reported
2. Expert opinion (with no histological confirmation) was not
used as a reference standard
’Expert opinion’ means diagnosis based on the standard clinical
examination, with no histology or lesion follow-up
***do not complete this item for teledermatology studies
• Yes - if expert opinion was not used as a reference standard
for any participant
• No - if expert opinion was used as a reference standard for
any participant
• Unclear - if not clearly reported
3. Was histology interpretation carried out by an experienced
histopathologist or by a dermatopathologist?
• Yes - if histology interpretation was reported to be carried
out by an experienced histopathologist or dermatopathologist
• No - if histology interpretation was reported to be carried
out by a less experienced histopathologist
• Unclear - if the experience/qualifications of the pathologist
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were not reported
Is there concern that the target condition as defined by the refer-
ence standard does not match the review question?
1. If answers to all questions 1, 2, and 3 ’Yes’
2. If answers to any 1 of questions 1, 2, or 3 ’No’
3. If answers to any 1 of questions 1, 2, or 3 ’Unclear’
***For teledermatology studies only
1. If answers to all questions 1 and 3 ’Yes’
2. If answers to questions 1 or 3 ’No’
3. If answers to questions 1 or 3 ’Unclear’
1. Concern is low
2. Concern is high
3. Concern is unclear
***For teledermatology studies only
1. Concern is low
2. Concern is high
3. Concern is unclear
Flow and timing 4. Risk of bias
1. Was there an appropriate interval between index test and refer-
ence standard?
A. For histopathological reference standard, was the interval be-
tween index test and reference standard ≤ 1 month?
B. If the reference standard includes clinical follow-up of border-
line/benign-appearing lesions, was there at least 3 months’ follow-
up following application of index test(s)?
A
• Yes - if study reports ≤ 1 month between index and
reference standard
• No - if study reports > 1 month between index and
reference standard
• Unclear - if study does not report interval between index
and reference standard
B
• Yes - if study reports ≥ 3 months’ follow-up
• No - if study reports < 3 months’ follow-up
• Unclear - if study does not report the length of clinical
follow-up
2. Did all participants receive the same reference standard? • Yes - if all participants underwent the same reference
standard
• No - if more than 1 reference standard was used
• Unclear - if not clearly reported
3. Were all participants included in the analysis? • Yes - if all participants were included in the analysis
• No - if some participants were excluded from the analysis
• Unclear- if not clearly reported
4. For within-person comparisons of index tests
• Was the interval between application of index tests ≤ 1
month?
• Yes - if study reports ≤ 1 month between index tests
• No - if study reports > 1 month between index tests
• Unclear - if study does not report the interval between
index tests
Could the participant flow have introduced bias?
For non-comparative and between-person comparison studies
1. If answers to questions 1, 2, and 3 ’Yes’
2. If answers to any 1 of questions 1, 2, or 3 ’No’
3. If answers to any 1 of questions 1, 2, or 3 ’Unclear’
For within-person comparative studies
1. If answers to all questions 1, 2, 3, and 4 ’Yes’
2. If answers to any 1 of questions 1, 2, 3, or 4 ’No’
For non-comparative and between-person comparison studies
1. Risk is low
2. Risk is high
3. Risk is unclear
For within-person comparative studies
1. Risk is low
2. Risk is high
3. Risk is unclear
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3. If answers to any 1 of questions 1, 2, 3, or 4 ’Unclear’
BCC: basal cell carcinoma; cSCC; cutaneous squamous cell carcinoma
Appendix 9. Summary study details: in-person evaluations
Study
Position on
clinical
pathway a,b
Outcomes
reported
Study type
Country
Setting
Inclusion
criteria
Number-
partici-
pants/
lesions
Index tests
(algorithm)
Diagnostic
approach
Threshold Ob-
server qual-
ification
(number)
Experience
Reference
standard
Final diag-
noses
Prevalence
(invasive
melanoma
or atypical
intraepi-
dermal
melanocytic
variants)
Exclusions
Limited prior testing (position 2 on clinical pathway)
Grimaldi
2009
Pathway:
clear
MEL
WPC
P-CS
Italy
Primary
Cu-
taneous PSL
requiring
confirma-
tion of diag-
nosis by tele-
dermatology
197/235 VI (no algo-
rithm)
Der-
moscopy
(no
algorithm)
In-person
(single)
Subjec-
tive impres-
sion (“suspi-
cious for
malig-
nancy”)
GP (n = 13)
Assumed to
be low (ex-
pertise NR;
simple pro-
tocols
for diagnosis
provided for
study
purposes)
Histology/
clinical FU
(6 months)
MEL 5;
BCC 0; BN
230 (NR)
20%
None
reported
Menzies
2009
Pathway:
clear
MEL
Any
WPC
P-CS
Australia
Primary
PSL that
would be
biopsied or
referred on
after routine
naked eye
examination
NR/374 VI (no algo-
rithm)
Der-
moscopy
(no
algorithm)
In-person
(single)
Subjective
impression
(“correct di-
agnosis of
melanoma”)
GP (n = 62)
As-
sumed to be
low (trained
for study; re-
quired his-
tory of exci-
sion or refer-
ral
of ≥ 10 pig-
mented skin
lesions over
Histology/
clin-
ical FU (3-
6 months)/
expert dx
MEL 32;
BD
2; BN 323;
Unknown 9
4%
6 BCC and
2 BD
excluded by
study
authors, 43
excluded as
both
VI + dermo-
scopic diag-
noses not
available
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the previous
12-month
period
but no prior
dermoscopy
use)
Walter 2012
Pathway:
clear
MM
MEL
Any
BPC
RCT
UK
Primary
Any sus-
picious PSL
that could
not im-
mediately be
diagnosed as
benign
654/
792 (control
arm only)
VI (7-point)
Siascope (iv
arm)
In-person
(single)
7PCL: ≥ 3 GP (n = 28)
Nurse prac-
titioner (n =
2)
Low
(excluded if
specialist
dermatology
training)
Histology/
clin-
ical FU (3-
6 months)/
expert dx
Control
group only:
MM 16;
MiS 2
BCC 4; SK
20; DF 2;
lentigo
5; “benign”
686; un-
known 10
6%
19 (5 due to
violation of
recruit-
ment criteria
or discon-
tinued pro-
to-
col; 1 died;
4 did not at-
tend for der-
matology as-
sessment; 2
missing his-
tology; 7 not
clearly ac-
counted for)
Limited prior testing (selected for excision) (position 3 on clinical pathway)
Collas 1999
Pathway -
unclear
MEL
NC
P-CS
France
Mixed (pri-
vate/
hospital)
PSL under-
going exci-
sion by der-
ma-
tologists in
private prac-
tice, and by
hospital der-
matologists
353/353 VI (1. no al-
gorithm; 2.
own new al-
gorithm)
In-person
1. subjective
impression
2. ≥ 1 of
3 character-
istics present
Dermatolo-
gist (n =NR;
exp NR)
Single
observer
Histology
MEL 38
BN 249;
other pig-
mented 55
38/353;
11%
None
reported
Gachon
2005
Pathway -
clear
NC
P-CS
France
Private
Melanocytic
skin lesions
removed for
any reason
NR/4036 VI (no algo-
rithm)
In-person;
single
Subjec-
tive impres-
sion (“con-
sidered sus-
picious”)
Dermatol-
ogists (135/
200)
Exp NR
Histology
MM 113;
MiS 36
BN 3887
149/4036;
4%
None
reported
McGovern
1992
Pathway -
clear
WPC-algs
P-CS
USA
Community
(Army Med-
ical Center
PSL (> 10
mm) excised
to rule out
dysplasia,
MiS or MM
179/237 VI (7-point;
(A)BCD)
In-person;
single
7-point: ≥
2, ≥ 3, ≥
4 character-
istics present
(A)BCD: ≥
1, ≥ 2, ≥
NR (pre-
sume der-
matologist)
Exp NR
Histology
MM 6; MiS
6
BCC 4; SK
32; BN 138;
AK 6; other
32 le-
sions unac-
counted for;
13 excluded
due to le-
sion size of
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Derm-
Clinic)
3 character-
istics present
45
12/205; 6%
≤ 8 mm.
192 evalu-
ated for
ABCD and
3-point; 205
evaluated
for 7-point
Referred for further assessment (position 4 on clinical pathway)
Barzegari
2005
Pathway -
clear
MEL
WPC
NR-CS
Iran
Secondary
PSL ≤ 15
mm diame-
ter referred
to dermatol-
ogy clinic
for diag-
nostic evalu-
ation or cos-
metic
reasons
91/122 VI (no algo-
rithm)
In-per-
son (consen-
sus diagnosis
of 2)
Melanoma
likely/
melanoma
possible
Mixed (n =
2; 1
at-
tending der-
matologist
and a third
year derma-
tology resi-
dent)
Histology
MM 3; MiS
3
SK 2; AK 1;
BN 106; DF
7
6/122; 5%
None
reported
Stanganelli
2000
Pathway -
clear
MEL
Any
WPC
R-CS
Italy
Specialist
clinic
PSL referred
by derma-
tologists and
GPs ei-
ther for pre-
surgical as-
sessment or
consultation
NR/3372 VI (ABCD)
Der-
moscopy
(no
algorithm)
In-person
(single)
NR
Subjective
impression
NR (as-
sumed der-
matologist:
described as
one
of the co-au-
thors; n = 1)
Histology/
registry FU
MEL 55
BCC 43;
BN 3274
55/3372;
2%
None
reported
Referred for further assessment (selected for excision) (position 5 on clinical pathway)
Benelli 1999
Pathway -
unclear
MEL
WPC
P-CS
Italy
Secondary
All PSL ob-
served
and excised
at the Der-
matologic
Surgery De-
partment
NR/401 1. VI
(ABCDE)
2. Der-
moscopy
(7FFM)
In-person
1. ≥ 1 char-
acter-
istic present;
≥ 2 charac-
teristics
present; ≥ 3
characteris-
tics present;
≥ 4 charac-
teristics
present; all
5 character-
istics present
2. Score ≥ 2
Dermatol-
ogist (n = 2;
exp NR)
Consensus
of 2
Histology
MM 54;
MiS 6
BCC 1
BN 337; LS
5; SK 1
60/401;
15%
None
reported
Bono 2002a
Pathway -
WPC
P-CS
PSL with a
more or less
298/313 VI (no algo-
rithm)
VI: subjec-
tive impres-
Surgical on-
cologist (n =
Histology
MM 55;
None
reported
313Visual inspection for diagnosing cutaneous melanoma in adults (Review)
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
(Continued)
clear
MEL
Italy
Specialist
clinic
important
suspicion for
MM on VI
and/or der-
moscopy
Der-
moscopy
(no
algorithm)
In-person
sion
Der-
moscopy: ≥
1 character-
istic present
4; high)
Single
observer
MiS 11
BCC 6; 8
SK; 3 SN;
BN 230
66/313;
21%
Bono 2002b
Pathway -
clear
MEL
WPC
P-CS
Italy
Specialist
clinic
PSL
≤ 6 mm re-
quiring sur-
gical biopsy
for diagno-
sis based on
clinical or
dermo-
scopic suspi-
cion of MM
157/161 VI (no algo-
rithm)
Der-
moscopy
(no
algorithm)
In-person
VI: subjec-
tive impres-
sion
Der-
moscopy: ≥
1 character-
istic present
Surgical on-
cologist (n =
2; high)
Single
observer
Histology
MM 10;
MiS 3
BCC 2; SK
4; SN 5; BN
124
13/161; 8%
None
reported
Bono 2006
Pathway -
clear
MEL
WPC
R-CS
Italy
Specialist
clinic
PSL≤ 3mm
undergoing
excision due
to a more
or less im-
portant
suspicion for
MM on VI
and/or der-
moscopy
204/206 VI (no algo-
rithm)
Der-
moscopy
(Menzies)
In-person
VI: subjec-
tive impres-
sion
Der-
moscopy:
NR
NR; as-
sumed sur-
gical oncol-
ogist
as per Bono
2002a;
Bono 2002b
(n = 4; exp
NR)
Single
observer
Histology
MM 19;
MiS 4
SN 3; BN
169; Other
11
23/206;
11%
None
reported
Carli 2002a
Pathway -
unclear
MEL
WPC
R-CS
Italy
Secondary
Clin-
ically equiv-
ocal and sus-
picious PSL
subjected
to excisional
biopsy at the
Insti-
tute of Der-
matology
NR/256 1. VI (no al-
gorithm)
2. Der-
moscopy
(pattern)
In-
person (der-
moscopy,
image-
based)
Subjective
impression
Derma-
tologist (n =
2; high exp
- “extensive
ex-
perience in
both clinical
and dermo-
scopic diag-
nosis”)
Consensus
of 2
Histology
MM 40;
MiS 14
BCC 5
BN 177; SN
16; SK 4
54/256;
21%
None
reported
Cristofolini
1994
Pathway -
unclear
MEL
WPC
P-CS
Italy
Secondary
Patients
with
PSLpresent-
ing during a
campaign
for the early
diagnosis
NR/220 1. VI
(ABCDE)
2. Der-
moscopy
(pattern)
In-person
1. ≥ 2 char-
acteristics
present
2. ≥ 1 char-
acteristic
present
Derma-
tologist (n =
4; high exp:
dermatol-
ogists had all
been trained
Histology
MEL 33
BCC 0
BN 181; SK
4; 2 throm-
bosed
None
reported
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of cutaneous
melanoma
at the Der-
matology
Department
in the recog-
nition of
pigmented
lesions)
Unclear ob-
server inter-
pretation
angioma
33/220;
15%
Cristofolini
1997
Pathway -
unclear
MEL
WPC-algs
NR-CS
Italy
Secondary
Patients
with small
and flat
common
and atypical
PSL re-
cruited dur-
ing a health
campaign
for the early
diagnosis of
melanoma;
all
underwent
skin biopsy
176/176 VI (ABCD)
In-person
NR Derma-
tologist (n =
3; high expe-
rience)
Consensus
of 3
Histology
MEL 35
BN 141
35/176;
20%
None
reported
Ek 2005
Pathway -
clear
MEL
Any
NC
P-CS
Australia
Specialist
clinic
Le-
sions excised
for which
malignancy
could not be
excluded
1223/2582 VI (no algo-
rithm)
In-person
Subjective
impression
Plastic sur-
geon (n = 4
or 5; mixed
experience;
3 consul-
tants, 1 plas-
tic surgery
trainee (usu-
ally 1st year,
on
6-month ro-
tation) and a
clinical assis-
tant)
Unclear
Histology
MEL 23
BCC 1214;
SCC 517;
BD 188; SK
63; 577
other
BN (includ-
ing 330 solar
keratosis)
23/2582;
1%
Incom-
plete or in-
correctly en-
tered profor-
mas were ex-
cluded - 79
participants
with 96 le-
sions
Green 1991
Pathway -
clear
MEL
NC
NR-CS
Australia
Secondary
PSL for exci-
sion
81/89 VI (no algo-
rithm)
In-person
Subjective
impression
NR (n =
NR; exp NR
“in the ma-
jor-
ity of cases
a surgeon or
a dermatolo-
gist”)
Single
Histology
MEL 5
BCC 2; SK
7; BN 54;
Other 2
5/70; 7%
19/89
lesions
excluded
(number of
partici-
pants not re-
ported) due
to incom-
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observer plete clinical
and histol-
ogy records
Langley
2001
Pathway -
unclear
MEL
NC
P-CS
USA
Specialist
clinic
Patients
with le-
sions sched-
uled for ex-
cision at the
pigmented
lesion clinic
to either re-
move atypi-
cal naevi or
to rule out
melanoma
or
for cosmetic
reasons
NR/38 VI (no algo-
rithm)
In-person
NR NR
(presume
dermatolo-
gist; n =NR;
exp NR)
Unclear
Histology
MM 3; MiS
3
BN 32
6/38; 16%
None
reported
Morales
Callaghan
2008
Pathway -
unclear
MEL
WPC
P-CS
Spain
Secondary
Randomly
selected
melanocytic
lesions;
melanocytic
on
both clinical
and dermo-
scopic crite-
ria
166/200 1. VI (no al-
gorithm)
2. Der-
moscopy
(no
algorithm)
In-person
NR Derma-
tologist (n =
2; high exp -
“experi-
ence in der-
moscopy”)
Consensus
of 2
Histology
MEL 6
BN 184; SN
1; Other 9
6/200; 3%
None
reported
Morton
1998a (high
exp)
, Morton
1998b (mod
exp),
and Morton
1998c (low
exp)
Pathway -
clear
MEL
NC
R-CS
UK
Specialist
clinic
Patients re-
ferred
by their GP
to the clinic
NR/1999 VI (no algo-
rithm)
In-person
NR Dermatol-
ogist (n = 2;
high); Der-
matology se-
nior
registrar (n =
1;moderate)
; Dermatol-
ogy registrar
(n = 1; low)
SIngle ob-
server per le-
sion
Histology
MM 104;
MiS 24
BN 1871
High exp:
69/763; 9%
Moderate
exp: 31/567;
5%
Low exp:
28/669; 4%
None
reported
Thomas
1998
Pathway -
unclear
MEL
NC
CCS
France
Secondary
All cases of
melanoma
and a nons-
elected con-
secu-
NR/1140 VI
(ABCDE)
In-person
≥ 1 charac-
teristic
present
≥ 2 charac-
Derma-
tologist (n =
2; high exp:
described as
Histology
MEL 460
BCC 8
BN 638; SN
None
reported
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tive group of
“non-
melanoma”
PSL
teristics
present
≥ 3 charac-
teristics
present
≥ 4 charac-
teristics
present
all 5 charac-
teristics
present
“trainedder-
matolo-
gists”)
Single
observer
2; Other 13
460/1140;
40%
Unlu 2014
Pathway -
unclear
MEL
WPC-algs
R-CS
Turkey
Specialist
clinic
Melanocytic
lesions ex-
cised at De-
partment of
Derma-
tology Pig-
mented Le-
sion Clinic
115/115 1. VI (no al-
gorithm)
2. Der-
moscopy (7-
point; 3-
point;
CASH;
ABCD)
In-person
1. subjective
impression
2. score ≥ 3;
≥ 2 charac-
teris-
tics present;
score ≥ 8;
score > 5.44
NR (pre-
sume der-
matologist;
n = 1 for VI;
n = 3 for der-
moscopy;
Exp NR for
VI)
Single ob-
server (VI);
consensus of
3 (der-
moscopy)
Histology
MEL 24
BN 91
24/115;
21%‘
None
reported
Zaumseil
1983
Pathway -
unclear
MEL
NC
NR-CS
Germany
Secondary
Skin lesions
undergoing
excision
NR/7063 VI (no algo-
rithm)
In-person
Subjective
impression
NR
(n =NR; exp
NR)
Single
observer
Histology
MEL 337
Not
melanoma
6726 (dx
listed only
for FPs)
337/7063;
5%
None
reported
Equivocal referred for further assessment (selected for excision) (position 5* on clinical pathway)
Dummer
1993
Pathway -
clear
MEL
WPC
P-CS
Germany
Patients
with
melanocytic
skin lesions
dif-
ficult to di-
agnose clini-
cally
NR/771 VI (no algo-
rithm)
Der-
moscopy
(pattern)
In-per-
son (image-
based for
der-
moscopy)
NR NR assume
derma-
tologist (as-
sumed) (n =
2; exp NR)
Single
observer
Histology
MM 19;
MiS 4
SK 4;
BN706; BN
NML 32;
other 6
23/771; 3%
53 non-
melanocytic
lesions
not included
in the final
analysis (no
melanomas
present in
this group)
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Soyer 1995
Pathway -
clear
MEL
WPC
NR-CS
Austria
PSL difficult
to diag-
nose on clin-
ical grounds
alone
NR/159 VI (no algo-
rithm)
Der-
moscopy
(pattern)
In-person
NR Derma-
tologist (n =
2; exp high;
“the exam-
ination was
performed
by a derma-
tologist ex-
pert in der-
moscopy”)
Single
observer
Histology
MM 50;
MiS 15
BCC 3; SK
18;
AK 4; BN
61; other 7
65/159;
41%
None
reported
Steiner 1987
Pathway -
unclear
MEL
P-CS
Austria
Specialist
clinic
Small (<
10 mm) di-
agnostically
equivocal
PSL; no ab-
solute agree-
ment on
clinical diag-
nosis among
inves-
tigating clin-
icians at
a pigmented
lesion clinic
NR/318 1. VI (no al-
gorithm)
2. Der-
moscopy
(pattern)
In-person
Subjective
impression
Derma-
tologists (n =
3; high exp:
“expe-
rienced der-
matolo-
gists”)
Consensus
diagnosis of
3 observers
Histology
MM 49;
MiS 24
BCC 20
BN 143; SK
20; lentigo
simplex and
nevoid
lentigo 19;
other 15
73/318;
23%
None
reported
apositions on the clinical pathway described in Figure 3.
bclear or unclear position on the clinical pathway.
AHM: atypical melanocytic naevi; AK: actinic keratosis; BCC: basal cell carcinoma; BD: Bowen’s disease; BN: benign naevi; BNM:
benign non-melanocytic; BPC: between-person comparison (of tests); CCS: case control study; CS: case series; cSCC: cutaneous
squamous cell carcinoma;DF: dermatofibroma; dx: diagnosis;ELM: epiluminescencemicroscopy;Exp: experience;FP: false-positive;
FU: follow-up; GP: general practitioner; LS: lentigo simplex; MEL: invasive melanoma or atypical intraepidermal melanocytic
variants;MM: malignant (invasive) melanoma;MiS: melanoma in situ (or lentigo maligna);NC: noncomparative; NR: not reported;
P: prospective; PLC: pigmented lesion clinic; PSL: pigmented skin lesion; R: retrospective; RCT: randomised controlled trial; SCC:
squamous cell carcinoma; SK: seborrhoeic keratosis; SN: Spitz naevi; VI: visual inspection; WPC: within-person comparison (of
tests);WPC-algs: within-person comparison (of algorithms); 7FFM: seven features for melanoma; 7PCL: seven-point checklist
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Appendix 10. Summary QUADAS: in-person evaluations
Studies clearly placed on clinical pathway Studies not clearly placed on clinical pathway
Pathway a,b Risk of bias Concerns about appli-
cability
Risk of bias Concerns about appli-
cability
Limited prior testing (position 2 on clinical pathway)
Studies N = 3; Grimaldi 2009; Menzies 2009; Walter 2012 N = 0
Participant selection Low (3/3) High (2/3)
Unclear (1/3)
Inclusion of multiple le-
sions per participant (
Grimaldi 2009; Walter
2012); patient numbers
NR (Menzies 2009)
- -
Index test Low (1/3)
Unclear (2/3)
Lack of clear pre-spec-
ification of threshold (
Grimaldi 2009; Menzies
2009)
Low (1/3)
High (2/3)
Lack of description of di-
agnostic threshold
(Grimaldi 2009; Menzies
2009). Non-expert test
interpretation (Menzies
2009; Walter 2012); not
clear in Grimaldi 2009
- -
Reference standard High (3/3)
< 80% of disease-negative
participants had histolog-
ical or clinical follow-up
reference standard
High (2/3)
Unclear (1/3)
Expert diagnosis as ref-
erence standard (Menzies
2009; Walter 2012); un-
clear histopathologist ex-
pertise (3/3)
- -
Flow and timing High (3/3)
Mixed reference
standards (3/3); partici-
pant exclusions (Menzies
2009; Walter 2012); all
unclear on index to refer-
ence interval
- - -
Limited prior testing (selected for excision) (position 3 on clinical pathway)
Studies N = 2; Gachon 2005; McGovern 1992 N = 1; Collas 1999
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(Continued)
Participant selection Low (1/2)
Unclear (1/2)
Unclear exclusion criteria
(1/2; Gachon 2005).
High (2/2)
Restric-
tion to melanocytic (1/2;
Gachon 2005) or primar-
ily excised lesions (2/2);
multiple lesions per par-
ticipant (1/2; McGovern
1992); number partici-
pants NR (1/2; Gachon
2005)
Unclear (1/1)
Participant sampling not
described; exclusion crite-
ria NR
High (1/1)
Excised only included
Index test Unclear (1/2)
High (1/2)
Lack of clear pre-specifi-
cation of the threshold (1/
2; Gachon 2005) or test-
ing of multiple thresholds
(1/2; McGovern 1992)
High (1/2)
Unclear (1/2)
Lack of threshold detail
(1/2; Gachon 2005); un-
clear description of ob-
server expertise (2/2)
Low (1/1) Unclear (1/1)
Observer expertise not
described
Reference standard Low (2/2) Low (1/2)
Unclear (1/2)
Lack of description of
histopathology expertise
(1/2; Gachon 2005)
Low (1/1) Unclear (1/1)
Histology expertise not
described (histologically
analysed by different pri-
vate and hospital patholo-
gists and reviewed by one
of the study authors)
Flow and timing High (1/2)
Unclear (1/2)
Participant exclusions (1/
2; McGovern 1992); un-
clear reference interval (2/
2).
- Low (1/1) -
Referred for further assessment (position 4 on clinical pathway)
Studies N = 2; Barzegari 2005; Stanganelli 2000 N = 0
Participant selection Low (2/2) High (2/2)
Included excisions for
cosmetic reasons (1/2;
Barzegari 2005), or mul-
tiple lesions per partici-
pant (2/2)
- -
Index test Low (1/2)
Unclear (1/2)
Lack of clear pre-speci-
High (1/2)
Unclear (1/2)
Consensus result (1/2;
- -
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(Continued)
fication of the threshold
(Barzegari 2005)
Barzegari 2005); insuffi-
cient threshold detail (1/
2; Barzegari 2005); ob-
server expertise not clear
(2/2)
Reference standard Low (1/2)
High (1/2)
< 80% of disease-nega-
tive participants had his-
tological or clinical fol-
low-up reference standard
(Stanganelli 2000)
Unclear (2/2)
Lack of description of
histopathology expertise
(2/2)
- -
Flow and timing High (1/2)
Unclear (1/2)
Unclear reference inter-
val (2/2); use of different
reference standards (1/2;
Stanganelli 2000)
- - -
Referred for further assessment (selected for excision) (position 5 on clinical pathway)
Studies N = 6; Bono 2002a; Bono 2002b; Bono 2006; Ek
2005; Green 1991; Morton 1998a; Morton 1998b;
Morton 1998c b
N = 9; Benelli 1999; Carli 2002b; Cristofolini 1994;
Cristofolini 1997; Langley 2001; Morales Callaghan
2008; Thomas 1998; Unlu 2014; Zaumseil 1983
Participant selection Low (2/6)
High (2/6)
Unclear (2/6)
Inappropriate (2/6; Bono
2002a; Ek 2005) or un-
clear (2/6; Green 1991;
Morton 1998a; Morton
1998b; Morton 1998c)
exclusions; consecutive
recruitment not reported
(1/6; Green 1991)
High (6/6)
Unrep-
resentative (6/6) partici-
pants; all excised. Multi-
ple lesions per participant
(2/6; Ek 2005; Green
1991) or number of par-
ticipants NR (Morton
1998a; Morton 1998b;
Morton 1998c)
High (4/9)
Unclear (5/9)
Inappropriate exclusions
(4/9) due to restriction
to melanocytic only (
Morales Callaghan 2008;
Unlu 2014)
, disagreement on histol-
ogy (Zaumseil 1983). Use
of case-control type de-
sign (1/9; Thomas 1998).
Unclear participant sam-
pling (6/9; Benelli 1999;
Carli 2002b; Cristofolini
1994; Cristofolini 1997;
Langley 2001; Zaumseil
1983).
High (9/9)
Inclusion of only excised
lesions (9/9). Multiple le-
sions per participant (2/
9; Langley 2001; Morales
Callaghan 2008); num-
ber of participants not
reported (6/9; Benelli
1999;
Carli 2002b; Cristofolini
1994; Cristofolini 1997;
Thomas 1998; Zaumseil
1983)
Index test Low (3/6)
Unclear (3/6)
Pre-specification
of threshold not reported
High (6/6)
All clinically applicable
application of test. No
threshold details (6/6).
Low (2/9)
High (2/9)
Unclear (5/9)
Threshold not prespeci-
Low (1/9)
High (7/9)
Unclear (1/9)
Test application not clin-
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(Continued)
(Ek 2005; Green 1991;
Morton 1998a; Morton
1998b; Morton 1998c)
Observer experience un-
clear (3/6; Bono 2006; Ek
2005; Green 1991).
fied (2/9; Benelli 1999;
Thomas 1998) or not
clear whether prespecified
(Carli 2002b;Cristofolini
1997; Langley 2001;
Morales Callaghan 2008;
Unlu 2014).
ically applicable
(4/9; Benelli 1999; Carli
2002b; Cristofolini 1997;
Morales Callaghan 2008)
or not clear (Cristofolini
1994; Langley 2001). No
threshold
detail (5/9; Carli 2002b;
Langley 2001; Morales
Callaghan 2008; Unlu
2014; Zaumseil 1983)
Reference standard Low (5/6)
High (1/6)
Inad-
equate reference standard
(1/6; Green 1991)
Low (1/6)
High (1/6)
Unclear (4/6)
Expert diagnosis used (1/
6; Green 1991). Lack of
descrip-
tion of histopathology ex-
pertise (5/6; all except
Morton 1998a; Morton
1998b; Morton 1998c)
Low (9/9) Low (2/9)
High (1/9)
Unclear (6/9)
Use of expert diagno-
sis (1/9; Langley 2001)
. Histopathology exper-
tise not reported (7/
9; Benelli 1999; Carli
2002b; Cristofolini 1994;
Cristofolini
1997; Langley 2001;
Morales Callaghan 2008;
Zaumseil 1983)
Flow and timing High (2/6)
Unclear (4/6)
Index to reference interval
not reported (5/6; Bono
2002a; Bonon 2002b;
Bono 2006; Green 1991;
Morton 1998a; Morton
1998b; Morton 1998c)
. Participant exclusions
due to incomplete data
(2/6; Ek 2005; Green
1991)
- Low (3/9)
Unclear (6/9)
Interval to reference stan-
dard not reported (6/9;
Benelli 1999; Cristofolini
1994; Langley 2001;
Thomas 1998; Unlu
2014; Zaumseil 1983)
-
Equivocal referred for further assessment (selected for excision) (position 5* on clinical pathway)
Studies N = 2; Dummer 1993; Soyer 1995 N = 1; Steiner 1987
Participant selection Unclear (2/2)
Unclear sampling meth-
ods (2/2); Unclear exclu-
sions (1/2; Soyer 1995)
High (1/2)
Unclear (1/2)
Participants not represen-
tative (1/2; Dummer
1993) or unclear (1/2;
Soyer 1995). Number of
Unclear (1/1)
Participant sampling not
described; exclusion crite-
ria not reported
High (1/1)
Restricted to small < 10
mm pigmented skin le-
sions; all excised
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(Continued)
participants NR (2/2)
Index test Unclear (2/2)
Pre-specification
of threshold not reported
(2/2)
High (2/2)
No threshold details (2/
2). Observer experience
unclear (1/2; Dummer
1993)
Unclear (1/1)
Pre-specification of
threshold NR
High (1/1)
Consensus decision re-
ported and no threshold
detail
Reference standard Low (2/2) Unclear (2/2)
Lack of description of
histopathology expertise
(2/2)
Low (1/1) Unclear (1/1)
Histology expertise not
described
Flow and timing High (1/2)
Unclear (1/2)
Participant exclusions (1/
2; Dummer 1993). Index
to reference interval not
reported (2/2)
- Low (1/1) -
a positions on the clinical pathway described in Figure 3.
bThe study byMorton et al is considered as a single study for quality assessment purposes but as three studies (Morton 1998a; Morton
1998b; Morton 1998c) for the analyses due to the reporting of three separate cohorts of participants
NR: not reported
Appendix 11. Summary study details: image-based evaluations
Study
Posi-
tion
on
path-
way
a,b
Out-
comes
re-
ported
Study
type
Coun-
try
Set-
ting
Inclusion criteria Numberpartici-
pants/lesions
Index tests (al-
gorithm)
Diagnostic ap-
proach
Thresh-
old
Ob-
server
quali-
fica-
tion
(num-
ber)
Expe-
rience
Refer-
ence
stan-
dard
Final
diag-
noses
Preva-
lence
(MEL)
Exclu-
sions
Limited prior testing (with selection on reference standard) (position 3 on clinical pathway)
Bourne
2012
Path-
WPC-
tests
R-CS
Aus-
All skin lesions excised to exclude
skin cancer (and 3 examples com-
mon lesions assessed as clearly be-
46/50 VI (no algorithm)
Dermoscopy (3-
point; Menzies; BLINCK
NR GP (n
= 3)
Clini-
Histol-
ogy/
clinical
5 non-
pig-
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(Continued)
way -
clear
tralia
Pri-
mary
nign and not biopsied) (excluded))
Image-based (blinded)
cal
nurse
(n = 1)
Mixed
experi-
ence
“vary-
ing lev-
els
of der-
mato-
scopic
experi-
ence”
Aver-
age
FU/ex-
pert dx
MM 1;
MiS 8
BCC
6; SK
5;
BN11;
other
19
9/45;
20%
mented
speci-
mens
(not
further
identi-
fied) in
the set
of 50
were
ex-
cluded
from
der-
mo-
scopic
evalua-
tions
Rosendahl
2011
Path-
way -
un-
clear
NC
R-CS
Aus-
tralia
Pri-
mary
PSL submitted for histology from
the primary care skin cancer practice
of one study author
389/
463
1. VI (no algorithm)
2. Dermoscopy (pattern)
1. Sub-
jective
im-
pres-
sion
2.
Both
charac-
teris-
tics
present
Der-
matol-
ogist
(n = 1)
Image-
based;
high
expe-
rience
(con-
firmed
by
study
au-
thor);
single
ob-
server
Histol-
ogy
MM 9;
MiS 20
BCC
72;
SCC 5
BN
217;
BD
18; AK
14*;
BNM
140
*con-
sidered
malig-
nant
by
study
au-
thors
29/
463;
6%
3poor-
quality
images
ex-
cluded
Referred for further assessment (position 4 on clinical pathway)
Stan-
ganelli
2005
WPC
R-CS
Italy
Melanocytic lesions re-
ferred to Skin Cancer Unit
for clinical and dermo-
NR/477 VI (no algorithm)
Dermsocopy (no
NR Der-
matol-
Histol-
ogy/
None
re-
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(Continued)
Path-
way -
clear
MEL
Spe-
cialist
clinic
scopic evaluation algorithm)
Image-based (average)
ogist
(n = 3)
; GP (n
= 3)
Der-
matol-
ogists
- high
expe-
rience
(“2
years
der-
moscopy
experi-
ence”)
; expe-
rience
NR for
GPs,
as-
sumed
low
reg-
istry
FU
MEL
31
BN
103
31/
134;
23%
ported
Referred for further assessment (with selection on reference standard) (position 5 on clinical pathway)
Benelli
2001
Path-
way -
un-
clear
WPC
R-CS
Italy
Training images
Slides of PSL se-
lected for evalua-
tion during
a training course
on dermoscopy.
Lesions not lo-
cated on head,
palms or soles
NR/49 1. VI (ABCDE)
2. Dermoscopy (7FFM)
1. ≥ 3
& ≥ 2
2. ≥ 2
Expert
author
(n = 1);
derma-
tolo-
gists (n
= 65)
Image-
based;
single
author
- high
expe-
rience;
Av-
erage
result
for
der-
matol-
Histol-
ogy
MM
10,
MiS 2
BCC 2
BN25,
SN 5,
SK 3,
other 2
(1
miss-
ing)
12/50;
24%
None
re-
ported
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(Continued)
ogist
group;
expe-
rience
NR
Carli
2002b
Path-
way -
un-
clear
WPC
R-CS
Italy
Secondary
Clinically suspi-
cious or equivo-
cal PSL undergo-
ing excision for
diagnostic pur-
poses; all ≤ 14
mm diameter
NR/57 1. VI (NR)
2. Dermoscopy (NR)
NR Der-
matol-
ogists
(n = 2)
Image-
based;
high
experi-
ence
(“with
experi-
ence in
the
field of
PSL”)
; con-
sensus
of 2
Histol-
ogy
MM 6,
MiS 5
BCC
10
BN31,
SK 1;
other 4
11/57;
19%
4 “not
evalu-
ables”
ex-
cluded
(1
MM, 3
be-
nign)
Do-
lianitis
2005
Path-
way -
un-
clear
WPC
CCS
Multi-centre
Training images
Melanocytic skin
lesions
selected from a
collection of der-
moscopic images
belonging to one
study author
NR/40 1. VI (no algorithm)
2. Dermoscopy (pattern
analysis; Menzies criteria;
7-point; ABCD)
1. Sub-
jective
im-
pres-
sion
2. Sub-
jective
im-
pres-
sion;
NR;
NR; >
4.75
Der-
matol-
ogists
(n =
16);
derma-
tology
trainees
(n =
16);
GPs (n
= 35)
Image-
based;
mixed
expe-
rience
(“range
of
expe-
rience
Histol-
ogy (n
= 39);
Ex-
pert di-
agnosis
(n = 1)
MM
18,
MiS 2
BN12;
SN 3;
other 4
20/20;
50%
None
re-
ported;
poor-
quality
images
exclu-
sion
crite-
rion
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(Continued)
levels
with
assess-
ment
of skin
le-
sions”)
; av-
erage
result
Pizzichetta
2004
Path-
way -
un-
clear
WPC
R-CS
USA/Italy
Secondary
Clinical and/or
dermoscopic hy-
pomelanotic (ex-
tent of pigmen-
tation ≤ 30%)
and amelanotic
skin lesions
151/151 1. VI (no algorithm)
2. Dermoscopy (pattern)
Sub-
jective
im-
pres-
sion
NR
(pre-
sume
derma-
tol-
ogist; n
= 1)
Image-
based;
experi-
ence
NR;
sin-
gle ob-
server
Histol-
ogy
AHM
34,
MiS 5
BCC
25,
SCC 5
BN47,
SN 5,
SK 8,
other
18
39/
108;
36%
(anal-
ysed)
23
lesions
ex-
cluded
due to
image
qual-
ity;
further
43
lesions
were
not
avail-
able
for
evalua-
tion by
clinical
images
(“mainly
benign
melanocytic
le-
sions”)
Stan-
ganelli
1998a
Path-
way -
un-
clear
WPC
R-CS
Italy
Training images
PSL images se-
lected from com-
puterised files of
the skin cancer
clinic
NR/30 1. VI (no algorithm)
2. Dermoscopy (no algo-
rithm)
NR Der-
matol-
o-
gists (n
= 20)
Image-
based;
expe-
rience
NR
(“expe-
Histol-
ogy
MEL
10
BCC 4
BN10,
SK 3,
other 3
10/30;
33%
None
re-
ported
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(Continued)
rience
in
ELM
but
(with)
no
formal
train-
ing”)
; aver-
age
Winkel-
mann
2016
Path-
way -
un-
clear
WPC
CCS
Unclear
Training images
Selected images
previously anal-
ysed by MSD-
SLA
NR/12 1. VI (no algorithm)
2. Dermoscopy (no algo-
rithm)
NR Der-
matol-
o-
gists (n
= 70)
Image-
based;
experi-
ence
NR;
aver-
age
Histol-
ogy
MM 3;
MiS 2
BN 7
5/12;
42%
None
re-
ported
Equivocal referred for further assessment (with selection on reference standard) (position 5* on clinical pathway)
Carli
2003a
Path-
way -
un-
clear
WPC
R-CS
Italy
Secondary
Clin-
ically
diffi-
cult to
diag-
nose or
equiv-
ocal
melanocytic
lesions
ran-
domly
se-
lected
from
image
database;
all
melanomas
< 1
mm
NR/200 1.
VI (no
algo-
rithm)
2. Der-
moscopy
(own
choice)
Sub-
jective
im-
pres-
sion
Der-
ma-
tology
regis-
trar (n
= 2)
; der-
matol-
ogists
(senior
experts
n = 2;
prac-
ticing
derma-
tolo-
gists n
= 4)
Histol-
ogy
MM
40;
MiS 24
BN
136
64/
200;
32%
None
re-
ported
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(Continued)
thick-
ness
Classed
as high
expe-
rience
(both
derma-
tolo-
gists
and
regis-
trars
“for-
mally
trained
in der-
moscopy”)
; Av-
erage
result
de
Giorgi
2012
Path-
way -
un-
clear
WPC
R-CS
Italy
Secondary
Pig-
mented
melanocytic
skin
lesions
≤ 6
mm
diam-
eter
excised
at
derma-
tology
depart-
ment
NR/103 VI
(ABCD)
1. ≥
2 char-
acteris-
tics
present
2. ≥
3 char-
acteris-
tics
present
Der-
matol-
ogists
(n = 3)
High
expe-
rience
(“more
than 5
years
of
prac-
tice in
der-
moscopy”)
; con-
sensus
of 3
Histol-
ogy
MM
16;
MiS 18
BN 69
34/
103;
33%
None
re-
ported
apositions on the clinical pathway described in Figure 3.
bclear or unclear position on the clinical pathway.
AHM: amelanotic hypomelanotic melanoma; AK: actinic keratosis; BCC: basal cell carcinoma; BD: Bowen’s disease; BLINCK:
Benign Lonely irregular Nervous Change Known Clues; BN: benign naevi; BNM: benign non-melanocytic; BPC: between-person
comparison (of tests); CCS: case-control study; CS: case series; cSCC: cutaneous squamous cell carcinoma;DF: dermatofibroma; dx:
diagnosis; ELM: epiluminescencemicroscopy; FU: follow-up;GP: general practitioner; LS: lentigo simplex;MEL: invasive melanoma
or atypical intraepidermal melanocytic variants; MiS: melanoma in situ (or lentigo maligna); MM: malignant (invasive) melanoma;
MSDSLA: multispectral digital skin lesion analysis device;NC: non comparative;NR: not reported; P: prospective; PLC: pigmented
lesion clinic; PSL: pigmented skin lesion; R: retrospective; RCT: randomised controlled trial; SCC: squamous cell carcinoma; SK:
seborrhoeic keratosis; SN: Spitz naevi; VI: visual inspection; WPC: within person comparison (of tests); 7FFM: seven features for
melanoma; 7PCL: seven-point checklist
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Appendix 12. Summary QUADAS: image-based evaluations
Studies clearly placed on clinical pathway Studies not clearly placed on clinical pathway
Pathway a Risk of bias Concerns about appli-
cability
Risk of bias Concerns about appli-
cability
Limited prior testing (with selection on reference standard) (position 3 on clinical pathway)
Studies N = 1; Bourne 2012 N = 1; Rosendahl 2011
Participant selection Unclear (1/1)
Unclear exclusion criteria
(Bourne 2012)
High (1/1)
Restriction to primarily
excised lesions (1/1)
Low (1/1) High (1/1)
Includes excised lesions
only; multiple lesions per
participant
Index test Unclear (1/1)
Lack of clear pre-speci-
fication of the threshold
(Bourne 2012)
High (1/1)
Blinded image interpreta-
tion and average observer
result presented (Bourne
2012); lack of threshold
detail (Bourne 2012); un-
clear description of ob-
server expertise
Unclear (1/1)
No clear pre-specification
of threshold
High (1/1)
Image-based study; no
threshold detail
Reference standard Low (1/1) High (1/1)
Use of expert diagnosis as
reference (Bourne 2012)
; lack of description of
histopathology expertise (
Bourne 2012)
Low (1/1) Unclear (1/1)
Histopathology
experience NR
Flow and timing High (1/1)
Use of different reference
standards (Bourne 2012)
; participant exclusions (
Bourne 2012)
- High (1/1)
Exclusions on
image quality Unclear in-
terval between index and
reference
-
Referred for further assessment (position 4 on clinical pathway)
Studies N = 1; Stanganelli 2005 N = 0
Participant selection Unclear (1/1)
Unclear participant sam-
pling across all items (
Stanganelli 2005)
High (1/1)
Sample
restricted to melanocytic
lesions (Stanganelli 2005)
- -
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(Continued)
. Patient numbers NR
Index test Unclear (1/1)
Lack of clear pre-speci-
fication of the threshold
(Stanganelli 2005)
High (1/1)
Average result presented
(Stanganelli 2005); insuf-
ficient threshold detail (
Stanganelli 2005)
- -
Reference standard Low (1/1) Unclear (1/1). Unclear
use of expert diagnosis
as reference standard (
Stanganelli 2005). Un-
clear histopathology ex-
pertise
- -
Flow and timing High (1/1)
Use of different reference
standards (Stanganelli
2005); unclear reference
interval
- - -
Referred for further assessment (with selection on reference standard) (position 5 on clinical pathway)
Studies N = 0 N = 6; Benelli 2001; Carli 2002b; Dolianitis 2005;
Pizzichetta 2004; Stanganelli 1998a; Winkelmann
2016
Participant selection - - High (3/6)
Unclear (3/6)
Case-control type design
used (3/3; Dolianitis
2005; Stanganelli 1998a;
Winkelmann 2016) or
unclear design (Benelli
2001; Pizzichetta 2004).
Unclear participant sam-
pling (5/6; Benelli 2001;
Carli 2002b; Pizzichetta
2004; Stanganelli 1998a;
Winkelmann 2016), de-
sign unclear (1/6), exclu-
sion criteria not clearly
reported (5/6; Benelli
2001;
Carli 2002b; Dolianitis
2005; Stanganelli 1998a;
Winkelmann 2016)
High (6/6)
Excised only included (6/
6), amelanotic/ hypome-
lanotic lesions only (1/6;
Pizzichetta 2004). Num-
ber participants NR (5/6;
Benelli 2001;
Carli 2002b’ Dolianitis
2005; Stanganelli 1998a;
Winkelmann 2016)
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(Continued)
Index test - - Low (1/6)
Unclear (5/6)
No clear pre-specification
of threshold
(5/
6; Carli 2002b; Dolianitis
2005; Pizzichetta
2004; Stanganelli 1998a;
Winkelmann 2016)
High (6/6)
Image-based evaluations
(6/6), blinded to all other
information (5/6; Benelli
2001;
Carli 2002b; Dolianitis
2005; Stanganelli 1998a;
Winkelmann 2016), with
con-
sensus (1/6; Carli 2002b)
or average result (4/6;
Benelli 2001; Dolianitis
2005; Stanganelli 1998a;
Winkelmann 2016) re-
ported. Threshold not
clearly specified (5/6;
Carli 2002b; Dolianitis
2005; Pizzichetta
2004; Stanganelli 1998a;
Winkelmann 2016). Ob-
server expertise NR (4/6;
Dolianitis 2005;
Pizzichetta
2004; Stanganelli 1998a;
Winkelmann 2016)
Reference standard - - Low (6/6) High (1/6)
Unclear (5/6)
Use of expert observer di-
agno-
sis (1/6; Dolianitis 2005)
; expertise of histopathol-
ogist not described (6/6)
Flow and timing - - Low (1/6)
High (2/6)
Unclear (3/6)
Lesions excluded
fromanalysis (reasonNR)
(2/6; Dolianitis 2005;
Pizzichetta 2004); differ-
ent reference standards
used (1/6; Dolianitis
2005). Index to reference
interval NR (5/6; Benelli
2001, Dolianitis 2005,
Pizzichetta
2004, Stanganelli 1998a,
Winkelmann 2016).
-
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Equivocal referred for further assessment (with selection on reference standard) (position 5* on clinical pathway)
Studies N = 0 N = 2; Carli 2003a; de Giorgi 2012
Participant selection - - High (2/2)
Exclusion of difficult to
diagnose, including pecu-
liar lesions (1/2; Carli
2003a), histology dis-
agreement (1/2; de Giorgi
2012)
High (2/2)
Restric-
tion to melanocytic only
(2/2), excised only (2/2).
Patient numbers NR (2/
2)
Index test - - High (1/2)
Unclear (1/2)
Mul-
tiple thresholds tested (1/
2; de Giorgi 2012); no
clear threshold specifica-
tion (1/2; Carli 2003a)
High (2/2)
Image-based evaluations
(2/2), blinded to all other
information (1/2; Carli
2003a), with consensus
(1/2; de Giorgi 2012) or
average result (1/2; Carli
2003a) reported. Thresh-
old not described (1/2;
Carli 2003a)
Reference standard - - Low (2/2) Low (2/2)
Flow and timing - - Unclear (2/2)
Index to reference interval
NR (2/2)
-
a positions on the clinical pathway described in Figure 3.
NR: not reported
Appendix 13. Summary study details: detection of invasive melanoma alone
Study
author
Outcomes
reported
Study type
Country
Setting
Inclusion
criteria
Number-
partici-
pants/
lesions
Index tests
(algorithm)
Diagnostic
approach
Threshold Observer
qualifica-
tions (num-
ber)
Experience
Reference
standard
Final diag-
noses
Prevalence
(MEL)
Exclusions
In-person
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(Continued)
Bono 1996 WPC-tests
Unclear
Italy
Specialist
clinic
Pig-
mented skin
lesions at
the Instituto
Nazionale
Tumori of
Milan
45/54 VI (no algo-
rithm)
Single
observer
Subjective
impression
Plastic sur-
geon
Histology
plus other
(31% of be-
nign had ex-
pert dx)
MM: 18
BN: 25
18/43; 42%
Only 43 le-
sions had
complete
clinical and
histologi-
cal informa-
tion. 11 le-
sions not
surgically re-
moved had
only clinical
diagno-
sis (benign)
andwere not
included in
the final ac-
curacy anal-
ysis
Green 1994 NC
NR-CS
Australia
Secondary
Pigmented
lesions for
excision
129/164 VI (no algo-
rithm)
Single
observer
Subjec-
tive impres-
sion; clinical
dx recorded
NR Histology
MM 18;
MiS 3
BN 128;
misc pig-
mented le-
sions includ-
ing SK,
BCC,
lentigines 15
18/164;
11%
-
Kopf 1975 NC
R-CS
USA
Specialist
clinic
All le-
sions subject
to biopsy at
the Oncol-
ogy Section
of the Skin
and Cancer
Unit
NR/5538 VI (no algo-
rithm)
Single
observer
No details;
“clinical di-
agnosis”
Oncologist Histology
MM 99
other dx
listed only
for false-
positives
99/5538;
2%
None
reported
Krahn 1998 WPC-tests
P-CS
Germany
Secondary
Excised pig-
mented skin
lesions
80/80 VI (no algo-
rithm)
Single
observer
No details Derma-
tologist (as-
sumed)
Histology
MM 39
BN40; SN1
39/80; 49%
None
reported
McGovern
1992
WPC-algs
P-CS
USA
PSL (> 10
mm) excised
to rule out
179/237 VI (7-point;
(A)BCD)
In-person;
7-point: ≥
2, ≥ 3, ≥
4 character-
NR (pre-
sume der-
Histology
MM 6; MiS
32 le-
sions unac-
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(Continued)
Community dysplasia,
MiS or MM
single istics present
(A)BCD: ≥
1, ≥ 2, ≥
3 character-
istics present
matologist)
experience.
NR
6
BCC 4; SK
32; BN 138;
AK 6; other
45
6/211; 3%
counted for;
13 excluded
due to le-
sion size of
≤ 8 mm.
192 evalu-
ated for
ABCD and
3-point; 205
evaluated
for 7-point
Viglizzo
2004
WPC-tests
NR-CS
Italy
Specialist
clinic
Pigmented
skin lesions
examined at
the Der-
moscopy
Ser-
vice and un-
dergoing ex-
cisions; high
andmedium
risk on der-
moscopy
were se-
lected for ex-
cision
and 2x2 can
be estimated
only for
melanocytic
subgroup
NR/79 VI (no algo-
rithm)
Single
observer
No details Derma-
tologist (as-
sumed)
Histology
Melanoma
(invasive):
11; MiS: 1
Melanocytic
lesion: 57
11/67 16%
None
reported
Walter 2012 BPC
RCT
UK
Primary
Any sus-
picious PSL
that could
not im-
mediately be
diagnosed as
benign
654/
792 (control
arm only)
VI (7-point)
Siascope (iv
arm)
In-person
(single)
NR GP (n = 28)
Nurse prac-
titioner. (n =
2)
Low
(excluded if
specialist
dermatology
training)
Histology/
clinical FU
(3-
6 months)/
expert dx
Control
group only:
MM 16;
MiS 2
BCC 4; SK
20; DF 2;
lentigo
5; “benign”
686; un-
known 10
16/773 2%
19 (5 due to
violation of
recruit-
ment criteria
or discon-
tinued pro-
to-
col; 1 died;
4 did not at-
tend for der-
matology as-
sessment; 2
missing his-
tology; 7 not
clearly ac-
counted for)
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(Continued)
Image-based
Lorentzen
1999
WPC-tests
P-CS
Denmark
Secondary
Patients
with lesions
suspicious
for CMM
referred to
outpatients
clinic
232/232 VI (no algo-
rithm)
(Der-
moscopy)
Single
observer
Subjec-
tive impres-
sion; clinical
diagnosis
Dermatolo-
gist
Histology
MM 49
“malignant
melanoma”
BCC 16, SK
12; BN: 137
other:
18 (includ-
ing SN, BD,
and others)
49/232;
21%
Poor-qual-
ity index test
im-
age 10 cases
excluded
Rao 1997 WPC-algs
(tests)
R-CS
USA
Private
Patients
with atypi-
cal
melanocytic
lesions
or suspected
early MM
63/72 VI (ABCD)
(Der-
moscopy)
Single
observer
Diagnosis of
melanoma
Dermatol-
ogy registrar
Histology
MM 21
Atypical
melanocytic
naevus 51
21/72; 29%
None
reported
Scope 2008 NC
R-CS
New
Zealand
Industry im-
age database
Images of
pigmented
skin lesions
selected
from a
database of
standardised
patient
images
provided
by a New
Zealand-
based teled-
ermatology
company
(MoleMap);
images were
selected on
the basis
that (1) ≥
8 clinically
atypical
naevi were
apparent on
the back;
12/145 VI (ugly
duckling)
Single
observer
Lesion id as
“completely
different”
or some-
what differ-
ent from the
other moles;
(Bx)
decision
Dermatolo-
gist
Histology or
FU
MM 5 “ma-
lignant
melanoma”
BN: 140
5/145; 3%
Unac-
ceptable im-
age quality
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(Continued)
(2) most of
the lesions
on the back
and all of
the atypical
naevi had
close-up
clinical dig-
ital images;
(3) 1-year
FU images
(close-up
clinical and
dermo-
scopic im-
ages) were
available
to show
that lesions
considered
to be benign
were in fact
biologically
indolent by
revealing
no change;
and (4)
the image
quality of
both the
overview
and the
close-up
images were
acceptable
Troyanova
2003
BPC/WPC-
tests
R-CCS
NR
Training im-
ages (source
NR)
Im-
ages of pig-
mented skin
lesions
selected for a
dermoscopy
training
study
NR/50 VI (no algo-
rithm)
(Der-
moscopy)
Single
observer
Subjec-
tive impres-
sion; dx of
melanoma
Dermatolo-
gist
Histology
MM: 25
“Benign”:
25
25/50; 50%
None
reported
Westerhoff
2000
WPC-tests
R-CCS
Australia
Training
Clinically
atypical pig-
mented skin
lesions;
NR/100 VI (no algo-
rithm)
(Der-
moscopy)
Subjec-
tive impres-
sion; dx of
melanoma
GP Histology or
FU
MM 50
“Benign”:50
None
reported
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(Continued)
images (Spe-
cialist unit)
50 invasive
melanomas
and 50 non-
melanomas
randomly
se-
lected from
the Sydney
Melanoma
Unit PSL
image
database
Single
observer
50/100;
50%
AK: actinic keratosis; BCC: basal cell carcinoma; BD: Bowen’s disease; BN: benign naevi; BPC: between person comparison (of tests)
; Bx: biopsy; CCS: case control study; CMM: cutaneous malignant melanoma; CS: case series; DF: dermatofibroma; FU: follow-
up; MEL: invasive melanoma or atypical intraepidermal melanocytic variants; MiS: melanoma in situ (or lentigo maligna); MM:
malignant melanoma; NC: non comparative; NR: not reported; P: prospective; PLC: pigmented lesion clinic; PSL: pigmented skin
lesion; R: retrospective; RCT: randomised controlled trial; SK: seborrhoeic keratosis; SN: Spitz naevi; VI: visual inspection; WPC:
within person comparison (of tests);WPC-algs: within-person comparison (of algorithms)
Appendix 14. Summary study details: detection of any skin lesion requiring excision
Study author
Outcomes
reported
Study
type
Coun-
try
Setting
Inclusion criteria Numberpartici-
pants/lesions
Index
tests (al-
go-
rithm)
Diag-
nostic
ap-
proach
Thresh-
old
Ob-
server
qualifi-
cations
(num-
ber)
Experi-
ence
Refer-
ence
stan-
dard
Final di-
agnoses
Preva-
lence
(MEL)
Exclu-
sions
In-person
Argenziano 2006 RCT
Italy,
Spain
Primary
Patients asking for
screening or exhibit-
ing ≥ 1 skin tu-
mours as seen dur-
ing routine physical
ex-
amination (patient-
finding screening)
Participating PCPs
randomised to ei-
ther VI alone or VI
NR/85 VI
(ABCD)
Der-
moscopy
(3-point
check-
list)
In per-
son (sin-
gle ob-
server)
Subjec-
tive im-
pres-
sion; dx
of malig-
nancy
GPs (n =
37)
All
trained
in
ABCD
rule
Histol-
ogy
MEL 6
BCC37;
SCC 10
benign
32
53/85;
62%
Only
those
partic-
ipants
who
were
con-
sidered
to have
lesions
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(Continued)
+ dermoscopy; only
excised lesions can
be included for each
arm
sug-
gestive
of skin
cancer
had
histol-
ogy and
could
be in-
cluded;
rest had
expert
diag-
nosis
(making
full
dataset
ineli-
gible
for this
review)
Chang 2013 NC
R-CS
Taiwan
Sec-
ondary
Po-
tentially malignant
biopsied or excised
skin lesions (nontu-
mour specimens ex-
cluded)
676/769 VI
(no algo-
rithm)
In-per-
son (sin-
gle ob-
server)
Subjec-
tive im-
pression;
defi-
nitely
malig-
nant
Derma-
tolo-
gists; n =
25
Board-
certified
Histol-
ogy
MM 4;
MiS 4
BCC:
110;
cSCC:
20
“Be-
nign” di-
agnoses:
595
152/
769;
20%
Poor-
qual-
ity index
test im-
age mis-
regis-
tered
or poor-
quality
im-
ages (un-
focused
or con-
taining a
motion
artifact)
Ek 2005 NC
P-CS
Australia
Special-
ist clinic
Lesions excised for
which malignancy
could not be ex-
cluded
1223/2582 VI
(no algo-
rithm)
In
person
Subjec-
tive im-
pression
Plastic
surgeon
(n = 4 or
5; mixed
experi-
ence; 3
consul-
tants, 1
plastic
Histol-
ogy
MEL 23
BCC
1214;
SCC
517; BD
188; SK
63; 577
Incom-
plete
or incor-
rectly
entered
profor-
mas
were ex-
cluded -
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surgery
trainee
(usually
1st year,
on 6-
month
rota-
tion)
and a
clinical
assis-
tant)
Unclear
other be-
nign (in-
cluding
330 so-
lar ker-
atosis)
1754/
2582;
68%
79 par-
ticipants
with 96
lesions
McGovern 1992 WPC-
algs
P-CS
USA
Com-
munity
PSL (> 10 mm) ex-
cised to rule out dys-
plasia, MiS or MM
179/237 VI (7-
point;
(A)
BCD)
In-per-
son; sin-
gle
7-point:
≥ 2, ≥
3, ≥ 4
charac-
teristics
present
(A)
BCD: ≥
1,
≥ 2, ≥ 3
charac-
teristics
present
NR
(pre-
sume
derma-
tologist)
experi-
ence.
NR
Histol-
ogy
MM 6;
MiS 6
BCC 4;
SK
32; BN
138; AK
6; other
45
15/192;
8%
32
lesions
unac-
counted
for; 13
excluded
due to
lesion
size of ≤
8 mm.
192
evalu-
ated for
ABCD
and 3-
point;
205
evalu-
ated for
7-point
Stanganelli 2000 WPC
R-CS
Italy
Special-
ist clinic
PSL referred by der-
matologists andGPs
either for pre-sur-
gical assessment or
consultation
NR/3372 VI
(ABCD)
Der-
moscopy
(no
algo-
rithm)
In per-
son (sin-
gle)
NR
Subjec-
tive im-
pression
NR (as-
sumed
derma-
tologist -
de-
scribed
as one of
the co-
authors;
n = 1)
Histol-
ogy/reg-
istry FU
MEL 55
BCC43;
BN
3274
98/
3372;
3%
None re-
ported
Steiner 1987 P-CS
Austria
Special-
Small (< 10 mm) di-
agnostically equivo-
cal PSL; no absolute
NR/318 1. VI
(no algo-
rithm)
Subjec-
tive im-
pression
Derma-
tologists
(n = 3;
Histol-
ogy
MM 49;
None re-
ported
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(Continued)
ist clinic agreement on clini-
cal diagnosis among
investigating clini-
cians at a PLC
2. Der-
moscopy
(pat-
tern)
In
person
high ex-
perience
- “expe-
rienced
derma-
tolo-
gists”)
Consen-
sus diag-
nosis
of 3 ob-
servers
MiS 24
BCC 20
BN 143;
SK 20;
lentigo
sim-
plex and
nevoid
lentigo
19;
other 15
93/318;
29%
Walter 2012 BPC
RCT
UK
Primary
Any suspicious PSL
that could not im-
mediately be diag-
nosed as benign
654/792 (control
arm only)
VI (7-
point)
Siascope
(iv arm)
In per-
son (sin-
gle)
NR GP (n =
28)
Nurse
practi-
tioner (n
= 2)
Low (ex-
cluded if
special-
ist
derma-
tology
training)
Histol-
ogy/
clinical
FU (3-6
months)
/expert
dx
Control
group
only:
MM 16;
MiS 2
BCC 4;
SK 20;
DF 2;
lentigo
5;
“benign”
686; un-
known
10
22/773;
3%
19 (5
due to
viola-
tion of
recruit-
ment
criteria
or dis-
contin-
ued pro-
tocol; 1
died; 4
did not
attend
for
derma-
tology
assess-
ment; 2
missing
histol-
ogy;
7 not
clearly
ac-
counted
for)
Image-based
Carli
2002b
WPC
R-CS
Italy
Secondary
Clini-
cally sus-
picious
or equiv-
ocal PSL
NR/57 1. VI (NR)
2. Dermoscopy
(NR)
NR Derma-
tologists
(n = 2)
Image-
based;
Histol-
ogy
MM 6,
MiS 5
BCC 10
4 ’not
evalu-
ables’ ex-
cluded
(1 MM,
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(Continued)
under-
go-
ing exci-
sion for
diagnos-
tic pur-
poses; all
≤ 14
mm di-
ameter
high ex-
perience
(“with
expe-
rience in
the field
of PSL”)
; consen-
sus of 2
BN 31,
SK 1;
other 4
20/54;
37%
3
benign)
Rosendahl
2011
NC
R-CS
Australia
Primary
PSL sub-
mitted
for his-
tology
from the
primary
care skin
cancer
practice
of one
study
author
389/463 1. VI (no algorithm)
2. Dermoscopy
(pattern)
1. Sub-
jec-
tive im-
pression
2. Both
charac-
teristics
present
Derma-
tologist
(n = 1)
Image-
based;
high ex-
perience
(con-
firmed
by study
author);
single
observer
Histol-
ogy
MM 9;
MiS 20
BCC72;
SCC 5
BN 217;
BD 18;
AK 14*;
BNM
140
*consid-
ered ma-
lignant
by study
authors
104/
463;
22%
3 poor-
quality
images
excluded
Stan-
ganelli
1998a
WPC
R-CS
Italy
Training images
PSL im-
ages se-
lected
from
comput-
erised
files of
the
skin can-
cer clinic
NR/30 1. VI (no algorithm)
2. Dermoscopy (no
algorithm)
NR Derma-
tologists
(n = 20)
Image-
based;
experi-
ence NR
(“expe-
rience
in ELM
but
(with)
no
formal
train-
ing”);
average
Histol-
ogy
MEL 10
BCC 4
BN 10,
SK 3,
other 3
14/30;
47%
None re-
ported
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AK: actinic keratosis; BN: benign naevi; BCC: basal cell carcinoma; BD: Bowen’s disease; BPC: between person comparison (of
tests); CCS: case control study; CS: case series; cSCC: cutaneous squamous cell carcinoma; DF: dermatofibroma; FU: follow-up;
dx: diagnosis; ELM: epiluminescence microscopy; GP: general practitioner; MEL: invasive melanoma or atypical intraepidermal
melanocytic variants; MiS: melanoma in situ (or lentigo maligna); MM: malignant (invasive) melanoma; NC: non comparative;
NR: not reported; P: prospective; PCP: primary care practitioner; PLC: pigmented lesion clinic; PSL: pigmented skin lesion; R:
retrospective;RCT: randomised controlled trial; SCC: squamous cell carcinoma; SK: seborrhoeic keratosis; SN: Spitz naevi; VI: visual
inspection; WPC: within person comparison (of tests);WPC-algs: within person comparison of algorithms
C O N T R I B U T I O N S O F A U T H O R S
JD was the contact person with the editorial base.
JD co-ordinated contributions from the co-authors and wrote the final draft of the review.
SB conducted the literature searches.
JD, NC, LFR, DT, KYW, RBA, RA, and MF screened papers against eligibility criteria.
JD and NC obtained data on ongoing and unpublished studies.
JD, NC, LFR, DT, KYW, RBA, RA, and MF appraised the quality of papers.
JD, NC, LFR, DT, KYW, RBA, RA, and MF extracted data for the review and sought additional information about papers.
JD entered data into Review Manager 5.
JD, MJG and JJD analysed and interpreted data.
JD, JJD, NC, LFR, YT and CD worked on the methods sections.
JD, FW, DT, KYW, RBA, RA, MF, RNM and HCW drafted the clinical sections of the background and responded to the clinical
comments of the referees.
JD, JJD, CD and YT responded to the methodology and statistics comments of the referees.
KG was the consumer co-author and checked the review for readability and clarity, as well as ensuring outcomes are relevant to
consumers.
JD is the guarantor of the update.
Disclaimer
This project was supported by the National Institute for Health Research, via Cochrane Infrastructure funding to Cochrane Skin and
Cochrane Programme Grant funding. The views and opinions expressed therein are those of the authors and do not necessarily reflect
those of the Systematic Reviews Programme, NIHR, NHS or the Department of Health.
343Visual inspection for diagnosing cutaneous melanoma in adults (Review)
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
D E C L A R A T I O N S O F I N T E R E S T
Jacqueline Dinnes: nothing to declare.
Jonathan J Deeks: nothing to declare.
Matthew J Grainge: nothing to declare.
Naomi Chuchu: nothing to declare.
Lavinia Ferrante di Ruffano: nothing to declare.
Rubeta N Matin: “my institution received a grant for a Barco NV commercially sponsored study to evaluate digital dermoscopy in
the skin cancer clinic. My institution also received Oxfordshire Health Services Research Charitable Funds for carrying out a study of
feasibility of using the Skin Cancer Quality of Life Impact Tool (SCQOLIT) in non melanoma skin cancer. I have received royalties for
the Oxford Handbook of Medical Dermatology (Oxford University Press) and payment from the UK Photopheresis Society for a lecture
on cutaneous graft versus host disease (October 2017). I have no conflicts of interest to declare that directly relate to the publication
of this work.”
David R Thomson: nothing to declare.
Kai Yuen Wong: nothing to declare.
Roger Benjamin Aldridge: nothing to declare.
Rachel Abbott: nothing to declare.
Monica Fawzy: nothing to declare.
Susan E Bayliss: nothing to declare.
Yemisi Takwoingi: nothing to declare.
Clare Davenport: nothing to declare.
Kathie Godfrey: nothing to declare.
Fiona M Walter: nothing to declare.
Hywel CWilliams: I am director of the NIHR HTA Programme. HTA is part of the NIHR, which also supports the NIHR systematic
reviews programme from which this work is funded.
S O U R C E S O F S U P P O R T
Internal sources
• No sources of support supplied
344Visual inspection for diagnosing cutaneous melanoma in adults (Review)
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
External sources
• NIHR Systematic Review Programme, UK.
• The National Institute for Health Research (NIHR), UK.
The NIHR, UK, is the largest single funder of Cochrane Skin
D I F F E R E N C E S B E TW E E N P R O T O C O L A N D R E V I E W
We set out to review visual inspection and dermoscopy for the detection of melanoma in a single review; however, due to the volume
of evidence identified, we prepared two separate reviews: one for visual inspection alone and one for dermoscopy, the latter including
direct comparisons with visual inspection where the same studies evaluated both tests.
We changed the primary objectives and primary target condition from detection of cutaneous invasive melanoma alone, to the detection
of cutaneous invasivemelanoma and atypical intraepidermalmelanocytic variants, as the latter ismore clinically relevant to the practicing
clinician. We included the detection of the target condition of invasive melanoma alone as a secondary objective instead.
We tailored secondary objectives to the individual test, and added two objectives, to determine the diagnostic accuracy of individual
algorithms for visual inspection, and to determine the effect of observer experience.
Sources of heterogeneity that could be investigated (as listed under Secondary objectives) were restricted due to lack of data.
We amended the text to clarify that studies available only as conference abstracts would be excluded from the review unless full
papers could be identified; studies available only as conference abstracts do not allow a comprehensive assessment of study methods or
methodological quality.
We excluded, rather than included, studies using cross-validation, such as ’leave-one-out’ cross-validation, as these methods are not
sufficiently robust and are likely to produce unrealistic estimates of test accuracy.
To improve clarity of methods, we replaced this text from the protocol, “we will include studies developing new algorithms or methods
of diagnosis (i.e. derivation studies) if they use a separate independent ’test set’ of participants or images to evaluate the new approach.
We will also include studies using other forms of cross validation, such as ’leave-one-out’ cross-validation (Efron 1983). We will note
for future reference (but not extract) any data on the accuracy of lesion characteristics individually, e.g. the presence or absence of a
pigment network or detection of asymmetry” with, “studies developing new algorithms or methods of diagnosis (i.e. derivation studies)
were included if they:
• used a separate independent ’test set’ of participants or images to evaluate the new approach, or
• investigated lesion characteristics that had previously been suggested as associated with melanoma and the study reported
accuracy based on the presence or absence of particular combinations of characteristics.
Studies were excluded if they:
• used a statistical model to produce a data driven equation, or algorithm based on multiple diagnostic features, with no separate
test set.
• used cross-validation approaches such as ’leave-one-out’ cross-validation (Efron 1983)
• evaluated the accuracy of the presence or absence of individual lesion characteristics or morphological features, with no overall
diagnosis of malignancy
• reported accuracy data for ‘clinical diagnosis’ with no clear description as to whether the reported data related to visual
inspection alone
• were based on the experience of a particular skin cancer clinic, where dermoscopy may or may not have been used on an
individual patient-basis.”
Although we extracted any reporting of special interest or accreditation in skin cancer according to observer expertise, we were unable
to analyse the effect on accuracy.
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Weproposed to supplement the database searches by searching the annual meetings of appropriate organisations (e.g. British Association
of Dermatologists Annual Meeting, American Academy of Dermatology Annual Meeting, European Academy of Dermatology and
Venereology Meeting, Society for Melanoma Research Congress, World Congress of Dermatology, European Association of Dermato
Oncology), however due to volume of evidence retrieved from database searches and time restrictions we were unable to do this.
For quality assessment, we further tailored the QUADAS-2 tool according to the review topic. In terms of analysis, due to lack of data
we did not restrict analyses to per-participant data only, nor perform sensitivity analyses as planned.
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